17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL induced coronary angiogenesis is dependent on vascular endothelial growth factor . 
3 NULL NULL NULL NULL NULL NULL NULL NULL bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor . NULL NULL 
17 NULL NULL NULL NULL NULL NULL bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor . NULL NULL NULL NULL 
0 NULL NULL bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL a marked coronary angiogenesis is known to occur with chronic bradycardia . NULL NULL 
0 NULL NULL NULL we tested the hypothesis that vascular endothelial growth factor ( vegf ) , an endothelial cell mitogen and 
0 ( vegf ) , an endothelial cell mitogen and a major regulator of angiogenesis , is upregulated in response to low 
0 vegf ) , an endothelial cell mitogen and a major regulator of angiogenesis , is upregulated in response to low heart 
3 , an endothelial cell mitogen and a major regulator of angiogenesis , is upregulated in response to low heart rate and 
17 cell mitogen and a major regulator of angiogenesis , is upregulated in response to low heart rate and consequential increased stroke 
0 and a major regulator of angiogenesis , is upregulated in response to low heart rate and consequential increased stroke volume . 
0 is upregulated in response to low heart rate and consequential increased stroke volume . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL bradycardia was induced in rats by administering the bradycardic drug alinidine ( 3 
19 NULL NULL NULL NULL bradycardia was induced in rats by administering the bradycardic drug alinidine ( 3 mg/kg body weight ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL heart rate decreased by 32 % for 20 to 40 minutes after injection 
0 decreased by 32 % for 20 to 40 minutes after injection and was chronically reduced by 10 % , 14 % 
0 for 20 to 40 minutes after injection and was chronically reduced by 10 % , 14 % , and 18.5 % 
0 % after 1 , 2 , and 3 weeks of treatment , respectively . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL arterial pressure and cardiac output were unchanged . NULL NULL NULL 
17 ventricular capillary length density ( mm/mm ( 3 ) ) increased gradually with alinidine administration ; a 15 % increase after 
19 ( mm/mm ( 3 ) ) increased gradually with alinidine administration ; a 15 % increase after 2 weeks and a 
17 ) increased gradually with alinidine administration ; a 15 % increase after 2 weeks and a 40 % increase after 3 
17 15 % increase after 2 weeks and a 40 % increase after 3 weeks of alinidine treatment were documented . NULL 
19 and a 40 % increase after 3 weeks of alinidine treatment were documented . NULL NULL NULL NULL NULL NULL NULL 
0 , body weight , and their ratio were not significantly altered by alinidine treatment . NULL NULL NULL NULL NULL NULL 
19 , and their ratio were not significantly altered by alinidine treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL after 1 week of treatment , before an increase in capillary length density , vegf 
17 NULL NULL after 1 week of treatment , before an increase in capillary length density , vegf mrna increased greater than 
0 , before an increase in capillary length density , vegf mrna increased greater than 2-fold and then declined to control levels 
17 before an increase in capillary length density , vegf mrna increased greater than 2-fold and then declined to control levels after 
18 density , vegf mrna increased greater than 2-fold and then declined to control levels after 3 weeks of treatment . NULL 
0 vegf mrna increased greater than 2-fold and then declined to control levels after 3 weeks of treatment . NULL NULL NULL 
0 mrna increased greater than 2-fold and then declined to control levels after 3 weeks of treatment . NULL NULL NULL NULL 
0 and then declined to control levels after 3 weeks of treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL vegf protein was higher in alinidine-treated rats than in controls after 2 
19 NULL NULL NULL NULL NULL vegf protein was higher in treated rats than in controls after 2 weeks and increased further 
0 NULL vegf protein was higher in alinidine-treated rats than in controls after 2 weeks and increased further after 3 weeks of 
17 in alinidine-treated rats than in controls after 2 weeks and increased further after 3 weeks of treatment . NULL NULL NULL 
0 after 2 weeks and increased further after 3 weeks of treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL injection of vegf-neutralizing antibodies over a 2-week period completely blocked alinidine-stimulated 
18 NULL injection of vegf-neutralizing antibodies over a 2-week period completely blocked alinidine-stimulated angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
17 injection of vegf-neutralizing antibodies over a 2-week period completely blocked stimulated angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 of vegf-neutralizing antibodies over a 2-week period completely blocked alinidine-stimulated angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL in contrast , bfgf mrna was not altered by alinidine treatment . NULL NULL NULL 
16 NULL NULL NULL in contrast , bfgf mrna was not altered by alinidine treatment . NULL NULL NULL NULL NULL NULL 
19 in contrast , bfgf mrna was not altered by alinidine treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL these data suggest that vegf plays a key role in the angiogenic response that occurs with 
16 NULL NULL NULL these data suggest that vegf plays a key role in the angiogenic response that occurs with chronic bradycardia 
16 NULL NULL these data suggest that vegf plays a key role in the angiogenic response that occurs with chronic bradycardia . 
3 data suggest that vegf plays a key role in the angiogenic response that occurs with chronic bradycardia . NULL NULL NULL 
0 suggest that vegf plays a key role in the angiogenic response that occurs with chronic bradycardia . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the mechanism underlying this vegf-associated angiogenesis may be an increase in stretch 
16 NULL NULL NULL NULL NULL NULL the mechanism underlying this associated angiogenesis may be an increase in stretch due to enhanced 
3 NULL NULL NULL NULL NULL the mechanism underlying this vegf-associated angiogenesis may be an increase in stretch due to enhanced diastolic 
0 NULL the mechanism underlying this vegf-associated angiogenesis may be an increase in stretch due to enhanced diastolic filling . NULL NULL 
0 vegf-associated angiogenesis may be an increase in stretch due to enhanced diastolic filling . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL uft and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma , as 
3 NULL NULL NULL NULL uft and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma , as determined by 
17 NULL NULL NULL uft and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma , as determined by a 
0 a molar ratio of 1 : 4 , is widely used in clinical practice in japan to treat cancer patients requiring 
0 ratio of 1 : 4 , is widely used in clinical practice in japan to treat cancer patients requiring a long-term 
19 , is widely used in clinical practice in japan to treat cancer patients requiring a long-term chemotherapy , and it is 
0 used in clinical practice in japan to treat cancer patients requiring a long-term chemotherapy , and it is associated with few 
19 practice in japan to treat cancer patients requiring a long-term chemotherapy , and it is associated with few side effects , 
0 cancer patients requiring a long-term chemotherapy , and it is associated with few side effects , if any . NULL NULL 
0 long-term chemotherapy , and it is associated with few side effects , if any . NULL NULL NULL NULL NULL NULL 
18 NULL NULL in this study , we have evaluated the inhibitory effect of uft against renca cell-induced angiogenesis by a dorsal 
18 NULL in this study , we have evaluated the inhibitory effect of uft against renca cell-induced angiogenesis by a dorsal air 
17 we have evaluated the inhibitory effect of uft against renca induced angiogenesis by a dorsal air sac assay . NULL NULL 
3 have evaluated the inhibitory effect of uft against renca cell-induced angiogenesis by a dorsal air sac assay . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL marked angiogenesis is induced by implantation of a chamber containing renca cells 
17 NULL NULL NULL NULL NULL NULL NULL marked angiogenesis is induced by implantation of a chamber containing renca cells into mice 
19 NULL NULL NULL NULL NULL marked angiogenesis is induced by implantation of a chamber containing renca cells into mice . NULL 
0 NULL NULL NULL NULL NULL in this model , uft showed a strong angiogenesis-inhibitory effect , whereas 5-fluorouracil ( 5-fu ) 
3 NULL NULL in this model , uft showed a strong angiogenesis effect , whereas 5-fluorouracil ( 5-fu ) and doxifluridine were 
3 NULL NULL in this model , uft showed a strong inhibitory effect , whereas 5-fluorouracil ( 5-fu ) and doxifluridine were 
18 NULL in this model , uft showed a strong angiogenesis-inhibitory effect , whereas 5-fluorouracil ( 5-fu ) and doxifluridine were less 
18 , whereas 5-fluorouracil ( 5-fu ) and doxifluridine were less effective . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL additional experiments revealed ft to be effective component of uft ; uracil remained ineffective in the inhibition 
16 ft to be effective component of uft ; uracil remained ineffective in the inhibition of angiogenesis . NULL NULL NULL NULL 
18 effective component of uft ; uracil remained ineffective in the inhibition of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 of uft ; uracil remained ineffective in the inhibition of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 gamma-butyrolactone , the metabolites of ft , possess a potent angiogenesis inhibitory effect that is amplified when the compounds are administered 
18 , the metabolites of ft , possess a potent angiogenesis inhibitory effect that is amplified when the compounds are administered by 
18 the metabolites of ft , possess a potent angiogenesis inhibitory effect that is amplified when the compounds are administered by a 
17 ft , possess a potent angiogenesis inhibitory effect that is amplified when the compounds are administered by a continuous infusion . 
19 angiogenesis inhibitory effect that is amplified when the compounds are administered by a continuous infusion . NULL NULL NULL NULL NULL 
0 is amplified when the compounds are administered by a continuous infusion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL this may reflect a transition in blood concentration of each metabolite resulting from 
0 NULL NULL NULL NULL NULL NULL this may reflect a transition in blood concentration of each metabolite resulting from the administration 
0 may reflect a transition in blood concentration of each metabolite resulting from the administration of uft . NULL NULL NULL NULL 
19 transition in blood concentration of each metabolite resulting from the administration of uft . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL similar results were also obtained with respect to 5-fu . NULL NULL 
0 NULL NULL NULL NULL NULL NULL similar results were also obtained with respect to 5-fu . NULL NULL NULL NULL NULL 
3 NULL NULL it was suggested that uft has a stronger angiogenesis effect than did other fluorinated pyrimidines , partly due to 
3 NULL NULL it was suggested that uft has a stronger inhibitory effect than did other fluorinated pyrimidines , partly due to 
18 NULL it was suggested that uft has a stronger angiogenesis-inhibitory effect than did other fluorinated pyrimidines , partly due to its 
0 did other fluorinated pyrimidines , partly due to its pharmacokinetic properties characterized by maintaining of higher and long-lasting blood levels of 
0 pyrimidines , partly due to its pharmacokinetic properties characterized by maintaining of higher and long-lasting blood levels of 5-fu and partly 
0 pharmacokinetic properties characterized by maintaining of higher and long-lasting blood levels of 5-fu and partly due the inhibitory effects derived from 
0 and long-lasting blood levels of 5-fu and partly due the inhibitory effects derived from gamma-hydroxybutyric acid and gamma-butyrolactone , uft-specific metabolites 
0 long-lasting blood levels of 5-fu and partly due the inhibitory effects derived from gamma-hydroxybutyric acid and gamma-butyrolactone , uft-specific metabolites . 
0 blood levels of 5-fu and partly due the inhibitory effects derived from gamma-hydroxybutyric acid and gamma-butyrolactone , uft-specific metabolites . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL external beam radiotherapy for subretinal neovascularization in age-related macular degeneration : is this 
3 NULL NULL NULL NULL NULL external beam radiotherapy for subretinal neovascularization in age-related macular degeneration : is this treatment efficient ? 
6 NULL external beam radiotherapy for subretinal neovascularization in age-related macular degeneration : is this treatment efficient ? NULL NULL NULL NULL 
0 for subretinal neovascularization in age-related macular degeneration : is this treatment efficient ? NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL purpose : control of the natural course of subretinal neovascularization ( srnv ) 
3 NULL purpose : control of the natural course of subretinal neovascularization ( srnv ) in age-related macular degeneration ( amd ) 
6 course of subretinal neovascularization ( srnv ) in age-related macular degeneration ( amd ) is difficult . NULL NULL NULL NULL 
0 NULL NULL NULL this prospective study aimed to determine the efficacy and individual benefit of external beam radiotherapy ( ebrt ) 
0 to determine the efficacy and individual benefit of external beam radiotherapy ( ebrt ) . NULL NULL NULL NULL NULL NULL 
3 materials : the prospective trial included 287 patients with subfoveal neovascularization due to amd which was verified by fluorescein angiography . 
0 subfoveal neovascularization due to amd which was verified by fluorescein angiography . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL patients have been treated between january 1996 and october 1997 . NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL all patients received a total dose of 16 gy in 2-gy daily fractions 
0 2-gy daily fractions with 5-6 mev photons based on computerized treatment planning in individual head mask fixation . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : all patients completed therapy and tolerability was good . 
19 NULL NULL NULL NULL NULL results : all patients completed therapy and tolerability was good . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL first clinical control with second angiography was performed 6 weeks after irradiation 
0 NULL NULL NULL NULL NULL NULL NULL NULL first clinical control with second angiography was performed 6 weeks after irradiation , 
0 NULL NULL NULL NULL NULL first clinical control with second angiography was performed 6 weeks after irradiation , then in 3-month 
18 NULL NULL NULL NULL NULL NULL eighteen patients with srnv refusing radiotherapy served as a control group and were matched with 
19 NULL NULL NULL NULL NULL eighteen patients with srnv refusing radiotherapy served as a control group and were matched with 18 
0 NULL eighteen patients with srnv refusing radiotherapy served as a control group and were matched with 18 irradiated patients . NULL 
19 served as a control group and were matched with 18 irradiated patients . NULL NULL NULL NULL NULL NULL NULL NULL 
19 median visual acuity ( va ) was 20/160 for the irradiated and 20/400 for the untreated patients . NULL NULL NULL 
19 ) was 20/160 for the irradiated and 20/400 for the untreated patients . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL one year after radiotherapy final median va was 20/400 in both groups . NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusion : these results suggest that 16 gy of conventionally fractionated external beam irradiation 
0 of conventionally fractionated external beam irradiation slows down the visual loss in exudative amd for only a few months . NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL increased serum levels of vascular endothelial growth factor in patients with 
0 NULL NULL NULL NULL NULL NULL NULL NULL increased serum levels of vascular endothelial growth factor in patients with renal cell 
0 NULL NULL NULL NULL increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma . NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL neovascularization , an essential event for the growth of solid tumors 
17 NULL NULL NULL NULL NULL NULL NULL neovascularization , an essential event for the growth of solid tumors , is regulated 
4 NULL NULL NULL neovascularization , an essential event for the growth of solid tumors , is regulated by a number of 
16 essential event for the growth of solid tumors , is regulated by a number of angiogenic factors . NULL NULL NULL 
3 of solid tumors , is regulated by a number of angiogenic factors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL one such factor , vascular endothelial growth factor ( vegf ) , is considered to exert a 
3 ( vegf ) , is considered to exert a potent angiogenic activity , as indicated by immunohistochemical and molecular evidence . 
0 vegf ) , is considered to exert a potent angiogenic activity , as indicated by immunohistochemical and molecular evidence . NULL 
0 to exert a potent angiogenic activity , as indicated by immunohistochemical and molecular evidence . NULL NULL NULL NULL NULL NULL 
0 in 40 rcc patients and 40 patients without cancer ( controls ) using a sandwich enzyme-linked immunoassay . NULL NULL NULL 
0 40 patients without cancer ( controls ) using a sandwich linked immunoassay . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in 20 rcc patients , serum samples were obtained separately from the bilateral renal veins . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL there were significant differences in s-vegf between the rcc patients and the controls 
0 significant differences in s-vegf between the rcc patients and the controls ( 207.3+/-32.9 vs. 71.5+/-9.1 pg/ml , mean+/-se ) ( p 
0 less than 0.01 ) and among the various parameters of tumor status such as tumor extent ( p less than 0.001 
0 and among the various parameters of tumor status such as tumor extent ( p less than 0.001 ) and existence of 
0 as tumor extent ( p less than 0.001 ) and existence of metastasis ( p less than 0.001 ) . NULL 
0 extent ( p less than 0.001 ) and existence of metastasis ( p less than 0.001 ) . NULL NULL NULL 
0 NULL NULL NULL NULL NULL s-vegf significantly correlated with the tumor volume obtained by a three-dimensional measurement ( r=0.802 , p 
0 NULL NULL NULL s-vegf significantly correlated with the tumor volume obtained by a three-dimensional measurement ( r=0.802 , p less than 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results indicate that tumor tissue of rcc liberates vegf into the 
0 NULL NULL NULL NULL NULL NULL the results indicate that tumor tissue of rcc liberates vegf into the systemic blood flow 
14 NULL NULL the results indicate that tumor tissue of rcc liberates vegf into the systemic blood flow and that s-vegf is 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL induced vascular endothelial growth factor expression in retina . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL insulin-induced vascular endothelial growth factor expression in retina . NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL insulin-induced vascular endothelial growth factor expression in retina . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL purpose : clinical studies have demonstrated that intensive insulin therapy causes a transient 
19 NULL purpose : clinical studies have demonstrated that intensive insulin therapy causes a transient worsening of retinopathy . NULL NULL NULL 
0 NULL NULL NULL NULL NULL the mechanisms underlying the initial induced deterioration of retinal status in patients with diabetes remain unknown 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) is known to be operative in 
0 ( vegf ) is known to be operative in the pathogenesis of diabetic retinopathy . NULL NULL NULL NULL NULL NULL 
16 NULL NULL the current study was conducted to characterize the effect of insulin on retinal vegf gene expression in vitro and 
9 to characterize the effect of insulin on retinal vegf gene expression in vitro and in vivo . NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL methods : the effect of insulin on vegf expression in vivo was examined by 
9 NULL NULL methods : the effect of insulin on vegf expression in vivo was examined by in situ hybridization studies of 
16 NULL NULL NULL to examine the mechanisms by which insulin regulates vegf expression , human retinal pigment epithelial ( rpe ) 
9 NULL to examine the mechanisms by which insulin regulates vegf expression , human retinal pigment epithelial ( rpe ) cells were 
19 , human retinal pigment epithelial ( rpe ) cells were exposed to insulin , and vegf mrna levels were quantified with 
0 rpe ) cells were exposed to insulin , and vegf mrna levels were quantified with rnase protection assays ( rpas ) 
0 ) cells were exposed to insulin , and vegf mrna levels were quantified with rnase protection assays ( rpas ) . 
0 insulin , and vegf mrna levels were quantified with rnase protection assays ( rpas ) . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL conditioned media from treated rpe cells were assayed for vegf protein and capillary endothelial 
19 NULL NULL NULL conditioned media from insulin-treated rpe cells were assayed for vegf protein and capillary endothelial cell proliferation . NULL 
0 conditioned media from insulin-treated rpe cells were assayed for vegf protein and capillary endothelial cell proliferation . NULL NULL NULL NULL 
1 cells were assayed for vegf protein and capillary endothelial cell proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL the capacity of insulin to stimulate the vegf promoter linked to a luciferase reporter gene was 
19 NULL the capacity of insulin to stimulate the vegf promoter linked to a luciferase reporter gene was characterized in transient transfection 
0 linked to a luciferase reporter gene was characterized in transient transfection assays . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : insulin increased vegf mrna levels in the ganglion , 
17 NULL NULL NULL NULL NULL NULL NULL results : insulin increased vegf mrna levels in the ganglion , inner nuclear , 
0 NULL NULL NULL NULL NULL results : insulin increased vegf mrna levels in the ganglion , inner nuclear , and rpe 
0 NULL NULL NULL NULL results : insulin increased vegf mrna levels in the ganglion , inner nuclear , and rpe cell 
17 NULL NULL NULL NULL NULL NULL in vitro , insulin increased vegf mrna levels in human rpe cells and enhanced vegf 
0 NULL NULL NULL NULL in vitro , insulin increased vegf mrna levels in human rpe cells and enhanced vegf promoter activity 
0 NULL NULL NULL in vitro , insulin increased vegf mrna levels in human rpe cells and enhanced vegf promoter activity without 
17 insulin increased vegf mrna levels in human rpe cells and enhanced vegf promoter activity without affecting transcript stability . NULL NULL 
0 mrna levels in human rpe cells and enhanced vegf promoter activity without affecting transcript stability . NULL NULL NULL NULL NULL 
0 in human rpe cells and enhanced vegf promoter activity without affecting transcript stability . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL insulin treatment also increased vegf protein levels in conditioned rpe cell media 
17 NULL NULL NULL NULL NULL NULL NULL insulin treatment also increased vegf protein levels in conditioned rpe cell media in a 
0 NULL NULL NULL NULL NULL insulin treatment also increased vegf protein levels in conditioned rpe cell media in a dose-dependent manner 
0 NULL NULL NULL NULL insulin treatment also increased vegf protein levels in conditioned rpe cell media in a dose-dependent manner with 
0 vegf protein levels in conditioned rpe cell media in a dependent manner with a median effective concentration of 5 nm . 
0 rpe cell media in a dose-dependent manner with a median effective concentration of 5 nm . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL the insulin-conditioned rpe cell media stimulated capillary endothelial cell proliferation , an effect that was completely 
1 NULL the insulin-conditioned rpe cell media stimulated capillary endothelial cell proliferation , an effect that was completely blocked by anti-vegf neutralizing 
0 rpe cell media stimulated capillary endothelial cell proliferation , an effect that was completely blocked by anti-vegf neutralizing antibody . NULL 
18 capillary endothelial cell proliferation , an effect that was completely blocked by anti-vegf neutralizing antibody . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL conclusions : insulin increases vegf mrna and secreted protein levels in rpe cells through 
0 NULL NULL NULL NULL NULL conclusions : insulin increases vegf mrna and secreted protein levels in rpe cells through enhanced transcription 
0 NULL NULL NULL conclusions : insulin increases vegf mrna and secreted protein levels in rpe cells through enhanced transcription of the 
0 NULL NULL conclusions : insulin increases vegf mrna and secreted protein levels in rpe cells through enhanced transcription of the vegf 
0 NULL conclusions : insulin increases vegf mrna and secreted protein levels in rpe cells through enhanced transcription of the vegf gene 
17 vegf mrna and secreted protein levels in rpe cells through enhanced transcription of the vegf gene . NULL NULL NULL NULL 
10 mrna and secreted protein levels in rpe cells through enhanced transcription of the vegf gene . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL intensive insulin therapy may cause a transient worsening of retinopathy in patients with 
17 a transient worsening of retinopathy in patients with diabetes through increased retinal vegf gene expression . NULL NULL NULL NULL NULL 
9 retinopathy in patients with diabetes through increased retinal vegf gene expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic agent linomide inhibits the growth rate of von hippel-lindau paraganglioma 
18 NULL NULL NULL NULL NULL NULL the antiangiogenic agent linomide inhibits the growth rate of von hippel-lindau paraganglioma xenografts to mice 
4 NULL NULL NULL NULL the antiangiogenic agent linomide inhibits the growth rate of von hippel-lindau paraganglioma xenografts to mice . NULL 
0 NULL the aim of this study was to ascertain the potential usefulness of the antiangiogenic compound linomide for treatment of von 
3 this study was to ascertain the potential usefulness of the angiogenic compound linomide for treatment of von hippel-lindau ( vhl ) 
19 ascertain the potential usefulness of the antiangiogenic compound linomide for treatment of von hippel-lindau ( vhl ) -related tumors . NULL 
19 NULL NULL NULL NULL NULL NULL NULL paraganglioma tissue fragments obtained at surgery from a vhl type 2a patient were transplanted 
0 NULL NULL NULL NULL NULL paraganglioma tissue fragments obtained at surgery from a vhl type 2a patient were transplanted s.c . 
19 obtained at surgery from a vhl type 2a patient were transplanted s.c . NULL NULL NULL NULL NULL NULL NULL NULL 
0 ) mice : ( a ) 2-3-mm fragments for `` prevention '' experiments ; and ( b ) 2-3-mm fragments allowed 
0 experiments ; and ( b ) 2-3-mm fragments allowed to grow to 1 cm for `` intervention '' studies . NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL both groups received either 0.5 mg/ml linomide in drinking water or acidified water 
0 in drinking water or acidified water and were followed until tumor diameter reached 3 cm or for 4 weeks . NULL 
0 NULL NULL NULL NULL NULL NULL NULL in both the prevention and intervention experiments , a significant diminution of tumor size 
0 NULL in both the prevention and intervention experiments , a significant diminution of tumor size and weight was observed in the 
18 in both the prevention and intervention experiments , a significant diminution of tumor size and weight was observed in the drug-treated 
0 the prevention and intervention experiments , a significant diminution of tumor size and weight was observed in the drug-treated animals . 
0 , a significant diminution of tumor size and weight was observed in the drug-treated animals . NULL NULL NULL NULL NULL 
0 diminution of tumor size and weight was observed in the treated animals . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL in vivo nuclear magnetic resonance analysis of tumor blood flow in linomide-treated animals showed localization of blood vessels 
19 vivo nuclear magnetic resonance analysis of tumor blood flow in treated animals showed localization of blood vessels almost exclusively to the 
0 magnetic resonance analysis of tumor blood flow in linomide-treated animals showed localization of blood vessels almost exclusively to the periphery of 
14 resonance analysis of tumor blood flow in linomide-treated animals showed localization of blood vessels almost exclusively to the periphery of the 
0 blood vessels almost exclusively to the periphery of the poorly vascularized tumors with a significant reduction of both vascular functionality and 
0 to the periphery of the poorly vascularized tumors with a significant reduction of both vascular functionality and vasodilation . NULL NULL 
0 the periphery of the poorly vascularized tumors with a significant reduction of both vascular functionality and vasodilation . NULL NULL NULL 
19 NULL NULL NULL NULL NULL histological examination of tumors from treated animals revealed marked avascularity . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treated animals also displayed a 2.4-fold reduction of tumor vascular endothelial 
18 NULL NULL NULL NULL treated animals also displayed a 2.4-fold reduction of tumor vascular endothelial growth factor mrna levels . NULL 
0 NULL NULL treated animals also displayed a 2.4-fold reduction of tumor vascular endothelial growth factor mrna levels . NULL NULL NULL 
0 animals also displayed a 2.4-fold reduction of tumor vascular endothelial growth factor mrna levels . NULL NULL NULL NULL NULL NULL 
0 displayed a 2.4-fold reduction of tumor vascular endothelial growth factor mrna levels . NULL NULL NULL NULL NULL NULL NULL NULL 
0 a 2.4-fold reduction of tumor vascular endothelial growth factor mrna levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 together , our data indicate that in vhl disease , therapy directed at inhibition of constitutively expressed vegf induction of angiogenesis 
18 data indicate that in vhl disease , therapy directed at inhibition of constitutively expressed vegf induction of angiogenesis by vhl tumors 
9 in vhl disease , therapy directed at inhibition of constitutively expressed vegf induction of angiogenesis by vhl tumors may constitute an 
17 disease , therapy directed at inhibition of constitutively expressed vegf induction of angiogenesis by vhl tumors may constitute an effective medical 
3 therapy directed at inhibition of constitutively expressed vegf induction of angiogenesis by vhl tumors may constitute an effective medical treatment . 
0 vegf induction of angiogenesis by vhl tumors may constitute an effective medical treatment . NULL NULL NULL NULL NULL NULL NULL 
0 of angiogenesis by vhl tumors may constitute an effective medical treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human 
17 NULL NULL NULL NULL NULL NULL NULL vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed 
9 NULL NULL NULL NULL NULL NULL vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to 
0 enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis . NULL NULL NULL NULL NULL 
0 NULL NULL NULL long-term peritoneal dialysis ( pd ) is associated with alterations in peritoneal permeability and loss of ultrafiltration . 
0 NULL long-term peritoneal dialysis ( pd ) is associated with alterations in peritoneal permeability and loss of ultrafiltration . NULL NULL 
0 pd ) is associated with alterations in peritoneal permeability and loss of ultrafiltration . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these changes originate from increased peritoneal surface area , but the morphologic 
0 NULL NULL NULL NULL NULL NULL NULL NULL these changes originate from increased peritoneal surface area , but the morphologic and 
17 NULL NULL NULL NULL NULL NULL these changes originate from increased peritoneal surface area , but the morphologic and molecular mechanisms 
0 peritoneal surface area , but the morphologic and molecular mechanisms involved remain unknown . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the hypothesis that modifications of activity and/or expression of nitric oxide synthase ( nos ) isozymes 
9 NULL NULL NULL the hypothesis that modifications of activity and/or expression of nitric oxide synthase ( nos ) isozymes might play 
16 expression of nitric oxide synthase ( nos ) isozymes might play a role in these modifications , via enhanced local production 
16 nitric oxide synthase ( nos ) isozymes might play a role in these modifications , via enhanced local production of nitric 
17 isozymes might play a role in these modifications , via enhanced local production of nitric oxide , was tested in this 
8 play a role in these modifications , via enhanced local production of nitric oxide , was tested in this study . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL nos activities were measured by the l-citrulline assay in peritoneal biopsies from 
0 measured by the l-citrulline assay in peritoneal biopsies from seven control subjects , eight uremic patients immediately before the onset of 
0 NULL NULL NULL NULL NULL NULL NULL NULL peritoneal nos activity is increased fivefold in long-term pd patients compared with control 
17 NULL NULL NULL NULL NULL NULL peritoneal nos activity is increased fivefold in long-term pd patients compared with control subjects . 
0 activity is increased fivefold in long-term pd patients compared with control subjects . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL in uremic patients , nos activity is positively correlated with the duration of pd . NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL increased nos activity is mediated solely by ca ( 2+ ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL increased nos activity is mediated solely by ca ( 2+ ) -dependent nos 
16 NULL NULL NULL NULL NULL NULL increased nos activity is mediated solely by ca ( 2+ ) -dependent nos and , 
0 nos activity is mediated solely by ca ( 2+ ) dependent nos and , as shown by immunoblotting , an upregulation 
17 -dependent nos and , as shown by immunoblotting , an upregulation of endothelial nos . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL the biologic relevance of increased nos in long-term pd was demonstrated by enhanced nitrotyrosine immunoreactivity 
17 relevance of increased nos in long-term pd was demonstrated by enhanced nitrotyrosine immunoreactivity and a significant increase in vascular density and 
0 long-term pd was demonstrated by enhanced nitrotyrosine immunoreactivity and a significant increase in vascular density and endothelial area in the peritoneum 
17 pd was demonstrated by enhanced nitrotyrosine immunoreactivity and a significant increase in vascular density and endothelial area in the peritoneum . 
17 NULL NULL NULL NULL immunoblotting and immunostaining studies demonstrated an upregulation of vascular endothelial growth factor ( vegf ) mostly along 
0 immunoblotting and immunostaining studies demonstrated an upregulation of vascular endothelial growth factor ( vegf ) mostly along the endothelium lining peritoneal 
14 NULL NULL NULL NULL NULL in the latter , vegf colocalized with the advanced glycation end product pentosidine deposits . NULL 
3 NULL NULL NULL NULL these data provide a morphologic ( angiogenesis and increased endothelial area ) and molecular ( enhanced nos 
17 NULL NULL these data provide a morphologic ( angiogenesis and increased endothelial area ) and molecular ( enhanced nos activity and 
17 ( angiogenesis and increased endothelial area ) and molecular ( enhanced nos activity and endothelial nos upregulation ) basis for explaining 
0 and increased endothelial area ) and molecular ( enhanced nos activity and endothelial nos upregulation ) basis for explaining the permeability 
17 ) and molecular ( enhanced nos activity and endothelial nos upregulation ) basis for explaining the permeability changes observed in long-term 
0 and endothelial nos upregulation ) basis for explaining the permeability changes observed in long-term pd . NULL NULL NULL NULL NULL 
0 endothelial nos upregulation ) basis for explaining the permeability changes observed in long-term pd . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL they also support the implication of local advanced glycation end product deposits and 
0 NULL NULL NULL NULL NULL NULL they also support the implication of local advanced glycation end product deposits and liberation of 
14 the implication of local advanced glycation end product deposits and liberation of vegf in that process . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL active hair growth ( anagen ) is associated with angiogenesis . 
4 NULL NULL NULL NULL NULL NULL NULL NULL active hair growth ( anagen ) is associated with angiogenesis . NULL NULL 
16 NULL NULL NULL active hair growth ( anagen ) is associated with angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 NULL active hair growth ( anagen ) is associated with angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL after the completion of skin development , angiogenesis , i.e. , the growth of new capillaries 
3 NULL NULL NULL after the completion of skin development , angiogenesis , i.e. , the growth of new capillaries from pre-existing 
4 completion of skin development , angiogenesis , i.e. , the growth of new capillaries from pre-existing blood vessels , is held 
2 has long been noted , however , that hair follicle cycling is associated with prominent changes in skin perfusion , that 
16 been noted , however , that hair follicle cycling is associated with prominent changes in skin perfusion , that the epithelial 
0 however , that hair follicle cycling is associated with prominent changes in skin perfusion , that the epithelial hair bulbs of 
0 hair follicle cycling is associated with prominent changes in skin perfusion , that the epithelial hair bulbs of anagen follicles display 
3 , that the epithelial hair bulbs of anagen follicles display angiogenic properties , and that the follicular dermal papilla can produce 
0 that the epithelial hair bulbs of anagen follicles display angiogenic properties , and that the follicular dermal papilla can produce angiogenic 
0 angiogenic properties , and that the follicular dermal papilla can produce angiogenic factors . NULL NULL NULL NULL NULL NULL NULL 
3 properties , and that the follicular dermal papilla can produce angiogenic factors . NULL NULL NULL NULL NULL NULL NULL NULL 
3 formal proof is as yet available for the concept that angiogenesis is a physiologic event that occurs all over the mature 
4 over the mature mammalian integument whenever hair follicles switch from resting ( telogen ) to active growth ( anagen ) . 
0 whenever hair follicles switch from resting ( telogen ) to active growth ( anagen ) . NULL NULL NULL NULL NULL 
4 hair follicles switch from resting ( telogen ) to active growth ( anagen ) . NULL NULL NULL NULL NULL NULL 
1 quantitative histomorphometry and double-immunohistologic detection techniques for the demarcation of proliferating endothelial cells , to show that synchronized hair follicle cycling 
2 proliferating endothelial cells , to show that synchronized hair follicle cycling in adolescent c57bl/6 mice is associated with substantial angiogenesis , 
16 that synchronized hair follicle cycling in adolescent c57bl/6 mice is associated with substantial angiogenesis , and that inhibiting angiogenesis in vivo 
3 follicle cycling in adolescent c57bl/6 mice is associated with substantial angiogenesis , and that inhibiting angiogenesis in vivo by the intraperitoneal 
18 c57bl/6 mice is associated with substantial angiogenesis , and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin 
3 mice is associated with substantial angiogenesis , and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative 
0 , and that inhibiting angiogenesis in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in 
0 in vivo by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice . NULL NULL 
0 by the intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice . NULL NULL NULL NULL 
0 intraperitoneal application of a fumagillin derivative retards experimentally induced anagen development in these mice . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL thus , angiogenesis is a physiologic event in normal postnatal murine skin , 
0 dictated by the hair follicle , and appears to be required for normal anagen development . NULL NULL NULL NULL NULL 
0 follicle , and appears to be required for normal anagen development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL associated angiogenesis offers an attractive model for identifying the physiologic controls 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of 
0 anagen-associated angiogenesis offers an attractive model for identifying the physiologic controls of cutaneous angiogenesis , and an interesting system for screening 
3 an attractive model for identifying the physiologic controls of cutaneous angiogenesis , and an interesting system for screening the effects of 
0 cutaneous angiogenesis , and an interesting system for screening the effects of potential antiangiogenic drugs in vivo . NULL NULL NULL 
0 , and an interesting system for screening the effects of potential antiangiogenic drugs in vivo . NULL NULL NULL NULL NULL 
3 and an interesting system for screening the effects of potential angiogenic drugs in vivo . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulating hormone modulates activation of nf-kappa b and ap-1 and secretion 
16 NULL NULL NULL NULL NULL NULL NULL NULL alpha-melanocyte-stimulating hormone modulates activation of nf-kappa b and ap-1 and secretion of interleukin-8 
17 NULL NULL NULL NULL NULL NULL NULL alpha-melanocyte-stimulating hormone modulates activation of nf-kappa b and ap-1 and secretion of interleukin-8 in 
14 alpha-melanocyte-stimulating hormone modulates activation of nf-kappa b and ap-1 and secretion of interleukin-8 in human dermal fibroblasts . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulating hormone ( alpha-msh ) has evolved as a mediator of 
16 NULL alpha-melanocyte-stimulating hormone ( alpha-msh ) has evolved as a mediator of diverse biological activities in an ever-growing number of non-melanocytic 
0 alpha-msh ) has evolved as a mediator of diverse biological activities in an ever-growing number of non-melanocytic cell types . NULL 
1 evolved as a mediator of diverse biological activities in an growing number of non-melanocytic cell types . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL one mechanism by which alpha-msh exerts its effects is modulation of ap-1 
0 NULL NULL NULL one mechanism by which alpha-msh exerts its effects is modulation of ap-1 and nf-kappa b . NULL NULL 
16 NULL one mechanism by which alpha-msh exerts its effects is modulation of ap-1 and nf-kappa b . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL these two transcription factors also play an important role in fibroblasts , in 
16 NULL NULL NULL NULL NULL these two transcription factors also play an important role in fibroblasts , in extracellular matrix composition 
16 NULL NULL NULL these two transcription factors also play an important role in fibroblasts , in extracellular matrix composition , and 
16 NULL NULL these two transcription factors also play an important role in fibroblasts , in extracellular matrix composition , and in 
0 also play an important role in fibroblasts , in extracellular matrix composition , and in cytokine expression . NULL NULL NULL 
0 fibroblasts , in extracellular matrix composition , and in cytokine expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL by use of electric mobility shift assays , we demonstrate that alpha-msh 
0 NULL NULL NULL NULL NULL NULL by use of electric mobility shift assays , we demonstrate that alpha-msh ( 10 ( 
17 ( -6 ) to 10 ( -14 ) m ) activates ap-1 in human dermal fibroblasts , whereas coincubation with interleukin-1 
19 m ) activates ap-1 in human dermal fibroblasts , whereas coincubation with interleukin-1 beta ( il-1 beta ) results in suppression 
0 , whereas coincubation with interleukin-1 beta ( il-1 beta ) results in suppression of its activation . NULL NULL NULL NULL 
18 coincubation with interleukin-1 beta ( il-1 beta ) results in suppression of its activation . NULL NULL NULL NULL NULL NULL 
0 beta ( il-1 beta ) results in suppression of its activation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL alpha-msh also induces activation of nf-kappa b but does not modulate dna binding 
17 NULL NULL NULL NULL NULL NULL NULL alpha-msh also induces activation of nf-kappa b but does not modulate dna binding on 
16 alpha-msh also induces activation of nf-kappa b but does not modulate dna binding on costimulation with il-1 beta . NULL NULL 
15 induces activation of nf-kappa b but does not modulate dna binding on costimulation with il-1 beta . NULL NULL NULL NULL 
17 of nf-kappa b but does not modulate dna binding on costimulation with il-1 beta . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL since ap-1 and nf-kappa b are key elements in controlling interleukin-8 ( il-8 ) transcription , human 
16 NULL since ap-1 and nf-kappa b are key elements in controlling interleukin-8 ( il-8 ) transcription , human fibroblasts were treated 
10 b are key elements in controlling interleukin-8 ( il-8 ) transcription , human fibroblasts were treated with alpha-msh and il-1 beta 
19 controlling interleukin-8 ( il-8 ) transcription , human fibroblasts were treated with alpha-msh and il-1 beta for 24 hours , and 
0 alpha-msh and il-1 beta for 24 hours , and cytokine levels in the supernatants were measured by elisa. alpha-msh alone had 
0 the supernatants were measured by elisa. alpha-msh alone had little effect , whereas coincubation with il-1 beta led to marked downregulation 
19 measured by elisa. alpha-msh alone had little effect , whereas coincubation with il-1 beta led to marked downregulation of il-8 secretion 
17 alone had little effect , whereas coincubation with il-1 beta led to marked downregulation of il-8 secretion ( at most 288 
18 effect , whereas coincubation with il-1 beta led to marked downregulation of il-8 secretion ( at most 288 +/- 152 ng/ml 
14 coincubation with il-1 beta led to marked downregulation of il-8 secretion ( at most 288 +/- 152 ng/ml ) when compared 
19 at most 288 +/- 152 ng/ml ) when compared to treatment with il-1 beta alone ( 919 +/- 157 ng/ml ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL our results indicate that alpha-msh exerts modulatory effects on the activation of 
16 NULL NULL NULL our results indicate that alpha-msh exerts modulatory effects on the activation of nf-kappa b and ap-1 , and 
17 our results indicate that alpha-msh exerts modulatory effects on the activation of nf-kappa b and ap-1 , and that it can 
0 of nf-kappa b and ap-1 , and that it can regulate chemokine secretion in human dermal fibroblasts . NULL NULL NULL 
0 b and ap-1 , and that it can regulate chemokine secretion in human dermal fibroblasts . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these effects of alpha-msh may have important regulatory functions in extracellular matrix 
16 NULL NULL NULL NULL these effects of alpha-msh may have important regulatory functions in extracellular matrix composition , wound healing , 
16 NULL NULL NULL these effects of alpha-msh may have important regulatory functions in extracellular matrix composition , wound healing , or 
16 NULL NULL these effects of alpha-msh may have important regulatory functions in extracellular matrix composition , wound healing , or angiogenesis 
0 effects of alpha-msh may have important regulatory functions in extracellular matrix composition , wound healing , or angiogenesis . NULL NULL 
3 functions in extracellular matrix composition , wound healing , or angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulated phosphoprotein is involved in stress-fiber and membrane ruffle formation in 
16 NULL NULL NULL NULL NULL NULL NULL vasodilator-stimulated phosphoprotein is involved in stress-fiber and membrane ruffle formation in endothelial cells . 
2 NULL vasodilator-stimulated phosphoprotein is involved in stress-fiber and membrane ruffle formation in endothelial cells . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulated phosphoprotein ( vasp ) is highly expressed in vascular endothelial 
9 NULL NULL NULL vasodilator-stimulated phosphoprotein ( vasp ) is highly expressed in vascular endothelial cells , where it has been implicated 
0 expressed in vascular endothelial cells , where it has been implicated in cellular reorganization during angiogenesis , as well as in 
0 endothelial cells , where it has been implicated in cellular reorganization during angiogenesis , as well as in endothelial retraction and 
3 , where it has been implicated in cellular reorganization during angiogenesis , as well as in endothelial retraction and changes in 
16 during angiogenesis , as well as in endothelial retraction and changes in vessel permeability . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL however , the cellular functions of vasp are not known . NULL NULL NULL NULL 
19 NULL NULL NULL NULL in this study , we have expressed wild-type and mutant forms of vasp in endothelial cells to 
0 vasp in endothelial cells to determine in what aspects of cytoskeletal behavior this protein participates . NULL NULL NULL NULL NULL 
0 cells to determine in what aspects of cytoskeletal behavior this protein participates . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of wild-type vasp induces marked membrane ruffling and formation of 
17 NULL NULL NULL NULL NULL NULL expression of wild-type vasp induces marked membrane ruffling and formation of prominent stress fibers in 
16 NULL NULL NULL expression of wild-type vasp induces marked membrane ruffling and formation of prominent stress fibers in bovine aortic endothelial 
2 NULL expression of wild-type vasp induces marked membrane ruffling and formation of prominent stress fibers in bovine aortic endothelial cells . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL deletion of the proline-rich domain of vasp abolishes its ability to 
18 NULL NULL NULL deletion of the proline-rich domain of vasp abolishes its ability to bind profilin but does not affect ruffling 
0 NULL deletion of the proline-rich domain of vasp abolishes its ability to bind profilin but does not affect ruffling or stress 
15 of the proline-rich domain of vasp abolishes its ability to bind profilin but does not affect ruffling or stress fiber formation 
16 vasp abolishes its ability to bind profilin but does not affect ruffling or stress fiber formation . NULL NULL NULL NULL 
0 abolishes its ability to bind profilin but does not affect ruffling or stress fiber formation . NULL NULL NULL NULL NULL 
2 bind profilin but does not affect ruffling or stress fiber formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 deletions reveal a sequence within the carboxy-terminal domain that is responsible for in vivo bundle formation . NULL NULL NULL NULL 
0 the carboxy-terminal domain that is responsible for in vivo bundle formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL ruffling occurs only on the expression of forms of vasp that 
9 NULL NULL NULL NULL NULL ruffling occurs only on the expression of forms of vasp that possess bundling activity and the 
0 on the expression of forms of vasp that possess bundling activity and the capacity to bind zyxin/vinculin-derived peptide . NULL NULL 
15 of vasp that possess bundling activity and the capacity to bind zyxin/vinculin-derived peptide . NULL NULL NULL NULL NULL NULL NULL 
0 vasp that possess bundling activity and the capacity to bind derived peptide . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the ability of distinct subdomains within vasp to bind adhesion proteins and 
15 NULL NULL the ability of distinct subdomains within vasp to bind adhesion proteins and induce f-actin bundling in vivo suggests that 
0 NULL the ability of distinct subdomains within vasp to bind adhesion proteins and induce f-actin bundling in vivo suggests that this 
17 of distinct subdomains within vasp to bind adhesion proteins and induce f-actin bundling in vivo suggests that this protein could function 
0 proteins and induce f-actin bundling in vivo suggests that this protein could function in the aggregation and tethering of actin filaments 
0 induce f-actin bundling in vivo suggests that this protein could function in the aggregation and tethering of actin filaments during the 
0 in vivo suggests that this protein could function in the aggregation and tethering of actin filaments during the formation of endothelial 
2 in the aggregation and tethering of actin filaments during the formation of endothelial cell-substrate and cell-cell contacts . NULL NULL NULL 
0 of actin filaments during the formation of endothelial cell-substrate and cell-cell contacts . NULL NULL NULL NULL NULL NULL NULL NULL 
0 actin filaments during the formation of endothelial cell-substrate and cell-cell contacts . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL these data provide a mechanism whereby vasp can influence endothelial migration and organization during capillary 
18 NULL NULL these data provide a mechanism whereby vasp can influence endothelial migration and organization during capillary formation and modulate vascular 
14 these data provide a mechanism whereby vasp can influence endothelial migration and organization during capillary formation and modulate vascular permeability via 
2 provide a mechanism whereby vasp can influence endothelial migration and organization during capillary formation and modulate vascular permeability via effects on 
2 whereby vasp can influence endothelial migration and organization during capillary formation and modulate vascular permeability via effects on endothelial cell contractility 
16 can influence endothelial migration and organization during capillary formation and modulate vascular permeability via effects on endothelial cell contractility . NULL 
16 and organization during capillary formation and modulate vascular permeability via effects on endothelial cell contractility . NULL NULL NULL NULL NULL 
14 types , the glycolipid-anchored urokinase receptor ( upar ) is colocalized pericellularly with components of the plasminogen activation system and endocytosis 
0 upar ) is colocalized pericellularly with components of the plasminogen activation system and endocytosis receptors . NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL upar is also coexpressed with caveolin and members of the integrin adhesion receptor superfamily 
0 is also coexpressed with caveolin and members of the integrin adhesion receptor superfamily . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the formation of functional units with these various proteins allows the upar 
0 functional units with these various proteins allows the upar to mediate the focused proteolysis required for cell migration and invasion and 
0 these various proteins allows the upar to mediate the focused proteolysis required for cell migration and invasion and to contribute both 
17 various proteins allows the upar to mediate the focused proteolysis required for cell migration and invasion and to contribute both directly 
14 the upar to mediate the focused proteolysis required for cell migration and invasion and to contribute both directly and indirectly to 
14 to mediate the focused proteolysis required for cell migration and invasion and to contribute both directly and indirectly to cell adhesive 
16 focused proteolysis required for cell migration and invasion and to contribute both directly and indirectly to cell adhesive processes in a 
15 invasion and to contribute both directly and indirectly to cell adhesive processes in a non-proteolytic fashion . NULL NULL NULL NULL 
15 and to contribute both directly and indirectly to cell adhesive processes in a non-proteolytic fashion . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL this dual activity , together with the initiation of signal transduction pathways by 
17 NULL NULL NULL this dual activity , together with the initiation of signal transduction pathways by upar , is believed to 
0 dual activity , together with the initiation of signal transduction pathways by upar , is believed to influence cellular behaviour in 
18 of signal transduction pathways by upar , is believed to influence cellular behaviour in angiogenesis , inflammation , wound repair and 
3 by upar , is believed to influence cellular behaviour in angiogenesis , inflammation , wound repair and tumor progression/metastasis and open 
0 to influence cellular behaviour in angiogenesis , inflammation , wound repair and tumor progression/metastasis and open up the way for upar-based 
0 cellular behaviour in angiogenesis , inflammation , wound repair and tumor progression/metastasis and open up the way for upar-based therapeutic approaches 
2 behaviour in angiogenesis , inflammation , wound repair and tumor progression and open up the way for upar-based therapeutic approaches . 
14 behaviour in angiogenesis , inflammation , wound repair and tumor metastasis and open up the way for upar-based therapeutic approaches . 
18 NULL NULL NULL NULL NULL NULL NULL nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis 
17 NULL NULL NULL NULL NULL NULL nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor 
18 NULL NULL nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions 
0 inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions . NULL NULL NULL NULL 
0 synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL nitric oxide ( no ) is an important molecule in regulating tumour blood flow and stimulating tumour angiogenesis 
0 nitric oxide ( no ) is an important molecule in regulating tumour blood flow and stimulating tumour angiogenesis . NULL NULL 
17 is an important molecule in regulating tumour blood flow and stimulating tumour angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 important molecule in regulating tumour blood flow and stimulating tumour angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of no synthase by l-name might induce an anti-tumour effect 
17 NULL NULL NULL inhibition of no synthase by l-name might induce an anti-tumour effect by limiting nutrients and oxygen to reach 
18 inhibition of no synthase by l-name might induce an anti-tumour effect by limiting nutrients and oxygen to reach tumour tissue or 
18 no synthase by l-name might induce an anti-tumour effect by limiting nutrients and oxygen to reach tumour tissue or affecting vascular 
14 induce an anti-tumour effect by limiting nutrients and oxygen to reach tumour tissue or affecting vascular growth . NULL NULL NULL 
16 by limiting nutrients and oxygen to reach tumour tissue or affecting vascular growth . NULL NULL NULL NULL NULL NULL NULL 
4 nutrients and oxygen to reach tumour tissue or affecting vascular growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL the anti-tumour effect of l-name after systemic administration was studied in a renal 
19 NULL NULL NULL the anti-tumour effect of l-name after systemic administration was studied in a renal subcapsular cc531 adenocarcinoma model in 
19 NULL NULL NULL NULL NULL NULL NULL moreover , regional administration of l-name , in combination with tnf and melphalan , 
0 combination with tnf and melphalan , was studied in an isolated limb perfusion ( ilp ) model using bn175 soft-tissue sarcomas 
0 tnf and melphalan , was studied in an isolated limb perfusion ( ilp ) model using bn175 soft-tissue sarcomas . NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL systemic treatment with l-name inhibited growth of adenocarcinoma significantly but was accompanied 
18 NULL NULL NULL NULL NULL NULL systemic treatment with l-name inhibited growth of adenocarcinoma significantly but was accompanied by impaired renal 
4 NULL NULL NULL NULL NULL systemic treatment with l-name inhibited growth of adenocarcinoma significantly but was accompanied by impaired renal function 
18 l-name inhibited growth of adenocarcinoma significantly but was accompanied by impaired renal function . NULL NULL NULL NULL NULL NULL NULL 
0 growth of adenocarcinoma significantly but was accompanied by impaired renal function . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL in ilp , reduced tumour growth was observed when l-name was used alone . 
4 NULL NULL NULL NULL NULL in ilp , reduced tumour growth was observed when l-name was used alone . NULL NULL 
0 NULL NULL NULL in ilp , reduced tumour growth was observed when l-name was used alone . NULL NULL NULL NULL 
0 ilp , reduced tumour growth was observed when l-name was used alone . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in combination with tnf or melphalan , l-name increased response rates significantly compared to perfusions without l-name ( 0-64 
0 NULL in combination with tnf or melphalan , l-name increased response rates significantly compared to perfusions without l-name ( 0-64 % 
18 NULL NULL NULL NULL NULL NULL NULL an additional anti-tumour effect was demonstrated when l-name was added to the synergistic combination 
19 NULL an additional anti-tumour effect was demonstrated when l-name was added to the synergistic combination of melphalan and tnf ( responses 
0 to the synergistic combination of melphalan and tnf ( responses increased from 70 to 100 % ) . NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of no synthase reduces tumour growth both after systemic and 
18 NULL NULL NULL NULL NULL NULL inhibition of no synthase reduces tumour growth both after systemic and regional ( ilp ) 
4 NULL NULL NULL NULL inhibition of no synthase reduces tumour growth both after systemic and regional ( ilp ) treatment . 
0 tumour growth both after systemic and regional ( ilp ) treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL a synergistic anti-tumour effect of l-name is observed in combination with melphalan and/or tnf 
0 NULL NULL NULL a synergistic anti-tumour effect of l-name is observed in combination with melphalan and/or tnf using ilp . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate a possible role of l-name for the treatment of 
16 NULL NULL NULL NULL NULL these results indicate a possible role of l-name for the treatment of solid tumours in a 
19 these results indicate a possible role of l-name for the treatment of solid tumours in a systemic or regional setting . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL rna damage and inhibition of neoplastic endothelial cell growth : effects of 
18 NULL NULL NULL NULL NULL NULL NULL rna damage and inhibition of neoplastic endothelial cell growth : effects of human and 
1 NULL NULL rna damage and inhibition of neoplastic endothelial cell growth : effects of human and amphibian ribonucleases . NULL NULL 
0 rna damage and inhibition of neoplastic endothelial cell growth : effects of human and amphibian ribonucleases . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis defines the many steps involved in the growth and migration 
0 NULL NULL NULL NULL NULL angiogenesis defines the many steps involved in the growth and migration of endothelial cell-derived blood vessels 
4 NULL NULL angiogenesis defines the many steps involved in the growth and migration of endothelial cell-derived blood vessels . NULL NULL 
14 angiogenesis defines the many steps involved in the growth and migration of endothelial cell-derived blood vessels . NULL NULL NULL NULL 
2 many steps involved in the growth and migration of endothelial derived blood vessels . NULL NULL NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL this process is necessary for the growth and metastasis of tumors , and considerable effort is being 
14 NULL NULL this process is necessary for the growth and metastasis of tumors , and considerable effort is being expended to 
0 and considerable effort is being expended to find inhibitors of tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 considerable effort is being expended to find inhibitors of tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL this usually involves screening of potential anti-angiogenic compounds on endothelial cells . NULL 
0 NULL NULL NULL NULL NULL this usually involves screening of potential anti-angiogenic compounds on endothelial cells . NULL NULL NULL NULL 
3 NULL NULL NULL NULL this usually involves screening of potential angiogenic compounds on endothelial cells . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL to this end , two candidate angiogenic rna-damaging agents , onconase and ( -4 ) rhedn , 
16 and ( -4 ) rhedn , were screened for their effects on endothelial cell proliferation using three distinct types of endothelial 
1 rhedn , were screened for their effects on endothelial cell proliferation using three distinct types of endothelial cells in culture : 
0 cell proliferation using three distinct types of endothelial cells in culture : hpv-16 e6/e7-immortalized human umbilical vein endothelial cells ( huvecs 
19 three distinct types of endothelial cells in culture : hpv-16 immortalized human umbilical vein endothelial cells ( huvecs ) , a 
19 human umbilical vein endothelial cells ( huvecs ) , a transformed hpv-16 e6/e7 huvec ( rhim et al. , carcinogenesis 4 
0 a kras-transformed hpv-16 e6/e7 huvec ( rhim et al. , carcinogenesis 4 , 673-681 , 1998 ) , and primary huvecs 
18 NULL NULL NULL NULL NULL NULL NULL NULL onconase similarly inhibited proliferation in all three cell lines ( ic ( 50 
1 NULL NULL NULL NULL NULL NULL NULL onconase similarly inhibited proliferation in all three cell lines ( ic ( 50 ) 
17 0.3-1.0 microm ) while ( -4 ) rhedn was more effective on immortalized huvec cell lines ( ic ( 50 ) 
19 ) while ( -4 ) rhedn was more effective on immortalized huvec cell lines ( ic ( 50 ) = 0.02-0.06 
0 implies that more than one endothelial cell type must be used in proliferation assays to screen for novel anti-angiogenic compounds . 
1 more than one endothelial cell type must be used in proliferation assays to screen for novel anti-angiogenic compounds . NULL NULL 
3 must be used in proliferation assays to screen for novel angiogenic compounds . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL il-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell 
0 NULL NULL NULL NULL NULL il-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk . NULL NULL 
3 NULL NULL NULL il-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk . NULL NULL NULL NULL 
0 NULL NULL il-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL in vivo dependent tumor inhibition rests on the ability of il-12 to activate 
0 NULL NULL NULL NULL NULL NULL NULL in vivo il-12-dependent tumor inhibition rests on the ability of il-12 to activate a 
18 NULL NULL NULL NULL NULL NULL in vivo il-12-dependent tumor inhibition rests on the ability of il-12 to activate a cd8-mediated 
0 NULL NULL in vivo il-12-dependent tumor inhibition rests on the ability of il-12 to activate a cd8-mediated cytotoxicity , inhibit angiogenesis 
0 il-12-dependent tumor inhibition rests on the ability of il-12 to activate a cd8-mediated cytotoxicity , inhibit angiogenesis , and cause vascular 
0 inhibition rests on the ability of il-12 to activate a mediated cytotoxicity , inhibit angiogenesis , and cause vascular injury . 
18 the ability of il-12 to activate a cd8-mediated cytotoxicity , inhibit angiogenesis , and cause vascular injury . NULL NULL NULL 
3 ability of il-12 to activate a cd8-mediated cytotoxicity , inhibit angiogenesis , and cause vascular injury . NULL NULL NULL NULL 
0 NULL NULL although in vivo studies have shown that such inhibition stems from complex interactions of immune cells and the production 
0 vivo studies have shown that such inhibition stems from complex interactions of immune cells and the production of ifn-gamma and other 
9 inhibition stems from complex interactions of immune cells and the production of ifn-gamma and other downstream angiostatic chemokines , the mechanisms 
0 of immune cells and the production of ifn-gamma and other downstream angiostatic chemokines , the mechanisms involved are still poorly defined 
0 of ifn-gamma and other downstream angiostatic chemokines , the mechanisms involved are still poorly defined . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL here we show that il-12 activates an anti-angiogenic program in con a-activated mouse spleen cells ( 
3 NULL NULL NULL here we show that il-12 activates an angiogenic program in con a-activated mouse spleen cells ( activated spc 
18 NULL NULL here we show that il-12 activates an anti-angiogenic program in con a-activated mouse spleen cells ( activated spc ) 
17 we show that il-12 activates an anti-angiogenic program in con activated mouse spleen cells ( activated spc ) or human pbmc 
17 an anti-angiogenic program in con a-activated mouse spleen cells ( activated spc ) or human pbmc ( activated pbmc ) . 
17 spleen cells ( activated spc ) or human pbmc ( activated pbmc ) . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the soluble factors they release in its presence arrest the cycle of endothelial cells ( 
0 NULL NULL NULL the soluble factors they release in its presence arrest the cycle of endothelial cells ( ec ) , 
18 NULL NULL the soluble factors they release in its presence arrest the cycle of endothelial cells ( ec ) , inhibit 
18 arrest the cycle of endothelial cells ( ec ) , inhibit in vitro angiogenesis , negatively modulate the production of matrix 
3 of endothelial cells ( ec ) , inhibit in vitro angiogenesis , negatively modulate the production of matrix metalloproteinase-9 , and 
18 cells ( ec ) , inhibit in vitro angiogenesis , negatively modulate the production of matrix metalloproteinase-9 , and the ability 
18 ( ec ) , inhibit in vitro angiogenesis , negatively modulate the production of matrix metalloproteinase-9 , and the ability of 
9 ) , inhibit in vitro angiogenesis , negatively modulate the production of matrix metalloproteinase-9 , and the ability of ec to 
0 inhibit in vitro angiogenesis , negatively modulate the production of matrix metalloproteinase-9 , and the ability of ec to adhere to 
0 negatively modulate the production of matrix metalloproteinase-9 , and the ability of ec to adhere to vitronectin and up-regulate icam-1 and 
15 of matrix metalloproteinase-9 , and the ability of ec to adhere to vitronectin and up-regulate icam-1 and vcam-1 expression . NULL 
17 and the ability of ec to adhere to vitronectin and up-regulate icam-1 and vcam-1 expression . NULL NULL NULL NULL NULL 
9 ec to adhere to vitronectin and up-regulate icam-1 and vcam-1 expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these effects do not require direct cell-cell contact , yet result from 
16 NULL NULL NULL NULL NULL NULL these effects do not require direct cell-cell contact , yet result from continuous interaction between 
0 NULL NULL NULL NULL NULL these effects do not require direct cell-cell contact , yet result from continuous interaction between activated 
0 NULL NULL NULL NULL these effects do not require direct cell-cell contact , yet result from continuous interaction between activated lymphoid 
15 NULL NULL NULL these effects do not require direct cell-cell contact , yet result from continuous interaction between activated lymphoid cells 
15 not require direct cell-cell contact , yet result from continuous interaction between activated lymphoid cells and ec . NULL NULL NULL 
17 direct cell-cell contact , yet result from continuous interaction between activated lymphoid cells and ec . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL we used neutralizing abs to show that the ifn-inducible protein-10 and monokine-induced 
0 NULL NULL we used neutralizing abs to show that the inducible protein-10 and monokine-induced by ifn-gamma chemokines are pivotal in inducing 
0 NULL we used neutralizing abs to show that the ifn-inducible protein and monokine-induced by ifn-gamma chemokines are pivotal in inducing these 
0 used neutralizing abs to show that the ifn-inducible protein-10 and induced by ifn-gamma chemokines are pivotal in inducing these effects . 
0 that the ifn-inducible protein-10 and monokine-induced by ifn-gamma chemokines are pivotal in inducing these effects . NULL NULL NULL NULL NULL 
0 and monokine-induced by ifn-gamma chemokines are pivotal in inducing these effects . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 experiments with nu/nu mice , nonobese diabetic-scid mice , or activated spc enriched in specific cell subpopulations demonstrated that cd4 ( 
16 + ) , and nk cells are all needed to mediate the full anti-angiogenetic effect of il-12 . NULL NULL NULL 
3 and nk cells are all needed to mediate the full angiogenetic effect of il-12 . NULL NULL NULL NULL NULL NULL 
16 nk cells are all needed to mediate the full anti-angiogenetic effect of il-12 . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor-b and vascular endothelial growth factor-c expression in renal cell 
0 NULL NULL NULL vascular endothelial growth factor-b and vascular endothelial growth factor-c expression in renal cell carcinomas : regulation by the 
9 NULL vascular endothelial growth factor-b and vascular endothelial growth factor-c expression in renal cell carcinomas : regulation by the von hippel-lindau 
0 vascular endothelial growth factor-c expression in renal cell carcinomas : regulation by the von hippel-lindau gene and hypoxia . NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis is essential for tumor growth and metastasis . NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis is essential for tumor growth and metastasis . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL angiogenesis is essential for tumor growth and metastasis . NULL NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL NULL angiogenesis is essential for tumor growth and metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL angiogenesis is essential for tumor growth and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL it is regulated by numerous angiogenic factors , one of the most important 
3 NULL NULL NULL NULL NULL it is regulated by numerous angiogenic factors , one of the most important being vascular endothelial 
0 regulated by numerous angiogenic factors , one of the most important being vascular endothelial growth factor ( vegf ) . NULL 
0 factors , one of the most important being vascular endothelial growth factor ( vegf ) . NULL NULL NULL NULL NULL 
15 two new vegf family members , have been identified that bind to the tyrosine kinase receptors flt-1 ( vegfr1 ) , 
0 of vegf-a has been shown in renal carcinomas , the contribution of these new ligands in kidney tumors is not clear 
0 NULL NULL NULL we have , therefore , measured the mrna level of vegf-b and vegf-c together with their receptors by 
0 of vegf-b and vegf-c together with their receptors by rnase protection assay ( rpa ) in 26 normal kidney samples and 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL we observed a significant up-regulation of vegf-b ( p = 0.002 ) 
0 NULL NULL NULL NULL NULL NULL NULL we observed a significant up-regulation of vegf-b ( p = 0.002 ) but not 
17 NULL NULL NULL NULL NULL NULL we observed a significant up-regulation of vegf-b ( p = 0.002 ) but not vegf-c 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , although vegf receptors were higher in tumors than normal 
0 higher in tumors than normal kidney , there was a significant up-regulation of only flt-1 ( p = 0.003 ) but 
17 in tumors than normal kidney , there was a significant up-regulation of only flt-1 ( p = 0.003 ) but not 
0 NULL NULL NULL NULL NULL NULL there was also a significant correlation between vegf-c and both of its receptors flt-4 ( 
0 ) and kdr ( p = 0.03 ) but no association between vegf-b and its receptor flt-1 ( p = 0.23 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL a significant increase was observed in flt-1 ( p less than 0.001 
17 NULL NULL NULL NULL NULL NULL NULL NULL a significant increase was observed in flt-1 ( p less than 0.001 ) 
0 NULL NULL NULL NULL NULL NULL a significant increase was observed in flt-1 ( p less than 0.001 ) , kdr 
9 = 0.82 ) or vegf-c ( p = 0.52 ) expression in clear cell compared with chromophil ( papillary ) carcinomas 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL no significant association was demonstrated between vegf-b , vegf-c , flt-1 , 
0 NULL NULL NULL NULL NULL NULL NULL NULL no significant association was demonstrated between vegf-b , vegf-c , flt-1 , kdr 
0 and flt-4 with patient sex , patient age , or tumor size ( p greater than 0.05 ) . NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effect of von hippel-lindau ( vhl ) gene and hypoxia on 
9 ( vhl ) gene and hypoxia on vegf-b and vegf-c expression in the renal carcinoma cell line 786-0 transfected with wild-type 
19 and vegf-c expression in the renal carcinoma cell line 786-0 transfected with wild-type and mutant vhl was determined by growing cells 
1 786-0 transfected with wild-type and mutant vhl was determined by growing cells under 21 % o2- and 0.1 % o2 . 
17 NULL in wild-type vhl cells , whereas vegf-a was significantly up-regulated under hypoxic compared with normoxic conditions ( p less than 
9 with normoxic conditions ( p less than 0.001 ) , expression of vegf-c was reduced ( p less than 0.002 ) 
18 p less than 0.001 ) , expression of vegf-c was reduced ( p less than 0.002 ) . NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL nevertheless , the repression of vegf-c was lost in mutant vhl cell lines under 
16 NULL NULL NULL NULL NULL in contrast vegf-b was not regulated by vhl despite clear up-regulation in vivo . NULL NULL 
17 in contrast vegf-b was not regulated by vhl despite clear up-regulation in vivo . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL these findings strongly support an enhanced role for this pathway in clear cell carcinomas 
0 NULL NULL NULL NULL NULL these findings strongly support an enhanced role for this pathway in clear cell carcinomas by regulating 
0 NULL NULL NULL NULL these findings strongly support an enhanced role for this pathway in clear cell carcinomas by regulating angiogenesis 
16 enhanced role for this pathway in clear cell carcinomas by regulating angiogenesis and/or lymphangiogenesis . NULL NULL NULL NULL NULL NULL 
3 role for this pathway in clear cell carcinomas by regulating angiogenesis and/or lymphangiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 this pathway in clear cell carcinomas by regulating angiogenesis and/or angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 the study shows that clear cell tumors are able to up-regulate angiogenic growth factor receptors more efficiently than chromophil ( papillary 
3 study shows that clear cell tumors are able to up-regulate angiogenic growth factor receptors more efficiently than chromophil ( papillary ) 
0 shows that clear cell tumors are able to up-regulate angiogenic growth factor receptors more efficiently than chromophil ( papillary ) , 
0 chromophil ( papillary ) , that clear cell tumors can use pathways independent of vhl to regulate angiogenesis , and that 
0 ( papillary ) , that clear cell tumors can use pathways independent of vhl to regulate angiogenesis , and that this 
0 papillary ) , that clear cell tumors can use pathways independent of vhl to regulate angiogenesis , and that this combined 
16 clear cell tumors can use pathways independent of vhl to regulate angiogenesis , and that this combined regulation may account for 
3 cell tumors can use pathways independent of vhl to regulate angiogenesis , and that this combined regulation may account for their 
0 of vhl to regulate angiogenesis , and that this combined regulation may account for their more aggressive phenotype , which suggests 
0 account for their more aggressive phenotype , which suggests that targeting vegfr1 ( flt-l ) may be particularly effective in these 
0 suggests that targeting vegfr1 ( flt-l ) may be particularly effective in these tumor types . NULL NULL NULL NULL NULL 
0 vegfr1 ( flt-l ) may be particularly effective in these tumor types . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effects of morphological patterning on endothelial cell migration . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL effects of morphological patterning on endothelial cell migration . NULL NULL NULL NULL 
14 NULL NULL NULL effects of morphological patterning on endothelial cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL the migration of vascular endothelial cells ( ecs ) plays an important 
16 NULL the migration of vascular endothelial cells ( ecs ) plays an important role in vascular remodeling . NULL NULL NULL 
16 migration of vascular endothelial cells ( ecs ) plays an important role in vascular remodeling . NULL NULL NULL NULL NULL 
16 of vascular endothelial cells ( ecs ) plays an important role in vascular remodeling . NULL NULL NULL NULL NULL NULL 
7 cells ( ecs ) plays an important role in vascular remodeling . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL here we studied the effects of cell morphology on the migration of bovine aortic ecs 
14 here we studied the effects of cell morphology on the migration of bovine aortic ecs by culturing cells on micropatterned strips 
19 cell morphology on the migration of bovine aortic ecs by culturing cells on micropatterned strips of collagen matrix ( 60- , 
0 aortic ecs by culturing cells on micropatterned strips of collagen matrix ( 60- , 30- , and 15-microm wide ) . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the spreading areas of the cells on 15- and 30-microm wide strips 
0 the direction of the strip , and had significantly lower shape index than those in all other groups . NULL NULL 
14 NULL on strips of all widths , ecs tended to migrate in the direction of strips . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL vinculin staining showed that the leading edge of ecs on 15-microm wide 
0 NULL NULL NULL NULL NULL NULL NULL NULL vinculin staining showed that the leading edge of ecs on 15-microm wide strips 
0 NULL NULL NULL NULL NULL vinculin staining showed that the leading edge of ecs on 15-microm wide strips had focal adhesions 
14 oriented with their lamellipodial protrusion and the direction of cell migration ; this arrangement of the focal adhesions may promote ec 
17 cell migration ; this arrangement of the focal adhesions may promote ec migration . NULL NULL NULL NULL NULL NULL NULL 
14 ; this arrangement of the focal adhesions may promote ec migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the present study provides direct evidence on the role of cell morphology 
0 NULL NULL NULL NULL NULL NULL the present study provides direct evidence on the role of cell morphology in ec migration 
16 NULL NULL the present study provides direct evidence on the role of cell morphology in ec migration , and will help 
14 direct evidence on the role of cell morphology in ec migration , and will help us to understand the mechanisms of 
14 and will help us to understand the mechanisms of ec migration during angiogenesis and wound healing . NULL NULL NULL NULL 
3 help us to understand the mechanisms of ec migration during angiogenesis and wound healing . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL thrombospondin-2 plays a protective role in multistep carcinogenesis : a novel host 
0 NULL NULL NULL NULL NULL NULL thrombospondin-2 plays a protective role in multistep carcinogenesis : a novel host anti-tumor defense mechanism 
0 NULL NULL NULL thrombospondin-2 plays a protective role in multistep carcinogenesis : a novel host anti-tumor defense mechanism . NULL NULL 
18 protective role in multistep carcinogenesis : a novel host anti-tumor defense mechanism . NULL NULL NULL NULL NULL NULL NULL NULL 
0 role in multistep carcinogenesis : a novel host anti-tumor defense mechanism . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic switch during tumorigenesis is thought to be induced by a 
17 NULL the angiogenic switch during tumorigenesis is thought to be induced by a change in the balance of pro- angiogenic and 
0 switch during tumorigenesis is thought to be induced by a change in the balance of pro- angiogenic and anti-angiogenic factors . 
3 be induced by a change in the balance of pro- angiogenic and anti-angiogenic factors . NULL NULL NULL NULL NULL NULL 
3 by a change in the balance of pro- angiogenic and angiogenic factors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL to elucidate the biological role of the endogenous angiogenesis inhibitor thrombospondin-2 ( tsp-2 ) during 
3 NULL NULL to elucidate the biological role of the endogenous angiogenesis inhibitor thrombospondin-2 ( tsp-2 ) during multistep carcinogenesis , we 
18 NULL to elucidate the biological role of the endogenous angiogenesis inhibitor thrombospondin-2 ( tsp-2 ) during multistep carcinogenesis , we subjected 
0 the endogenous angiogenesis inhibitor thrombospondin-2 ( tsp-2 ) during multistep carcinogenesis , we subjected tsp-2-deficient and wild-type mice to a chemical 
19 inhibitor thrombospondin-2 ( tsp-2 ) during multistep carcinogenesis , we subjected tsp-2-deficient and wild-type mice to a chemical skin carcinogenesis regimen 
9 thrombospondin-2 ( tsp-2 ) during multistep carcinogenesis , we subjected deficient and wild-type mice to a chemical skin carcinogenesis regimen . 
0 we subjected tsp-2-deficient and wild-type mice to a chemical skin carcinogenesis regimen . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL surprisingly , tsp-2 expression was strongly upregulated in the mesenchymal stroma of wild-type mice 
17 NULL NULL NULL NULL surprisingly , tsp-2 expression was strongly upregulated in the mesenchymal stroma of wild-type mice throughout the consecutive 
3 wild-type mice throughout the consecutive stages of tumorigenesis whereas the angiogenesis factor , vascular endothelial growth factor , was induced predominantly 
0 stages of tumorigenesis whereas the angiogenesis factor , vascular endothelial growth factor , was induced predominantly in tumor cells . NULL 
17 the angiogenesis factor , vascular endothelial growth factor , was induced predominantly in tumor cells . NULL NULL NULL NULL NULL 
0 , vascular endothelial growth factor , was induced predominantly in tumor cells . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL tsp-2 deficiency dramatically enhanced susceptibility to skin carcinogenesis and resulted in accelerated 
0 NULL NULL NULL NULL NULL NULL NULL tsp-2 deficiency dramatically enhanced susceptibility to skin carcinogenesis and resulted in accelerated and increased 
0 NULL NULL NULL tsp-2 deficiency dramatically enhanced susceptibility to skin carcinogenesis and resulted in accelerated and increased tumor formation . NULL 
0 NULL tsp-2 deficiency dramatically enhanced susceptibility to skin carcinogenesis and resulted in accelerated and increased tumor formation . NULL NULL NULL 
0 deficiency dramatically enhanced susceptibility to skin carcinogenesis and resulted in accelerated and increased tumor formation . NULL NULL NULL NULL NULL 
17 enhanced susceptibility to skin carcinogenesis and resulted in accelerated and increased tumor formation . NULL NULL NULL NULL NULL NULL NULL 
0 susceptibility to skin carcinogenesis and resulted in accelerated and increased tumor formation . NULL NULL NULL NULL NULL NULL NULL NULL 
2 to skin carcinogenesis and resulted in accelerated and increased tumor formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic switch occurred in early stages of pre-malignant tumor formation , 
0 NULL NULL the angiogenic switch occurred in early stages of malignant tumor formation , and tumor angiogenesis was significantly enhanced in 
0 NULL the angiogenic switch occurred in early stages of pre-malignant tumor formation , and tumor angiogenesis was significantly enhanced in tsp-2-deficient 
2 the angiogenic switch occurred in early stages of pre-malignant tumor formation , and tumor angiogenesis was significantly enhanced in tsp-2-deficient mice 
0 occurred in early stages of pre-malignant tumor formation , and tumor angiogenesis was significantly enhanced in tsp-2-deficient mice . NULL NULL 
3 in early stages of pre-malignant tumor formation , and tumor angiogenesis was significantly enhanced in tsp-2-deficient mice . NULL NULL NULL 
17 of pre-malignant tumor formation , and tumor angiogenesis was significantly enhanced in tsp-2-deficient mice . NULL NULL NULL NULL NULL NULL 
9 tumor formation , and tumor angiogenesis was significantly enhanced in deficient mice . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL while tsp-2 deficiency did not affect tumor differentiation or proliferation , tumor cell 
16 NULL NULL NULL NULL NULL while tsp-2 deficiency did not affect tumor differentiation or proliferation , tumor cell apoptosis was significantly 
0 NULL NULL NULL NULL while tsp-2 deficiency did not affect tumor differentiation or proliferation , tumor cell apoptosis was significantly reduced 
2 NULL NULL NULL while tsp-2 deficiency did not affect tumor differentiation or proliferation , tumor cell apoptosis was significantly reduced . 
4 NULL while tsp-2 deficiency did not affect tumor differentiation or proliferation , tumor cell apoptosis was significantly reduced . NULL NULL 
0 tsp-2 deficiency did not affect tumor differentiation or proliferation , tumor cell apoptosis was significantly reduced . NULL NULL NULL NULL 
5 did not affect tumor differentiation or proliferation , tumor cell apoptosis was significantly reduced . NULL NULL NULL NULL NULL NULL 
18 tumor differentiation or proliferation , tumor cell apoptosis was significantly reduced . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results reveal upregulation of an endogenous angiogenesis inhibitor during multi step 
0 NULL NULL NULL NULL NULL NULL NULL these results reveal upregulation of an endogenous angiogenesis inhibitor during multi step tumorigenesis and 
3 NULL NULL NULL these results reveal upregulation of an endogenous angiogenesis inhibitor during multi step tumorigenesis and identify enhanced stromal tsp-2 
0 NULL NULL these results reveal upregulation of an endogenous angiogenesis inhibitor during multi step tumorigenesis and identify enhanced stromal tsp-2 expression 
17 an endogenous angiogenesis inhibitor during multi step tumorigenesis and identify enhanced stromal tsp-2 expression as a novel host anti-tumor defense mechanism 
9 inhibitor during multi step tumorigenesis and identify enhanced stromal tsp-2 expression as a novel host anti-tumor defense mechanism . NULL NULL 
18 identify enhanced stromal tsp-2 expression as a novel host anti-tumor defense mechanism . NULL NULL NULL NULL NULL NULL NULL NULL 
0 enhanced stromal tsp-2 expression as a novel host anti-tumor defense mechanism . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL current prospects for controlling cancer growth with non-cytotoxic agents -- nutrients , phytochemicals , 
4 NULL NULL NULL NULL NULL current prospects for controlling cancer growth with non-cytotoxic agents -- nutrients , phytochemicals , herbal extracts 
19 NULL NULL NULL NULL NULL NULL in animal or cell culture studies , the growth and spread of cancer can be 
4 NULL NULL in animal or cell culture studies , the growth and spread of cancer can be slowed by many nutrients 
14 in animal or cell culture studies , the growth and spread of cancer can be slowed by many nutrients , food 
18 studies , the growth and spread of cancer can be slowed by many nutrients , food factors , herbal extracts , 
0 , and well-tolerated , available drugs that are still rarely used in the clinical management of cancer , in part because 
0 , available drugs that are still rarely used in the clinical management of cancer , in part because they seem unlikely 
0 , in part because they seem unlikely to constitute definitive therapies in themselves . NULL NULL NULL NULL NULL NULL NULL 
0 NULL however , it is reasonable to expect that mechanistically complementary combinations of these measures could have a worthwhile impact on 
0 mechanistically complementary combinations of these measures could have a worthwhile impact on survival times and , when used as adjuvants , 
0 combinations of these measures could have a worthwhile impact on survival times and , when used as adjuvants , could improve 
0 have a worthwhile impact on survival times and , when used as adjuvants , could improve the cure rates achievable with 
0 survival times and , when used as adjuvants , could improve the cure rates achievable with standard therapies . NULL NULL 
0 adjuvants , could improve the cure rates achievable with standard therapies . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 therapeutic options available in this regard include measures that : down-regulate serum free igf-i ; suppress the synthesis of mevalonic acid 
0 available in this regard include measures that : down-regulate serum free igf-i ; suppress the synthesis of mevalonic acid and/or certain 
18 regard include measures that : down-regulate serum free igf-i ; suppress the synthesis of mevalonic acid and/or certain derivatives thereof ; 
8 measures that : down-regulate serum free igf-i ; suppress the synthesis of mevalonic acid and/or certain derivatives thereof ; modulate arachidonate 
16 the synthesis of mevalonic acid and/or certain derivatives thereof ; modulate arachidonate metabolism by inhibiting 5-lipoxygenase , 12-lipoxygenase , or cox-2 
18 acid and/or certain derivatives thereof ; modulate arachidonate metabolism by inhibiting 5-lipoxygenase , 12-lipoxygenase , or cox-2 ; antagonize the activation 
18 metabolism by inhibiting 5-lipoxygenase , 12-lipoxygenase , or cox-2 ; antagonize the activation of ap-1 transcription factors ; promote the activation 
17 inhibiting 5-lipoxygenase , 12-lipoxygenase , or cox-2 ; antagonize the activation of ap-1 transcription factors ; promote the activation of ppar-gamma 
0 12-lipoxygenase , or cox-2 ; antagonize the activation of ap-1 transcription factors ; promote the activation of ppar-gamma transcription factors ; 
17 cox-2 ; antagonize the activation of ap-1 transcription factors ; promote the activation of ppar-gamma transcription factors ; and that suppress 
17 antagonize the activation of ap-1 transcription factors ; promote the activation of ppar-gamma transcription factors ; and that suppress angiogenesis by 
0 of ap-1 transcription factors ; promote the activation of ppar-gamma transcription factors ; and that suppress angiogenesis by additional mechanisms . 
18 promote the activation of ppar-gamma transcription factors ; and that suppress angiogenesis by additional mechanisms . NULL NULL NULL NULL NULL 
3 the activation of ppar-gamma transcription factors ; and that suppress angiogenesis by additional mechanisms . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL many of these measures appear suitable for use in cancer prevention . NULL NULL NULL NULL NULL NULL 
18 many of these measures appear suitable for use in cancer prevention . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of pdgf-stimulated and matrix-mediated proliferation of human vascular smooth muscle 
17 NULL NULL NULL NULL NULL NULL NULL NULL inhibition of stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by 
17 NULL NULL NULL NULL NULL NULL inhibition of pdgf-stimulated and mediated proliferation of human vascular smooth muscle cells by sparc is 
1 NULL NULL NULL NULL NULL inhibition of pdgf-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by sparc is independent 
16 proliferation of human vascular smooth muscle cells by sparc is independent of changes in cell shape or cyclin-dependent kinase inhibitors . 
2 human vascular smooth muscle cells by sparc is independent of changes in cell shape or cyclin-dependent kinase inhibitors . NULL NULL 
0 muscle cells by sparc is independent of changes in cell shape or cyclin-dependent kinase inhibitors . NULL NULL NULL NULL NULL 
0 by sparc is independent of changes in cell shape or dependent kinase inhibitors . NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL interactions among growth factors , cells , and extracellular matrix regulate 
0 NULL NULL NULL NULL NULL NULL NULL NULL interactions among growth factors , cells , and extracellular matrix regulate proliferation during 
0 NULL interactions among growth factors , cells , and extracellular matrix regulate proliferation during normal development and in pathologies such as 
16 interactions among growth factors , cells , and extracellular matrix regulate proliferation during normal development and in pathologies such as atherosclerosis 
1 among growth factors , cells , and extracellular matrix regulate proliferation during normal development and in pathologies such as atherosclerosis . 
0 , cells , and extracellular matrix regulate proliferation during normal development and in pathologies such as atherosclerosis . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL sparc ( secreted protein , acidic , and rich in cysteine ) is 
0 NULL NULL NULL NULL NULL NULL NULL sparc ( secreted protein , acidic , and rich in cysteine ) is a 
15 , acidic , and rich in cysteine ) is a associated glycoprotein that modulates the adhesion and proliferation of vascular cells 
16 and rich in cysteine ) is a matrix-associated glycoprotein that modulates the adhesion and proliferation of vascular cells . NULL NULL 
15 in cysteine ) is a matrix-associated glycoprotein that modulates the adhesion and proliferation of vascular cells . NULL NULL NULL NULL 
1 ) is a matrix-associated glycoprotein that modulates the adhesion and proliferation of vascular cells . NULL NULL NULL NULL NULL NULL 
18 NULL NULL in this study , we demonstrate that sparc inhibits human arterial smooth muscle cell proliferation stimulated by platelet-derived growth 
0 in this study , we demonstrate that sparc inhibits human arterial smooth muscle cell proliferation stimulated by platelet-derived growth factor or 
1 we demonstrate that sparc inhibits human arterial smooth muscle cell proliferation stimulated by platelet-derived growth factor or by adhesion to monomeric 
17 demonstrate that sparc inhibits human arterial smooth muscle cell proliferation stimulated by platelet-derived growth factor or by adhesion to monomeric type 
0 sparc inhibits human arterial smooth muscle cell proliferation stimulated by derived growth factor or by adhesion to monomeric type i collagen 
0 inhibits human arterial smooth muscle cell proliferation stimulated by platelet-derived growth factor or by adhesion to monomeric type i collagen . 
15 muscle cell proliferation stimulated by platelet-derived growth factor or by adhesion to monomeric type i collagen . NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL binding studies with sparc and sparc peptides indicate specific and saturable 
15 studies with sparc and sparc peptides indicate specific and saturable interaction with smooth muscle cells that involves the c-terminal ca2+-binding region 
0 indicate specific and saturable interaction with smooth muscle cells that involves the c-terminal ca2+-binding region of the protein . NULL NULL 
0 saturable interaction with smooth muscle cells that involves the c-terminal binding region of the protein . NULL NULL NULL NULL NULL 
0 muscle cells that involves the c-terminal ca2+-binding region of the protein . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL we also report that sparc arrests monomeric collagen-supported smooth muscle cell proliferation in the late g1-phase 
17 NULL NULL NULL we also report that sparc arrests monomeric supported smooth muscle cell proliferation in the late g1-phase of the 
1 also report that sparc arrests monomeric collagen-supported smooth muscle cell proliferation in the late g1-phase of the cell cycle in the 
16 g1-phase of the cell cycle in the absence of an effect on cell shape or on levels of cyclin-dependent kinase inhibitors 
0 cell cycle in the absence of an effect on cell shape or on levels of cyclin-dependent kinase inhibitors . NULL NULL 
0 the absence of an effect on cell shape or on levels of cyclin-dependent kinase inhibitors . NULL NULL NULL NULL NULL 
0 of an effect on cell shape or on levels of dependent kinase inhibitors . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL dependent kinase-2 activity , p107 and cyclin a levels , and 
0 NULL NULL NULL NULL NULL NULL NULL NULL cyclin-dependent kinase-2 activity , p107 and cyclin a levels , and retinoblastoma protein 
0 NULL NULL cyclin-dependent kinase-2 activity , p107 and cyclin a levels , and retinoblastoma protein phosphorylation are markedly reduced in response 
0 activity , p107 and cyclin a levels , and retinoblastoma protein phosphorylation are markedly reduced in response to the addition of 
12 , p107 and cyclin a levels , and retinoblastoma protein phosphorylation are markedly reduced in response to the addition of exogenous 
18 cyclin a levels , and retinoblastoma protein phosphorylation are markedly reduced in response to the addition of exogenous sparc and/or peptides 
17 levels , and retinoblastoma protein phosphorylation are markedly reduced in response to the addition of exogenous sparc and/or peptides derived from 
19 retinoblastoma protein phosphorylation are markedly reduced in response to the addition of exogenous sparc and/or peptides derived from specific domains of 
0 in response to the addition of exogenous sparc and/or peptides derived from specific domains of sparc . NULL NULL NULL NULL 
0 NULL NULL thus , sparc , previously characterized as an inhibitor of platelet-derived growth factor binding to its receptor , also 
0 thus , sparc , previously characterized as an inhibitor of derived growth factor binding to its receptor , also antagonizes smooth 
0 , sparc , previously characterized as an inhibitor of platelet-derived growth factor binding to its receptor , also antagonizes smooth muscle 
15 , previously characterized as an inhibitor of platelet-derived growth factor binding to its receptor , also antagonizes smooth muscle cell proliferation 
18 of platelet-derived growth factor binding to its receptor , also antagonizes smooth muscle cell proliferation mediated by monomeric collagen at the 
1 binding to its receptor , also antagonizes smooth muscle cell proliferation mediated by monomeric collagen at the level of cyclin-dependent kinase-2 
16 to its receptor , also antagonizes smooth muscle cell proliferation mediated by monomeric collagen at the level of cyclin-dependent kinase-2 activity 
0 cell proliferation mediated by monomeric collagen at the level of dependent kinase-2 activity . NULL NULL NULL NULL NULL NULL NULL 
0 mediated by monomeric collagen at the level of cyclin-dependent kinase-2 activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL upregulation of vascular endothelial growth factor receptors is associated with advanced 
0 NULL NULL NULL NULL NULL NULL upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma . NULL NULL 
0 NULL NULL upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL background : angiogenesis is essential for tumor growth and relies on the production 
17 NULL NULL NULL NULL NULL NULL background : angiogenesis is essential for tumor growth and relies on the production of angiogenic 
0 NULL NULL NULL NULL background : angiogenesis is essential for tumor growth and relies on the production of angiogenic factors . 
4 NULL NULL NULL background : angiogenesis is essential for tumor growth and relies on the production of angiogenic factors . NULL 
0 angiogenesis is essential for tumor growth and relies on the production of angiogenic factors . NULL NULL NULL NULL NULL NULL 
3 essential for tumor growth and relies on the production of angiogenic factors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) is a major regulator of angiogenesis 
0 NULL vascular endothelial growth factor ( vegf ) is a major regulator of angiogenesis that binds to tyrosine kinase receptors flt-1 
0 vascular endothelial growth factor ( vegf ) is a major regulator of angiogenesis that binds to tyrosine kinase receptors flt-1 and 
3 growth factor ( vegf ) is a major regulator of angiogenesis that binds to tyrosine kinase receptors flt-1 and kdr . 
15 ( vegf ) is a major regulator of angiogenesis that binds to tyrosine kinase receptors flt-1 and kdr . NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL the interaction of vegf and its receptors at gene and protein levels 
0 the interaction of vegf and its receptors at gene and protein levels in neuroblastoma remains widely unknown . NULL NULL NULL 
0 interaction of vegf and its receptors at gene and protein levels in neuroblastoma remains widely unknown . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL methods : tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients 
0 NULL NULL methods : tumor biopsy specimens and serum were obtained from 37 neuroblastoma patients ; adrenal biopsy sections and sera 
0 biopsy sections and sera of 7 normal children served as controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL biopsy specimens were examined by real-time reverse transcription polymerase chain reaction ( rt-pcr ) and western blotting ; 
0 rt-pcr ) and western blotting ; serum was analyzed by linked immunosorbent assay ( elisa ) . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : vegf isoforms and its receptors ' mrna were expressed 
0 NULL NULL results : vegf isoforms and its receptors ' mrna were expressed in neuroblastoma and control tissues . NULL NULL 
10 results : vegf isoforms and its receptors ' mrna were expressed in neuroblastoma and control tissues . NULL NULL NULL NULL 
0 and its receptors ' mrna were expressed in neuroblastoma and control tissues . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL whereas the ligands were increased in stages iii and iv , the receptors were upregulated 
0 increased in stages iii and iv , the receptors were upregulated in stage iii only . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL at protein level , vegf-b and c , flt-1 , and kdr 
9 vegf-b and c , flt-1 , and kdr were not detectable in tissue lysates , whereas vegf-a was increased in stages 
17 were not detectable in tissue lysates , whereas vegf-a was increased in stages iii and iv . NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL serum vegf protein levels were upregulated in stage iii . NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL serum vegf protein levels were upregulated in stage iii . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL serum vegf protein levels were upregulated in stage iii . NULL NULL NULL NULL NULL NULL 
0 conclusions : vegf-a ( 165 ) is one of the major angiogenesis regulators among the ligands ' family of vegf , 
3 : vegf-a ( 165 ) is one of the major angiogenesis regulators among the ligands ' family of vegf , whereas 
0 its receptors kdr , and most probably flt-1 , may contribute to a poor prognosis ( angiogenic ) phenotype , as 
3 probably flt-1 , may contribute to a poor prognosis ( angiogenic ) phenotype , as indicated by their upregulated mrna levels 
0 prognosis ( angiogenic ) phenotype , as indicated by their upregulated mrna levels in stage iii neuroblastoma . NULL NULL NULL 
0 ( angiogenic ) phenotype , as indicated by their upregulated mrna levels in stage iii neuroblastoma . NULL NULL NULL NULL 
0 angiogenic ) phenotype , as indicated by their upregulated mrna levels in stage iii neuroblastoma . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL vegf-a ( 165 ) mainly contributes to increased serum vegf levels and may serve as a 
17 NULL NULL NULL vegf-a ( 165 ) mainly contributes to increased serum vegf levels and may serve as a diagnostic tool 
0 vegf-a ( 165 ) mainly contributes to increased serum vegf levels and may serve as a diagnostic tool in advanced-stage neuroblastoma 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL optimizing treatment of choroidal neovascularization feeder vessels associated with age-related macular degeneration 
3 NULL NULL NULL NULL NULL NULL optimizing treatment of choroidal neovascularization feeder vessels associated with age-related macular degeneration . NULL NULL 
16 NULL NULL NULL optimizing treatment of choroidal neovascularization feeder vessels associated with age-related macular degeneration . NULL NULL NULL NULL NULL 
6 treatment of choroidal neovascularization feeder vessels associated with age-related macular degeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL purpose : to optimize the method of treating choroidal neovascularization ( cnv ) associated with age-related macular degeneration 
3 NULL purpose : to optimize the method of treating choroidal neovascularization ( cnv ) associated with age-related macular degeneration ( amd 
3 : to optimize the method of treating choroidal neovascularization ( cnv ) associated with age-related macular degeneration ( amd ) . 
16 optimize the method of treating choroidal neovascularization ( cnv ) associated with age-related macular degeneration ( amd ) . NULL NULL 
6 treating choroidal neovascularization ( cnv ) associated with age-related macular degeneration ( amd ) . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL methods : the parameters associated with locating and then photocoagulating cnv feeder vessels were identified 
19 NULL methods : the parameters associated with locating and then photocoagulating cnv feeder vessels were identified and optimized using published data 
3 methods : the parameters associated with locating and then photocoagulating cnv feeder vessels were identified and optimized using published data and 
0 vessels were identified and optimized using published data and data derived from modeling the choroidal vasculature . NULL NULL NULL NULL 
0 identified and optimized using published data and data derived from modeling the choroidal vasculature . NULL NULL NULL NULL NULL NULL 
0 NULL NULL based on these optimized parameters , a prototype treatment system was designed that captures high-speed indocyanine green ( icg 
0 captures high-speed indocyanine green ( icg ) angiogram images and facilitates analysis of the images by enhancing visualization of dye movement 
0 ) angiogram images and facilitates analysis of the images by enhancing visualization of dye movement through cnv feeder vessels ( fvs 
3 of the images by enhancing visualization of dye movement through cnv feeder vessels ( fvs ) . NULL NULL NULL NULL 
0 NULL NULL NULL the system also permits precise aiming and delivery of 810- nm wavelength photocoagulation laser energy to target fvs 
0 also permits precise aiming and delivery of 810- nm wavelength photocoagulation laser energy to target fvs on a real-time icg angiogram 
0 and delivery of 810- nm wavelength photocoagulation laser energy to target fvs on a real-time icg angiogram image of the choroidal 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL target fvs are tracked by a joy-stick controlled laser aiming beam 
0 NULL NULL NULL target fvs are tracked by a joy-stick controlled laser aiming beam until an intravenously-injected high-concentration icg dye bolus 
19 tracked by a joy-stick controlled laser aiming beam until an intravenously-injected high-concentration icg dye bolus is observed to enter the target 
14 aiming beam until an intravenously-injected high-concentration icg dye bolus is observed to enter the target vessel , at which time the 
0 until an intravenously-injected high-concentration icg dye bolus is observed to enter the target vessel , at which time the laser is 
0 intravenously-injected high-concentration icg dye bolus is observed to enter the target vessel , at which time the laser is fired . 
0 NULL NULL NULL NULL proof of principle of the combined treatment system design for performing dye-enhanced photocoagulation ( dep ) in 
0 of principle of the combined diagnosis/treatment system design for performing enhanced photocoagulation ( dep ) in the clinical setting and determination 
0 principle of the combined diagnosis/treatment system design for performing dye-enhanced photocoagulation ( dep ) in the clinical setting and determination of 
0 design for performing dye-enhanced photocoagulation ( dep ) in the clinical setting and determination of the minimum dep laser energy needed 
3 determination of the minimum dep laser energy needed to close cnv fvs was made in 11 amd patients requiring treatment of 
17 to close cnv fvs was made in 11 amd patients requiring treatment of cnv , but for whom other treatment was 
19 close cnv fvs was made in 11 amd patients requiring treatment of cnv , but for whom other treatment was not 
3 fvs was made in 11 amd patients requiring treatment of cnv , but for whom other treatment was not appropriate . 
0 patients requiring treatment of cnv , but for whom other treatment was not appropriate . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : using icg-dep , cnv feeder vessels were closed with 
3 NULL NULL NULL NULL NULL results : using icg-dep , cnv feeder vessels were closed with single pulse laser energy , 
19 NULL results : using icg-dep , cnv feeder vessels were closed with single pulse laser energy , delivering as little as 
0 j of energy to the fundus , producing no visible change in the fundus . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL successful fv closure was usually indicated immediately by presence of incarcerated icg dye 
0 NULL NULL successful fv closure was usually indicated immediately by presence of incarcerated icg dye in the vessel adjacent to the 
0 in front of the device , feeder vessel dep and treatment evaluation required 15 to 20 minutes . NULL NULL NULL 
0 of the device , feeder vessel dep and treatment evaluation required 15 to 20 minutes . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL conclusions : indocyanine green enhanced photocoagulation of cnv feeder vessels , facilitated by use of 
19 NULL NULL NULL NULL NULL conclusions : indocyanine green dye-enhanced photocoagulation of cnv feeder vessels , facilitated by use of a 
3 NULL NULL NULL conclusions : indocyanine green dye-enhanced photocoagulation of cnv feeder vessels , facilitated by use of a device that 
0 green dye-enhanced photocoagulation of cnv feeder vessels , facilitated by use of a device that permits real-time visualization of the choroidal 
0 permits real-time visualization of the choroidal circulation while aiming the treatment laser beam , appears to minimize the amount of energy 
0 applied to the fundus and the volume of fundus tissue affected by treatment , compared with other treatment modalities . NULL 
0 the fundus and the volume of fundus tissue affected by treatment , compared with other treatment modalities . NULL NULL NULL 
0 of fundus tissue affected by treatment , compared with other treatment modalities . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the combination treatment device should be useful in optimizing fv treatment and in 
19 the combination diagnosis/treatment device should be useful in optimizing fv treatment and in refining and evaluating the efficacy of dep in 
0 in optimizing fv treatment and in refining and evaluating the efficacy of dep in future clinical trials . NULL NULL NULL 
0 in refining and evaluating the efficacy of dep in future clinical trials . NULL NULL NULL NULL NULL NULL NULL NULL 
0 refining and evaluating the efficacy of dep in future clinical trials . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid 
3 NULL NULL NULL NULL NULL NULL NULL NULL inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid . NULL 
0 linoleic acid ( cla ) has been shown previously to inhibit rat mammary carcinogenesis . NULL NULL NULL NULL NULL NULL 
0 cla ) has been shown previously to inhibit rat mammary carcinogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition to direct effects on mammary epithelial cells , including decreased 
0 NULL NULL NULL NULL NULL NULL NULL in addition to direct effects on mammary epithelial cells , including decreased proliferation and 
16 NULL NULL NULL NULL NULL NULL in addition to direct effects on mammary epithelial cells , including decreased proliferation and induction 
18 addition to direct effects on mammary epithelial cells , including decreased proliferation and induction of apoptosis , cla may exert its 
1 to direct effects on mammary epithelial cells , including decreased proliferation and induction of apoptosis , cla may exert its effects 
17 effects on mammary epithelial cells , including decreased proliferation and induction of apoptosis , cla may exert its effects indirectly by 
5 mammary epithelial cells , including decreased proliferation and induction of apoptosis , cla may exert its effects indirectly by inhibiting the 
16 proliferation and induction of apoptosis , cla may exert its effects indirectly by inhibiting the differentiation of mammary stromal cells to 
18 of apoptosis , cla may exert its effects indirectly by inhibiting the differentiation of mammary stromal cells to an endothelial cell 
2 , cla may exert its effects indirectly by inhibiting the differentiation of mammary stromal cells to an endothelial cell type . 
18 NULL NULL NULL NULL specifically , cla was found to decrease the ability of mammary stromal cells to form complex anastomosing 
0 NULL NULL specifically , cla was found to decrease the ability of mammary stromal cells to form complex anastomosing microcapillary networks 
2 found to decrease the ability of mammary stromal cells to form complex anastomosing microcapillary networks in vitro on engelbreth-holm-swarm-derived reconstituted basement 
0 cells to form complex anastomosing microcapillary networks in vitro on derived reconstituted basement membrane . NULL NULL NULL NULL NULL NULL 
0 to form complex anastomosing microcapillary networks in vitro on engelbreth-holm-swarm-derived reconstituted basement membrane . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL this suggested that cla might inhibit angiogenesis in vivo . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL this suggested that cla might inhibit angiogenesis in vivo . NULL NULL NULL NULL NULL NULL NULL 
19 test this possibility , cd2/f ( 1 ) mice were placed on synthetic diets containing 0 , 1 , or 2 
3 , or 2 % cla for 6 weeks , before angiogenic challenge by s.c . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL injection with an angiogenic gel substrate ( matrigel pellet assay ) 
3 NULL NULL NULL NULL NULL NULL NULL injection with an angiogenic gel substrate ( matrigel pellet assay ) . NULL NULL 
0 NULL NULL after 7 days , the pellets from animals fed the control diet were infiltrated by abundant branching networks of 
0 after 7 days , the pellets from animals fed the control diet were infiltrated by abundant branching networks of blood vessels 
17 pellets from animals fed the control diet were infiltrated by abundant branching networks of blood vessels with patent lumen-containing rbcs . 
2 from animals fed the control diet were infiltrated by abundant branching networks of blood vessels with patent lumen-containing rbcs . NULL 
19 NULL NULL NULL NULL in contrast , pellets from the fed animals contained fewer infiltrating cells , which formed limited branching 
14 in contrast , pellets from the cla-fed animals contained fewer infiltrating cells , which formed limited branching cellular networks , the 
2 from the cla-fed animals contained fewer infiltrating cells , which formed limited branching cellular networks , the majority of which had 
0 the cla-fed animals contained fewer infiltrating cells , which formed limited branching cellular networks , the majority of which had collapsed 
0 cla-fed animals contained fewer infiltrating cells , which formed limited branching cellular networks , the majority of which had collapsed lumen 
6 limited branching cellular networks , the majority of which had collapsed lumen and no rbcs . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL both levels of dietary cla showed similar effects , with the number 
0 NULL NULL NULL NULL NULL both levels of dietary cla showed similar effects , with the number of rbc-containing vessels per 
0 NULL NULL NULL both levels of dietary cla showed similar effects , with the number of rbc-containing vessels per 20x field 
0 , with the number of rbc-containing vessels per 20x field decreased to a third of that seen in control . NULL 
0 20x field decreased to a third of that seen in control . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL dietary cla decreased serum levels of vascular endothelial growth factor ( vegf ) 
0 NULL NULL NULL NULL NULL NULL dietary cla decreased serum levels of vascular endothelial growth factor ( vegf ) and whole 
0 NULL NULL dietary cla decreased serum levels of vascular endothelial growth factor ( vegf ) and whole mammary gland levels of 
0 endothelial growth factor ( vegf ) and whole mammary gland levels of vegf and its receptor flk-1 . NULL NULL NULL 
16 cis-9 , trans-11 and trans-10 , cis-12 cla isomers were effective in inhibiting angiogenesis in vitro in a dose-dependent fashion . 
18 trans-11 and trans-10 , cis-12 cla isomers were effective in inhibiting angiogenesis in vitro in a dose-dependent fashion . NULL NULL 
3 and trans-10 , cis-12 cla isomers were effective in inhibiting angiogenesis in vitro in a dose-dependent fashion . NULL NULL NULL 
0 isomers were effective in inhibiting angiogenesis in vitro in a dependent fashion . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the ability of cla to inhibit angiogenesis may contribute to its efficacy 
18 NULL NULL NULL NULL NULL the ability of cla to inhibit angiogenesis may contribute to its efficacy as a chemopreventive agent 
3 NULL NULL NULL NULL the ability of cla to inhibit angiogenesis may contribute to its efficacy as a chemopreventive agent . 
0 NULL NULL the ability of cla to inhibit angiogenesis may contribute to its efficacy as a chemopreventive agent . NULL NULL 
0 ability of cla to inhibit angiogenesis may contribute to its efficacy as a chemopreventive agent . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells . NULL 
0 NULL NULL NULL NULL NULL NULL molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells . NULL NULL 
3 NULL NULL NULL little is known about the specificity of angiogenic properties of oral cancer cells and the possible mechanisms . 
0 NULL NULL little is known about the specificity of angiogenic properties of oral cancer cells and the possible mechanisms . NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulatory effects on proliferation and migration of human umbilical vein endothelial 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulatory effects on proliferation and migration of human umbilical vein endothelial cells 
1 NULL NULL NULL NULL NULL NULL NULL stimulatory effects on proliferation and migration of human umbilical vein endothelial cells ( huvec 
14 NULL NULL NULL NULL NULL stimulatory effects on proliferation and migration of human umbilical vein endothelial cells ( huvec ) characterized 
3 human umbilical vein endothelial cells ( huvec ) characterized the angiogenic properties of oral cancer cells but not normal oral keratinocytes 
0 umbilical vein endothelial cells ( huvec ) characterized the angiogenic properties of oral cancer cells but not normal oral keratinocytes ( 
0 NULL NULL NULL NULL NULL NULL NULL elisa found the presence of vascular endothelial growth factors ( vegf ) both in 
0 NULL NULL NULL elisa found the presence of vascular endothelial growth factors ( vegf ) both in the tested oral cancer 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL attenuation of the proangiogenic effects by neutralizing vegf antibodies suggests vegf 
3 NULL NULL NULL NULL NULL NULL NULL attenuation of the angiogenic effects by neutralizing vegf antibodies suggests vegf play a key 
0 NULL NULL NULL NULL NULL NULL attenuation of the proangiogenic effects by neutralizing vegf antibodies suggests vegf play a key role 
16 of the proangiogenic effects by neutralizing vegf antibodies suggests vegf play a key role in the acquisition of the angiogenic phenotype 
16 proangiogenic effects by neutralizing vegf antibodies suggests vegf play a key role in the acquisition of the angiogenic phenotype in oral 
16 effects by neutralizing vegf antibodies suggests vegf play a key role in the acquisition of the angiogenic phenotype in oral cancer 
3 vegf play a key role in the acquisition of the angiogenic phenotype in oral cancer cells . NULL NULL NULL NULL 
18 ) together with p53 dna sequencing analysis indicate that p53 function loss by mutation or overexpression of mdm2 occurred in all 
18 together with p53 dna sequencing analysis indicate that p53 function loss by mutation or overexpression of mdm2 occurred in all tested 
9 sequencing analysis indicate that p53 function loss by mutation or overexpression of mdm2 occurred in all tested oral cancer cells regardless 
3 NULL NULL NULL NULL NULL NULL in summary , the angiogenic property of oral cancer cells is mediated by many factors 
0 NULL NULL NULL NULL NULL in summary , the angiogenic property of oral cancer cells is mediated by many factors in 
16 summary , the angiogenic property of oral cancer cells is mediated by many factors in addition to vegf and the functional 
0 of oral cancer cells is mediated by many factors in addition to vegf and the functional status of p53 . NULL 
6 NULL NULL NULL NULL NULL retinal microangiopathies overlying pigment epithelial detachment in age-related macular degeneration . NULL NULL NULL NULL NULL 
6 NULL retinal microangiopathies overlying pigment epithelial detachment in age-related macular degeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
7 NULL NULL NULL NULL NULL NULL purpose : to evaluate alterations in the retinal vasculature overlying pigment epithelial detachments ( ped 
6 to evaluate alterations in the retinal vasculature overlying pigment epithelial detachments ( ped ) in exudative age-related macular degeneration ( armd 
6 pigment epithelial detachments ( ped ) in exudative age-related macular degeneration ( armd ) using indocyanine green and fluorescein angiography . 
0 macular degeneration ( armd ) using indocyanine green and fluorescein angiography . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 methods : forty-one patients ( 41 eyes ) with a clinical diagnosis of exudative armd with ped underwent simultaneous fluorescein and 
0 ) with a clinical diagnosis of exudative armd with ped underwent simultaneous fluorescein and indocyanine green angiography , also under high 
19 exudative armd with ped underwent simultaneous fluorescein and indocyanine green angiography , also under high ( 10 degrees ) magnification . 
0 vascular abnormalities in the retina were compared between patients with vascularized ( n = 34 , group 1 ) and nonvascularized 
0 = 7 , group 2 ) ped on indocyanine green angiography and correlated with the size of the ped and the 
0 and correlated with the size of the ped and the presence of serous retinal detachment . NULL NULL NULL NULL NULL 
6 size of the ped and the presence of serous retinal detachment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : in all , 67 vascular abnormalities were found by 
0 all , 67 vascular abnormalities were found by indocyanine green angiography and only 22 by fluorescein angiography ; this finding was 
0 found by indocyanine green angiography and only 22 by fluorescein angiography ; this finding was statistically significant ( p less than 
0 only 22 by fluorescein angiography ; this finding was statistically significant ( p less than 0.0001 ) . NULL NULL NULL 
0 patients in group 2 ) was directly correlated with the presence of choroidal neovascularizations ( p = 0.002 ) . NULL 
3 2 ) was directly correlated with the presence of choroidal neovascularizations ( p = 0.002 ) . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL there was also a direct correlation between the presence of choroidal neovascularization and size of 
0 NULL NULL there was also a direct correlation between the presence of choroidal neovascularization and size of the ped ( p 
3 was also a direct correlation between the presence of choroidal neovascularization and size of the ped ( p = 0.03 ) 
17 of retinal vascular findings was not significantly correlated with serous elevation of the retina . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL conclusions : retinal vasculopathies may be observed in eyes with ped and are detectable by indocyanine green 
0 vasculopathies may be observed in eyes with ped and are detectable by indocyanine green and fluorescein angiography . NULL NULL NULL 
19 with ped and are detectable by indocyanine green and fluorescein angiography . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis 
0 NULL NULL NULL NULL NULL NULL enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor 
0 NULL NULL NULL NULL enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in 
16 NULL NULL enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine 
2 expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model . 
18 tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model . NULL NULL 
0 inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model . NULL NULL NULL 
4 of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model . NULL NULL NULL NULL 
0 functional capillary morphogenesis and inhibits tumor growth in a murine tumor model . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL homeostasis of the extracellular matrix is a delicate balance between degradation and remodeling , the 
6 homeostasis of the extracellular matrix is a delicate balance between degradation and remodeling , the balance being maintained by the interaction 
7 the extracellular matrix is a delicate balance between degradation and remodeling , the balance being maintained by the interaction of activated 
16 delicate balance between degradation and remodeling , the balance being maintained by the interaction of activated matrix metalloproteinases ( mmps ) 
15 degradation and remodeling , the balance being maintained by the interaction of activated matrix metalloproteinases ( mmps ) and specific tissue 
17 remodeling , the balance being maintained by the interaction of activated matrix metalloproteinases ( mmps ) and specific tissue inhibitors of 
0 , the balance being maintained by the interaction of activated matrix metalloproteinases ( mmps ) and specific tissue inhibitors of matrix 
0 matrix metalloproteinases ( mmps ) and specific tissue inhibitors of matrix metalloproteinases ( timps ) . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL up-regulation of mmp activity , favoring proteolytic degradation of the basement 
0 NULL NULL NULL NULL NULL NULL NULL up-regulation of mmp activity , favoring proteolytic degradation of the basement membrane and extracellular 
6 NULL NULL NULL up-regulation of mmp activity , favoring proteolytic degradation of the basement membrane and extracellular matrix , has been 
0 , favoring proteolytic degradation of the basement membrane and extracellular matrix , has been linked to tumor growth and metastasis , 
0 of the basement membrane and extracellular matrix , has been linked to tumor growth and metastasis , as well as tumor-associated 
0 basement membrane and extracellular matrix , has been linked to tumor growth and metastasis , as well as tumor-associated angiogenesis , 
4 membrane and extracellular matrix , has been linked to tumor growth and metastasis , as well as tumor-associated angiogenesis , whereas 
14 extracellular matrix , has been linked to tumor growth and metastasis , as well as tumor-associated angiogenesis , whereas inhibition of 
0 linked to tumor growth and metastasis , as well as associated angiogenesis , whereas inhibition of mmp activity appears to restrict 
3 to tumor growth and metastasis , as well as tumor-associated angiogenesis , whereas inhibition of mmp activity appears to restrict these 
18 and metastasis , as well as tumor-associated angiogenesis , whereas inhibition of mmp activity appears to restrict these processes . NULL 
0 as well as tumor-associated angiogenesis , whereas inhibition of mmp activity appears to restrict these processes . NULL NULL NULL NULL 
18 tumor-associated angiogenesis , whereas inhibition of mmp activity appears to restrict these processes . NULL NULL NULL NULL NULL NULL NULL 
0 , whereas inhibition of mmp activity appears to restrict these processes . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL we have used retroviral-mediated gene delivery to effect sustained autocrine expression of timp-3 
0 NULL NULL NULL NULL NULL NULL NULL we have used mediated gene delivery to effect sustained autocrine expression of timp-3 in 
0 NULL NULL NULL NULL NULL we have used retroviral-mediated gene delivery to effect sustained autocrine expression of timp-3 in murine neuroblastoma 
17 NULL NULL NULL we have used retroviral-mediated gene delivery to effect sustained autocrine expression of timp-3 in murine neuroblastoma and melanoma 
9 we have used retroviral-mediated gene delivery to effect sustained autocrine expression of timp-3 in murine neuroblastoma and melanoma tumor cells in 
0 sustained autocrine expression of timp-3 in murine neuroblastoma and melanoma tumor cells in order to further examine the ability of timps 
0 and melanoma tumor cells in order to further examine the ability of timps to inhibit angiogenesis in vivo . NULL NULL 
18 in order to further examine the ability of timps to inhibit angiogenesis in vivo . NULL NULL NULL NULL NULL NULL 
3 order to further examine the ability of timps to inhibit angiogenesis in vivo . NULL NULL NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL growth of both histologic types of gene-modified tumor cells in severe 
0 NULL NULL NULL growth of both histologic types of gene-modified tumor cells in severe combined immunodeficiency ( scid ) mice was 
18 in severe combined immunodeficiency ( scid ) mice was significantly restricted when compared with controls . NULL NULL NULL NULL NULL 
0 ( scid ) mice was significantly restricted when compared with controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL histologic evaluation revealed that although tumors overexpressing timp-3 had an increased number of cd31 ( + ) 
0 histologic evaluation revealed that although tumors overexpressing timp-3 had an increased number of cd31 ( + ) endothelial cells , these 
2 + ) endothelial cells , these endothelial cells had not formed functional tubules , as evidenced by decreased vessel continuity and 
18 cells had not formed functional tubules , as evidenced by decreased vessel continuity and minimal pericyte recruitment . NULL NULL NULL 
14 , as evidenced by decreased vessel continuity and minimal pericyte recruitment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL this effect appears to be mediated , in part , by decreased 
0 NULL NULL NULL NULL NULL this effect appears to be mediated , in part , by decreased expression of vascular endothelial 
18 effect appears to be mediated , in part , by decreased expression of vascular endothelial ( ve ) -cadherin by endothelial 
9 appears to be mediated , in part , by decreased expression of vascular endothelial ( ve ) -cadherin by endothelial cells 
0 endothelial ( ve ) -cadherin by endothelial cells in the presence of timp-3 as seen both in an in vitro assay 
9 as seen both in an in vitro assay and in overexpressing tumors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL taken together , these results demonstrate that overexpression of timp-3 can inhibit angiogenesis and associated 
9 NULL NULL NULL taken together , these results demonstrate that overexpression of timp-3 can inhibit angiogenesis and associated tumor growth , 
18 together , these results demonstrate that overexpression of timp-3 can inhibit angiogenesis and associated tumor growth , and that the antiangiogenic 
3 , these results demonstrate that overexpression of timp-3 can inhibit angiogenesis and associated tumor growth , and that the antiangiogenic effects 
0 results demonstrate that overexpression of timp-3 can inhibit angiogenesis and associated tumor growth , and that the antiangiogenic effects of timp-3 
0 demonstrate that overexpression of timp-3 can inhibit angiogenesis and associated tumor growth , and that the antiangiogenic effects of timp-3 appear 
4 that overexpression of timp-3 can inhibit angiogenesis and associated tumor growth , and that the antiangiogenic effects of timp-3 appear to 
3 inhibit angiogenesis and associated tumor growth , and that the angiogenic effects of timp-3 appear to be mediated through the inhibition 
18 angiogenesis and associated tumor growth , and that the antiangiogenic effects of timp-3 appear to be mediated through the inhibition of 
16 and that the antiangiogenic effects of timp-3 appear to be mediated through the inhibition of functional capillary morphogenesis . NULL NULL 
18 antiangiogenic effects of timp-3 appear to be mediated through the inhibition of functional capillary morphogenesis . NULL NULL NULL NULL NULL 
2 appear to be mediated through the inhibition of functional capillary morphogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL brn-3a , a neuronal transcription factor of the pou gene family : indications for its 
0 factor of the pou gene family : indications for its involvement in cancer and angiogenesis . NULL NULL NULL NULL NULL 
3 gene family : indications for its involvement in cancer and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 ( so-called because of the similarity with the group of transcription factors pit , oct , and unc ) , was 
16 , and unc ) , was found in neuronal cells engaged in the transcription activity of the p1 and p2 promoters 
10 ) , was found in neuronal cells engaged in the transcription activity of the p1 and p2 promoters of the most 
0 , was found in neuronal cells engaged in the transcription activity of the p1 and p2 promoters of the most powerful 
0 NULL NULL NULL NULL NULL the alternative splicing of brn-3a mrna produces two molecular forms : a longer , bcl-2 transactivating 
9 NULL NULL NULL NULL the alternative splicing of brn-3a mrna produces two molecular forms : a longer , bcl-2 transactivating form 
0 produces two molecular forms : a longer , bcl-2 transactivating form , and a shorter inactive form , lacking 84 aa 
0 longer , bcl-2 transactivating form , and a shorter inactive form , lacking 84 aa in the aminoterminus . NULL NULL 
19 NULL NULL NULL in neuronal cells , following brn-3a gene transfection and superexpression , an increase of 30 fold of the 
9 NULL in neuronal cells , following brn-3a gene transfection and superexpression , an increase of 30 fold of the bcl-2 protein 
17 cells , following brn-3a gene transfection and superexpression , an increase of 30 fold of the bcl-2 protein occurs , leading 
0 superexpression , an increase of 30 fold of the bcl-2 protein occurs , leading to apoptosis protection . NULL NULL NULL 
17 increase of 30 fold of the bcl-2 protein occurs , leading to apoptosis protection . NULL NULL NULL NULL NULL NULL 
5 30 fold of the bcl-2 protein occurs , leading to apoptosis protection . NULL NULL NULL NULL NULL NULL NULL NULL 
18 fold of the bcl-2 protein occurs , leading to apoptosis protection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL however , recent works demonstrate that brn-3a expression is not restricted to neuronal cells , as its activity 
18 however , recent works demonstrate that brn-3a expression is not restricted to neuronal cells , as its activity was detected also 
0 expression is not restricted to neuronal cells , as its activity was detected also in cancer cells of non-neuronal nature . 
0 not restricted to neuronal cells , as its activity was detected also in cancer cells of non-neuronal nature . NULL NULL 
0 NULL NULL NULL NULL looking for mechanisms linking brn-3a to carcinogenesis , we discuss the role of this transcription factor in 
16 for mechanisms linking brn-3a to carcinogenesis , we discuss the role of this transcription factor in influencing bcl-2/p53 antagonism and bcl-2/vegf 
0 brn-3a to carcinogenesis , we discuss the role of this transcription factor in influencing bcl-2/p53 antagonism and bcl-2/vegf induction of tumor 
18 , we discuss the role of this transcription factor in influencing bcl-2/p53 antagonism and bcl-2/vegf induction of tumor angiogenesis , concluding 
18 discuss the role of this transcription factor in influencing bcl-2/p53 antagonism and bcl-2/vegf induction of tumor angiogenesis , concluding this review 
17 of this transcription factor in influencing bcl-2/p53 antagonism and bcl-2/vegf induction of tumor angiogenesis , concluding this review with a proposal 
0 transcription factor in influencing bcl-2/p53 antagonism and bcl-2/vegf induction of tumor angiogenesis , concluding this review with a proposal for the 
3 factor in influencing bcl-2/p53 antagonism and bcl-2/vegf induction of tumor angiogenesis , concluding this review with a proposal for the oncogenic 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation 
0 NULL NULL NULL NULL NULL NULL NULL roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and 
0 NULL NULL NULL NULL roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to 
3 NULL NULL NULL roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude 
17 NULL NULL roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats 
19 roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL roles of cell adhesion molecules mediating the interaction of cancer and 
0 NULL NULL NULL NULL NULL NULL NULL roles of cell adhesion molecules mediating the interaction of cancer and endothelial cells in 
17 NULL NULL NULL NULL NULL roles of cell adhesion molecules mediating the interaction of cancer and endothelial cells in tumor angiogenesis 
15 NULL NULL NULL roles of cell adhesion molecules mediating the interaction of cancer and endothelial cells in tumor angiogenesis were investigated 
0 molecules mediating the interaction of cancer and endothelial cells in tumor angiogenesis were investigated using new in vitro and in vivo 
3 mediating the interaction of cancer and endothelial cells in tumor angiogenesis were investigated using new in vitro and in vivo model 
19 new in vitro and in vivo model systems with a cultured murine endothelial cell line ( f-2 ) and human cultured 
19 cultured murine endothelial cell line ( f-2 ) and human cultured epidermoid cancer cells ( a431 ) . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the a431 cells exhibited typical in vitro cell adhesion to the endothelial f-2 cells 
15 NULL NULL the a431 cells exhibited typical in vitro cell adhesion to the endothelial f-2 cells . NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL the initial step of adhesion was mediated by sialyl lewis ( x ) ( le 
17 NULL NULL NULL NULL the initial step of adhesion was mediated by sialyl lewis ( x ) ( le ( x 
0 and sialyl le ( a ) , the carbohydrate determinants expressed on the cancer cells , and e-selectin expressed constitutively on 
9 carbohydrate determinants expressed on the cancer cells , and e-selectin expressed constitutively on f-2 cells . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL prolonged culture led to the implantation of cancer cells into the 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL prolonged culture led to the implantation of cancer cells into the monolayer 
0 NULL NULL NULL NULL NULL NULL NULL NULL prolonged culture led to the implantation of cancer cells into the monolayer of 
19 NULL NULL NULL NULL NULL prolonged culture led to the implantation of cancer cells into the monolayer of the f-2 cells 
16 into the monolayer of the f-2 cells , which was mediated mainly by alpha ( 3 ) beta ( 1 ) 
19 NULL NULL NULL NULL NULL NULL NULL NULL f-2 cells cultured on matrigel showed evident tube formation , and coculture of 
0 NULL NULL NULL NULL NULL f-2 cells cultured on matrigel showed evident tube formation , and coculture of f-2 cells with 
2 NULL NULL f-2 cells cultured on matrigel showed evident tube formation , and coculture of f-2 cells with a431 cells led 
19 cells cultured on matrigel showed evident tube formation , and coculture of f-2 cells with a431 cells led to the formation 
0 formation , and coculture of f-2 cells with a431 cells led to the formation of a431 cell nests constantly surrounded by 
0 coculture of f-2 cells with a431 cells led to the formation of a431 cell nests constantly surrounded by tube-like networks consisting 
0 NULL NULL NULL NULL NULL NULL NULL this in vitro morphogenesis was inhibited by the addition of anti-sialyl le ( x 
0 NULL NULL NULL NULL NULL this in vitro morphogenesis was inhibited by the addition of anti-sialyl le ( x ) /le 
0 NULL NULL this in vitro morphogenesis was inhibited by the addition of anti-sialyl le ( x ) /le ( a ) 
0 ) or anti-beta ( 1 ) -integrin antibodies , which led to the formation of cancer cell aggregates that were independent 
17 ( 1 ) -integrin antibodies , which led to the formation of cancer cell aggregates that were independent from the f-2 
15 antibodies , which led to the formation of cancer cell aggregates that were independent from the f-2 cell networks . NULL 
16 led to the formation of cancer cell aggregates that were independent from the f-2 cell networks . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL this in vitro morphological appearance was exactly reproduced in the in vivo tumors , 
0 NULL NULL NULL NULL NULL NULL this in vitro morphological appearance was exactly reproduced in the in vivo tumors , which 
0 NULL NULL NULL this in vitro morphological appearance was exactly reproduced in the in vivo tumors , which were formed when 
2 exactly reproduced in the in vivo tumors , which were formed when the mixture of a431 and f-2 cells at the 
19 f-2 cells at the ratio of 10 : 1 were cotransplanted s.c . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL the tumors of a431 supplemented with f-2 cells were profoundly vascularized throughout by the tubular 
0 the tumors of a431 supplemented with f-2 cells were profoundly vascularized throughout by the tubular structures formed by f-2 cells , 
2 f-2 cells were profoundly vascularized throughout by the tubular structures formed by f-2 cells , the lumen of which contained the 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the tumor mass thus formed was an average 5.8-fold as large as 
2 NULL NULL NULL NULL NULL NULL the tumor mass thus formed was an average 5.8-fold as large as control a431 tumors 
0 mass thus formed was an average 5.8-fold as large as control a431 tumors that were grown without f-2 cells . NULL 
4 average 5.8-fold as large as control a431 tumors that were grown without f-2 cells . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL the co-injection of anti-le ( x ) /le ( a ) or 
17 ( a ) or anti-beta ( 1 ) -integrin antibodies produced a marked reduction in the size of a431 tumors , 
18 or anti-beta ( 1 ) -integrin antibodies produced a marked reduction in the size of a431 tumors , which were not 
0 in the size of a431 tumors , which were not vascularized and accompanied an independent tiny remnant clump of f-2 cells 
0 a431 tumors , which were not vascularized and accompanied an independent tiny remnant clump of f-2 cells . NULL NULL NULL 
0 these a431 tumors did not differ significantly from those of control a431 tumors raised without f-2 cells . NULL NULL NULL 
4 did not differ significantly from those of control a431 tumors raised without f-2 cells . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate that the interaction of tumor cells and endothelial cells 
15 NULL NULL NULL NULL NULL these results indicate that the interaction of tumor cells and endothelial cells in orderly tumor angiomorphogenesis 
0 NULL NULL NULL these results indicate that the interaction of tumor cells and endothelial cells in orderly tumor angiomorphogenesis is highly 
0 the interaction of tumor cells and endothelial cells in orderly tumor angiomorphogenesis is highly dependent on the action of cell adhesion 
3 interaction of tumor cells and endothelial cells in orderly tumor angiomorphogenesis is highly dependent on the action of cell adhesion molecules 
17 cells and endothelial cells in orderly tumor angiomorphogenesis is highly dependent on the action of cell adhesion molecules mediating the adhesion 
0 cells in orderly tumor angiomorphogenesis is highly dependent on the action of cell adhesion molecules mediating the adhesion of cancer cells 
0 tumor angiomorphogenesis is highly dependent on the action of cell adhesion molecules mediating the adhesion of cancer cells to endothelial cells 
16 is highly dependent on the action of cell adhesion molecules mediating the adhesion of cancer cells to endothelial cells , inhibition 
15 dependent on the action of cell adhesion molecules mediating the adhesion of cancer cells to endothelial cells , inhibition of which 
18 mediating the adhesion of cancer cells to endothelial cells , inhibition of which remarkably retards tumor growth and angiogenesis . NULL 
18 cancer cells to endothelial cells , inhibition of which remarkably retards tumor growth and angiogenesis . NULL NULL NULL NULL NULL 
0 cells to endothelial cells , inhibition of which remarkably retards tumor growth and angiogenesis . NULL NULL NULL NULL NULL NULL 
4 to endothelial cells , inhibition of which remarkably retards tumor growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 cells , inhibition of which remarkably retards tumor growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL adaptor protein crk is required for ephrin-b1-induced membrane ruffling and focal complex 
17 NULL NULL NULL NULL NULL NULL adaptor protein crk is required for ephrin-b1-induced membrane ruffling and focal complex assembly of human 
17 NULL NULL NULL NULL adaptor protein crk is required for induced membrane ruffling and focal complex assembly of human aortic endothelial 
14 NULL NULL adaptor protein crk is required for ephrin-b1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells . 
15 crk is required for ephrin-b1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells . NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell migration is an essential step in vasculogenesis and angiogenesis , in 
17 NULL NULL NULL NULL NULL endothelial cell migration is an essential step in vasculogenesis and angiogenesis , in which receptor tyrosine 
3 NULL NULL endothelial cell migration is an essential step in vasculogenesis and angiogenesis , in which receptor tyrosine kinases play a 
3 endothelial cell migration is an essential step in vasculogenesis and angiogenesis , in which receptor tyrosine kinases play a pivotal role 
16 in vasculogenesis and angiogenesis , in which receptor tyrosine kinases play a pivotal role . NULL NULL NULL NULL NULL NULL 
16 and angiogenesis , in which receptor tyrosine kinases play a pivotal role . NULL NULL NULL NULL NULL NULL NULL NULL 
16 angiogenesis , in which receptor tyrosine kinases play a pivotal role . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL we investigated the mechanism by which ephrin-b1 promotes membrane ruffling in human aortic endothelial 
17 NULL NULL NULL we investigated the mechanism by which ephrin-b1 promotes membrane ruffling in human aortic endothelial cells , because membrane 
14 NULL we investigated the mechanism by which ephrin-b1 promotes membrane ruffling in human aortic endothelial cells , because membrane ruffling heralds 
14 membrane ruffling in human aortic endothelial cells , because membrane ruffling heralds cell body migration . NULL NULL NULL NULL NULL 
14 aortic endothelial cells , because membrane ruffling heralds cell body migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL we especially focused on the role of crk adaptor protein in ephb-mediated signaling . NULL NULL 
0 NULL we especially focused on the role of crk adaptor protein in ephb-mediated signaling . NULL NULL NULL NULL NULL NULL 
17 especially focused on the role of crk adaptor protein in mediated signaling . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL using tagged crk and a fluorescent time-lapse microscope , we showed that 
0 using dsred-tagged crk and a fluorescent time-lapse microscope , we showed that crk was recruited to the nascent focal complex after 
14 a fluorescent time-lapse microscope , we showed that crk was recruited to the nascent focal complex after ephrin-b1 stimulation . NULL 
17 crk was recruited to the nascent focal complex after ephrin-b1 stimulation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 that p130 ( cas ) , but not paxillin , recruited crk to the nascent focal complex . NULL NULL NULL 
17 that p130 ( cas ) , but not paxillin , recruited crk to the nascent focal complex . NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the necessity of crk in ephrin-b1-induced membrane ruffling was shown both by 
17 NULL NULL NULL NULL NULL the necessity of crk in induced membrane ruffling was shown both by the overexpression of dominant 
14 NULL NULL NULL the necessity of crk in ephrin-b1-induced membrane ruffling was shown both by the overexpression of dominant negative crk 
0 crk in ephrin-b1-induced membrane ruffling was shown both by the overexpression of dominant negative crk mutants and by the depletion of 
0 membrane ruffling was shown both by the overexpression of dominant negative crk mutants and by the depletion of crk by using 
18 the overexpression of dominant negative crk mutants and by the depletion of crk by using rna interference . NULL NULL NULL 
0 mutants and by the depletion of crk by using rna interference . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL then , we examined the role of two major downstream molecules of crk , rac1 and 
0 NULL NULL then , we examined the role of two major downstream molecules of crk , rac1 and rap1 . NULL 
0 NULL then , we examined the role of two major downstream molecules of crk , rac1 and rap1 . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the dominant negative mutant of rac1 completely inhibited ephrin-b1-induced membrane ruffling and focal 
18 NULL NULL NULL the dominant negative mutant of rac1 completely inhibited ephrin-b1-induced membrane ruffling and focal complex assembly . NULL NULL 
17 NULL NULL the dominant negative mutant of rac1 completely inhibited induced membrane ruffling and focal complex assembly . NULL NULL NULL 
14 the dominant negative mutant of rac1 completely inhibited ephrin-b1-induced membrane ruffling and focal complex assembly . NULL NULL NULL NULL NULL 
15 of rac1 completely inhibited ephrin-b1-induced membrane ruffling and focal complex assembly . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL in contrast , rap1gapii , a negative regulator of rap1 , did not inhibit ephrin-b1-induced membrane ruffling 
0 NULL NULL NULL in contrast , rap1gapii , a negative regulator of rap1 , did not inhibit ephrin-b1-induced membrane ruffling . 
18 rap1gapii , a negative regulator of rap1 , did not inhibit ephrin-b1-induced membrane ruffling . NULL NULL NULL NULL NULL NULL 
17 , a negative regulator of rap1 , did not inhibit induced membrane ruffling . NULL NULL NULL NULL NULL NULL NULL 
14 negative regulator of rap1 , did not inhibit ephrin-b1-induced membrane ruffling . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL however , in expressing cells , ephrin-b1 did not induce membrane spreading , probably 
17 NULL however , in rap1gapii-expressing cells , ephrin-b1 did not induce membrane spreading , probably due to instability of the focal 
14 , in rap1gapii-expressing cells , ephrin-b1 did not induce membrane spreading , probably due to instability of the focal complex . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicated that crk plays a critical role in rac1-induced membrane 
16 NULL NULL NULL NULL NULL these results indicated that crk plays a critical role in rac1-induced membrane ruffling and rap1-mediated nascent 
16 NULL NULL NULL these results indicated that crk plays a critical role in rac1-induced membrane ruffling and rap1-mediated nascent focal complex 
16 NULL NULL these results indicated that crk plays a critical role in rac1-induced membrane ruffling and rap1-mediated nascent focal complex stabilization 
17 these results indicated that crk plays a critical role in induced membrane ruffling and rap1-mediated nascent focal complex stabilization contributing to 
14 indicated that crk plays a critical role in rac1-induced membrane ruffling and rap1-mediated nascent focal complex stabilization contributing to ephrin-b1-induced human 
16 crk plays a critical role in rac1-induced membrane ruffling and mediated nascent focal complex stabilization contributing to ephrin-b1-induced human aortic endothelial 
19 role in rac1-induced membrane ruffling and rap1-mediated nascent focal complex stabilization contributing to ephrin-b1-induced human aortic endothelial cells migration . NULL 
16 in rac1-induced membrane ruffling and rap1-mediated nascent focal complex stabilization contributing to ephrin-b1-induced human aortic endothelial cells migration . NULL NULL 
17 membrane ruffling and rap1-mediated nascent focal complex stabilization contributing to induced human aortic endothelial cells migration . NULL NULL NULL NULL 
14 focal complex stabilization contributing to ephrin-b1-induced human aortic endothelial cells migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL regulation of transforming growth factor-beta signaling and vascular diseases . NULL 
0 NULL NULL NULL NULL NULL NULL NULL regulation of transforming growth factor-beta signaling and vascular diseases . NULL NULL NULL NULL 
0 NULL NULL NULL NULL purpose : members of the transforming growth factor ( tgf ) -beta superfamily play critical roles in 
0 of the transforming growth factor ( tgf ) -beta superfamily play critical roles in regulation of various cellular functions . NULL 
0 the transforming growth factor ( tgf ) -beta superfamily play critical roles in regulation of various cellular functions . NULL NULL 
0 transforming growth factor ( tgf ) -beta superfamily play critical roles in regulation of various cellular functions . NULL NULL NULL 
0 factor ( tgf ) -beta superfamily play critical roles in regulation of various cellular functions . NULL NULL NULL NULL NULL 
0 -beta superfamily play critical roles in regulation of various cellular functions . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL dysregulation of the signaling mechanisms of the tgf-beta superfamily proteins is 
0 of the signaling mechanisms of the tgf-beta superfamily proteins is associated with clinical diseases such as cancer , fibrotic diseases , 
0 signaling mechanisms of the tgf-beta superfamily proteins is associated with clinical diseases such as cancer , fibrotic diseases , and vascular 
0 may provide us with novel ways to develop strategies for treating clinical diseases induced by these cytokines . NULL NULL NULL 
0 provide us with novel ways to develop strategies for treating clinical diseases induced by these cytokines . NULL NULL NULL NULL 
0 with novel ways to develop strategies for treating clinical diseases induced by these cytokines . NULL NULL NULL NULL NULL NULL 
16 of the mechanisms of tgf-beta signaling , focusing on the roles of tgf-beta in regulation of vascular wall cells and on 
16 tgf-beta signaling , focusing on the roles of tgf-beta in regulation of vascular wall cells and on the regulation of tgf-beta 
16 tgf-beta in regulation of vascular wall cells and on the regulation of tgf-beta superfamily signals by inhibitory smads . NULL NULL 
0 vascular wall cells and on the regulation of tgf-beta superfamily signals by inhibitory smads . NULL NULL NULL NULL NULL NULL 
18 cells and on the regulation of tgf-beta superfamily signals by inhibitory smads . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL postoperative progression of pulmonary metastasis in osteosarcoma . NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL postoperative progression of pulmonary metastasis in osteosarcoma . NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL early relapse with distant metastasis often is observed in patients with cancer after resection of 
0 NULL NULL NULL early relapse with distant metastasis often is observed in patients with cancer after resection of the primary tumor 
19 distant metastasis often is observed in patients with cancer after resection of the primary tumor . NULL NULL NULL NULL NULL 
0 observed in patients with cancer after resection of the primary tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL it is considered that resection of the primary tumor induces activation of systemic angiogenesis and 
0 NULL NULL it is considered that resection of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote 
17 NULL it is considered that resection of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis 
17 it is considered that resection of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis . 
3 that resection of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis . NULL NULL NULL 
17 of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis . NULL NULL NULL NULL NULL 
17 the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis . NULL NULL NULL NULL NULL NULL 
14 induces activation of systemic angiogenesis and enhances progression of remote metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL the authors show that resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis 
0 NULL the authors show that resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis in animal osteosarcoma models . 
17 the authors show that resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis in animal osteosarcoma models . NULL 
17 authors show that resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis in animal osteosarcoma models . NULL NULL 
14 resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis in animal osteosarcoma models . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL matrigel plug neovascularization assay revealed that systemic angiogenic activity was elevated after primary 
3 NULL NULL NULL matrigel plug neovascularization assay revealed that systemic angiogenic activity was elevated after primary tumor removal ( tumor intact 
0 NULL NULL matrigel plug neovascularization assay revealed that systemic angiogenic activity was elevated after primary tumor removal ( tumor intact group 
17 matrigel plug neovascularization assay revealed that systemic angiogenic activity was elevated after primary tumor removal ( tumor intact group , 1.61 
0 assay revealed that systemic angiogenic activity was elevated after primary tumor removal ( tumor intact group , 1.61 +/- 0.21 g/dl 
19 revealed that systemic angiogenic activity was elevated after primary tumor removal ( tumor intact group , 1.61 +/- 0.21 g/dl ; 
0 systemic angiogenic activity was elevated after primary tumor removal ( tumor intact group , 1.61 +/- 0.21 g/dl ; tumor removed 
0 ( tumor intact group , 1.61 +/- 0.21 g/dl ; tumor removed group , 4.92 +/- 0.35 g/dl ) . NULL 
0 tumor intact group , 1.61 +/- 0.21 g/dl ; tumor removed group , 4.92 +/- 0.35 g/dl ) . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , serum concentration of the angiogenesis inhibitor , endostatin , 
3 NULL NULL NULL in addition , serum concentration of the angiogenesis inhibitor , endostatin , decreased significantly after primary tumor removal 
0 NULL NULL in addition , serum concentration of the angiogenesis inhibitor , endostatin , decreased significantly after primary tumor removal . 
18 , serum concentration of the angiogenesis inhibitor , endostatin , decreased significantly after primary tumor removal . NULL NULL NULL NULL 
0 the angiogenesis inhibitor , endostatin , decreased significantly after primary tumor removal . NULL NULL NULL NULL NULL NULL NULL NULL 
19 angiogenesis inhibitor , endostatin , decreased significantly after primary tumor removal . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment with the antiangiogenic reagent tnp-470 suppressed postoperative progression of pulmonary 
3 NULL NULL NULL NULL NULL NULL NULL treatment with the angiogenic reagent tnp-470 suppressed postoperative progression of pulmonary metastasis . NULL 
18 NULL NULL NULL NULL treatment with the antiangiogenic reagent tnp-470 suppressed postoperative progression of pulmonary metastasis . NULL NULL NULL NULL 
17 NULL NULL treatment with the antiangiogenic reagent tnp-470 suppressed postoperative progression of pulmonary metastasis . NULL NULL NULL NULL NULL NULL 
14 with the antiangiogenic reagent tnp-470 suppressed postoperative progression of pulmonary metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate the possibility that activation of angiogenic activity after resection 
17 NULL NULL NULL NULL these results indicate the possibility that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression 
3 NULL NULL these results indicate the possibility that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary 
0 NULL these results indicate the possibility that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis 
19 results indicate the possibility that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis . NULL 
17 that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis . NULL NULL NULL NULL NULL 
17 activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis . NULL NULL NULL NULL NULL NULL 
14 activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL the current data also suggest that administration of antiangiogenic reagents can prevent progression of pulmonary metastasis in 
3 NULL NULL the current data also suggest that administration of angiogenic reagents can prevent progression of pulmonary metastasis in osteosarcoma postoperatively 
18 current data also suggest that administration of antiangiogenic reagents can prevent progression of pulmonary metastasis in osteosarcoma postoperatively . NULL NULL 
17 data also suggest that administration of antiangiogenic reagents can prevent progression of pulmonary metastasis in osteosarcoma postoperatively . NULL NULL NULL 
14 that administration of antiangiogenic reagents can prevent progression of pulmonary metastasis in osteosarcoma postoperatively . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL arteriogenesis : the development and growth of collateral arteries . NULL 
2 NULL NULL NULL NULL NULL NULL NULL arteriogenesis : the development and growth of collateral arteries . NULL NULL NULL NULL 
4 NULL NULL NULL NULL NULL arteriogenesis : the development and growth of collateral arteries . NULL NULL NULL NULL NULL NULL 
0 in patients with atherosclerotic vascular diseases , collateral vessels bypassing major arterial obstructions have frequently been observed . NULL NULL NULL 
0 patients with atherosclerotic vascular diseases , collateral vessels bypassing major arterial obstructions have frequently been observed . NULL NULL NULL NULL 
0 , collateral vessels bypassing major arterial obstructions have frequently been observed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL the term `` arteriogenesis '' was introduced to differentiate the formation of collateral arteries 
0 NULL NULL the term `` arteriogenesis '' was introduced to differentiate the formation of collateral arteries from angiogenesis , which mainly 
2 the term `` arteriogenesis '' was introduced to differentiate the formation of collateral arteries from angiogenesis , which mainly occurs in 
3 was introduced to differentiate the formation of collateral arteries from angiogenesis , which mainly occurs in the ischemic , collateral flow-dependent 
17 angiogenesis , which mainly occurs in the ischemic , collateral dependent tissue . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL many observations in various animal models and humans support that the remodeling of preexisting collateral vessels is the mechanism 
7 observations in various animal models and humans support that the remodeling of preexisting collateral vessels is the mechanism of collateral artery 
0 support that the remodeling of preexisting collateral vessels is the mechanism of collateral artery formation . NULL NULL NULL NULL NULL 
2 of preexisting collateral vessels is the mechanism of collateral artery formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
7 NULL NULL NULL NULL NULL NULL NULL NULL NULL this remodeling process seems to be mainly flow-mediated . NULL NULL NULL 
0 NULL NULL NULL this remodeling process seems to be mainly mediated . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL it involves endothelial cell activation , basal membrane degradation , leukocyte invasion 
17 NULL NULL NULL NULL NULL NULL it involves endothelial cell activation , basal membrane degradation , leukocyte invasion , proliferation of 
6 NULL NULL it involves endothelial cell activation , basal membrane degradation , leukocyte invasion , proliferation of vascular cells , neointima 
14 involves endothelial cell activation , basal membrane degradation , leukocyte invasion , proliferation of vascular cells , neointima formation ( in 
1 cell activation , basal membrane degradation , leukocyte invasion , proliferation of vascular cells , neointima formation ( in most species 
2 , leukocyte invasion , proliferation of vascular cells , neointima formation ( in most species studied ) , and changes of 
16 neointima formation ( in most species studied ) , and changes of the extracellular matrix . NULL NULL NULL NULL NULL 
0 most species studied ) , and changes of the extracellular matrix . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the contribution of ischemia to arteriogenesis is still unclear , but arteriogenesis 
3 NULL NULL NULL NULL NULL the contribution of ischemia to arteriogenesis is still unclear , but arteriogenesis clearly can occur in 
3 contribution of ischemia to arteriogenesis is still unclear , but arteriogenesis clearly can occur in the absence of any significant ischemia 
0 but arteriogenesis clearly can occur in the absence of any significant ischemia . NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL it is questionable , whether collateral arteries also form de novo in ischemic vascular diseases . NULL NULL NULL 
3 NULL NULL NULL a better understanding of the mechanisms of arteriogenesis will be important for the design of more effective strategies 
0 a better understanding of the mechanisms of arteriogenesis will be important for the design of more effective strategies for the treatment 
0 of arteriogenesis will be important for the design of more effective strategies for the treatment of patients with ischemic vascular diseases 
0 important for the design of more effective strategies for the treatment of patients with ischemic vascular diseases . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL possible role of cyclooxygenase ii in the acquisition of ovarian luteal function 
0 role of cyclooxygenase ii in the acquisition of ovarian luteal function in rodents . NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL the development of the corpus luteum ( cl ) , which involves 
0 development of the corpus luteum ( cl ) , which involves angiogenesis , is essential for the establishment of early pregnancy 
3 of the corpus luteum ( cl ) , which involves angiogenesis , is essential for the establishment of early pregnancy . 
0 luteum ( cl ) , which involves angiogenesis , is essential for the establishment of early pregnancy . NULL NULL NULL 
0 ) , which involves angiogenesis , is essential for the establishment of early pregnancy . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL we investigated the roles of the prostaglandin synthases cyclooxygenase ( cox ) i and 
3 prostaglandin synthases cyclooxygenase ( cox ) i and cox-ii in angiogenesis and progesterone production in the newly formed cl , using 
8 ( cox ) i and cox-ii in angiogenesis and progesterone production in the newly formed cl , using inhibitors of the 
2 and cox-ii in angiogenesis and progesterone production in the newly formed cl , using inhibitors of the cox enzymes and the 
17 cl , using inhibitors of the cox enzymes and the induced pseudopregnant rat as a model . NULL NULL NULL NULL 
19 , using inhibitors of the cox enzymes and the gonadotropin-induced pseudopregnant rat as a model . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL injection of indomethacin , a nonselective cox inhibitor , on the 
0 NULL NULL NULL injection of indomethacin , a nonselective cox inhibitor , on the day of ovulation and the following day 
18 , on the day of ovulation and the following day decreased serum levels of progesterone , as did injection of the 
0 the day of ovulation and the following day decreased serum levels of progesterone , as did injection of the selective cox-ii 
19 following day decreased serum levels of progesterone , as did injection of the selective cox-ii inhibitor ns-398 . NULL NULL NULL 
0 of progesterone , as did injection of the selective cox-ii inhibitor ns-398 . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL in contrast , a selective cox-i inhibitor , sc-560 , had no effect on serum progesterone concentrations 
16 , a selective cox-i inhibitor , sc-560 , had no effect on serum progesterone concentrations . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL none of the inhibitors had any effect on the weight of the superovulated ovaries or on the 
8 on the weight of the superovulated ovaries or on the synthesis of progesterone by cultured luteal cells . NULL NULL NULL 
0 the superovulated ovaries or on the synthesis of progesterone by cultured luteal cells . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL to determine whether changes in angiogenesis are responsible for the decrease in progesterone synthesis 
3 NULL NULL NULL NULL NULL to determine whether changes in angiogenesis are responsible for the decrease in progesterone synthesis , we 
16 NULL NULL NULL to determine whether changes in angiogenesis are responsible for the decrease in progesterone synthesis , we measured hemoglobin 
18 to determine whether changes in angiogenesis are responsible for the decrease in progesterone synthesis , we measured hemoglobin and cd34 levels 
8 changes in angiogenesis are responsible for the decrease in progesterone synthesis , we measured hemoglobin and cd34 levels in luteinized ovaries 
0 decrease in progesterone synthesis , we measured hemoglobin and cd34 levels in luteinized ovaries following injection of cox inhibitors and measured 
2 progesterone synthesis , we measured hemoglobin and cd34 levels in luteinized ovaries following injection of cox inhibitors and measured the relative 
0 we measured hemoglobin and cd34 levels in luteinized ovaries following injection of cox inhibitors and measured the relative frequency of cells 
0 of cox inhibitors and measured the relative frequency of cells positive for platelet-endothelial cell adhesion molecule as a specific marker for 
0 measured the relative frequency of cells positive for platelet-endothelial cell adhesion molecule as a specific marker for endothelial cells . NULL 
0 NULL NULL NULL NULL NULL all of these parameters were reduced by the cox-ii inhibitors , suggesting that changes in the 
16 parameters were reduced by the cox-ii inhibitors , suggesting that changes in the vasculature are responsible for the decrease in serum 
16 cox-ii inhibitors , suggesting that changes in the vasculature are responsible for the decrease in serum progesterone . NULL NULL NULL 
18 suggesting that changes in the vasculature are responsible for the decrease in serum progesterone . NULL NULL NULL NULL NULL NULL 
18 NULL histological examination of ovarian corrosion casts indicated that ns-398 inhibited the establishment of luteal capillary vessels following the injection of 
2 examination of ovarian corrosion casts indicated that ns-398 inhibited the establishment of luteal capillary vessels following the injection of hcg . 
19 ns-398 inhibited the establishment of luteal capillary vessels following the injection of hcg . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results are consistent with the hypothesis that the activity of cox-ii 
0 NULL the results are consistent with the hypothesis that the activity of cox-ii is associated with the formation of functional cl 
16 consistent with the hypothesis that the activity of cox-ii is associated with the formation of functional cl via its stimulation of 
2 hypothesis that the activity of cox-ii is associated with the formation of functional cl via its stimulation of angiogenesis . NULL 
17 is associated with the formation of functional cl via its stimulation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 with the formation of functional cl via its stimulation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion 
16 NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule 
15 NULL NULL NULL NULL NULL tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression . NULL 
18 NULL tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression . NULL NULL NULL NULL NULL 
0 angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression . NULL NULL NULL NULL NULL NULL NULL 
9 leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL the expression of endothelial cell ( ec ) adhesion molecules involved in 
0 NULL NULL the expression of endothelial cell ( ec ) adhesion molecules involved in leukocyte-vessel wall interactions is suppressed in malignancies 
16 the expression of endothelial cell ( ec ) adhesion molecules involved in leukocyte-vessel wall interactions is suppressed in malignancies . NULL 
15 cell ( ec ) adhesion molecules involved in leukocyte-vessel wall interactions is suppressed in malignancies . NULL NULL NULL NULL NULL 
0 ec ) adhesion molecules involved in leukocyte-vessel wall interactions is suppressed in malignancies . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the present study , we investigated in vivo the regulation of leukocyte-vessel 
16 in the present study , we investigated in vivo the regulation of leukocyte-vessel wall interactions by the presence of a tumor 
15 , we investigated in vivo the regulation of leukocyte-vessel wall interactions by the presence of a tumor . NULL NULL NULL 
0 in vivo the regulation of leukocyte-vessel wall interactions by the presence of a tumor . NULL NULL NULL NULL NULL NULL 
0 regulation of leukocyte-vessel wall interactions by the presence of a tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL by means of intravital microscopy , tumor necrosis factor alpha-stimulated leukocyte-vessel wall interactions were studied in ear 
0 NULL NULL NULL by means of intravital microscopy , tumor necrosis factor alpha-stimulated leukocyte-vessel wall interactions were studied in ear skin 
17 NULL by means of intravital microscopy , tumor necrosis factor stimulated leukocyte-vessel wall interactions were studied in ear skin microvessels of 
15 of intravital microscopy , tumor necrosis factor alpha-stimulated leukocyte-vessel wall interactions were studied in ear skin microvessels of nude mice bearing 
15 NULL NULL NULL NULL NULL NULL NULL NULL leukocyte-vessel wall interactions were studied both within and outside small tumors growing in 
4 wall interactions were studied both within and outside small tumors growing in the ear , and in ear microvessels of mice 
0 , and in ear microvessels of mice with a large tumor growing on their flank . NULL NULL NULL NULL NULL 
4 and in ear microvessels of mice with a large tumor growing on their flank . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL free mice were used as controls . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL tumor-free mice were used as controls . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL tumor-free mice were used as controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 of the ear and in the contralateral ear , leukocyte adhesion was found to be diminished significantly in vessels inside the 
18 the contralateral ear , leukocyte adhesion was found to be diminished significantly in vessels inside the ear tumor in both mouse 
0 found to be diminished significantly in vessels inside the ear tumor in both mouse models . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL this reduction disappeared with increasing distance from the tumor . NULL NULL 
0 NULL NULL NULL NULL NULL NULL this reduction disappeared with increasing distance from the tumor . NULL NULL NULL NULL NULL 
0 NULL NULL this reduction disappeared with increasing distance from the tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL surprisingly , the level of leukocyte adhesion in ear venules of mice with a large flank tumor 
0 adhesion in ear venules of mice with a large flank tumor was also reduced significantly . NULL NULL NULL NULL NULL 
18 venules of mice with a large flank tumor was also reduced significantly . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL leukocyte rolling , i.e. , the step preceding adhesion , was not influenced by the presence of a tumor 
0 the step preceding adhesion , was not influenced by the presence of a tumor in nude mice , but was down-regulated 
0 adhesion , was not influenced by the presence of a tumor in nude mice , but was down-regulated in immune-competent c57bl/6 
0 presence of a tumor in nude mice , but was down-regulated in immune-competent c57bl/6 mice . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment of mice bearing a small ear tumor with a humanized 
0 NULL NULL NULL treatment of mice bearing a small ear tumor with a humanized antivascular endothelial growth factor antibody prevented the 
0 bearing a small ear tumor with a humanized antivascular endothelial growth factor antibody prevented the down-regulation of leukocyte-vessel wall interactions inside 
18 ear tumor with a humanized antivascular endothelial growth factor antibody prevented the down-regulation of leukocyte-vessel wall interactions inside the tumor vessels 
18 with a humanized antivascular endothelial growth factor antibody prevented the down-regulation of leukocyte-vessel wall interactions inside the tumor vessels compared with 
15 endothelial growth factor antibody prevented the down-regulation of leukocyte-vessel wall interactions inside the tumor vessels compared with the nontreated group . 
0 antibody prevented the down-regulation of leukocyte-vessel wall interactions inside the tumor vessels compared with the nontreated group . NULL NULL NULL 
19 leukocyte-vessel wall interactions inside the tumor vessels compared with the nontreated group . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL activated cell sorter analysis showed that isolated tumor ecs have suppressed 
0 NULL NULL NULL NULL NULL NULL fluorescence-activated cell sorter analysis showed that isolated tumor ecs have suppressed levels of intercellular adhesion 
0 NULL NULL NULL NULL fluorescence-activated cell sorter analysis showed that isolated tumor ecs have suppressed levels of intercellular adhesion molecule 1 
0 NULL NULL NULL fluorescence-activated cell sorter analysis showed that isolated tumor ecs have suppressed levels of intercellular adhesion molecule 1 as 
18 fluorescence-activated cell sorter analysis showed that isolated tumor ecs have suppressed levels of intercellular adhesion molecule 1 as compared with ecs 
0 cell sorter analysis showed that isolated tumor ecs have suppressed levels of intercellular adhesion molecule 1 as compared with ecs from 
0 showed that isolated tumor ecs have suppressed levels of intercellular adhesion molecule 1 as compared with ecs from normal mouse tissues 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in cultured b.end5 cells the tumor necrosis factor alpha-induced up-regulation of intercellular 
0 NULL NULL NULL NULL NULL in cultured b.end5 cells the tumor necrosis factor alpha-induced up-regulation of intercellular adhesion molecule 1 and 
0 NULL NULL NULL NULL in cultured b.end5 cells the tumor necrosis factor alpha-induced up-regulation of intercellular adhesion molecule 1 and vascular 
17 NULL NULL in cultured b.end5 cells the tumor necrosis factor induced up-regulation of intercellular adhesion molecule 1 and vascular cell adhesion 
17 NULL in cultured b.end5 cells the tumor necrosis factor alpha-induced up-regulation of intercellular adhesion molecule 1 and vascular cell adhesion molecule 
0 b.end5 cells the tumor necrosis factor alpha-induced up-regulation of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 was reduced 
0 alpha-induced up-regulation of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 was reduced in ecs that were preincubated with 
18 adhesion molecule 1 and vascular cell adhesion molecule 1 was reduced in ecs that were preincubated with basic fibroblast growth factor 
19 cell adhesion molecule 1 was reduced in ecs that were preincubated with basic fibroblast growth factor or vascular endothelial growth factor 
0 was reduced in ecs that were preincubated with basic fibroblast growth factor or vascular endothelial growth factor . NULL NULL NULL 
0 were preincubated with basic fibroblast growth factor or vascular endothelial growth factor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the current results may have an impact on the effectiveness of clinical immunotherapeutic 
0 NULL NULL NULL NULL the current results may have an impact on the effectiveness of clinical immunotherapeutic treatment protocols , because 
0 NULL the current results may have an impact on the effectiveness of clinical immunotherapeutic treatment protocols , because immune effector cells 
0 current results may have an impact on the effectiveness of clinical immunotherapeutic treatment protocols , because immune effector cells may not 
0 may have an impact on the effectiveness of clinical immunotherapeutic treatment protocols , because immune effector cells may not be able 
14 , because immune effector cells may not be able to enter tumor tissue . NULL NULL NULL NULL NULL NULL NULL 
0 because immune effector cells may not be able to enter tumor tissue . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL antiapoptotic effect of coagulation factor viia . NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL binding of factor viia ( fviia ) to its cellular receptor 
17 receptor tissue factor ( tf ) was previously shown to induce various intracellular signaling events , which were thought to be 
0 various intracellular signaling events , which were thought to be responsible for tf-mediated biologic effects , including angiogenesis , tumor metastasis 
17 signaling events , which were thought to be responsible for mediated biologic effects , including angiogenesis , tumor metastasis , and 
0 , which were thought to be responsible for tf-mediated biologic effects , including angiogenesis , tumor metastasis , and restenosis . 
3 thought to be responsible for tf-mediated biologic effects , including angiogenesis , tumor metastasis , and restenosis . NULL NULL NULL 
0 be responsible for tf-mediated biologic effects , including angiogenesis , tumor metastasis , and restenosis . NULL NULL NULL NULL NULL 
14 responsible for tf-mediated biologic effects , including angiogenesis , tumor metastasis , and restenosis . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL to understand the mechanisms behind these processes , we have examined the effect of fviia on apoptosis 
0 the mechanisms behind these processes , we have examined the effect of fviia on apoptosis . NULL NULL NULL NULL NULL 
0 processes , we have examined the effect of fviia on apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL serum induced apoptosis of bhk ( +tf ) cells was characterized by 
5 NULL NULL NULL NULL NULL NULL NULL NULL serum deprivation-induced apoptosis of bhk ( +tf ) cells was characterized by apoptotic 
0 by apoptotic blebs , nuclei with chromatin-condensed bodies , dna degradation , and activation of caspase 3 . NULL NULL NULL 
17 , nuclei with chromatin-condensed bodies , dna degradation , and activation of caspase 3 . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL fviia markedly decreased the number of cells with apoptotic morphology and prevented the 
0 markedly decreased the number of cells with apoptotic morphology and prevented the dna degradation as measured by means of tdt-mediated dutp 
0 number of cells with apoptotic morphology and prevented the dna degradation as measured by means of tdt-mediated dutp nick end labeling 
0 and prevented the dna degradation as measured by means of mediated dutp nick end labeling ( tunel ) . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the antiapoptotic effect of fviia was confirmed by the observation that fviia attenuated 
18 effect of fviia was confirmed by the observation that fviia attenuated caspase 3 activation . NULL NULL NULL NULL NULL NULL 
17 was confirmed by the observation that fviia attenuated caspase 3 activation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL induced antiapoptotic effect was dependent on its proteolytic activity and tf 
0 NULL NULL NULL NULL NULL NULL NULL NULL fviia-induced antiapoptotic effect was dependent on its proteolytic activity and tf but independent 
0 NULL NULL NULL NULL NULL NULL fviia-induced antiapoptotic effect was dependent on its proteolytic activity and tf but independent of factor 
0 NULL NULL fviia-induced antiapoptotic effect was dependent on its proteolytic activity and tf but independent of factor xa and thrombin . 
0 effect was dependent on its proteolytic activity and tf but independent of factor xa and thrombin . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL induced cell survival correlated with the activation of akt and was 
5 NULL NULL NULL NULL NULL NULL NULL NULL fviia-induced cell survival correlated with the activation of akt and was inhibited markedly 
17 NULL NULL NULL NULL fviia-induced cell survival correlated with the activation of akt and was inhibited markedly by the specific pi3-kinase 
0 cell survival correlated with the activation of akt and was inhibited markedly by the specific pi3-kinase inhibitor , ly294002 . NULL 
0 of akt and was inhibited markedly by the specific pi3-kinase inhibitor , ly294002 . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL blocking the activation of p44/42 mitogen-activated protein kinase ( mapk ) 
17 NULL NULL NULL NULL NULL NULL NULL NULL blocking the activation of p44/42 mitogen-activated protein kinase ( mapk ) by the 
0 NULL NULL NULL NULL NULL blocking the activation of p44/42 activated protein kinase ( mapk ) by the specific mitogen-induced extracellular 
0 NULL NULL NULL NULL blocking the activation of p44/42 mitogen-activated protein kinase ( mapk ) by the specific mitogen-induced extracellular kinase 
0 p44/42 mitogen-activated protein kinase ( mapk ) by the specific induced extracellular kinase ( mek ) inhibitor , u0126 , impaired 
0 ) by the specific mitogen-induced extracellular kinase ( mek ) inhibitor , u0126 , impaired modestly the ability of fviia to 
18 mitogen-induced extracellular kinase ( mek ) inhibitor , u0126 , impaired modestly the ability of fviia to promote cell survival . 
0 ( mek ) inhibitor , u0126 , impaired modestly the ability of fviia to promote cell survival . NULL NULL NULL 
17 , u0126 , impaired modestly the ability of fviia to promote cell survival . NULL NULL NULL NULL NULL NULL NULL 
5 , impaired modestly the ability of fviia to promote cell survival . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL in conclusion , fviia binding to tf provided protection against apoptosis induced by growth factor 
0 NULL NULL in conclusion , fviia binding to tf provided protection against apoptosis induced by growth factor deprivation , primarily through 
0 in conclusion , fviia binding to tf provided protection against apoptosis induced by growth factor deprivation , primarily through activation of 
0 conclusion , fviia binding to tf provided protection against apoptosis induced by growth factor deprivation , primarily through activation of pi3-kinase/akt 
0 fviia binding to tf provided protection against apoptosis induced by growth factor deprivation , primarily through activation of pi3-kinase/akt pathway , 
17 against apoptosis induced by growth factor deprivation , primarily through activation of pi3-kinase/akt pathway , and to a lesser extent , 
0 NULL NULL NULL NULL NULL NULL prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous 
9 NULL NULL NULL NULL NULL prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell 
0 NULL prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus 
9 value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus . NULL 
19 p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the most common genetic alterations found in a wide variety of cancers are p53 tumor 
0 alterations found in a wide variety of cancers are p53 tumor suppressor gene mutations . NULL NULL NULL NULL NULL NULL 
0 found in a wide variety of cancers are p53 tumor suppressor gene mutations . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL p53 appears to be a nuclear transcription factor that plays a role in the control of cell 
0 NULL p53 appears to be a nuclear transcription factor that plays a role in the control of cell proliferation , apoptosis 
0 appears to be a nuclear transcription factor that plays a role in the control of cell proliferation , apoptosis , and 
16 a nuclear transcription factor that plays a role in the control of cell proliferation , apoptosis , and the maintenance of 
1 factor that plays a role in the control of cell proliferation , apoptosis , and the maintenance of genetic stability . 
5 plays a role in the control of cell proliferation , apoptosis , and the maintenance of genetic stability . NULL NULL 
0 the control of cell proliferation , apoptosis , and the maintenance of genetic stability . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis is a critical process in solid tumor growth and metastasis 
16 NULL NULL NULL NULL NULL NULL NULL angiogenesis is a critical process in solid tumor growth and metastasis . NULL NULL 
0 NULL NULL NULL angiogenesis is a critical process in solid tumor growth and metastasis . NULL NULL NULL NULL NULL NULL 
4 NULL NULL angiogenesis is a critical process in solid tumor growth and metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 angiogenesis is a critical process in solid tumor growth and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) , a recently identified growth factor 
0 endothelial growth factor ( vegf ) , a recently identified growth factor with significant angiogenic properties , may be a major 
0 ( vegf ) , a recently identified growth factor with significant angiogenic properties , may be a major tumor angiogenesis regulator 
3 vegf ) , a recently identified growth factor with significant angiogenic properties , may be a major tumor angiogenesis regulator . 
0 ) , a recently identified growth factor with significant angiogenic properties , may be a major tumor angiogenesis regulator . NULL 
0 growth factor with significant angiogenic properties , may be a major tumor angiogenesis regulator . NULL NULL NULL NULL NULL NULL 
0 factor with significant angiogenic properties , may be a major tumor angiogenesis regulator . NULL NULL NULL NULL NULL NULL NULL 
3 with significant angiogenic properties , may be a major tumor angiogenesis regulator . NULL NULL NULL NULL NULL NULL NULL NULL 
16 significant angiogenic properties , may be a major tumor angiogenesis regulator . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL few studies have investigated the association between p53 and vegf expressions and prognosis in esophageal carcinoma 
9 few studies have investigated the association between p53 and vegf expressions and prognosis in esophageal carcinoma . NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL forty-seven specimens resected from patients with stage ii and iii squamous cell carcinoma 
0 carcinoma ( scc ) of the esophagus were studied using immunohistochemical staining . NULL NULL NULL NULL NULL NULL NULL NULL 
0 ( scc ) of the esophagus were studied using immunohistochemical staining . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL vegf and p53 expressions were observed in 40 % and 53 % of the 
0 NULL NULL NULL NULL NULL vegf and p53 expressions were observed in 40 % and 53 % of the tumors , 
0 NULL NULL NULL NULL NULL NULL the p53 and vegf staining statuses were coincident in only 21 % of the tumors 
0 in only 21 % of the tumors , and no significant correlation was found between p53 and vegf statuses . NULL 
9 no clinicopathologic factors were significantly correlated with p53 or vegf expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL no significant association between p53 and vegf expressions and poor prognosis was 
0 NULL NULL NULL NULL NULL NULL NULL NULL no significant association between p53 and vegf expressions and poor prognosis was found 
9 NULL NULL NULL no significant association between p53 and vegf expressions and poor prognosis was found . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the role of organ vascularization and lipoplex-serum initial contact in intravenous murine 
3 NULL NULL NULL NULL NULL NULL the role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection . NULL 
0 NULL NULL the role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection . NULL NULL NULL NULL NULL 
19 of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL following intravenous administration of cationic lipid-dna complexes ( lipoplexes ) into mice , 
0 of cationic lipid-dna complexes ( lipoplexes ) into mice , transfection ( lipofection ) occurs predominantly in the lungs . NULL 
0 lipid-dna complexes ( lipoplexes ) into mice , transfection ( lipofection ) occurs predominantly in the lungs . NULL NULL NULL 
14 NULL NULL NULL NULL NULL this was attributed to high entrapment of lipoplexes in the extended lung vascular tree . NULL 
0 this was attributed to high entrapment of lipoplexes in the extended lung vascular tree . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL to determine whether lipofection in other organs could be enhanced by increasing the degree 
17 NULL to determine whether lipofection in other organs could be enhanced by increasing the degree of vascularization , we used a 
17 determine whether lipofection in other organs could be enhanced by increasing the degree of vascularization , we used a transgenic mouse 
3 other organs could be enhanced by increasing the degree of vascularization , we used a transgenic mouse model with tissue-specific angiogenesis 
0 be enhanced by increasing the degree of vascularization , we used a transgenic mouse model with tissue-specific angiogenesis in liver . 
0 by increasing the degree of vascularization , we used a transgenic mouse model with tissue-specific angiogenesis in liver . NULL NULL 
3 vascularization , we used a transgenic mouse model with tissue-specific angiogenesis in liver . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL tail vein injection of n- ( 1- ( 2 , 3-dioleoyloxy ) propyl 
17 , n , n-trimethylammonium chloride ( dotap ) /cholesterol lipoplexes resulted in increased lipoplex entrapment in hypervascularized liver but did not 
17 , n-trimethylammonium chloride ( dotap ) /cholesterol lipoplexes resulted in increased lipoplex entrapment in hypervascularized liver but did not boost luciferase 
14 chloride ( dotap ) /cholesterol lipoplexes resulted in increased lipoplex entrapment in hypervascularized liver but did not boost luciferase expression , 
17 in increased lipoplex entrapment in hypervascularized liver but did not boost luciferase expression , suggesting that lipoplex delivery is not a 
9 lipoplex entrapment in hypervascularized liver but did not boost luciferase expression , suggesting that lipoplex delivery is not a sufficient condition 
14 but did not boost luciferase expression , suggesting that lipoplex delivery is not a sufficient condition for efficient organ lipofection . 
17 luciferase expression , suggesting that lipoplex delivery is not a sufficient condition for efficient organ lipofection . NULL NULL NULL NULL 
19 lipoplex delivery is not a sufficient condition for efficient organ lipofection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL because the intravenously injected lipoplexes migrated within seconds to lungs , we checked whether 
14 NULL NULL NULL NULL NULL because the intravenously injected lipoplexes migrated within seconds to lungs , we checked whether the effects 
0 migrated within seconds to lungs , we checked whether the effects of immediate contact with serum correlate with lung lipofection efficiency 
0 to lungs , we checked whether the effects of immediate contact with serum correlate with lung lipofection efficiency of different dotap-based 
19 the effects of immediate contact with serum correlate with lung lipofection efficiency of different dotap-based formulations . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL under conditions mimicking the injection environment , the lipoplex-serum interaction was strongly dependent on helper 
0 NULL under conditions mimicking the injection environment , the lipoplex-serum interaction was strongly dependent on helper lipid and ionic strength : 
0 mimicking the injection environment , the lipoplex-serum interaction was strongly dependent on helper lipid and ionic strength : lipoplexes prepared in 
15 greater than 33 mol % ) cholesterol were found to aggregate immediately . NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL this aggregation process was irreversible and was inversely correlated with the percentage 
19 cells that took up lipoplexes and with the efficiency of lipofection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL no other structural changes in serum were observed for cholesterol-based lipoplexes . NULL 
0 NULL NULL NULL NULL NULL NULL NULL no other structural changes in serum were observed for cholesterol-based lipoplexes . NULL NULL 
0 NULL NULL NULL no other structural changes in serum were observed for cholesterol-based lipoplexes . NULL NULL NULL NULL NULL NULL 
0 NULL NULL dioleoyl phosphatidylethanolamine-based lipoplexes were found to give low expression , apparently because of an immediate loss of integrity in 
0 to give low expression , apparently because of an immediate loss of integrity in serum , without lipid-dna dissociation . NULL 
0 NULL NULL NULL our study suggests that efficient in vivo lipofection is the result of cross-talk between lipoplex composition , interaction 
0 lipofection is the result of cross-talk between lipoplex composition , interaction with serum , hemodynamics , and target tissue `` susceptibility 
0 lipoplex composition , interaction with serum , hemodynamics , and target tissue `` susceptibility '' to transfection . NULL NULL NULL 
0 , hemodynamics , and target tissue `` susceptibility '' to transfection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL proliferative diabetic retinopathy is associated with a low level of the 
0 NULL NULL NULL NULL NULL NULL proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent 
3 is associated with a low level of the natural ocular angiogenic agent pigment epithelium-derived factor ( pedf ) in aqueous humor 
0 a low level of the natural ocular anti-angiogenic agent pigment derived factor ( pedf ) in aqueous humor . NULL NULL 
0 is the most common microvascular diabetes complication and represents a major threat to the eyesight . NULL NULL NULL NULL NULL 
0 NULL the aim of this study was to address the role of pro- and anti-angiogenic molecules in diabetic retinopathy in the 
3 this study was to address the role of pro- and angiogenic molecules in diabetic retinopathy in the aqueous humor of the 
19 NULL NULL NULL NULL NULL NULL NULL aqueous humor was collected at cataract surgery from 19 diabetic patients and from 13 
0 NULL NULL NULL NULL aqueous humor was collected at cataract surgery from 19 diabetic patients and from 13 age- and sex-matched 
0 19 diabetic patients and from 13 age- and sex-matched normoglycemic controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL levels of pro-angiogenic vascular endothelial growth factor ( vegf ) and 
3 NULL NULL NULL NULL NULL NULL NULL NULL levels of angiogenic vascular endothelial growth factor ( vegf ) and angiogenic inhibitor 
0 NULL NULL NULL NULL NULL levels of pro-angiogenic vascular endothelial growth factor ( vegf ) and angiogenic inhibitor pigment epithelium-derived factor 
3 of pro-angiogenic vascular endothelial growth factor ( vegf ) and angiogenic inhibitor pigment epithelium-derived factor ( pedf ) were determined . 
0 pro-angiogenic vascular endothelial growth factor ( vegf ) and angiogenic inhibitor pigment epithelium-derived factor ( pedf ) were determined . NULL 
0 endothelial growth factor ( vegf ) and angiogenic inhibitor pigment derived factor ( pedf ) were determined . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic activity of the aqueous humor was quantified by measuring its 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic activity of the aqueous humor was quantified by measuring its effect 
16 activity of the aqueous humor was quantified by measuring its effect on the migration of capillary endothelial cells . NULL NULL 
14 aqueous humor was quantified by measuring its effect on the migration of capillary endothelial cells . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL in the aqueous fluid , vegf levels were increased in diabetics ( mean values : 501 vs. 
17 NULL NULL in the aqueous fluid , vegf levels were increased in diabetics ( mean values : 501 vs. 367 pg/ml 
0 367 pg/ml ; p = 0.05 ) , compared to controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL pedf was found to be decreased in diabetics ( mean values : 2080 vs. 5780 ng/ml 
0 vs. 5780 ng/ml ; p = 0.04 ) compared to controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL in seven diabetic patients with proliferative retinopathy , the most profound finding was a significant decrease 
0 with proliferative retinopathy , the most profound finding was a significant decrease of the pedf level ( mean value : 237 
18 proliferative retinopathy , the most profound finding was a significant decrease of the pedf level ( mean value : 237 ng/ml 
0 ( mean value : 237 ng/ml ) , whereas vegf levels were comparable to diabetic patients without proliferation ( mean value 
0 , whereas vegf levels were comparable to diabetic patients without proliferation ( mean value : 3153 ; p = 0.003 ) 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic activity in samples of patients from the control group was 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic activity in samples of patients from the control group was generally 
0 NULL NULL angiogenic activity in samples of patients from the control group was generally inhibitory due to pedf , and inhibition 
18 in samples of patients from the control group was generally inhibitory due to pedf , and inhibition was blocked by neutralizing 
18 control group was generally inhibitory due to pedf , and inhibition was blocked by neutralizing antibodies to pedf . NULL NULL 
18 was generally inhibitory due to pedf , and inhibition was blocked by neutralizing antibodies to pedf . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL likewise , in diabetics without proliferation , angiogenic activity was also blocked by antibodies to pedf 
3 NULL NULL NULL likewise , in diabetics without proliferation , angiogenic activity was also blocked by antibodies to pedf . NULL 
0 NULL NULL likewise , in diabetics without proliferation , angiogenic activity was also blocked by antibodies to pedf . NULL NULL 
18 , in diabetics without proliferation , angiogenic activity was also blocked by antibodies to pedf . NULL NULL NULL NULL NULL 
3 will demonstrate here that the level of the natural ocular angiogenic agent pedf is inversely associated with proliferative retinopathy . NULL 
0 level of the natural ocular anti-angiogenic agent pedf is inversely associated with proliferative retinopathy . NULL NULL NULL NULL NULL NULL 
0 the natural ocular anti-angiogenic agent pedf is inversely associated with proliferative retinopathy . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL pedf is an important negative regulator of angiogenic activity of aqueous humor . NULL 
18 NULL NULL NULL NULL NULL NULL pedf is an important negative regulator of angiogenic activity of aqueous humor . NULL NULL 
18 NULL NULL NULL NULL NULL pedf is an important negative regulator of angiogenic activity of aqueous humor . NULL NULL NULL 
3 NULL NULL NULL pedf is an important negative regulator of angiogenic activity of aqueous humor . NULL NULL NULL NULL NULL 
0 NULL NULL pedf is an important negative regulator of angiogenic activity of aqueous humor . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL our data may have implications for the development of novel regimens for diabetic retinopathy . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis -- biomedical technology . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL all of these studies show that angiogenesis research can benefit from new biomedical technology tools currently being 
0 research can benefit from new biomedical technology tools currently being developed , as well as contribute by providing new technologies that 
0 biomedical technology tools currently being developed , as well as contribute by providing new technologies that can be used in other 
0 well as contribute by providing new technologies that can be used in other areas of medicine . NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat . NULL 
6 NULL NULL interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL interleukin-1 ( il-1 ) synthesis in the brain is stimulated by mechanical injury and il-1 
17 NULL interleukin-1 ( il-1 ) synthesis in the brain is stimulated by mechanical injury and il-1 mimics some effects of injury 
0 brain is stimulated by mechanical injury and il-1 mimics some effects of injury , such as gliosis and neovascularization . NULL 
3 mimics some effects of injury , such as gliosis and neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
5 NULL NULL NULL NULL NULL NULL we report that neuronal death resulting from focal cerebral ischaemia ( middle cerebral artery occlusion 
0 NULL NULL NULL NULL NULL we report that neuronal death resulting from focal cerebral ischaemia ( middle cerebral artery occlusion , 
18 middle cerebral artery occlusion , 24 h ) is significantly inhibited ( by 50 % ) in rats injected with a 
19 is significantly inhibited ( by 50 % ) in rats injected with a recombinant il-1 receptor antagonist ( il-1ra , 10 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL excitotoxic damage due to striatal infusion of an nmda-receptor agonist ( cis-2 
19 NULL NULL NULL NULL NULL excitotoxic damage due to striatal infusion of an nmda-receptor agonist ( cis-2 , 4-methanoglutamate ) was 
0 nmda-receptor agonist ( cis-2 , 4-methanoglutamate ) was also markedly inhibited ( 71 % ) by injection of the il-1ra . 
19 ) was also markedly inhibited ( 71 % ) by injection of the il-1ra . NULL NULL NULL NULL NULL NULL 
17 NULL NULL these data indicate that endogenous il-1 is a mediator of ischaemic and excitotoxic brain damage , and that inhibitors 
6 endogenous il-1 is a mediator of ischaemic and excitotoxic brain damage , and that inhibitors of il-1 action may be of 
0 and excitotoxic brain damage , and that inhibitors of il-1 action may be of therapeutic value in the treatment of acute 
0 of il-1 action may be of therapeutic value in the treatment of acute or chronic neuronal death . NULL NULL NULL 
5 therapeutic value in the treatment of acute or chronic neuronal death . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL laser treatment of eccentric leaks in central serous chorioretinopathy resulting in disappearance 
0 NULL NULL NULL NULL laser treatment of eccentric leaks in central serous chorioretinopathy resulting in disappearance of untreated juxtafoveal leaks . 
0 NULL laser treatment of eccentric leaks in central serous chorioretinopathy resulting in disappearance of untreated juxtafoveal leaks . NULL NULL NULL 
0 eccentric leaks in central serous chorioretinopathy resulting in disappearance of untreated juxtafoveal leaks . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in central serous chorioretinopathy ( cscr ) laser treatment of leaking points 
0 NULL NULL in central serous chorioretinopathy ( cscr ) laser treatment of leaking points close to the macular center should be 
17 avoided because of the possibility of producing juxtafoveal scotoma and stimulating choroidal neovascularization . NULL NULL NULL NULL NULL NULL NULL 
3 of the possibility of producing juxtafoveal scotoma and stimulating choroidal neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
6 cscr had two or more leaking points within a macular detachment , one of which was foveal or near to the 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL photocoagulation with green argon laser was performed in all eyes , 
0 with green argon laser was performed in all eyes , treating all the leaking points except for the central one . 
0 eyes , treating all the leaking points except for the central one . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL visual symptoms regressed after treatment , and the serous detachment was resolved 10 
0 NULL NULL NULL NULL NULL NULL visual symptoms regressed after treatment , and the serous detachment was resolved 10 days to 
0 NULL visual symptoms regressed after treatment , and the serous detachment was resolved 10 days to 4 weeks after photocoagulation in 
0 serous detachment was resolved 10 days to 4 weeks after photocoagulation in all cases . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL fluorescein angiography showed no leakage at either the central leakage point or 
0 NULL NULL NULL NULL NULL NULL NULL NULL fluorescein angiography showed no leakage at either the central leakage point or the 
0 NULL NULL NULL NULL NULL NULL fluorescein angiography showed no leakage at either the central leakage point or the leakage point 
0 NULL NULL fluorescein angiography showed no leakage at either the central leakage point or the leakage point that had been treated 
0 NULL fluorescein angiography showed no leakage at either the central leakage point or the leakage point that had been treated . 
0 no leakage at either the central leakage point or the leakage point that had been treated . NULL NULL NULL NULL 
0 central leakage point or the leakage point that had been treated . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results led us to believe that the central or dependent leak 
0 NULL NULL NULL NULL NULL NULL NULL NULL these results led us to believe that the central or dependent leak in 
0 NULL NULL these results led us to believe that the central or dependent leak in our cases was not sufficient to 
0 these results led us to believe that the central or dependent leak in our cases was not sufficient to maintain the 
0 the central or dependent leak in our cases was not sufficient to maintain the serous detachment by itself . NULL NULL 
0 in our cases was not sufficient to maintain the serous detachment by itself . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL an alternative hypothesis is that the untreated leak did not represent real fluid movement but only diffusion 
6 cases of cscr with multiple leaks within a single macular detachment , we believe that a foveal leak may be a 
0 , we believe that a foveal leak may be a dependent or false leak and that direct treatment is not necessary 
0 leak may be a dependent or false leak and that direct treatment is not necessary . NULL NULL NULL NULL NULL 
0 may be a dependent or false leak and that direct treatment is not necessary . NULL NULL NULL NULL NULL NULL 
10 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL transcriptional and post-translation regulation of the tie1 receptor by fluid shear 
16 NULL NULL NULL NULL NULL NULL NULL transcriptional and post-translation regulation of the tie1 receptor by fluid shear stress changes in 
0 post-translation regulation of the tie1 receptor by fluid shear stress changes in vascular endothelial cells . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the interaction between the vascular endothelium and hemodynamic forces ( and more 
0 ( and more specifically , fluid shear stress ) , induced by the flow of blood , plays a major role 
16 stress ) , induced by the flow of blood , plays a major role in vascular remodeling and in new blood 
16 , induced by the flow of blood , plays a major role in vascular remodeling and in new blood vessels formation 
16 induced by the flow of blood , plays a major role in vascular remodeling and in new blood vessels formation via 
7 flow of blood , plays a major role in vascular remodeling and in new blood vessels formation via a process termed 
2 major role in vascular remodeling and in new blood vessels formation via a process termed arteriogenesis . NULL NULL NULL NULL 
3 and in new blood vessels formation via a process termed arteriogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL tie1 is an orphan tyrosine kinase receptor expressed almost exclusively in endothelial cells and is required for normal 
17 kinase receptor expressed almost exclusively in endothelial cells and is required for normal vascular development and maintenance . NULL NULL NULL 
2 exclusively in endothelial cells and is required for normal vascular development and maintenance . NULL NULL NULL NULL NULL NULL NULL 
16 endothelial cells and is required for normal vascular development and maintenance . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the present study demonstrates that tie1 expression is rapidly down-regulated in endothelial 
9 NULL NULL NULL NULL the present study demonstrates that tie1 expression is rapidly down-regulated in endothelial cells exposed to shear stress 
18 NULL the present study demonstrates that tie1 expression is rapidly down-regulated in endothelial cells exposed to shear stress , and more 
19 demonstrates that tie1 expression is rapidly down-regulated in endothelial cells exposed to shear stress , and more so to shear stress 
0 to shear stress , and more so to shear stress changes . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL this down-regulation is accompanied by a rapid cleavage of tie1 and binding 
11 NULL NULL NULL this down-regulation is accompanied by a rapid cleavage of tie1 and binding of the cleaved tie1 45 kda 
15 down-regulation is accompanied by a rapid cleavage of tie1 and binding of the cleaved tie1 45 kda endodomain to tie2 . 
11 by a rapid cleavage of tie1 and binding of the cleaved tie1 45 kda endodomain to tie2 . NULL NULL NULL 
11 NULL NULL NULL NULL NULL NULL NULL NULL the rapid cleavage of tie1 is followed by a transcriptional down-regulation in response 
10 NULL the rapid cleavage of tie1 is followed by a transcriptional down-regulation in response to shear stress . NULL NULL NULL 
18 the rapid cleavage of tie1 is followed by a transcriptional down-regulation in response to shear stress . NULL NULL NULL NULL 
0 cleavage of tie1 is followed by a transcriptional down-regulation in response to shear stress . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the activity of the tie1 promoter is suppressed by shear stress and 
18 NULL NULL NULL the activity of the tie1 promoter is suppressed by shear stress and by tumor necrosis factor alpha . 
0 the tie1 promoter is suppressed by shear stress and by tumor necrosis factor alpha . NULL NULL NULL NULL NULL NULL 
0 tie1 promoter is suppressed by shear stress and by tumor necrosis factor alpha . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL shear induced transcriptional suppression of tie1 is mediated by a negative shear 
10 NULL NULL NULL NULL NULL NULL NULL NULL shear stress-induced transcriptional suppression of tie1 is mediated by a negative shear stress 
18 NULL NULL NULL NULL NULL NULL NULL shear stress-induced transcriptional suppression of tie1 is mediated by a negative shear stress response 
16 NULL NULL NULL shear stress-induced transcriptional suppression of tie1 is mediated by a negative shear stress response element , localized in 
0 shear stress-induced transcriptional suppression of tie1 is mediated by a negative shear stress response element , localized in a region of 
0 suppression of tie1 is mediated by a negative shear stress response element , localized in a region of 250 bp within 
0 is mediated by a negative shear stress response element , localized in a region of 250 bp within the promoter . 
18 NULL NULL NULL NULL NULL NULL NULL NULL the rapid down-regulation of tie1 by shear stress changes and its rapid binding 
0 NULL NULL the rapid down-regulation of tie1 by shear stress changes and its rapid binding to tie2 may be required for 
15 down-regulation of tie1 by shear stress changes and its rapid binding to tie2 may be required for destabilization of endothelial cells 
17 stress changes and its rapid binding to tie2 may be required for destabilization of endothelial cells in order to initiate the 
18 and its rapid binding to tie2 may be required for destabilization of endothelial cells in order to initiate the process of 
17 be required for destabilization of endothelial cells in order to initiate the process of vascular restructuring . NULL NULL NULL NULL 
7 endothelial cells in order to initiate the process of vascular restructuring . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL therapeutic angiogenesis : a complex problem requiring a sophisticated approach . NULL 
0 NULL NULL NULL NULL therapeutic angiogenesis : a complex problem requiring a sophisticated approach . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL ischemia , involving restricted blood flow to tissues is the most common consequence 
0 NULL NULL NULL NULL NULL NULL NULL ischemia , involving restricted blood flow to tissues is the most common consequence of 
6 flow to tissues is the most common consequence of vessel dysfunction resulting in the disruption of oxygen and nutrient delivery and 
0 to tissues is the most common consequence of vessel dysfunction resulting in the disruption of oxygen and nutrient delivery and the 
11 the most common consequence of vessel dysfunction resulting in the disruption of oxygen and nutrient delivery and the accumulation of waste 
0 vessel dysfunction resulting in the disruption of oxygen and nutrient delivery and the accumulation of waste metabolites . NULL NULL NULL 
0 in the disruption of oxygen and nutrient delivery and the accumulation of waste metabolites . NULL NULL NULL NULL NULL NULL 
5 NULL NULL NULL NULL NULL NULL NULL cells can not survive extended severe ischemia but may be able to adapt to 
0 NULL NULL NULL NULL NULL NULL cells can not survive extended severe ischemia but may be able to adapt to a 
0 where diffusion to and from bordering nonischemic regions sustains vital functions . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL under this condition , the secondary functions of effected cells are likely to be impaired , and 
16 NULL NULL under this condition , the secondary functions of effected cells are likely to be impaired , and a new 
0 the secondary functions of effected cells are likely to be impaired , and a new metabolic equilibrium is established , determined 
0 to be impaired , and a new metabolic equilibrium is established , determined by the level of cross-diffusion and degree of 
0 NULL NULL NULL in tissues with a normally high metabolic turnover such as skeletal and cardiac muscle , even mild ischemia 
0 even mild ischemia causes hypoxia , acidosis , and depressed function ( contractility ) and eventually threatens myocyte viability and organ 
0 ( contractility ) and eventually threatens myocyte viability and organ function . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL ischemic cardiac muscle is additionally vulnerable because reperfusion is essential for survival but reperfusion itself poses additional stress principally from 
0 cardiac muscle is additionally vulnerable because reperfusion is essential for survival but reperfusion itself poses additional stress principally from increased production 
0 for survival but reperfusion itself poses additional stress principally from increased production of free radicals during reoxygenation . NULL NULL NULL 
0 survival but reperfusion itself poses additional stress principally from increased production of free radicals during reoxygenation . NULL NULL NULL NULL 
0 reperfusion itself poses additional stress principally from increased production of free radicals during reoxygenation . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the latter effect is called reperfusion injury and can cause as much damage 
0 effect is called reperfusion injury and can cause as much damage as the ischemia . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the treatment possibilities for ischemia-related vascular disease are limited . NULL NULL 
0 NULL NULL the treatment possibilities for ischemia-related vascular disease are limited . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 lipid/cholesterol-lowering agents , diet and antiplatelet adherence ( aspirin ) therapy may help slow the progression of vessel disease in some 
0 diet and antiplatelet adherence ( aspirin ) therapy may help slow the progression of vessel disease in some instances ; but 
0 antiplatelet adherence ( aspirin ) therapy may help slow the progression of vessel disease in some instances ; but surgical reconstruction 
0 the progression of vessel disease in some instances ; but surgical reconstruction may be the only option in advanced stages , 
0 NULL NULL NULL an alternative and rather obvious strategy to treat ischemia is to activate endogenous angiogenic or arteriogenic pathways to 
17 alternative and rather obvious strategy to treat ischemia is to activate endogenous angiogenic or arteriogenic pathways to stimulate revascularization of the 
3 rather obvious strategy to treat ischemia is to activate endogenous angiogenic or arteriogenic pathways to stimulate revascularization of the tissue . 
3 strategy to treat ischemia is to activate endogenous angiogenic or arteriogenic pathways to stimulate revascularization of the tissue . NULL NULL 
3 to treat ischemia is to activate endogenous angiogenic or arteriogenic pathways to stimulate revascularization of the tissue . NULL NULL NULL 
17 ischemia is to activate endogenous angiogenic or arteriogenic pathways to stimulate revascularization of the tissue . NULL NULL NULL NULL NULL 
3 is to activate endogenous angiogenic or arteriogenic pathways to stimulate revascularization of the tissue . NULL NULL NULL NULL NULL NULL 
0 NULL the feasibility of such a strategy has now been established through the results of studies over the past decade , 
0 of such a strategy has now been established through the results of studies over the past decade , and a new 
3 the past decade , and a new discipline called therapeutic angiogenesis has emerged . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL this review focuses on the application of therapeutic angiogenesis for treating ischemic muscle disease and includes 
3 NULL NULL this review focuses on the application of therapeutic angiogenesis for treating ischemic muscle disease and includes a critical evaluation 
0 this review focuses on the application of therapeutic angiogenesis for treating ischemic muscle disease and includes a critical evaluation of the 
0 therapeutic angiogenesis for treating ischemic muscle disease and includes a critical evaluation of the parameters and limitations of current procedures . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the development of this technology has benefited from its application to both 
0 NULL the development of this technology has benefited from its application to both peripheral and coronary artery disease and results from 
0 its application to both peripheral and coronary artery disease and results from both are reviewed here . NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression , regulation , and function of igf-1 , igf-1r , 
16 NULL NULL NULL NULL NULL NULL NULL NULL expression , regulation , and function of igf-1 , igf-1r , and igf-1 
0 NULL NULL NULL NULL NULL expression , regulation , and function of igf-1 , igf-1r , and igf-1 binding proteins in 
0 , and function of igf-1 , igf-1r , and igf-1 binding proteins in blood vessels . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the vascular insulin-like growth factor ( igf ) -1 system includes the igfs , 
0 , the igf-1 receptor ( igf-1r ) , and multiple binding proteins . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL this growth factor system exerts multiple physiologic effects on the vasculature through 
0 NULL NULL NULL this growth factor system exerts multiple physiologic effects on the vasculature through both endocrine and autocrine/paracrine mechanisms . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effects of igf-1 are mediated principally through the igf-1r but are 
16 NULL NULL NULL NULL NULL the effects of igf-1 are mediated principally through the igf-1r but are modulated by complex interactions 
0 of igf-1 are mediated principally through the igf-1r but are modulated by complex interactions with multiple igf binding proteins that themselves 
15 mediated principally through the igf-1r but are modulated by complex interactions with multiple igf binding proteins that themselves are regulated by 
0 igf-1r but are modulated by complex interactions with multiple igf binding proteins that themselves are regulated by phosphorylation , proteolysis , 
16 complex interactions with multiple igf binding proteins that themselves are regulated by phosphorylation , proteolysis , polymerization , and cell or 
12 with multiple igf binding proteins that themselves are regulated by phosphorylation , proteolysis , polymerization , and cell or matrix association 
11 igf binding proteins that themselves are regulated by phosphorylation , proteolysis , polymerization , and cell or matrix association . NULL 
15 proteins that themselves are regulated by phosphorylation , proteolysis , polymerization , and cell or matrix association . NULL NULL NULL 
0 by phosphorylation , proteolysis , polymerization , and cell or matrix association . NULL NULL NULL NULL NULL NULL NULL NULL 
15 phosphorylation , proteolysis , polymerization , and cell or matrix association . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL during the last decade , a significant body of evidence has accumulated , indicating that expression of 
0 the last decade , a significant body of evidence has accumulated , indicating that expression of the components of the igf 
0 a significant body of evidence has accumulated , indicating that expression of the components of the igf system are regulated by 
0 that expression of the components of the igf system are regulated by multiple factors , including growth factors , cytokines , 
0 the igf system are regulated by multiple factors , including growth factors , cytokines , lipoproteins , reactive oxygen species , 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , cross-talk between the igf system and other growth factors 
0 in addition , cross-talk between the igf system and other growth factors and integrin receptors has been demonstrated . NULL NULL 
16 NULL NULL NULL NULL there is accumulating evidence of a role for igf-1 in multiple vascular pathologies , including atherosclerosis , 
3 vascular pathologies , including atherosclerosis , hypertension , restenosis , angiogenesis , and diabetic vascular disease . NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL this review will discuss the regulation of expression of igf-1 , igf-1r , and igf binding 
9 NULL NULL NULL this review will discuss the regulation of expression of igf-1 , igf-1r , and igf binding proteins in 
0 regulation of expression of igf-1 , igf-1r , and igf binding proteins in the vasculature and summarize evidence implicating involvement of 
0 igf binding proteins in the vasculature and summarize evidence implicating involvement of this system in vascular diseases . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL angiopoietin/tie-2 as mediators of angiogenesis : a role in congestive heart failure ? NULL NULL 
0 NULL NULL NULL angiopoietin/tie-2 as mediators of angiogenesis : a role in congestive heart failure ? NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic factors , in particular vascular endothelial growth factor ( vegf 
0 NULL NULL NULL angiogenic factors , in particular vascular endothelial growth factor ( vegf ) and the angiopoietins , ang-1 and 
0 the angiopoietins , ang-1 and -2 , have recently generated significant interest , especially in oncology . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL the process of angiogenesis is also thought to occur in response to ischaemic conditions 
0 the process of angiogenesis is also thought to occur in response to ischaemic conditions , which lie at the core of 
3 however , current data do not conclusively show evidence of angiogenesis per se in these conditions , despite ( for example 
14 in these conditions , despite ( for example ) the presence of high levels of vegf and ang-2 . NULL NULL 
0 , despite ( for example ) the presence of high levels of vegf and ang-2 . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL high levels of these angiogenic factors in heart disease also have not 
3 NULL NULL NULL NULL NULL NULL high levels of these angiogenic factors in heart disease also have not translated into clinically 
0 factors in heart disease also have not translated into clinically significant new vessel formation , as in accelerated cancer growth or 
2 disease also have not translated into clinically significant new vessel formation , as in accelerated cancer growth or proliferative retinopathy . 
17 translated into clinically significant new vessel formation , as in accelerated cancer growth or proliferative retinopathy . NULL NULL NULL NULL 
4 clinically significant new vessel formation , as in accelerated cancer growth or proliferative retinopathy . NULL NULL NULL NULL NULL NULL 
0 new vessel formation , as in accelerated cancer growth or proliferative retinopathy . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL indeed , we would hypothesize that these angiogenic markers -- especially the angiopoietins -- do not necessarily translate 
16 angiogenic markers -- especially the angiopoietins -- do not necessarily translate into new vessel formation in congestive heart failure ( chf 
2 the angiopoietins -- do not necessarily translate into new vessel formation in congestive heart failure ( chf ) , but may 
16 congestive heart failure ( chf ) , but may well reflect disturbances of endothelial integrity in chf . NULL NULL NULL 
6 heart failure ( chf ) , but may well reflect disturbances of endothelial integrity in chf . NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL morphogenesis of embryonic cns vessels . NULL NULL NULL NULL NULL 
2 NULL this chapter focuses on the morphology of blood vessel formation in and around the early central nervous system ( cns 
0 morphology of blood vessel formation in and around the early central nervous system ( cns , i.e. , brain and spinal 
1 NULL NULL NULL NULL NULL we discuss cell lineages , proliferation and interactions of endothelial cells , pericytes and smooth muscle 
15 NULL NULL NULL we discuss cell lineages , proliferation and interactions of endothelial cells , pericytes and smooth muscle cells , 
16 to space limitations , we can not review the molecular control of cns angiogenesis , but refer the reader to other 
3 , we can not review the molecular control of cns angiogenesis , but refer the reader to other chapters in this 
2 chapters in this book and to recent publications on the assembly of the vasculature ( 1 , 2 ) . NULL 
18 NULL NULL NULL NULL NULL NULL NULL the candidate tumour suppressor protein ing4 regulates brain tumour growth and angiogenesis . NULL 
0 NULL NULL NULL NULL NULL NULL the candidate tumour suppressor protein ing4 regulates brain tumour growth and angiogenesis . NULL NULL 
16 NULL NULL NULL NULL the candidate tumour suppressor protein ing4 regulates brain tumour growth and angiogenesis . NULL NULL NULL NULL 
4 NULL the candidate tumour suppressor protein ing4 regulates brain tumour growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 candidate tumour suppressor protein ing4 regulates brain tumour growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL gliomas are the most common primary tumours of the central nervous system , with nearly 15 , 000 diagnosed annually 
17 NULL NULL NULL NULL NULL NULL NULL NULL the marked induction of angiogenesis in glioblastomas suggests that it is a necessary 
3 NULL NULL NULL NULL NULL NULL the marked induction of angiogenesis in glioblastomas suggests that it is a necessary part of 
2 in glioblastomas suggests that it is a necessary part of malignant progression ; however , the precise molecular mechanisms underlying the 
2 glioblastomas suggests that it is a necessary part of malignant progression ; however , the precise molecular mechanisms underlying the regulation 
16 progression ; however , the precise molecular mechanisms underlying the regulation of brain tumour growth and angiogenesis remain unresolved . NULL 
4 the precise molecular mechanisms underlying the regulation of brain tumour growth and angiogenesis remain unresolved . NULL NULL NULL NULL NULL 
3 molecular mechanisms underlying the regulation of brain tumour growth and angiogenesis remain unresolved . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL here we report that a candidate tumour suppressor gene , ing4 , is involved in regulating brain tumour 
0 that a candidate tumour suppressor gene , ing4 , is involved in regulating brain tumour growth and angiogenesis . NULL NULL 
16 candidate tumour suppressor gene , ing4 , is involved in regulating brain tumour growth and angiogenesis . NULL NULL NULL NULL 
4 gene , ing4 , is involved in regulating brain tumour growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 ing4 , is involved in regulating brain tumour growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of ing4 is significantly reduced in gliomas as compared with 
18 NULL NULL NULL NULL NULL expression of ing4 is significantly reduced in gliomas as compared with normal human brain tissue , 
18 with normal human brain tissue , and the extent of reduction correlates with the progression from lower to higher grades of 
2 tissue , and the extent of reduction correlates with the progression from lower to higher grades of tumours . NULL NULL 
18 mice , xenografts of human glioblastoma u87mg , which has decreased expression of ing4 , grow significantly faster and have higher 
9 , xenografts of human glioblastoma u87mg , which has decreased expression of ing4 , grow significantly faster and have higher vascular 
4 glioblastoma u87mg , which has decreased expression of ing4 , grow significantly faster and have higher vascular volume fractions than control 
0 grow significantly faster and have higher vascular volume fractions than control tumours . NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL we show that ing4 physically interacts with p65 ( rela ) subunit of nuclear factor nf-kappab 
16 ) subunit of nuclear factor nf-kappab , and that ing4 regulates brain tumour angiogenesis through transcriptional repression of nf-kappab-responsive genes . 
3 nuclear factor nf-kappab , and that ing4 regulates brain tumour angiogenesis through transcriptional repression of nf-kappab-responsive genes . NULL NULL NULL 
0 nf-kappab , and that ing4 regulates brain tumour angiogenesis through transcriptional repression of nf-kappab-responsive genes . NULL NULL NULL NULL NULL 
0 , and that ing4 regulates brain tumour angiogenesis through transcriptional repression of nf-kappab-responsive genes . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate that ing4 has an important role in brain tumour 
16 NULL NULL NULL these results indicate that ing4 has an important role in brain tumour pathogenesis . NULL NULL NULL NULL 
16 NULL NULL these results indicate that ing4 has an important role in brain tumour pathogenesis . NULL NULL NULL NULL NULL 
2 indicate that ing4 has an important role in brain tumour pathogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL tgfbeta1 , back to the future : revisiting its role as a transforming growth factor . NULL NULL NULL NULL 
0 to the future : revisiting its role as a transforming growth factor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL tgfbeta1 was initially identified in culture media from transformed cells as part of a factor that 
0 NULL NULL tgfbeta1 was initially identified in culture media from transformed cells as part of a factor that could produce a 
0 from transformed cells as part of a factor that could produce a transformed phenotype in a nontransformed cell line . NULL 
0 cells as part of a factor that could produce a transformed phenotype in a nontransformed cell line . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL subsequently this activity was separated into tgfbeta and tgfalpha an egf receptor ligand 
4 NULL NULL with the discovery that tgfbeta1 was a potent growth inhibitor of epithelial cells , and the identification of inactivating 
0 NULL with the discovery that tgfbeta1 was a potent growth inhibitor of epithelial cells , and the identification of inactivating mutations 
18 growth inhibitor of epithelial cells , and the identification of inactivating mutations within the tgfbeta1 signaling pathway in cancers it became 
0 in cancers it became clear that tgfbeta1 signaling is a tumor suppressor pathway for early stages of cancer . NULL NULL 
0 cancers it became clear that tgfbeta1 signaling is a tumor suppressor pathway for early stages of cancer . NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL however many human carcinomas overexpress tgfbeta1 and this is associated with poor patient prognosis and 
0 NULL however many human carcinomas overexpress tgfbeta1 and this is associated with poor patient prognosis and increased frequency of metastasis . 
17 tgfbeta1 and this is associated with poor patient prognosis and increased frequency of metastasis . NULL NULL NULL NULL NULL NULL 
14 is associated with poor patient prognosis and increased frequency of metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL similar results have been obtained with tumor cell lines and experimental animal 
0 NULL NULL NULL NULL NULL NULL similar results have been obtained with tumor cell lines and experimental animal models . NULL 
0 NULL NULL NULL NULL similar results have been obtained with tumor cell lines and experimental animal models . NULL NULL NULL 
0 NULL NULL NULL NULL NULL thus stage specific duality of function is the emerging paradigm for the role of tgfbeta1 in 
16 specific duality of function is the emerging paradigm for the role of tgfbeta1 in cancer . NULL NULL NULL NULL NULL 
0 review will focus on the evidence for tgfbeta1 as a tumor promoting and metastasis factor and examine the biological and molecular 
17 will focus on the evidence for tgfbeta1 as a tumor promoting and metastasis factor and examine the biological and molecular basis 
14 on the evidence for tgfbeta1 as a tumor promoting and metastasis factor and examine the biological and molecular basis for these 
0 factor and examine the biological and molecular basis for these effects . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL it is proposed that the switch from tumor suppressor to oncogene reflects genetic or epigenetic alterations in signaling 
0 NULL NULL it is proposed that the switch from tumor suppressor to oncogene reflects genetic or epigenetic alterations in signaling pathways 
0 switch from tumor suppressor to oncogene reflects genetic or epigenetic alterations in signaling pathways in tumor cells that alter the readout 
0 suppressor to oncogene reflects genetic or epigenetic alterations in signaling pathways in tumor cells that alter the readout from the tgfbeta1 
0 oncogene reflects genetic or epigenetic alterations in signaling pathways in tumor cells that alter the readout from the tgfbeta1 pathway . 
16 or epigenetic alterations in signaling pathways in tumor cells that alter the readout from the tgfbeta1 pathway . NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL role of thrombin in angiogenesis and tumor progression . NULL NULL 
3 NULL NULL NULL NULL NULL NULL role of thrombin in angiogenesis and tumor progression . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL role of thrombin in angiogenesis and tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL role of thrombin in angiogenesis and tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical , laboratory , histopathological , and pharmacological evidence support the 
0 NULL clinical , laboratory , histopathological , and pharmacological evidence support the notion that the coagulation system , which is activated 
17 support the notion that the coagulation system , which is activated in most cancer patients , plays an important role in 
16 system , which is activated in most cancer patients , plays an important role in tumor biology . NULL NULL NULL 
16 which is activated in most cancer patients , plays an important role in tumor biology . NULL NULL NULL NULL NULL 
16 is activated in most cancer patients , plays an important role in tumor biology . NULL NULL NULL NULL NULL NULL 
0 in most cancer patients , plays an important role in tumor biology . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL our laboratory has provided evidence that thrombin activates angiogenesis , a process which is essential in tumor growth 
3 NULL NULL our laboratory has provided evidence that thrombin activates angiogenesis , a process which is essential in tumor growth and 
17 evidence that thrombin activates angiogenesis , a process which is essential in tumor growth and metastasis . NULL NULL NULL NULL 
0 thrombin activates angiogenesis , a process which is essential in tumor growth and metastasis . NULL NULL NULL NULL NULL NULL 
4 activates angiogenesis , a process which is essential in tumor growth and metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 , a process which is essential in tumor growth and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL this event is independent of fibrin formation . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL this event is independent of fibrin formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL at the cellular level many actions of thrombin can contribute to activation of angiogenesis : ( 1 ) . NULL 
17 the cellular level many actions of thrombin can contribute to activation of angiogenesis : ( 1 ) . NULL NULL NULL 
3 level many actions of thrombin can contribute to activation of angiogenesis : ( 1 ) . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL thrombin decreases the ability of endothelial cells to attach to basement membrane 
0 NULL NULL NULL NULL NULL NULL NULL thrombin decreases the ability of endothelial cells to attach to basement membrane proteins . 
15 NULL NULL thrombin decreases the ability of endothelial cells to attach to basement membrane proteins . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL thrombin greatly potentiates vascular endothelial growth factor- ( vegf- ) induced endothelial cell 
0 NULL NULL NULL NULL NULL thrombin greatly potentiates vascular endothelial growth factor- ( vegf- ) induced endothelial cell proliferation . NULL 
17 thrombin greatly potentiates vascular endothelial growth factor- ( vegf- ) induced endothelial cell proliferation . NULL NULL NULL NULL NULL NULL 
1 vascular endothelial growth factor- ( vegf- ) induced endothelial cell proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL this potentiation is accompanied by up-regulation of the expression of vegf receptors ( kinase insert domain-containing 
9 NULL NULL this potentiation is accompanied by up-regulation of the expression of vegf receptors ( kinase insert domain-containing receptor [ kdr 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL thrombin increases the mrna and protein levels of alpha ( v ) 
10 NULL NULL NULL NULL NULL NULL NULL thrombin increases the mrna and protein levels of alpha ( v ) beta ( 
9 NULL NULL NULL NULL NULL thrombin increases the mrna and protein levels of alpha ( v ) beta ( 3 ) 
9 NULL NULL NULL NULL thrombin increases the mrna and protein levels of alpha ( v ) beta ( 3 ) integrin 
17 NULL NULL NULL NULL NULL NULL NULL furthermore , thrombin increases the secretion of vegf and enhances the expression and protein 
14 NULL NULL NULL NULL NULL furthermore , thrombin increases the secretion of vegf and enhances the expression and protein synthesis of 
17 NULL furthermore , thrombin increases the secretion of vegf and enhances the expression and protein synthesis of matrix metalloprotease-9 and alpha 
9 , thrombin increases the secretion of vegf and enhances the expression and protein synthesis of matrix metalloprotease-9 and alpha ( v 
0 increases the secretion of vegf and enhances the expression and protein synthesis of matrix metalloprotease-9 and alpha ( v ) beta 
0 the secretion of vegf and enhances the expression and protein synthesis of matrix metalloprotease-9 and alpha ( v ) beta ( 
0 of vegf and enhances the expression and protein synthesis of matrix metalloprotease-9 and alpha ( v ) beta ( 3 ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results could explain the angiogenic and tumor-promoting effect of thrombin and 
3 NULL NULL NULL NULL NULL these results could explain the angiogenic and tumor-promoting effect of thrombin and provide the basis for 
17 NULL NULL NULL these results could explain the angiogenic and promoting effect of thrombin and provide the basis for development of 
0 NULL NULL these results could explain the angiogenic and tumor-promoting effect of thrombin and provide the basis for development of thrombin 
0 and tumor-promoting effect of thrombin and provide the basis for development of thrombin receptor mimetics or antagonists for therapeutic application . 
0 for development of thrombin receptor mimetics or antagonists for therapeutic application . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL hypothesis : induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is 
3 NULL NULL NULL NULL NULL NULL NULL hypothesis : induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a 
19 NULL NULL NULL NULL NULL hypothesis : induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying 
0 NULL NULL hypothesis : induced angiogenesis after surgery in premenopausal positive breast cancer patients is a major underlying reason why adjuvant 
0 after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those 
19 breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients . NULL NULL NULL 
19 NULL NULL NULL NULL NULL background : we suggest that surgical extirpation of primary breast cancer among other effects accelerates relapse 
19 NULL NULL NULL NULL background : we suggest that surgical extirpation of primary breast cancer among other effects accelerates relapse for 
0 suggest that surgical extirpation of primary breast cancer among other effects accelerates relapse for some premenopausal node-positive patients . NULL NULL 
0 breast cancer among other effects accelerates relapse for some premenopausal positive patients . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these accelerated relapses occur within 10 months of surgery for untreated patients 
19 NULL NULL these accelerated relapses occur within 10 months of surgery for untreated patients . NULL NULL NULL NULL NULL NULL 
19 these accelerated relapses occur within 10 months of surgery for untreated patients . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the mechanism proposed is a stimulation of angiogenesis for distant dormant micrometastases 
17 NULL NULL NULL NULL NULL the mechanism proposed is a stimulation of angiogenesis for distant dormant micrometastases . NULL NULL NULL 
3 NULL NULL NULL the mechanism proposed is a stimulation of angiogenesis for distant dormant micrometastases . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL we could imagine that it also plays a role in adjuvant chemotherapy effectiveness since , perhaps not 
0 NULL NULL we could imagine that it also plays a role in adjuvant chemotherapy effectiveness since , perhaps not coincidentally , 
19 could imagine that it also plays a role in adjuvant chemotherapy effectiveness since , perhaps not coincidentally , this is most 
0 imagine that it also plays a role in adjuvant chemotherapy effectiveness since , perhaps not coincidentally , this is most beneficial 
0 effectiveness since , perhaps not coincidentally , this is most beneficial for premenopausal node-positive patients . NULL NULL NULL NULL NULL 
0 perhaps not coincidentally , this is most beneficial for premenopausal positive patients . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL hypothesis : we speculate that there is a burst of angiogenesis of distant dormant micrometastases after surgery in approximately 
3 hypothesis : we speculate that there is a burst of angiogenesis of distant dormant micrometastases after surgery in approximately 20 % 
19 is a burst of angiogenesis of distant dormant micrometastases after surgery in approximately 20 % of premenopausal node-positive patients . NULL 
0 dormant micrometastases after surgery in approximately 20 % of premenopausal positive patients . NULL NULL NULL NULL NULL NULL NULL NULL 
19 highly chemosensitive state and is the underlying reason why adjuvant chemotherapy works particularly well for that patient category . NULL NULL 
17 NULL NULL NULL NULL NULL NULL testing the hypothesis : stimulation of dormant micrometastases by primary tumor removal is known to 
0 testing the hypothesis : stimulation of dormant micrometastases by primary tumor removal is known to occur in animal models . NULL 
19 the hypothesis : stimulation of dormant micrometastases by primary tumor removal is known to occur in animal models . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL transient circulating levels of angioactive molecules and serial high-resolution imaging studies of 
0 NULL NULL NULL NULL NULL NULL NULL NULL transient circulating levels of angioactive molecules and serial high-resolution imaging studies of focal 
3 NULL NULL NULL NULL NULL NULL transient circulating levels of angioactive molecules and serial high-resolution imaging studies of focal angiogenesis might 
3 of angioactive molecules and serial high-resolution imaging studies of focal angiogenesis might help . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL implications : short-course cytotoxic chemotherapy after surgery has probably reached its zenith , and other 
0 NULL NULL NULL NULL implications : short-course cytotoxic chemotherapy after surgery has probably reached its zenith , and other strategies , 
3 probably reached its zenith , and other strategies , perhaps angiogenic methods , are needed to successfully treat more patients . 
19 strategies , perhaps antiangiogenic methods , are needed to successfully treat more patients . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , the hypothesis predicts that early detection , which is 
0 detection , which is designed to find more patients without involved lymph nodes , may not be a synergistic strategy with 
19 nodes , may not be a synergistic strategy with adjuvant chemotherapy , which works best with positive lymph node patients . 
0 synergistic strategy with adjuvant chemotherapy , which works best with positive lymph node patients . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 
0 NULL NULL NULL NULL NULL NULL NULL NULL matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue 
0 NULL NULL NULL NULL NULL NULL matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue inhibitor of 
0 NULL NULL NULL matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human 
0 and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human dermal wound healing . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL proteolytic activity is required for the turnover of the extracellular matrix during 
0 NULL NULL NULL NULL NULL NULL NULL proteolytic activity is required for the turnover of the extracellular matrix during wound healing 
7 NULL NULL NULL NULL proteolytic activity is required for the turnover of the extracellular matrix during wound healing . NULL NULL 
0 proteolytic activity is required for the turnover of the extracellular matrix during wound healing . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL matrix metalloproteinases can collectively cleave all components of the extracellular matrix 
6 NULL NULL NULL NULL NULL NULL matrix metalloproteinases can collectively cleave all components of the extracellular matrix , with the endogenous 
17 NULL NULL NULL NULL NULL NULL matrix metalloproteinases can collectively cleave all components of the extracellular matrix , with the endogenous 
0 matrix metalloproteinases can collectively cleave all components of the extracellular matrix , with the endogenous tissue inhibitor of metalloproteinase-1 regulating their 
0 components of the extracellular matrix , with the endogenous tissue inhibitor of metalloproteinase-1 regulating their activity . NULL NULL NULL NULL 
16 extracellular matrix , with the endogenous tissue inhibitor of metalloproteinase-1 regulating their activity . NULL NULL NULL NULL NULL NULL NULL 
0 , with the endogenous tissue inhibitor of metalloproteinase-1 regulating their activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 at varying postoperative times ( n= 92 ) or during surgery ( controls , n= 17 ) , was used to 
0 postoperative times ( n= 92 ) or during surgery ( controls , n= 17 ) , was used to investigate the 
0 during surgery ( controls , n= 17 ) , was used to investigate the temporal and spatial activity of matrix metalloproteinase-2 
0 ) , was used to investigate the temporal and spatial activity of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 
0 was used to investigate the temporal and spatial activity of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human 
0 and spatial activity of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human wound healing . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL matrix metalloproteinase activity , determined using a quenched fluorescence substrate assay 
0 NULL NULL NULL NULL NULL NULL NULL NULL matrix metalloproteinase activity , determined using a quenched fluorescence substrate assay , increased 
17 activity , determined using a quenched fluorescence substrate assay , increased during early healing ( 3-8 weeks ) compared to controls 
0 increased during early healing ( 3-8 weeks ) compared to controls , and then decreased between 24 and 36 weeks after 
18 ( 3-8 weeks ) compared to controls , and then decreased between 24 and 36 weeks after surgery ( p less 
0 , and then decreased between 24 and 36 weeks after surgery ( p less than 0.05 until 24 weeks , mann-whitney 
0 NULL NULL NULL NULL NULL NULL NULL immunohistochemistry scores for matrix metalloproteinase-9 expression were significantly elevated compared to controls in scar 
9 NULL NULL NULL NULL NULL immunohistochemistry scores for matrix metalloproteinase-9 expression were significantly elevated compared to controls in scar endothelial cells 
17 NULL NULL immunohistochemistry scores for matrix metalloproteinase-9 expression were significantly elevated compared to controls in scar endothelial cells and fibroblasts from 
0 scores for matrix metalloproteinase-9 expression were significantly elevated compared to controls in scar endothelial cells and fibroblasts from 2 until 12 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL matrix metalloproteinase-2 staining was observed exclusively in fibroblasts , reaching maximum 
0 NULL NULL NULL NULL NULL NULL NULL NULL matrix metalloproteinase-2 staining was observed exclusively in fibroblasts , reaching maximum levels 8-12 
0 NULL NULL NULL NULL NULL NULL matrix metalloproteinase-2 staining was observed exclusively in fibroblasts , reaching maximum levels 8-12 weeks after 
0 metalloproteinase-2 staining was observed exclusively in fibroblasts , reaching maximum levels 8-12 weeks after surgery , decreasing by 1.5 years but 
0 exclusively in fibroblasts , reaching maximum levels 8-12 weeks after surgery , decreasing by 1.5 years but remaining significantly increased . 
18 fibroblasts , reaching maximum levels 8-12 weeks after surgery , decreasing by 1.5 years but remaining significantly increased . NULL NULL 
17 after surgery , decreasing by 1.5 years but remaining significantly increased . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL tissue inhibitor of metalloproteinase-1 staining was relatively sparse but was significantly increased 
0 NULL NULL NULL NULL NULL NULL tissue inhibitor of metalloproteinase-1 staining was relatively sparse but was significantly increased until 8 weeks 
17 inhibitor of metalloproteinase-1 staining was relatively sparse but was significantly increased until 8 weeks after surgery . NULL NULL NULL NULL 
0 relatively sparse but was significantly increased until 8 weeks after surgery . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results show that matrix metalloproteinases are present at elevated levels during 
0 NULL NULL NULL NULL NULL NULL these results show that matrix metalloproteinases are present at elevated levels during early wound healing 
9 NULL NULL NULL these results show that matrix metalloproteinases are present at elevated levels during early wound healing , when angiogenesis 
17 NULL these results show that matrix metalloproteinases are present at elevated levels during early wound healing , when angiogenesis occurs , 
0 these results show that matrix metalloproteinases are present at elevated levels during early wound healing , when angiogenesis occurs , and 
3 present at elevated levels during early wound healing , when angiogenesis occurs , and suggest that matrix metalloproteinase-9 may play a 
0 wound healing , when angiogenesis occurs , and suggest that matrix metalloproteinase-9 may play a significant role . NULL NULL NULL 
16 when angiogenesis occurs , and suggest that matrix metalloproteinase-9 may play a significant role . NULL NULL NULL NULL NULL NULL 
16 occurs , and suggest that matrix metalloproteinase-9 may play a significant role . NULL NULL NULL NULL NULL NULL NULL NULL 
16 , and suggest that matrix metalloproteinase-9 may play a significant role . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL the later expression of matrix metalloproteinase-2 and -9 in fibroblasts suggests a role 
0 NULL NULL NULL NULL NULL NULL the later expression of matrix metalloproteinase-2 and -9 in fibroblasts suggests a role in extracellular 
16 expression of matrix metalloproteinase-2 and -9 in fibroblasts suggests a role in extracellular matrix remodeling . NULL NULL NULL NULL NULL 
0 metalloproteinase-2 and -9 in fibroblasts suggests a role in extracellular matrix remodeling . NULL NULL NULL NULL NULL NULL NULL NULL 
7 and -9 in fibroblasts suggests a role in extracellular matrix remodeling . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) in seizures : a double-edged sword 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) is a vascular growth factor which 
0 vascular endothelial growth factor ( vegf ) is a vascular growth factor which induces angiogenesis ( the development of new blood 
17 factor ( vegf ) is a vascular growth factor which induces angiogenesis ( the development of new blood vessels ) , 
3 ( vegf ) is a vascular growth factor which induces angiogenesis ( the development of new blood vessels ) , vascular 
2 is a vascular growth factor which induces angiogenesis ( the development of new blood vessels ) , vascular permeability , and 
0 NULL NULL in brain , receptors for vegf have been localized to vascular endothelium , neurons , and glia . NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL vegf is upregulated after hypoxic injury to the brain , which can occur 
0 during cerebral ischemia or high-altitude edema , and has been implicated in the blood-brain barrier breakdown associated with these conditions . 
6 edema , and has been implicated in the blood-brain barrier breakdown associated with these conditions . NULL NULL NULL NULL NULL 
0 , and has been implicated in the blood-brain barrier breakdown associated with these conditions . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL given its recently-described role as an inflammatory mediator , vegf could 
0 NULL NULL NULL NULL NULL NULL NULL given its recently-described role as an inflammatory mediator , vegf could also contribute to 
0 NULL NULL NULL given its recently-described role as an inflammatory mediator , vegf could also contribute to the inflammatory responses observed 
0 recently-described role as an inflammatory mediator , vegf could also contribute to the inflammatory responses observed in cerebral ischemia . NULL 
0 mediator , vegf could also contribute to the inflammatory responses observed in cerebral ischemia . NULL NULL NULL NULL NULL NULL 
6 NULL NULL NULL NULL NULL after seizures , blood-brain barrier breakdown and inflammation is also observed in brain , albeit on 
0 after seizures , blood-brain barrier breakdown and inflammation is also observed in brain , albeit on a lower scale than that 
0 in brain , albeit on a lower scale than that observed after stroke . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL recent evidence has suggested a role for inflammation in seizure disorders . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL we have described striking increases in vegf protein in both neurons and glia after pilocarpine-induced 
0 NULL NULL NULL we have described striking increases in vegf protein in both neurons and glia after pilocarpine-induced status epilepticus in 
0 increases in vegf protein in both neurons and glia after induced status epilepticus in the brain . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL increases in vegf could contribute to the blood-brain barrier breakdown and 
17 NULL NULL NULL NULL NULL NULL increases in vegf could contribute to the blood-brain barrier breakdown and inflammation observed after seizures 
6 NULL increases in vegf could contribute to the blood-brain barrier breakdown and inflammation observed after seizures . NULL NULL NULL NULL 
0 vegf could contribute to the blood-brain barrier breakdown and inflammation observed after seizures . NULL NULL NULL NULL NULL NULL NULL 
18 neuroprotective across several experimental paradigms , and hence could potentially protect vulnerable cells from damage associated with seizures . NULL NULL 
6 paradigms , and hence could potentially protect vulnerable cells from damage associated with seizures . NULL NULL NULL NULL NULL NULL 
0 , and hence could potentially protect vulnerable cells from damage associated with seizures . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL therefore , the role of vegf after seizures could be either protective or destructive 
0 further research will determine the exact nature of vegf 's role after seizures , preliminary data indicate that vegf plays a 
0 's role after seizures , preliminary data indicate that vegf plays a protective role after seizures . NULL NULL NULL NULL 
0 seizures , preliminary data indicate that vegf plays a protective role after seizures . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration 
0 NULL NULL safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration . NULL NULL NULL 
0 safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration . NULL NULL NULL NULL NULL 
6 treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL photodynamic therapy ( pdt ) is a novel treatment entity that 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL photodynamic therapy ( pdt ) is a novel treatment entity that exploits 
0 NULL NULL NULL NULL NULL NULL NULL photodynamic therapy ( pdt ) is a novel treatment entity that exploits the photophysical 
0 NULL NULL photodynamic therapy ( pdt ) is a novel treatment entity that exploits the photophysical properties of various photosensitive chemical 
0 ) is a novel treatment entity that exploits the photophysical properties of various photosensitive chemical entities which , upon light activation 
0 properties of various photosensitive chemical entities which , upon light activation , results in targeted photooxidation and subsequent tissue destruction . 
0 various photosensitive chemical entities which , upon light activation , results in targeted photooxidation and subsequent tissue destruction . NULL NULL 
0 chemical entities which , upon light activation , results in targeted photooxidation and subsequent tissue destruction . NULL NULL NULL NULL 
6 light activation , results in targeted photooxidation and subsequent tissue destruction . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic properties of pdt have been adapted for treatment of subfoveal 
18 NULL NULL NULL NULL NULL NULL NULL NULL the antiangiogenic properties of pdt have been adapted for treatment of subfoveal choroidal 
0 NULL NULL NULL NULL NULL NULL the antiangiogenic properties of pdt have been adapted for treatment of subfoveal choroidal neovascular membranes 
19 NULL the antiangiogenic properties of pdt have been adapted for treatment of subfoveal choroidal neovascular membranes due to disease states such 
0 of pdt have been adapted for treatment of subfoveal choroidal neovascular membranes due to disease states such as age-related macular degeneration 
6 neovascular membranes due to disease states such as age-related macular degeneration ( amd ) . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL historically , pdt has been limited by a lack of suitable photosensitive dyes 
0 NULL NULL NULL NULL NULL historically , pdt has been limited by a lack of suitable photosensitive dyes . NULL NULL 
0 NULL NULL however , agents such as verteporfin , a generation benzoporphyrin derivative , appear to be free from the extensive 
0 verteporfin , a second-generation benzoporphyrin derivative , appear to be free from the extensive phototoxicity that limited the success of previous 
0 , appear to be free from the extensive phototoxicity that limited the success of previous agents . NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL verteporfin has a high affinity for choroidal neovascular membranes , typically found with exudative amd 
0 NULL NULL NULL verteporfin has a high affinity for choroidal neovascular membranes , typically found with exudative amd , and upon 
17 , typically found with exudative amd , and upon photoactivation results in targeted microvascular damage and thrombus formation with resultant vessel 
0 found with exudative amd , and upon photoactivation results in targeted microvascular damage and thrombus formation with resultant vessel occlusion . 
6 exudative amd , and upon photoactivation results in targeted microvascular damage and thrombus formation with resultant vessel occlusion . NULL NULL 
2 and upon photoactivation results in targeted microvascular damage and thrombus formation with resultant vessel occlusion . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL scrutiny of diagnostic indicators for verteporfin administration , including critical angiographic evaluation of lesion size and visual 
0 NULL scrutiny of diagnostic indicators for verteporfin administration , including critical angiographic evaluation of lesion size and visual acuity , is 
0 angiographic evaluation of lesion size and visual acuity , is essential to treatment success . NULL NULL NULL NULL NULL NULL 
0 of lesion size and visual acuity , is essential to treatment success . NULL NULL NULL NULL NULL NULL NULL NULL 
0 better ) may be at particular risk for marked vision loss following verteporfin administration . NULL NULL NULL NULL NULL NULL 
19 be at particular risk for marked vision loss following verteporfin administration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL lesion composition also appears to influence visual outcome with verteporfin use . NULL NULL NULL NULL 
19 lesion composition also appears to influence visual outcome with verteporfin use . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL the safety of verteporfin is directly dependent upon the appropriate integration of dosage , infusion and light 
0 is directly dependent upon the appropriate integration of dosage , infusion and light activation required for a suitable pharmacotherapeutic outcome . 
0 upon the appropriate integration of dosage , infusion and light activation required for a suitable pharmacotherapeutic outcome . NULL NULL NULL 
0 the appropriate integration of dosage , infusion and light activation required for a suitable pharmacotherapeutic outcome . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL when used appropriately , and with adequate patient education regarding photosensitivity , 
19 regarding photosensitivity , the risk-benefit of verteporfin for the medical treatment of neovascular amd is favourable . NULL NULL NULL NULL 
0 , the risk-benefit of verteporfin for the medical treatment of neovascular amd is favourable . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin . NULL NULL NULL 
19 NULL NULL NULL retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin . NULL NULL NULL NULL 
0 NULL retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin . NULL NULL NULL NULL NULL NULL 
0 retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin . NULL NULL NULL NULL NULL NULL NULL 
3 to describe visual acuity and angiographic outcomes of juxtafoveal choroidal neovascularization ( cnv ) treated with photodynamic therapy and verteporfin ( 
3 visual acuity and angiographic outcomes of juxtafoveal choroidal neovascularization ( cnv ) treated with photodynamic therapy and verteporfin ( pdt ) 
19 and angiographic outcomes of juxtafoveal choroidal neovascularization ( cnv ) treated with photodynamic therapy and verteporfin ( pdt ) . NULL 
0 outcomes of juxtafoveal choroidal neovascularization ( cnv ) treated with photodynamic therapy and verteporfin ( pdt ) . NULL NULL NULL 
0 of juxtafoveal choroidal neovascularization ( cnv ) treated with photodynamic therapy and verteporfin ( pdt ) . NULL NULL NULL NULL 
0 ( cnv ) treated with photodynamic therapy and verteporfin ( pdt ) . NULL NULL NULL NULL NULL NULL NULL NULL 
19 methods : four hundred eighty-four consecutive eyes of 446 patients treated with pdt from january 1 , 2001 , to june 
0 four hundred eighty-four consecutive eyes of 446 patients treated with pdt from january 1 , 2001 , to june 30 , 
3 NULL NULL fluorescein angiograms were reviewed retrospectively to identify juxtafoveal cnv . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL eligible patients had cnv in which the central boundary of the lesion was between 
0 NULL NULL NULL eligible patients had cnv in which the central boundary of the lesion was between 1 and 199 microm 
19 NULL patient charts were reviewed for visual acuity of the treated eye before pdt and at 6- and 12-month follow-up examinations 
0 were reviewed for visual acuity of the treated eye before pdt and at 6- and 12-month follow-up examinations . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL presence of subfoveal cnv at 6 and 12 months of follow-up 
3 NULL NULL NULL NULL NULL NULL NULL presence of subfoveal cnv at 6 and 12 months of follow-up was determined by 
0 NULL NULL NULL a lesion was considered subfoveal if it extended underneath the geometric center of the faz . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : twenty-one eyes had juxtafoveal cnv . NULL NULL NULL 
3 NULL NULL NULL NULL results : twenty-one eyes had juxtafoveal cnv . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL median change in visual acuity both 6 and 12 months after the 
0 visual acuity both 6 and 12 months after the initial pdt was 0 lines ( n = 18 at 6 months 
2 NULL NULL NULL NULL NULL NULL NULL NULL eleven lesions progressed to a subfoveal location by 12 months . NULL NULL 
0 NULL NULL NULL visual acuity in eyes with progressive lesions decreased a median of 4 lines of vision . NULL NULL 
0 NULL NULL conclusions : despite a small sample size and limited length of follow-up , this study shows that visual acuity 
0 average can remain stable for at least 12 months after pdt of juxtafoveal lesions . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL growth through the foveal center still can occur , however , 
0 still can occur , however , and this can be associated with substantial visual loss . NULL NULL NULL NULL NULL 
0 however , and this can be associated with substantial visual loss . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL enhanced igf-1 expression improves smooth muscle cell engraftment after cell transplantation 
9 NULL NULL NULL NULL NULL NULL NULL NULL enhanced igf-1 expression improves smooth muscle cell engraftment after cell transplantation . NULL 
17 NULL NULL NULL NULL NULL NULL NULL enhanced igf-1 expression improves smooth muscle cell engraftment after cell transplantation . NULL NULL 
2 NULL NULL NULL enhanced igf-1 expression improves smooth muscle cell engraftment after cell transplantation . NULL NULL NULL NULL NULL NULL 
19 enhanced igf-1 expression improves smooth muscle cell engraftment after cell transplantation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL the functional benefit of cell transplantation after a myocardial infarction is diminished by early cell losses 
0 functional benefit of cell transplantation after a myocardial infarction is diminished by early cell losses . NULL NULL NULL NULL NULL 
5 transplantation after a myocardial infarction is diminished by early cell losses . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL igf-1 enhances cell proliferation and survival . NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL igf-1 enhances cell proliferation and survival . NULL NULL NULL NULL NULL NULL NULL 
5 NULL NULL NULL NULL NULL igf-1 enhances cell proliferation and survival . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL we hypothesized that transfected smooth muscle cells ( smcs ) would enhance cell survival 
17 hypothesized that igf-1-transfected smooth muscle cells ( smcs ) would enhance cell survival and improve engraftment after cell transplantation . NULL 
5 igf-1-transfected smooth muscle cells ( smcs ) would enhance cell survival and improve engraftment after cell transplantation . NULL NULL NULL 
17 muscle cells ( smcs ) would enhance cell survival and improve engraftment after cell transplantation . NULL NULL NULL NULL NULL 
2 cells ( smcs ) would enhance cell survival and improve engraftment after cell transplantation . NULL NULL NULL NULL NULL NULL 
19 ) would enhance cell survival and improve engraftment after cell transplantation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL the igf-1 gene was transfected into male smcs and compared with smcs transfected with a 
19 gene was transfected into male smcs and compared with smcs transfected with a plasmid vector ( vector control ) and nontransfected 
0 compared with smcs transfected with a plasmid vector ( vector control ) and nontransfected smcs ( cell control ) . NULL 
19 transfected with a plasmid vector ( vector control ) and nontransfected smcs ( cell control ) . NULL NULL NULL NULL 
0 vector ( vector control ) and nontransfected smcs ( cell control ) . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL igf-1 mrna ( n=10/group ) and protein levels ( n=6/group ) were 
0 NULL NULL NULL NULL igf-1 mrna ( n=10/group ) and protein levels ( n=6/group ) were higher ( p less than 
0 NULL NULL NULL igf-1 mrna ( n=10/group ) and protein levels ( n=6/group ) were higher ( p less than 0.05 
0 at 3 , 7 , and 14 days compared with controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL vegf was also increased in parallel to enhanced igf-1 expression . NULL NULL NULL 
17 NULL NULL NULL vegf was also increased in parallel to enhanced igf-1 expression . NULL NULL NULL NULL NULL NULL NULL 
9 NULL vegf was also increased in parallel to enhanced igf-1 expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL transfected cells demonstrated greater cell proliferation , stimulated angiogenesis , and 
1 NULL NULL NULL NULL NULL igf-1-transfected cells demonstrated greater cell proliferation , stimulated angiogenesis , and decreased caspase-3 activity after simulated 
17 NULL NULL NULL igf-1-transfected cells demonstrated greater cell proliferation , stimulated angiogenesis , and decreased caspase-3 activity after simulated ischemia and 
3 NULL NULL igf-1-transfected cells demonstrated greater cell proliferation , stimulated angiogenesis , and decreased caspase-3 activity after simulated ischemia and reperfusion 
18 cells demonstrated greater cell proliferation , stimulated angiogenesis , and decreased caspase-3 activity after simulated ischemia and reperfusion ( p less 
0 greater cell proliferation , stimulated angiogenesis , and decreased caspase-3 activity after simulated ischemia and reperfusion ( p less than 0.05 
0 than 0.05 for all groups compared with vector or cell controls ) . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL a uniform left ventricular injury was produced in female rats using a cryoprobe . NULL NULL NULL 
19 x 10 ( 6 ) cells from three groups were implanted into the scar . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL one week later , transfected smcs had increased myocardial igf-1 and vegf levels , increased 
17 NULL NULL NULL one week later , igf-1-transfected smcs had increased myocardial igf-1 and vegf levels , increased bcl2 expression , 
0 later , igf-1-transfected smcs had increased myocardial igf-1 and vegf levels , increased bcl2 expression , limited cell apoptosis , and 
17 igf-1-transfected smcs had increased myocardial igf-1 and vegf levels , increased bcl2 expression , limited cell apoptosis , and enhanced vessel 
9 had increased myocardial igf-1 and vegf levels , increased bcl2 expression , limited cell apoptosis , and enhanced vessel formation in 
18 myocardial igf-1 and vegf levels , increased bcl2 expression , limited cell apoptosis , and enhanced vessel formation in the myocardial 
5 and vegf levels , increased bcl2 expression , limited cell apoptosis , and enhanced vessel formation in the myocardial scar compared 
17 , increased bcl2 expression , limited cell apoptosis , and enhanced vessel formation in the myocardial scar compared with the two 
2 bcl2 expression , limited cell apoptosis , and enhanced vessel formation in the myocardial scar compared with the two control groups 
0 vessel formation in the myocardial scar compared with the two control groups ( p less than 0.05 for all groups ) 
5 NULL NULL NULL NULL NULL NULL the proportion of smcs surviving in the implanted region was greater ( p less than 
19 NULL NULL NULL the proportion of smcs surviving in the implanted region was greater ( p less than 0.05 ) in 
19 was greater ( p less than 0.05 ) in the transfected group than in the vector or cell controls . NULL 
0 in the igf-1-transfected group than in the vector or cell controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL gene enhancement with igf-1 improved donor cell proliferation , survival , and 
17 NULL NULL NULL NULL NULL NULL gene enhancement with igf-1 improved donor cell proliferation , survival , and engraftment after cell 
1 NULL NULL NULL gene enhancement with igf-1 improved donor cell proliferation , survival , and engraftment after cell transplantation , perhaps 
5 NULL gene enhancement with igf-1 improved donor cell proliferation , survival , and engraftment after cell transplantation , perhaps mediated by 
2 with igf-1 improved donor cell proliferation , survival , and engraftment after cell transplantation , perhaps mediated by enhanced angiogenesis and 
19 donor cell proliferation , survival , and engraftment after cell transplantation , perhaps mediated by enhanced angiogenesis and reduced apoptosis . 
0 , survival , and engraftment after cell transplantation , perhaps mediated by enhanced angiogenesis and reduced apoptosis . NULL NULL NULL 
17 , and engraftment after cell transplantation , perhaps mediated by enhanced angiogenesis and reduced apoptosis . NULL NULL NULL NULL NULL 
3 and engraftment after cell transplantation , perhaps mediated by enhanced angiogenesis and reduced apoptosis . NULL NULL NULL NULL NULL NULL 
0 after cell transplantation , perhaps mediated by enhanced angiogenesis and reduced apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL 
0 cell transplantation , perhaps mediated by enhanced angiogenesis and reduced apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 ischemic syndrome ( ois ) is often poorly diagnosed and treated as primary open angle glaucoma or later on , as 
0 as primary open angle glaucoma or later on , as neovascular glaucoma . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL we present a 54 year old male , treated topical since 23 
19 NULL NULL we present a 54 year old male , treated topical since 23 years for glaucoma and sent to our 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : because of typical signs of ios ( iris neovascularization 
3 results : because of typical signs of ios ( iris neovascularization , mid-peripheral dot and blot hemorrhages in both eyes , 
0 performed : doppler ultrasonography of carotid arteries , digital subtractional angiography of the carotid vessels and magnetic resonance angiography . NULL 
0 digital subtractional angiography of the carotid vessels and magnetic resonance angiography . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the examinations showed occlusion of the right common carotid artery and with 80 
19 NULL NULL NULL NULL NULL NULL NULL after phacoemulsification with implantation of intraocular lens because of rapid intumescence cataract in the 
3 , and endarterectomy of left external carotid artery , the neovascularization of the iris regressed in both eyes . NULL NULL 
18 left external carotid artery , the neovascularization of the iris regressed in both eyes . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL conclusion : in case of iris neovascularization or mid-peripheral hemorrhages the doppler sonography of carotid arteries should 
0 radiologist and vascular surgeon following endarterectomy seems to stop progressing changes of ocular ischemic syndrome . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL hypoxia-responsive mediated soluble tie2 vector exhibits an anti-angiogenic activity in vitro under 
3 NULL NULL NULL hypoxia-responsive element-mediated soluble tie2 vector exhibits an angiogenic activity in vitro under hypoxic condition . NULL NULL NULL 
18 NULL NULL hypoxia-responsive element-mediated soluble tie2 vector exhibits an anti-angiogenic activity in vitro under hypoxic condition . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inducible factor-1 ( hif-1 ) is one of the key mammalian 
0 NULL hypoxia-inducible factor-1 ( hif-1 ) is one of the key mammalian transcription factors and shows increased levels in both protein 
0 factor-1 ( hif-1 ) is one of the key mammalian transcription factors and shows increased levels in both protein stability and 
0 is one of the key mammalian transcription factors and shows increased levels in both protein stability and intrinsic transcriptional activity during 
0 one of the key mammalian transcription factors and shows increased levels in both protein stability and intrinsic transcriptional activity during low 
0 key mammalian transcription factors and shows increased levels in both protein stability and intrinsic transcriptional activity during low oxygen tension . 
0 and shows increased levels in both protein stability and intrinsic transcriptional activity during low oxygen tension . NULL NULL NULL NULL 
0 shows increased levels in both protein stability and intrinsic transcriptional activity during low oxygen tension . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL activated functional hif-1 protein binds to hypoxia-responsive elements ( hre ) 
0 NULL NULL NULL NULL NULL NULL NULL hypoxia-activated functional hif-1 protein binds to hypoxia-responsive elements ( hre ) in the enhancers 
15 NULL NULL NULL NULL NULL NULL hypoxia-activated functional hif-1 protein binds to hypoxia-responsive elements ( hre ) in the enhancers of 
0 in the enhancers of several genes including vegf , the major player in angiogenesis , and initiates their mrna expression . 
3 of several genes including vegf , the major player in angiogenesis , and initiates their mrna expression . NULL NULL NULL 
17 including vegf , the major player in angiogenesis , and initiates their mrna expression . NULL NULL NULL NULL NULL NULL 
0 , the major player in angiogenesis , and initiates their mrna expression . NULL NULL NULL NULL NULL NULL NULL NULL 
10 the major player in angiogenesis , and initiates their mrna expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the molecular mechanisms regulating the gene expression under hypoxic conditions could increase the therapeutic 
0 NULL NULL NULL NULL the molecular mechanisms regulating the gene expression under hypoxic conditions could increase the therapeutic window of tumor-specific 
0 molecular mechanisms regulating the gene expression under hypoxic conditions could increase the therapeutic window of tumor-specific delivery systems . NULL NULL 
0 under hypoxic conditions could increase the therapeutic window of tumor-specific delivery systems . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL in this study , to examine hypoxia-specific production of anti-angiogenic therapeutic gene , we constructed 5 copies of 
3 NULL in this study , to examine hypoxia-specific production of angiogenic therapeutic gene , we constructed 5 copies of hre ( 
19 to examine hypoxia-specific production of anti-angiogenic therapeutic gene , we constructed 5 copies of hre ( 5xhre ) of human vegf 
19 5 copies of hre ( 5xhre ) of human vegf linked to soluble tie2 ( stie2 ) driven by minimal sv40 
0 NULL NULL NULL NULL NULL NULL NULL NULL our data showed that under hypoxia the secreted stie2 selectively inhibited tube formation 
14 NULL NULL NULL our data showed that under hypoxia the secreted stie2 selectively inhibited tube formation and migration capacities of endothelial 
18 our data showed that under hypoxia the secreted stie2 selectively inhibited tube formation and migration capacities of endothelial cells in vitro 
2 showed that under hypoxia the secreted stie2 selectively inhibited tube formation and migration capacities of endothelial cells in vitro . NULL 
14 under hypoxia the secreted stie2 selectively inhibited tube formation and migration capacities of endothelial cells in vitro . NULL NULL NULL 
18 system , 5xhre/sv40/stie2 , might be a useful tool for down-regulating tumor angiogenesis under hypoxic condition . NULL NULL NULL NULL 
0 , 5xhre/sv40/stie2 , might be a useful tool for down-regulating tumor angiogenesis under hypoxic condition . NULL NULL NULL NULL NULL 
3 5xhre/sv40/stie2 , might be a useful tool for down-regulating tumor angiogenesis under hypoxic condition . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha , tumor growth , and angiogenesis and 
0 NULL NULL NULL NULL NULL NULL NULL NULL 2-methoxyestradiol inhibits inducible factor 1alpha , tumor growth , and angiogenesis and augments 
0 NULL NULL NULL NULL 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha , tumor growth , and angiogenesis and augments paclitaxel efficacy in head 
4 NULL NULL NULL 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha , tumor growth , and angiogenesis and augments paclitaxel efficacy in head and 
3 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha , tumor growth , and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell 
0 1alpha , tumor growth , and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma . NULL NULL 
9 head and neck squamous cell carcinomas have been reported to overexpress hypoxia-inducible factor ( hif ) -1alpha , a transcription factor 
0 and neck squamous cell carcinomas have been reported to overexpress inducible factor ( hif ) -1alpha , a transcription factor that 
0 to overexpress hypoxia-inducible factor ( hif ) -1alpha , a transcription factor that promotes expression of angiogenesis factors and resistance to 
0 factor ( hif ) -1alpha , a transcription factor that promotes expression of angiogenesis factors and resistance to programmed and therapy-induced 
0 ( hif ) -1alpha , a transcription factor that promotes expression of angiogenesis factors and resistance to programmed and therapy-induced cell 
3 ) -1alpha , a transcription factor that promotes expression of angiogenesis factors and resistance to programmed and therapy-induced cell death . 
17 promotes expression of angiogenesis factors and resistance to programmed and therapy cell death . NULL NULL NULL NULL NULL NULL NULL 
17 promotes expression of angiogenesis factors and resistance to programmed and induced cell death . NULL NULL NULL NULL NULL NULL NULL 
5 of angiogenesis factors and resistance to programmed and therapy-induced cell death . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 2-methoxyestradiol ( 2me2 ) is a natural compound with hif-1alpha inhibitory activity that is currently being evaluated in phase 1 and 
0 ( 2me2 ) is a natural compound with hif-1alpha inhibitory activity that is currently being evaluated in phase 1 and 2 
19 that is currently being evaluated in phase 1 and 2 clinical trials for advanced solid tumors and multiple myeloma . NULL 
19 is currently being evaluated in phase 1 and 2 clinical trials for advanced solid tumors and multiple myeloma . NULL NULL 
16 knowledge , this is the first study to evaluate the effects of 2me2 in head and neck squamous cell carcinoma . 
0 NULL NULL NULL NULL NULL experimental design : in the present study , we investigated the effects of 2me2 alone and 
16 design : in the present study , we investigated the effects of 2me2 alone and in combination with paclitaxel , an 
0 of 2me2 alone and in combination with paclitaxel , an active agent in recurrent or advanced head and neck squamous cell 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : 2me2 exhibited antiproliferative and cytotoxic effects in a panel 
16 NULL NULL NULL NULL NULL NULL NULL results : 2me2 exhibited antiproliferative and cytotoxic effects in a panel of five head 
0 NULL NULL NULL results : 2me2 exhibited antiproliferative and cytotoxic effects in a panel of five head and neck squamous cell 
17 lines in the 0.5 to 10 micromol/l range , including induction of g2-m blockade , caspase-3/7 activation , and apoptosis at 
0 0.5 to 10 micromol/l range , including induction of g2-m blockade , caspase-3/7 activation , and apoptosis at 48 hours . 
17 micromol/l range , including induction of g2-m blockade , caspase-3/7 activation , and apoptosis at 48 hours . NULL NULL NULL 
5 including induction of g2-m blockade , caspase-3/7 activation , and apoptosis at 48 hours . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL 2me2 resulted in decreased nuclear hif-1alpha-binding activity and affected the expression of 
18 NULL NULL NULL NULL NULL NULL NULL 2me2 resulted in decreased nuclear hif-1alpha-binding activity and affected the expression of downstream genes 
15 NULL NULL NULL NULL NULL 2me2 resulted in decreased nuclear binding activity and affected the expression of downstream genes , such 
0 NULL NULL NULL NULL 2me2 resulted in decreased nuclear hif-1alpha-binding activity and affected the expression of downstream genes , such as 
16 NULL NULL 2me2 resulted in decreased nuclear hif-1alpha-binding activity and affected the expression of downstream genes , such as bid , 
9 2me2 resulted in decreased nuclear hif-1alpha-binding activity and affected the expression of downstream genes , such as bid , a proapoptotic 
0 in decreased nuclear hif-1alpha-binding activity and affected the expression of downstream genes , such as bid , a proapoptotic bcl-2 family 
0 , a proapoptotic bcl-2 family member , and vascular endothelial growth factor , a proangiogenic cytokine . NULL NULL NULL NULL 
3 family member , and vascular endothelial growth factor , a angiogenic cytokine . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the up-regulation of bid ( 57.5 % at 12 hours , p 
18 at 12 hours , p less than 0.0006 ) and inhibition of vascular endothelial growth factor secretion ( 57.7 % at 
0 p less than 0.0006 ) and inhibition of vascular endothelial growth factor secretion ( 57.7 % at 24 hours , p 
14 than 0.0006 ) and inhibition of vascular endothelial growth factor secretion ( 57.7 % at 24 hours , p less than 
16 less than 0.0006 ) could be partially attributed to the effects on hif-1alpha , because hif-1alpha small interfering rnas produced similar 
0 the effects on hif-1alpha , because hif-1alpha small interfering rnas produced similar effects . NULL NULL NULL NULL NULL NULL NULL 
0 on hif-1alpha , because hif-1alpha small interfering rnas produced similar effects . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 and neck squamous cell carcinoma using um-scc-11a cells , 2me2 exhibited antitumor and antiangiogenic activity , as measured by cd31 immunostaining 
3 cell carcinoma using um-scc-11a cells , 2me2 exhibited antitumor and angiogenic activity , as measured by cd31 immunostaining . NULL NULL 
18 carcinoma using um-scc-11a cells , 2me2 exhibited antitumor and antiangiogenic activity , as measured by cd31 immunostaining . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusions : these results provide support for the use of 2me2 in combination with 
0 NULL NULL NULL NULL NULL conclusions : these results provide support for the use of 2me2 in combination with paclitaxel for 
0 NULL NULL conclusions : these results provide support for the use of 2me2 in combination with paclitaxel for the treatment of 
19 the use of 2me2 in combination with paclitaxel for the treatment of recurrent or advanced head and neck squamous cell carcinoma 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression and purification of the catalytic domain of human vascular endothelial 
0 and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening . NULL NULL NULL 
0 domain of human vascular endothelial growth factor receptor 2 for inhibitor screening . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) , an endothelial cell-specific mitogen , 
16 ( vegf ) , an endothelial cell-specific mitogen , can act in tumor-induced angiogenesis by binding to specific receptors on the 
17 ) , an endothelial cell-specific mitogen , can act in induced angiogenesis by binding to specific receptors on the surface of 
3 , an endothelial cell-specific mitogen , can act in tumor-induced angiogenesis by binding to specific receptors on the surface of endothelial 
15 endothelial cell-specific mitogen , can act in tumor-induced angiogenesis by binding to specific receptors on the surface of endothelial cells . 
16 NULL NULL NULL NULL one such receptor , vegfr-2/kdr , plays a key role in vegf-induced angiogenesis . NULL NULL NULL 
16 NULL NULL one such receptor , vegfr-2/kdr , plays a key role in vegf-induced angiogenesis . NULL NULL NULL NULL NULL 
16 NULL one such receptor , vegfr-2/kdr , plays a key role in vegf-induced angiogenesis . NULL NULL NULL NULL NULL NULL 
17 such receptor , vegfr-2/kdr , plays a key role in induced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 receptor , vegfr-2/kdr , plays a key role in vegf-induced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL here , we expressed the catalytic domain of vegfr-2 as a soluble active kinase 
0 we expressed the catalytic domain of vegfr-2 as a soluble active kinase using bac-to-bac expression system , and investigated correlations between 
0 domain of vegfr-2 as a soluble active kinase using bac-to-bac expression system , and investigated correlations between vegfr-2 activity and enzyme 
0 using bac-to-bac expression system , and investigated correlations between vegfr-2 activity and enzyme concentration , atp concentration , substrate concentration and 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL we used these data to establish a convenient , effective and non-radioactive 
0 NULL we used these data to establish a convenient , effective and non-radioactive elisa screening technique for the identification and evaluation 
0 non-radioactive elisa screening technique for the identification and evaluation of potential inhibitors for vegfr-2 kinase . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL we screened 200 rtk target compounds and identified one ( tki-31 ) that potently inhibited 
18 target-based compounds and identified one ( tki-31 ) that potently inhibited vegfr-2 kinase activity ( ic50=0.596 microm ) . NULL NULL 
0 identified one ( tki-31 ) that potently inhibited vegfr-2 kinase activity ( ic50=0.596 microm ) . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment of nih3t3/kdr cells with tki-31 blocked vegf-induced phosphorylation of kdr 
18 NULL NULL NULL NULL treatment of nih3t3/kdr cells with tki-31 blocked vegf-induced phosphorylation of kdr in a dose-dependent manner . NULL 
17 NULL NULL NULL treatment of nih3t3/kdr cells with tki-31 blocked induced phosphorylation of kdr in a dose-dependent manner . NULL NULL 
12 NULL NULL treatment of nih3t3/kdr cells with tki-31 blocked vegf-induced phosphorylation of kdr in a dose-dependent manner . NULL NULL NULL 
0 cells with tki-31 blocked vegf-induced phosphorylation of kdr in a dependent manner . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL moreover , tki-31 dose-dependently suppressed huvec tube formation . NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL moreover , tki-31 dose-dependently suppressed huvec tube formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 tki-31 , that may prove to be a useful new angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 , that may prove to be a useful new angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 an evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing . 
0 low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL background : abdominal surgery can lead to intra-abdominal adhesions with significant morbidity and mortality 
0 NULL NULL NULL NULL NULL background : abdominal surgery can lead to intra-abdominal adhesions with significant morbidity and mortality . NULL 
0 background : abdominal surgery can lead to intra-abdominal adhesions with significant morbidity and mortality . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL to prevent adhesions , an experimental study was planned to designate the 
0 adhesions , an experimental study was planned to designate the effects of low molecular weight ( lmw ) heparins and hyperbaric 
19 ( lmw ) heparins and hyperbaric oxygen ( hbo ) therapy both on the formation of adhesions and wound healing . 
0 and hyperbaric oxygen ( hbo ) therapy both on the formation of adhesions and wound healing . NULL NULL NULL NULL 
19 NULL NULL NULL NULL methods : thirty-eight wistar albino rats underwent laparotomy to cause intra-abdominal adhesions by mechanical abrasion of the 
19 albino rats underwent laparotomy to cause intra-abdominal adhesions by mechanical abrasion of the cecum and ethanol application . NULL NULL NULL 
19 intra-abdominal adhesions by mechanical abrasion of the cecum and ethanol application . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the control group ( group 1 ) no further management was undertaken 
19 NULL NULL NULL NULL NULL NULL NULL group 2 was treated by enoxaparine na , group 3 received hbo therapy , 
0 group 2 was treated by enoxaparine na , group 3 received hbo therapy , and group 4 was given both enoxaparine 
19 was treated by enoxaparine na , group 3 received hbo therapy , and group 4 was given both enoxaparine na and 
0 group 3 received hbo therapy , and group 4 was given both enoxaparine na and hbo treatment . NULL NULL NULL 
19 and group 4 was given both enoxaparine na and hbo treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : there was a statistically significant difference between the control 
0 NULL NULL NULL NULL results : there was a statistically significant difference between the control and enoxaparine na groups regarding adhesions 
0 results : there was a statistically significant difference between the control and enoxaparine na groups regarding adhesions . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL statistically significant differences were observed between groups 1 and 4 and between 
0 NULL NULL NULL NULL NULL NULL statistically significant differences were observed between groups 1 and 4 and between groups 1 and 
0 analysis of the abdominal wounds , there was no statistically significant difference between any of the groups , including the control 
0 significant difference between any of the groups , including the control group , regarding inflammation . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL statistically significant differences were observed regarding angiogenesis between the control group and 
0 NULL NULL NULL NULL NULL NULL statistically significant differences were observed regarding angiogenesis between the control group and groups 3 and 
3 NULL NULL NULL NULL statistically significant differences were observed regarding angiogenesis between the control group and groups 3 and 4 . 
0 NULL statistically significant differences were observed regarding angiogenesis between the control group and groups 3 and 4 . NULL NULL NULL 
0 NULL NULL NULL NULL NULL there was also a statistically significant difference regarding fibrosis between groups 1 and 4 . NULL 
0 NULL NULL NULL NULL NULL NULL conclusions : enoxaparine na decreased intra-abdominal adhesions , and hbo therapy had no beneficial effect 
19 conclusions : enoxaparine na decreased intra-abdominal adhesions , and hbo therapy had no beneficial effect on adhesions . NULL NULL NULL 
0 na decreased intra-abdominal adhesions , and hbo therapy had no beneficial effect on adhesions . NULL NULL NULL NULL NULL NULL 
0 decreased intra-abdominal adhesions , and hbo therapy had no beneficial effect on adhesions . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL enoxaparine na had no harmful effects on wound healing , and hbo therapy increased the process 
19 had no harmful effects on wound healing , and hbo therapy increased the process of wound healing . NULL NULL NULL 
0 no harmful effects on wound healing , and hbo therapy increased the process of wound healing . NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL novel biological agents for the treatment of hormone-refractory prostate cancer ( hrpc ) . NULL NULL 
2 cancer ( hrpc ) is an inevitable evolution of prostate carcinogenesis , through which the normal dependence on hormones for growth 
0 carcinogenesis , through which the normal dependence on hormones for growth and survival is bypassed . NULL NULL NULL NULL NULL 
0 through which the normal dependence on hormones for growth and survival is bypassed . NULL NULL NULL NULL NULL NULL NULL 
0 and quality of life improvement have been addressed with current treatment options , innovative approaches are needed to improve survival rates 
0 with current treatment options , innovative approaches are needed to improve survival rates . NULL NULL NULL NULL NULL NULL NULL 
0 current treatment options , innovative approaches are needed to improve survival rates . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL a thorough understanding of associated molecular pathways and mechanisms of resistance are a prerequisite for 
0 NULL NULL NULL NULL a thorough understanding of hrpc-associated molecular pathways and mechanisms of resistance are a prerequisite for novel potential 
0 pathways and mechanisms of resistance are a prerequisite for novel potential therapeutic interventions . NULL NULL NULL NULL NULL NULL NULL 
0 mechanisms of resistance are a prerequisite for novel potential therapeutic interventions . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL preclinical and early clinical studies are ongoing to evaluate new therapies that target specific 
0 preclinical and early clinical studies are ongoing to evaluate new therapies that target specific molecular entities . NULL NULL NULL NULL 
0 early clinical studies are ongoing to evaluate new therapies that target specific molecular entities . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL agents under development include growth factor receptor inhibitors , small molecules targeting signal 
0 NULL NULL NULL NULL NULL NULL agents under development include growth factor receptor inhibitors , small molecules targeting signal transduction pathways 
0 under development include growth factor receptor inhibitors , small molecules targeting signal transduction pathways , apoptosis and cell-cycle regulators , angiogenesis 
0 growth factor receptor inhibitors , small molecules targeting signal transduction pathways , apoptosis and cell-cycle regulators , angiogenesis and metastasis inhibitors 
0 receptor inhibitors , small molecules targeting signal transduction pathways , apoptosis and cell-cycle regulators , angiogenesis and metastasis inhibitors , differentiation 
3 targeting signal transduction pathways , apoptosis and cell-cycle regulators , angiogenesis and metastasis inhibitors , differentiation agents , telomerase inactivators , 
0 transduction pathways , apoptosis and cell-cycle regulators , angiogenesis and metastasis inhibitors , differentiation agents , telomerase inactivators , and epigenetic 
0 apoptosis and cell-cycle regulators , angiogenesis and metastasis inhibitors , differentiation agents , telomerase inactivators , and epigenetic therapeutics . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL incorporation of these agents into existing treatment regimens will guide us 
0 NULL NULL NULL NULL incorporation of these agents into existing treatment regimens will guide us in the development of a multidisciplinary 
0 agents into existing treatment regimens will guide us in the development of a multidisciplinary treatment strategy of hrpc . NULL NULL 
0 regimens will guide us in the development of a multidisciplinary treatment strategy of hrpc . NULL NULL NULL NULL NULL NULL 
0 on new biological agents that are being tested in hrpc clinical trials , highlights ongoing research and considers the future perspectives 
0 new biological agents that are being tested in hrpc clinical trials , highlights ongoing research and considers the future perspectives of 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL role of thrombogenic factors in the development of atherosclerosis . NULL 
0 NULL NULL NULL NULL role of thrombogenic factors in the development of atherosclerosis . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL hemostatic factors play a crucial role in generating thrombotic plugs at sites of 
17 NULL NULL NULL NULL NULL NULL hemostatic factors play a crucial role in generating thrombotic plugs at sites of vascular damage 
17 NULL NULL NULL NULL NULL hemostatic factors play a crucial role in generating thrombotic plugs at sites of vascular damage ( 
2 NULL NULL NULL hemostatic factors play a crucial role in generating thrombotic plugs at sites of vascular damage ( atherothrombosis ) 
6 crucial role in generating thrombotic plugs at sites of vascular damage ( atherothrombosis ) . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL however , whether hemostatic factors contribute directly or indirectly to the pathogenesis of atherosclerosis remains uncertain 
0 , whether hemostatic factors contribute directly or indirectly to the pathogenesis of atherosclerosis remains uncertain . NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL autopsy studies have revealed that intimal thickening represents the first stage of atherosclerosis and that lipid-rich plaque 
17 NULL NULL NULL NULL NULL NULL NULL NULL several factors contribute to the start of intimal thickening . NULL NULL NULL 
4 NULL NULL several factors contribute to the start of intimal thickening . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL platelets release several growth factors and bioactive agents that play a central 
0 NULL NULL NULL NULL NULL NULL NULL platelets release several growth factors and bioactive agents that play a central role in 
17 NULL platelets release several growth factors and bioactive agents that play a central role in development of not only thrombus but 
17 release several growth factors and bioactive agents that play a central role in development of not only thrombus but also of 
17 several growth factors and bioactive agents that play a central role in development of not only thrombus but also of intimal 
2 factors and bioactive agents that play a central role in development of not only thrombus but also of intimal thickening . 
4 in development of not only thrombus but also of intimal thickening . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 investigating which coagulation factors simultaneously , or subsequently with platelet aggregation , participate in thrombus formation . NULL NULL NULL NULL 
17 coagulation factors simultaneously , or subsequently with platelet aggregation , participate in thrombus formation . NULL NULL NULL NULL NULL NULL 
2 , or subsequently with platelet aggregation , participate in thrombus formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL tissue factor ( tf ) is an essential initiator of blood coagulation that is expressed in various stages 
9 ) is an essential initiator of blood coagulation that is expressed in various stages of atherosclerotic lesions in humans and other 
16 NULL NULL factors including thrombin and fibrin , which are downstream of the coagulation cascade activated by tf , also contribute 
17 and fibrin , which are downstream of the coagulation cascade activated by tf , also contribute to atherosclerosis . NULL NULL 
0 downstream of the coagulation cascade activated by tf , also contribute to atherosclerosis . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL tf is involved in cell migration , embryogenesis and angiogenesis . NULL NULL 
14 NULL NULL NULL NULL NULL tf is involved in cell migration , embryogenesis and angiogenesis . NULL NULL NULL NULL NULL 
3 NULL tf is involved in cell migration , embryogenesis and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL thus tf , in addition to factors downstream of the coagulation cascade and the protease-activated 
0 NULL NULL NULL thus tf , in addition to factors downstream of the coagulation cascade and the protease-activated receptor 2 activation 
0 addition to factors downstream of the coagulation cascade and the activated receptor 2 activation system , would be a multifactorial regulator 
0 downstream of the coagulation cascade and the protease-activated receptor 2 activation system , would be a multifactorial regulator of atherogenesis . 
0 protease-activated receptor 2 activation system , would be a multifactorial regulator of atherogenesis . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL rofecoxib as adjunctive therapy for haemophilic arthropathy . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL joint haemorrhage and subsequent haemophilic arthropathy are significant complications in haemophilia . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the pathophysiology involves inflammation and angiogenesis . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL the pathophysiology involves inflammation and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 inhibitors are anti-inflammatory agents , which have potent anti-inflammatory , angiogenic and analgesic properties yet do not affect platelet function in 
18 agents , which have potent anti-inflammatory , anti-angiogenic and analgesic properties yet do not affect platelet function in the manner of 
16 potent anti-inflammatory , anti-angiogenic and analgesic properties yet do not affect platelet function in the manner of traditional non-steroidal anti-inflammatory drugs 
0 , anti-angiogenic and analgesic properties yet do not affect platelet function in the manner of traditional non-steroidal anti-inflammatory drugs . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these properties make such agents potentially useful as adjunctive therapy in haemophilia 
0 NULL these properties make such agents potentially useful as adjunctive therapy in haemophilia . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL there is only one prior report describing rofecoxib treatment in a single haemophilia patient . NULL NULL NULL NULL 
0 NULL NULL our objectives were to determine the safety and efficacy of rofecoxib in treating acute haemarthrosis , chronic synovitis , 
19 were to determine the safety and efficacy of rofecoxib in treating acute haemarthrosis , chronic synovitis , target joints and pain 
0 of rofecoxib in treating acute haemarthrosis , chronic synovitis , target joints and pain . NULL NULL NULL NULL NULL NULL 
19 NULL we conducted a retrospective medical record review of patients treated with rofecoxib for acute haemarthrosis , chronic synovitis , target 
0 treated with rofecoxib for acute haemarthrosis , chronic synovitis , target joint or pain . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the safety and efficacy of rofecoxib treatment were determined based on subjective patient reports 
19 NULL NULL NULL NULL the safety and efficacy of rofecoxib treatment were determined based on subjective patient reports and physical examinations 
19 28 patients between 3 and 37 years of age were treated for a total of 42 courses of rofecoxib treatment . 
19 were treated for a total of 42 courses of rofecoxib treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL all courses were evaluated for safety and 31 for efficacy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL rofecoxib was used for eight acute haemarthrosis , four target joints , seven 
0 NULL rofecoxib was used for eight acute haemarthrosis , four target joints , seven cases of synovitis and 12 episodes of 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL efficacy was demonstrated particularly for chronic synovitis and pain and no 
0 the largest study to date evaluating cox-2 inhibitors as adjunctive therapy in haemophilia and suggests that these agents may be an 
0 in haemophilia and suggests that these agents may be an important adjunctive therapy in the management of haemophilia . NULL NULL 
0 and suggests that these agents may be an important adjunctive therapy in the management of haemophilia . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL targeted therapy : therapeutic potential and recent advances . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL vegf-targeted therapy : therapeutic potential and recent advances . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL vegf-targeted therapy : therapeutic potential and recent advances . NULL NULL NULL NULL NULL NULL 
0 NULL NULL after over 30 years of theorizing , the use of angiogenesis inhibitors as anticancer therapy has finally moved from 
3 after over 30 years of theorizing , the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm 
0 of theorizing , the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm of research to reality 
4 NULL NULL NULL NULL NULL NULL in contrast , the growth of tumors requires constant vascular growth and remodeling in order 
17 NULL NULL NULL in contrast , the growth of tumors requires constant vascular growth and remodeling in order for solid tumors 
4 in contrast , the growth of tumors requires constant vascular growth and remodeling in order for solid tumors to grow beyond 
7 , the growth of tumors requires constant vascular growth and remodeling in order for solid tumors to grow beyond 1-2 mm 
4 vascular growth and remodeling in order for solid tumors to grow beyond 1-2 mm ( 3 ) in size . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) and its receptors are key regulators 
0 endothelial growth factor ( vegf ) and its receptors are key regulators of the process of angiogenesis , which makes them 
3 and its receptors are key regulators of the process of angiogenesis , which makes them attractive therapeutic targets . NULL NULL 
0 the process of angiogenesis , which makes them attractive therapeutic targets . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL a multitude of targeted inhibitory agents are currently being investigated for the treatment of 
0 NULL NULL NULL NULL NULL NULL a multitude of vegf-targeted inhibitory agents are currently being investigated for the treatment of cancer 
0 of vegf-targeted inhibitory agents are currently being investigated for the treatment of cancer . NULL NULL NULL NULL NULL NULL NULL 
0 NULL this review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast , lung 
3 review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast , lung , and 
19 recent developments in the use of angiogenesis inhibitors for the treatment of breast , lung , and colorectal cancers . NULL 
18 NULL NULL NULL NULL NULL NULL NULL thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical 
0 NULL NULL NULL NULL NULL NULL thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer 
4 NULL NULL NULL NULL NULL thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer . 
0 NULL NULL NULL NULL NULL objective : to determine the impact of thalidomide and angiostatin on tumor growth , angiogenesis , 
0 : to determine the impact of thalidomide and angiostatin on tumor growth , angiogenesis , and apoptosis in a xenograft model 
4 to determine the impact of thalidomide and angiostatin on tumor growth , angiogenesis , and apoptosis in a xenograft model of 
3 the impact of thalidomide and angiostatin on tumor growth , angiogenesis , and apoptosis in a xenograft model of cervical cancer 
5 thalidomide and angiostatin on tumor growth , angiogenesis , and apoptosis in a xenograft model of cervical cancer . NULL NULL 
19 NULL NULL NULL methods : human umbilical endothelial cells were treated with angiostatin or thalidomide and bfgf-induced proliferation was assessed with 
0 umbilical endothelial cells were treated with angiostatin or thalidomide and induced proliferation was assessed with the mtt assay . NULL NULL 
0 endothelial cells were treated with angiostatin or thalidomide and bfgf-induced proliferation was assessed with the mtt assay . NULL NULL NULL 
19 human cervical cancer cells ( caski and siha ) were injected into the flanks of nude mice . NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL after tumors developed , mice were treated with angiostatin 20 mg/kg/day or thalidomide 
19 NULL NULL NULL NULL after tumors developed , mice were treated with angiostatin 20 mg/kg/day or thalidomide 200 mg/kg/day for 30 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL fractional tumor growth was determined and immunohistochemical analysis of tumors was used 
4 NULL NULL NULL NULL NULL NULL NULL NULL fractional tumor growth was determined and immunohistochemical analysis of tumors was used to 
0 NULL NULL NULL NULL fractional tumor growth was determined and immunohistochemical analysis of tumors was used to determine degree of angiogenesis 
0 tumor growth was determined and immunohistochemical analysis of tumors was used to determine degree of angiogenesis . NULL NULL NULL NULL 
3 immunohistochemical analysis of tumors was used to determine degree of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL tunel assay was used to assess apoptosis . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL tunel assay was used to assess apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : angiostatin inhibited endothelial cell proliferation by 50-60 % . 
18 NULL NULL NULL NULL NULL NULL NULL results : angiostatin inhibited endothelial cell proliferation by 50-60 % . NULL NULL NULL 
1 NULL NULL NULL NULL results : angiostatin inhibited endothelial cell proliferation by 50-60 % . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL thalidomide had no direct effect on endothelial cells . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL thalidomide had no direct effect on endothelial cells . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL angiostatin and thalidomide both inhibited tumor growth by about 55 % . NULL NULL NULL 
0 NULL NULL NULL NULL NULL angiostatin and thalidomide both inhibited tumor growth by about 55 % . NULL NULL NULL NULL 
4 NULL NULL NULL NULL angiostatin and thalidomide both inhibited tumor growth by about 55 % . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL we found no additive or synergistic effect when the two agents were combined . NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL both agents inhibited angiogenesis and induced apoptosis when compared to tumors from control 
3 NULL NULL NULL NULL NULL NULL NULL both agents inhibited angiogenesis and induced apoptosis when compared to tumors from control animals 
0 NULL NULL NULL NULL NULL both agents inhibited angiogenesis and induced apoptosis when compared to tumors from control animals . NULL 
0 NULL NULL NULL NULL both agents inhibited angiogenesis and induced apoptosis when compared to tumors from control animals . NULL NULL 
0 inhibited angiogenesis and induced apoptosis when compared to tumors from control animals . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL conclusions : angiostatin and thalidomide inhibit tumor growth , angiogenesis , and induce apoptosis in this 
0 NULL NULL NULL NULL conclusions : angiostatin and thalidomide inhibit tumor growth , angiogenesis , and induce apoptosis in this xenograft 
4 NULL NULL NULL conclusions : angiostatin and thalidomide inhibit tumor growth , angiogenesis , and induce apoptosis in this xenograft model 
3 NULL conclusions : angiostatin and thalidomide inhibit tumor growth , angiogenesis , and induce apoptosis in this xenograft model of cervical 
17 angiostatin and thalidomide inhibit tumor growth , angiogenesis , and induce apoptosis in this xenograft model of cervical cancer . NULL 
5 and thalidomide inhibit tumor growth , angiogenesis , and induce apoptosis in this xenograft model of cervical cancer . NULL NULL 
4 temf ) and gamma irradiation on human breast cancer xenograft growth , angiogenesis and metastasis . NULL NULL NULL NULL NULL 
3 and gamma irradiation on human breast cancer xenograft growth , angiogenesis and metastasis . NULL NULL NULL NULL NULL NULL NULL 
0 irradiation on human breast cancer xenograft growth , angiogenesis and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL background : the effects of a rectified semi-sinewave signal ( 15 mt amplitude , 
0 alone and in combination with gamma irradiation ( ir ) therapy in nude mice bearing a human mda mb231 breast cancer 
0 NULL NULL NULL NULL NULL NULL NULL NULL green fluorescence protein transfected cancer cells were injected into the mammary fat pad 
19 NULL NULL NULL NULL NULL NULL NULL green fluorescence protein transfected cancer cells were injected into the mammary fat pad of 
19 NULL NULL NULL green fluorescence protein transfected cancer cells were injected into the mammary fat pad of young female mice . 
0 six weeks later , mice were randomly divided into four treatment groups : untreated controls ; 10 minute daily temf ; 
0 , mice were randomly divided into four treatment groups : untreated controls ; 10 minute daily temf ; 200 cgy of 
0 mice were randomly divided into four treatment groups : untreated controls ; 10 minute daily temf ; 200 cgy of ir 
19 NULL NULL NULL NULL some mice in each group were euthanized 24 hours after the end of ir . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL temf treatment continued for 3 additional weeks . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor sections were stained for : endothelial cells with cd31 and 
0 for : endothelial cells with cd31 and pas or hypoxia inducible factor 1alpha ( hif ) . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : most tumors less than 35 mm3 were white but 
0 tumors greater than 35 mm3 were pink and had a vascularized capsule . NULL NULL NULL NULL NULL NULL NULL NULL 
3 the cortex within 100 microns of the capsule had little vascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL tumors greater than 35 mm3 treated with ir 24 hours previously or with temf had decreased 
18 treated with ir 24 hours previously or with temf had decreased blood vessels in the subcortex and more endothelial pseudopods projecting 
0 subcortex and more endothelial pseudopods projecting into hypoxic , hif positive areas than tumors from the control group . NULL NULL 
0 into hypoxic , hif positive areas than tumors from the control group . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL mice that received either ir or temf had significantly fewer lung metastatic sites 
0 that received either ir or temf had significantly fewer lung metastatic sites and slower tumor growth than did untreated mice . 
0 or temf had significantly fewer lung metastatic sites and slower tumor growth than did untreated mice . NULL NULL NULL NULL 
4 temf had significantly fewer lung metastatic sites and slower tumor growth than did untreated mice . NULL NULL NULL NULL NULL 
19 fewer lung metastatic sites and slower tumor growth than did untreated mice . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL no harmful side effects were attributed to temf . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusion : temf therapy provided a safe means for retarding tumor vascularization , growth 
18 NULL conclusion : temf therapy provided a safe means for retarding tumor vascularization , growth and metastasis . NULL NULL NULL 
0 conclusion : temf therapy provided a safe means for retarding tumor vascularization , growth and metastasis . NULL NULL NULL NULL 
3 : temf therapy provided a safe means for retarding tumor vascularization , growth and metastasis . NULL NULL NULL NULL NULL 
4 therapy provided a safe means for retarding tumor vascularization , growth and metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 a safe means for retarding tumor vascularization , growth and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 thrombospondins , metallo proteases and thrombospondin receptors messenger rna and protein expression in different tumour sublines of the dunning prostate cancer 
9 , metallo proteases and thrombospondin receptors messenger rna and protein expression in different tumour sublines of the dunning prostate cancer model 
10 , metallo proteases and thrombospondin receptors messenger rna and protein expression in different tumour sublines of the dunning prostate cancer model 
0 NULL NULL NULL NULL NULL NULL thrombospondin is a potent inhibitor of angiogenesis and might therefore be important in controlling tumour 
3 NULL NULL NULL NULL thrombospondin is a potent inhibitor of angiogenesis and might therefore be important in controlling tumour growth . 
0 is a potent inhibitor of angiogenesis and might therefore be important in controlling tumour growth . NULL NULL NULL NULL NULL 
16 potent inhibitor of angiogenesis and might therefore be important in controlling tumour growth . NULL NULL NULL NULL NULL NULL NULL 
4 of angiogenesis and might therefore be important in controlling tumour growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL tsp interacts with a number of proteases and receptors and in this 
18 a number of proteases and receptors and in this way inhibits stimulation of angiogenesis . NULL NULL NULL NULL NULL NULL 
17 number of proteases and receptors and in this way inhibits stimulation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 proteases and receptors and in this way inhibits stimulation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL an earlier study showed that thrombospondin is expressed in benign prostatic hyperplasia ( bph 
9 NULL NULL NULL an earlier study showed that thrombospondin is expressed in benign prostatic hyperplasia ( bph ) and high-grade prostatic 
9 and high-grade prostatic intraepithelial neoplasia ( pin ) but is absent in prostate cancer . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the present study was therefore designed to evaluate the expression of thrombospondin 
9 NULL the present study was therefore designed to evaluate the expression of thrombospondin 1 and 2 ( tsp-1 , tsp-2 ) 
0 tsp-2 ) , tsp receptors cd36 and cd47 , and matrix 2 and 9 ( mmp- , mmp-9 ) in a 
9 using immunohistochemistry , western blot , and real-time pcr the expression patterns of tsp-1 , tsp-2 , cd36 , cd47 , 
0 mmp-9 were investigated in normal rat prostate tissue and five malignant dunning sublines tissue . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL tsp-1 mrna levels were decreased in all tumours compared with normal prostate 
0 NULL NULL NULL NULL NULL NULL NULL NULL tsp-1 mrna levels were decreased in all tumours compared with normal prostate . 
18 NULL NULL NULL NULL NULL NULL tsp-1 mrna levels were decreased in all tumours compared with normal prostate . NULL NULL 
10 NULL NULL NULL however , there was no difference in expression of tsp-2 and cd36 mrna in these samples . NULL 
0 there was no difference in expression of tsp-2 and cd36 mrna in these samples . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL mmp-2 was increased with malignancy , but no expression of mmp-9 was seen 
9 NULL NULL mmp-2 was increased with malignancy , but no expression of mmp-9 was seen . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL the cd47 receptor did slightly increase with malignancy except for h3327 . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results showed that thrombospondin is expressed in normal prostate but not 
0 NULL NULL NULL NULL NULL NULL NULL NULL the results showed that thrombospondin is expressed in normal prostate but not in 
9 NULL NULL NULL NULL the results showed that thrombospondin is expressed in normal prostate but not in prostate tumours in a 
9 NULL NULL NULL NULL NULL NULL NULL simultaneously , mmp-2 expression increases with malignancy . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL simultaneously , mmp-2 expression increases with malignancy . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL minimal contribution of marrow-derived endothelial precursors to tumor vasculature . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL minimal contribution of derived endothelial precursors to tumor vasculature . NULL NULL NULL NULL 
0 NULL NULL NULL minimal contribution of marrow-derived endothelial precursors to tumor vasculature . NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL during embryogenesis , vascular and hemopoietic cells originate from a common precursor , the hemangioblast . NULL NULL 
14 NULL NULL NULL NULL NULL NULL recent evidence suggests the existence of endothelial precursors in adult bone marrow cells , but 
16 , but it is unclear whether those precursors have a role in tumor neovascularization . NULL NULL NULL NULL NULL NULL 
0 it is unclear whether those precursors have a role in tumor neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL 
3 is unclear whether those precursors have a role in tumor neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 a cell with self-renewing capacity , and can integrate into tumor microvasculature , albeit at a very low frequency . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL a transgenic double-reporter strategy allowed us to demonstrate definitively that tumor bone 
0 a transgenic double-reporter strategy allowed us to demonstrate definitively that tumor bone marrow-derived endothelial cells arise by transdifferentiation of marrow progenitors 
0 double-reporter strategy allowed us to demonstrate definitively that tumor bone derived endothelial cells arise by transdifferentiation of marrow progenitors rather than 
2 demonstrate definitively that tumor bone marrow-derived endothelial cells arise by transdifferentiation of marrow progenitors rather than by cell fusion . NULL 
2 arise by transdifferentiation of marrow progenitors rather than by cell fusion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL single cell transplants showed that a common precursor contributes to both the hemopoietic 
0 NULL NULL NULL NULL NULL NULL NULL single cell transplants showed that a common precursor contributes to both the hemopoietic and 
16 NULL NULL single cell transplants showed that a common precursor contributes to both the hemopoietic and endothelial lineages , thus demonstrating 
0 both the hemopoietic and endothelial lineages , thus demonstrating the presence of an adult hemangioblast . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL furthermore , we demonstrate that increased vascular endothelial growth factor ( vegf ) -a secretion by 
0 NULL NULL furthermore , we demonstrate that increased vascular endothelial growth factor ( vegf ) -a secretion by tumor cells , 
14 that increased vascular endothelial growth factor ( vegf ) -a secretion by tumor cells , as well as activation of vegf 
0 vascular endothelial growth factor ( vegf ) -a secretion by tumor cells , as well as activation of vegf receptor-2 in 
17 ) -a secretion by tumor cells , as well as activation of vegf receptor-2 in bone marrow cells does not alter 
0 activation of vegf receptor-2 in bone marrow cells does not alter the mobilization and incorporation of marrow-derived endothelial progenitors into tumor 
0 vegf receptor-2 in bone marrow cells does not alter the mobilization and incorporation of marrow-derived endothelial progenitors into tumor vasculature . 
14 in bone marrow cells does not alter the mobilization and incorporation of marrow-derived endothelial progenitors into tumor vasculature . NULL NULL 
0 marrow cells does not alter the mobilization and incorporation of derived endothelial progenitors into tumor vasculature . NULL NULL NULL NULL 
0 alter the mobilization and incorporation of marrow-derived endothelial progenitors into tumor vasculature . NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL by ruling out cell fusion , we clearly demonstrate the existence of an adult hemangioblast 
14 by ruling out cell fusion , we clearly demonstrate the existence of an adult hemangioblast , but the differentiation of marrow 
2 demonstrate the existence of an adult hemangioblast , but the differentiation of marrow stem cells toward the endothelial lineage is an 
17 NULL NULL NULL NULL furthermore , we show that vegf-a stimulation of hemopoietic cells does not significantly alter this process . 
0 show that vegf-a stimulation of hemopoietic cells does not significantly alter this process . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the merits of vascular targeting for gynecologic malignancies . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL neovascularization is an early and critical step in tumor development and 
0 NULL NULL NULL NULL NULL neovascularization is an early and critical step in tumor development and progression . NULL NULL NULL 
0 NULL NULL neovascularization is an early and critical step in tumor development and progression . NULL NULL NULL NULL NULL NULL 
2 NULL neovascularization is an early and critical step in tumor development and progression . NULL NULL NULL NULL NULL NULL NULL 
2 is an early and critical step in tumor development and progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor vessels are distinct from their normal counterparts morphologically as well 
0 NULL NULL NULL NULL NULL NULL recent studies on factors involved in tumor vascular development have identified new therapeutic targets for 
0 NULL NULL NULL NULL recent studies on factors involved in tumor vascular development have identified new therapeutic targets for inhibiting tumor 
2 NULL NULL recent studies on factors involved in tumor vascular development have identified new therapeutic targets for inhibiting tumor neovascularization and 
0 factors involved in tumor vascular development have identified new therapeutic targets for inhibiting tumor neovascularization and thus tumor progression . NULL 
18 in tumor vascular development have identified new therapeutic targets for inhibiting tumor neovascularization and thus tumor progression . NULL NULL NULL 
0 tumor vascular development have identified new therapeutic targets for inhibiting tumor neovascularization and thus tumor progression . NULL NULL NULL NULL 
3 vascular development have identified new therapeutic targets for inhibiting tumor neovascularization and thus tumor progression . NULL NULL NULL NULL NULL 
0 identified new therapeutic targets for inhibiting tumor neovascularization and thus tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 new therapeutic targets for inhibiting tumor neovascularization and thus tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL however , the process of tumor blood vessel formation is complex , and each tumor exhibits 
2 NULL NULL however , the process of tumor blood vessel formation is complex , and each tumor exhibits unique features in 
0 of tumor blood vessel formation is complex , and each tumor exhibits unique features in its vasculature . NULL NULL NULL 
0 NULL NULL NULL NULL NULL an understanding of the relative contribution of various pathways in the development of tumor vasculature is 
0 NULL NULL an understanding of the relative contribution of various pathways in the development of tumor vasculature is critical for developing 
2 understanding of the relative contribution of various pathways in the development of tumor vasculature is critical for developing effective and selective 
0 the relative contribution of various pathways in the development of tumor vasculature is critical for developing effective and selective therapeutic approaches 
0 of various pathways in the development of tumor vasculature is critical for developing effective and selective therapeutic approaches . NULL NULL 
0 pathways in the development of tumor vasculature is critical for developing effective and selective therapeutic approaches . NULL NULL NULL NULL 
0 in the development of tumor vasculature is critical for developing effective and selective therapeutic approaches . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL several such agents are currently in clinical trials , and many others are under development . NULL 
0 NULL NULL NULL several such agents are currently in clinical trials , and many others are under development . NULL NULL 
0 currently in clinical trials , and many others are under development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in this review , the mechanisms and factors involved in tumor blood vessel formation are discussed . NULL NULL 
0 in this review , the mechanisms and factors involved in tumor blood vessel formation are discussed . NULL NULL NULL NULL 
2 , the mechanisms and factors involved in tumor blood vessel formation are discussed . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , selected novel classes of antivascular therapies , including those 
0 NULL NULL in addition , selected novel classes of antivascular therapies , including those targeting tumor endothelial cells and other components 
19 , selected novel classes of antivascular therapies , including those targeting tumor endothelial cells and other components of the tumor vasculature 
0 selected novel classes of antivascular therapies , including those targeting tumor endothelial cells and other components of the tumor vasculature , 
0 those targeting tumor endothelial cells and other components of the tumor vasculature , are summarized . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through akt 
18 NULL NULL domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through akt . NULL NULL NULL NULL 
16 NULL NULL domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through akt . NULL NULL NULL NULL 
14 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through akt . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL domain 5 ( d5 ) of cleaved high molecular weight kininogen ( hka ) inhibits angiogenesis in 
18 ) of cleaved high molecular weight kininogen ( hka ) inhibits angiogenesis in vivo and endothelial cell migration in vitro , 
3 of cleaved high molecular weight kininogen ( hka ) inhibits angiogenesis in vivo and endothelial cell migration in vitro , but 
14 ( hka ) inhibits angiogenesis in vivo and endothelial cell migration in vitro , but the cell signaling pathways involved in 
0 endothelial cell migration in vitro , but the cell signaling pathways involved in hka and d5 inhibition of endothelial cell migration 
16 cell migration in vitro , but the cell signaling pathways involved in hka and d5 inhibition of endothelial cell migration are 
18 but the cell signaling pathways involved in hka and d5 inhibition of endothelial cell migration are incompletely delineated . NULL NULL 
14 pathways involved in hka and d5 inhibition of endothelial cell migration are incompletely delineated . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL this study examines the mechanism of hka and d5 inhibition of two potent stimulators of 
18 NULL this study examines the mechanism of hka and d5 inhibition of two potent stimulators of endothelial cell migration , sphingosine 
14 and d5 inhibition of two potent stimulators of endothelial cell migration , sphingosine 1-phosphate ( s1p ) and vascular endothelial growth 
0 migration , sphingosine 1-phosphate ( s1p ) and vascular endothelial growth factor ( vegf ) , that act through the p13-kinase-akt 
16 and vascular endothelial growth factor ( vegf ) , that act through the p13-kinase-akt signaling pathway . NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL hka and d5 inhibit bovine pulmonary artery endothelial cell ( bpae ) or human 
14 cell ( bpae ) or human umbilical vein endothelial cell chemotaxis in the modified-boyden chamber in response tovegf or s1p . 
17 umbilical vein endothelial cell chemotaxis in the modified-boyden chamber in response tovegf or s1p . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL the inhibition of migration by hka is reversed by antibodies to urokinase-type 
14 NULL NULL NULL NULL NULL NULL NULL the inhibition of migration by hka is reversed by antibodies to urokinase-type plasminogen activator 
18 NULL NULL NULL the inhibition of migration by hka is reversed by antibodies to urokinase-type plasminogen activator receptor . NULL NULL 
0 migration by hka is reversed by antibodies to urokinase-type plasminogen activator receptor . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL both hka and d5 decrease the speed of bpae cell migration and alter the morphology 
14 both hka and d5 decrease the speed of bpae cell migration and alter the morphology in live , time-lapse microscopy after 
0 and d5 decrease the speed of bpae cell migration and alter the morphology in live , time-lapse microscopy after stimulation with 
17 and alter the morphology in live , time-lapse microscopy after stimulation with s1p or vegf . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL hka and d5 reduce the localization of paxillin to the focal adhesions after s1p 
14 NULL NULL NULL NULL NULL hka and d5 reduce the localization of paxillin to the focal adhesions after s1p and vegf 
17 of paxillin to the focal adhesions after s1p and vegf stimulation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL to better understand the intracellular signaling pathways , we examined the effect of hka on the phosphorylation 
16 better understand the intracellular signaling pathways , we examined the effect of hka on the phosphorylation of akt and its downstream 
12 pathways , we examined the effect of hka on the phosphorylation of akt and its downstream effector , gsk-3alpha hka and 
0 effect of hka on the phosphorylation of akt and its downstream effector , gsk-3alpha hka and d5 inhibit phosphorylation of akt 
18 akt and its downstream effector , gsk-3alpha hka and d5 inhibit phosphorylation of akt and gsk-3alpha after stimulation withvegf and s1p 
12 and its downstream effector , gsk-3alpha hka and d5 inhibit phosphorylation of akt and gsk-3alpha after stimulation withvegf and s1p . 
17 hka and d5 inhibit phosphorylation of akt and gsk-3alpha after stimulation withvegf and s1p . NULL NULL NULL NULL NULL NULL 
0 NULL NULL inhibitors of akt and p13-kinase , the upstream activator of akt , block endothelial cell migration and disrupt paxillin 
18 akt and p13-kinase , the upstream activator of akt , block endothelial cell migration and disrupt paxillin localization to the focal 
14 , the upstream activator of akt , block endothelial cell migration and disrupt paxillin localization to the focal adhesions after stimulation 
18 upstream activator of akt , block endothelial cell migration and disrupt paxillin localization to the focal adhesions after stimulation with vegf 
14 of akt , block endothelial cell migration and disrupt paxillin localization to the focal adhesions after stimulation with vegf and s1p 
17 migration and disrupt paxillin localization to the focal adhesions after stimulation with vegf and s1p . NULL NULL NULL NULL NULL 
16 NULL therefore we suggest that hka through its d5 domain alters p13-kinase-akt signaling to inhibit endothelial cell migration through alterations in 
18 that hka through its d5 domain alters p13-kinase-akt signaling to inhibit endothelial cell migration through alterations in the focal adhesions . 
14 its d5 domain alters p13-kinase-akt signaling to inhibit endothelial cell migration through alterations in the focal adhesions . NULL NULL NULL 
16 domain alters p13-kinase-akt signaling to inhibit endothelial cell migration through alterations in the focal adhesions . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effect of thalidomide affecting vegf secretion , cell migration , adhesion 
16 NULL NULL NULL NULL NULL NULL NULL effect of thalidomide affecting vegf secretion , cell migration , adhesion and capillary tube 
14 NULL NULL NULL NULL NULL effect of thalidomide affecting vegf secretion , cell migration , adhesion and capillary tube formation of 
14 NULL NULL effect of thalidomide affecting vegf secretion , cell migration , adhesion and capillary tube formation of human endothelial ea.hy 
15 effect of thalidomide affecting vegf secretion , cell migration , adhesion and capillary tube formation of human endothelial ea.hy 926 cells 
2 vegf secretion , cell migration , adhesion and capillary tube formation of human endothelial ea.hy 926 cells . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis , new blood vessel formation , is a multistep process 
2 NULL NULL NULL NULL NULL angiogenesis , new blood vessel formation , is a multistep process , precisely regulated by pro-angiogenic 
16 blood vessel formation , is a multistep process , precisely regulated by pro-angiogenic cytokines , which stimulate endothelial cells to migrate 
3 formation , is a multistep process , precisely regulated by angiogenic cytokines , which stimulate endothelial cells to migrate , proliferate 
17 multistep process , precisely regulated by pro-angiogenic cytokines , which stimulate endothelial cells to migrate , proliferate and differentiate to form 
14 regulated by pro-angiogenic cytokines , which stimulate endothelial cells to migrate , proliferate and differentiate to form new capillary microvessels . 
1 pro-angiogenic cytokines , which stimulate endothelial cells to migrate , proliferate and differentiate to form new capillary microvessels . NULL NULL 
2 , which stimulate endothelial cells to migrate , proliferate and differentiate to form new capillary microvessels . NULL NULL NULL NULL 
2 stimulate endothelial cells to migrate , proliferate and differentiate to form new capillary microvessels . NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL excessive vascular development and blood vessel remodeling appears in psoriasis , rheumatoid arthritis 
7 NULL NULL NULL NULL excessive vascular development and blood vessel remodeling appears in psoriasis , rheumatoid arthritis , diabetic retinopathy and 
2 psoriasis , rheumatoid arthritis , diabetic retinopathy and solid tumors formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 n-phthalimido ) -glutarimide ] is known to be a potent inhibitor of angiogenesis , but the mechanism of its inhibitory action 
3 -glutarimide ] is known to be a potent inhibitor of angiogenesis , but the mechanism of its inhibitory action remains unclear 
0 to be a potent inhibitor of angiogenesis , but the mechanism of its inhibitory action remains unclear . NULL NULL NULL 
18 potent inhibitor of angiogenesis , but the mechanism of its inhibitory action remains unclear . NULL NULL NULL NULL NULL NULL 
18 inhibitor of angiogenesis , but the mechanism of its inhibitory action remains unclear . NULL NULL NULL NULL NULL NULL NULL 
0 NULL the aim of the study was to investigate the potential influence of thalidomide on the several steps of angiogenesis , 
16 the aim of the study was to investigate the potential influence of thalidomide on the several steps of angiogenesis , using 
3 the potential influence of thalidomide on the several steps of angiogenesis , using in vitro models . NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL we have evaluated the effect of thalidomide on vegf secretion , cell migration , adhesion 
14 NULL we have evaluated the effect of thalidomide on vegf secretion , cell migration , adhesion as well as in capillary 
14 evaluated the effect of thalidomide on vegf secretion , cell migration , adhesion as well as in capillary formation of human 
15 effect of thalidomide on vegf secretion , cell migration , adhesion as well as in capillary formation of human endothelial cell 
2 , cell migration , adhesion as well as in capillary formation of human endothelial cell line ea.hy 926 . NULL NULL 
18 thalidomide at the concentrations of 0.01 microm and 10 microm inhibited vegf secretion into supernatants , decreased the number of formed 
14 the concentrations of 0.01 microm and 10 microm inhibited vegf secretion into supernatants , decreased the number of formed capillary tubes 
18 microm and 10 microm inhibited vegf secretion into supernatants , decreased the number of formed capillary tubes and increased cell adhesion 
2 inhibited vegf secretion into supernatants , decreased the number of formed capillary tubes and increased cell adhesion to collagen . NULL 
17 supernatants , decreased the number of formed capillary tubes and increased cell adhesion to collagen . NULL NULL NULL NULL NULL 
15 decreased the number of formed capillary tubes and increased cell adhesion to collagen . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL administration of thalidomide at the concentration of 0.01 microm increased cell 
17 NULL administration of thalidomide at the concentration of 0.01 microm increased cell migration , while at 10 microm , it decreased 
14 of thalidomide at the concentration of 0.01 microm increased cell migration , while at 10 microm , it decreased cell migration 
18 increased cell migration , while at 10 microm , it decreased cell migration . NULL NULL NULL NULL NULL NULL NULL 
14 migration , while at 10 microm , it decreased cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 in concentrations from 0.1 microm to 10 microm did not change cell proliferation of 72-h cell cultures . NULL NULL NULL 
1 from 0.1 microm to 10 microm did not change cell proliferation of 72-h cell cultures . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL we conclude that angiogenic action of thalidomide is due to direct inhibitory action on 
18 NULL NULL NULL NULL NULL NULL we conclude that anti-angiogenic action of thalidomide is due to direct inhibitory action on vegf 
0 we conclude that anti-angiogenic action of thalidomide is due to direct inhibitory action on vegf secretion and capillary microvessel formation as 
18 conclude that anti-angiogenic action of thalidomide is due to direct inhibitory action on vegf secretion and capillary microvessel formation as well 
18 that anti-angiogenic action of thalidomide is due to direct inhibitory action on vegf secretion and capillary microvessel formation as well as 
14 of thalidomide is due to direct inhibitory action on vegf secretion and capillary microvessel formation as well as immunomodulatory influence on 
2 to direct inhibitory action on vegf secretion and capillary microvessel formation as well as immunomodulatory influence on ea.hy 926 cells migration 
16 vegf secretion and capillary microvessel formation as well as immunomodulatory influence on ea.hy 926 cells migration and adhesion . NULL NULL 
14 formation as well as immunomodulatory influence on ea.hy 926 cells migration and adhesion . NULL NULL NULL NULL NULL NULL NULL 
15 well as immunomodulatory influence on ea.hy 926 cells migration and adhesion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL regulation of skin microvasculature angiogenesis , cell migration , and permeability 
3 NULL NULL NULL NULL NULL NULL regulation of skin microvasculature angiogenesis , cell migration , and permeability by a specific inhibitor 
14 NULL NULL NULL regulation of skin microvasculature angiogenesis , cell migration , and permeability by a specific inhibitor of pkcalpha . 
0 angiogenesis , cell migration , and permeability by a specific inhibitor of pkcalpha . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL activation of protein kinase c ( pkc ) induces phenotypic changes 
0 NULL NULL NULL NULL NULL NULL NULL NULL activation of protein kinase c ( pkc ) induces phenotypic changes in the 
17 NULL NULL activation of protein kinase c ( pkc ) induces phenotypic changes in the morphology of microvascular endothelial cells that 
0 NULL activation of protein kinase c ( pkc ) induces phenotypic changes in the morphology of microvascular endothelial cells that affect 
16 activation of protein kinase c ( pkc ) induces phenotypic changes in the morphology of microvascular endothelial cells that affect major 
16 phenotypic changes in the morphology of microvascular endothelial cells that affect major functions of the microvasculature . NULL NULL NULL NULL 
0 changes in the morphology of microvascular endothelial cells that affect major functions of the microvasculature . NULL NULL NULL NULL NULL 
0 in the morphology of microvascular endothelial cells that affect major functions of the microvasculature . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these functions include the first stages of sprouting in angiogenesis , cell 
0 NULL NULL NULL these functions include the first stages of sprouting in angiogenesis , cell migration following wounding , and vascular 
3 NULL these functions include the first stages of sprouting in angiogenesis , cell migration following wounding , and vascular permeability . 
14 include the first stages of sprouting in angiogenesis , cell migration following wounding , and vascular permeability . NULL NULL NULL 
16 NULL NULL the specific isoform ( s ) of pkc responsible for each of these changes has not been previously identified 
0 ( s ) of pkc responsible for each of these changes has not been previously identified . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL in this study , we used two inflammatory agents , il-1beta and phorbol myristic acetate , 
17 inflammatory agents , il-1beta and phorbol myristic acetate , to activate pkc isozymes and specific inhibitors of pkcalpha ( go6976 ) 
16 to distinguish how each of these isoform ( s ) controls angiogenesis , wound healing , and permeability . NULL NULL 
3 distinguish how each of these isoform ( s ) controls angiogenesis , wound healing , and permeability . NULL NULL NULL 
18 NULL NULL NULL NULL NULL in all cases , only inhibition of pkcalpha inhibited each of these functions when compared to 
0 NULL NULL in all cases , only inhibition of pkcalpha inhibited each of these functions when compared to the inhibition of 
0 cases , only inhibition of pkcalpha inhibited each of these functions when compared to the inhibition of pkcbeta . NULL NULL 
18 pkcalpha inhibited each of these functions when compared to the inhibition of pkcbeta . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL additional analysis of the mechanism of action of go6976 ( rt-pcr , western blots , 
0 NULL NULL NULL NULL additional analysis of the mechanism of action of go6976 ( rt-pcr , western blots , and immunohistochemistry 
16 rt-pcr , western blots , and immunohistochemistry ) of the changes in the phosphorylated and nonphosphorylated forms of pkcalpha in the 
12 blots , and immunohistochemistry ) of the changes in the phosphorylated and nonphosphorylated forms of pkcalpha in the cell membrane and 
12 and immunohistochemistry ) of the changes in the phosphorylated and nonphosphorylated forms of pkcalpha in the cell membrane and cytoplasm confirmed 
18 the cell membrane and cytoplasm confirmed the specificity of pkcalpha inhibition by go6976 . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL these studies therefore indicate a specific and a regulatory role of the pkcalpha isoform in three major endothelial cell 
0 NULL these studies therefore indicate a specific and a regulatory role of the pkcalpha isoform in three major endothelial cell functions 
0 and a regulatory role of the pkcalpha isoform in three major endothelial cell functions that are important in the maintenance of 
0 role of the pkcalpha isoform in three major endothelial cell functions that are important in the maintenance of microvascular homeostasis . 
0 pkcalpha isoform in three major endothelial cell functions that are important in the maintenance of microvascular homeostasis . NULL NULL NULL 
0 three major endothelial cell functions that are important in the maintenance of microvascular homeostasis . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL the differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor 
0 differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of 
0 human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas 
0 factor may contribute to the clinically more aggressive behavior of positive breast carcinomas . NULL NULL NULL NULL NULL NULL NULL 
0 a myoepithelial cell marker in the normal mammary gland but positive neoplastic cells may be found in up to 11 % 
9 NULL this study aims to verify the relationship between p63 expression and several clinicopathological features and tumor markers of clinical significance 
0 the relationship between p63 expression and several clinicopathological features and tumor markers of clinical significance in breast pathology including key regulators 
0 p63 expression and several clinicopathological features and tumor markers of clinical significance in breast pathology including key regulators of the cell 
0 and tumor markers of clinical significance in breast pathology including key regulators of the cell cycle , oncogenes , apoptosis-related proteins 
0 including key regulators of the cell cycle , oncogenes , apoptosis proteins , metalloproteinases and their inhibitors . NULL NULL NULL 
0 immunohistochemistry with 27 primary antibodies was performed in 100 formalin-fixed embedded samples of invasive ductal carcinomas . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL positive cells were found in 16 % of carcinomas . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL positive carcinomas were poorly differentiated , hormone receptor-negative neoplasms with a 
2 NULL NULL NULL NULL NULL NULL p63-positive carcinomas were poorly differentiated , hormone receptor-negative neoplasms with a high proliferation rate . 
0 NULL NULL NULL p63-positive carcinomas were poorly differentiated , hormone negative neoplasms with a high proliferation rate . NULL NULL NULL 
4 were poorly differentiated , hormone receptor-negative neoplasms with a high proliferation rate . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL p63 also correlated with advanced pathological stage , tumor size , and the expression of human telomerase reverse transcriptase 
9 with advanced pathological stage , tumor size , and the expression of human telomerase reverse transcriptase ( htert ) , tissue 
0 of human telomerase reverse transcriptase ( htert ) , tissue inhibitor of matrix metalloproteinase 1 ( timp1 ) and vascular endothelial 
0 telomerase reverse transcriptase ( htert ) , tissue inhibitor of matrix metalloproteinase 1 ( timp1 ) and vascular endothelial growth factor 
0 of matrix metalloproteinase 1 ( timp1 ) and vascular endothelial growth factor ( vegf ) . NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL the expression of timp1 suggests that the anti-proteolytic stimuli may be preponderant 
0 timp1 suggests that the anti-proteolytic stimuli may be preponderant in positive carcinomas . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL htert activity is associated with nodal metastases and cellular proliferation . NULL 
0 NULL NULL NULL NULL NULL NULL NULL htert activity is associated with nodal metastases and cellular proliferation . NULL NULL NULL 
0 NULL NULL NULL NULL htert activity is associated with nodal metastases and cellular proliferation . NULL NULL NULL NULL NULL NULL 
0 NULL htert activity is associated with nodal metastases and cellular proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL vegf regulates angiogenesis , which is also a fundamental event in the 
3 NULL NULL NULL NULL NULL NULL NULL NULL vegf regulates angiogenesis , which is also a fundamental event in the process 
0 which is also a fundamental event in the process of tumor growth and metastatic dissemination . NULL NULL NULL NULL NULL 
4 is also a fundamental event in the process of tumor growth and metastatic dissemination . NULL NULL NULL NULL NULL NULL 
14 a fundamental event in the process of tumor growth and metastatic dissemination . NULL NULL NULL NULL NULL NULL NULL NULL 
14 fundamental event in the process of tumor growth and metastatic dissemination . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL thus , the differential regulation of htert and vegf in p63-positive breast carcinomas may contribute 
0 thus , the differential regulation of htert and vegf in positive breast carcinomas may contribute to the clinically more aggressive behavior 
0 regulation of htert and vegf in p63-positive breast carcinomas may contribute to the clinically more aggressive behavior of these neoplasms . 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL regulation of tumor angiogenesis by thrombospondin-1 . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL regulation of tumor angiogenesis by thrombospondin-1 . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL regulation of tumor angiogenesis by thrombospondin-1 . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis plays a critical role in the growth and metastasis of 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis plays a critical role in the growth and metastasis of tumors 
16 NULL NULL NULL NULL NULL NULL NULL angiogenesis plays a critical role in the growth and metastasis of tumors . NULL 
16 NULL NULL NULL NULL NULL NULL angiogenesis plays a critical role in the growth and metastasis of tumors . NULL NULL 
4 NULL NULL NULL angiogenesis plays a critical role in the growth and metastasis of tumors . NULL NULL NULL NULL NULL 
14 NULL angiogenesis plays a critical role in the growth and metastasis of tumors . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL thrombospondin-1 ( tsp-1 ) is a potent angiogenesis inhibitor , and down-regulation of tsp-1 has been suggested to 
0 NULL NULL thrombospondin-1 ( tsp-1 ) is a potent angiogenesis inhibitor , and down-regulation of tsp-1 has been suggested to alter 
18 ( tsp-1 ) is a potent angiogenesis inhibitor , and down-regulation of tsp-1 has been suggested to alter tumor growth by 
16 inhibitor , and down-regulation of tsp-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor 
0 , and down-regulation of tsp-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types 
4 and down-regulation of tsp-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types . 
16 of tsp-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types . NULL NULL 
3 tsp-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types . NULL NULL NULL 
0 alter tumor growth by modulating angiogenesis in a variety of tumor types . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of tsp-1 is up-regulated by the tumor suppressor gene , 
17 NULL NULL NULL NULL NULL NULL expression of tsp-1 is up-regulated by the tumor suppressor gene , p53 , and down-regulated 
0 NULL NULL NULL expression of tsp-1 is up-regulated by the tumor suppressor gene , p53 , and down-regulated by oncogenes such 
0 NULL NULL expression of tsp-1 is up-regulated by the tumor suppressor gene , p53 , and down-regulated by oncogenes such as 
18 up-regulated by the tumor suppressor gene , p53 , and down-regulated by oncogenes such as myc and ras . NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL tsp-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by 
3 NULL NULL NULL NULL NULL NULL NULL NULL tsp-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing 
18 NULL NULL NULL NULL NULL NULL tsp-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis . 
14 NULL NULL NULL tsp-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis . NULL NULL NULL 
1 NULL tsp-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis . NULL NULL NULL NULL NULL 
0 by inhibiting endothelial cell migration and proliferation and by inducing apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , activation of transforming growth factor beta ( tgf-beta ) 
17 NULL NULL NULL NULL NULL NULL NULL in addition , activation of transforming growth factor beta ( tgf-beta ) by tsp-1 
0 NULL NULL NULL NULL in addition , activation of transforming growth factor beta ( tgf-beta ) by tsp-1 plays a crucial 
16 of transforming growth factor beta ( tgf-beta ) by tsp-1 plays a crucial role in the regulation of tumor progression . 
16 growth factor beta ( tgf-beta ) by tsp-1 plays a crucial role in the regulation of tumor progression . NULL NULL 
16 factor beta ( tgf-beta ) by tsp-1 plays a crucial role in the regulation of tumor progression . NULL NULL NULL 
16 tgf-beta ) by tsp-1 plays a crucial role in the regulation of tumor progression . NULL NULL NULL NULL NULL NULL 
0 by tsp-1 plays a crucial role in the regulation of tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 tsp-1 plays a crucial role in the regulation of tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL an understanding of the molecular basis of mediated inhibition of angiogenesis and tumor progression will aid in the 
18 NULL NULL an understanding of the molecular basis of tsp-1-mediated inhibition of angiogenesis and tumor progression will aid in the development 
3 an understanding of the molecular basis of tsp-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel 
0 of the molecular basis of tsp-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for 
2 the molecular basis of tsp-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the 
0 inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer . NULL 
0 will aid in the development of novel therapeutics for the treatment of cancer . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL regulation of the composition of the extracellular matrix by low density 
0 NULL NULL NULL regulation of the composition of the extracellular matrix by low density lipoprotein receptor-related protein-1 : activities based on 
0 composition of the extracellular matrix by low density lipoprotein receptor-related protein : activities based on regulation of mrna expression . NULL 
0 the extracellular matrix by low density lipoprotein receptor-related protein-1 : activities based on regulation of mrna expression . NULL NULL NULL 
0 by low density lipoprotein receptor-related protein-1 : activities based on regulation of mrna expression . NULL NULL NULL NULL NULL NULL 
0 density lipoprotein receptor-related protein-1 : activities based on regulation of mrna expression . NULL NULL NULL NULL NULL NULL NULL NULL 
0 lipoprotein receptor-related protein-1 : activities based on regulation of mrna expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL low density lipoprotein receptor-related protein ( lrp-1 ) is a catabolic receptor for extracellular matrix 
0 protein-1 ( lrp-1 ) is a catabolic receptor for extracellular matrix ( ecm ) structural proteins and for proteins that bind 
0 is a catabolic receptor for extracellular matrix ( ecm ) structural proteins and for proteins that bind to ecm . NULL 
15 matrix ( ecm ) structural proteins and for proteins that bind to ecm . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL lrp-1 also is implicated in integrin maturation . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL lrp-1 also is implicated in integrin maturation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 , we applied a proteomics strategy to identify novel proteins involved in ecm modeling that are regulated by lrp-1 . NULL 
2 a proteomics strategy to identify novel proteins involved in ecm modeling that are regulated by lrp-1 . NULL NULL NULL NULL 
16 to identify novel proteins involved in ecm modeling that are regulated by lrp-1 . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL we show that lrp-1 deficiency in murine embryonic fibroblasts ( mefs ) is associated with 
0 lrp-1 deficiency in murine embryonic fibroblasts ( mefs ) is associated with increased levels of type iii collagen and pigment epithelium-derived 
17 in murine embryonic fibroblasts ( mefs ) is associated with increased levels of type iii collagen and pigment epithelium-derived factor , 
0 murine embryonic fibroblasts ( mefs ) is associated with increased levels of type iii collagen and pigment epithelium-derived factor , which 
0 associated with increased levels of type iii collagen and pigment derived factor , which accumulate in the substratum surrounding cells . 
17 NULL NULL the collagen receptor , upar-ap/endo-180 , is also increased in lrp-1-deficient mefs . NULL NULL NULL NULL NULL NULL 
9 the collagen receptor , upar-ap/endo-180 , is also increased in deficient mefs . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL human lrp-1 reversed the changes in protein expression associated with lrp-1 deficiency ; 
0 NULL NULL NULL NULL NULL NULL human lrp-1 reversed the changes in protein expression associated with lrp-1 deficiency ; however , 
0 NULL NULL NULL NULL human lrp-1 reversed the changes in protein expression associated with lrp-1 deficiency ; however , the endocytic 
0 NULL NULL NULL human lrp-1 reversed the changes in protein expression associated with lrp-1 deficiency ; however , the endocytic activity 
0 NULL NULL human lrp-1 reversed the changes in protein expression associated with lrp-1 deficiency ; however , the endocytic activity of 
9 lrp-1 reversed the changes in protein expression associated with lrp-1 deficiency ; however , the endocytic activity of lrp-1 was not 
0 expression associated with lrp-1 deficiency ; however , the endocytic activity of lrp-1 was not involved . NULL NULL NULL NULL 
0 ; however , the endocytic activity of lrp-1 was not involved . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL instead , regulation occurred at the mrna level . NULL NULL NULL NULL 
0 NULL NULL NULL NULL instead , regulation occurred at the mrna level . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of c-jun amino-terminal kinase ( jnk ) blocked type iii 
18 NULL NULL inhibition of c-jun amino-terminal kinase ( jnk ) blocked type iii collagen expression in lrp-1-deficient mefs , suggesting regulation 
9 c-jun amino-terminal kinase ( jnk ) blocked type iii collagen expression in lrp-1-deficient mefs , suggesting regulation of jnk activity as 
9 kinase ( jnk ) blocked type iii collagen expression in deficient mefs , suggesting regulation of jnk activity as a mechanism 
16 blocked type iii collagen expression in lrp-1-deficient mefs , suggesting regulation of jnk activity as a mechanism by which lrp-1 controls 
0 collagen expression in lrp-1-deficient mefs , suggesting regulation of jnk activity as a mechanism by which lrp-1 controls mrna expression . 
0 lrp-1-deficient mefs , suggesting regulation of jnk activity as a mechanism by which lrp-1 controls mrna expression . NULL NULL NULL 
0 regulation of jnk activity as a mechanism by which lrp-1 controls mrna expression . NULL NULL NULL NULL NULL NULL NULL 
0 of jnk activity as a mechanism by which lrp-1 controls mrna expression . NULL NULL NULL NULL NULL NULL NULL NULL 
0 jnk activity as a mechanism by which lrp-1 controls mrna expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the ability of lrp-1 to regulate expression of the factors identified here 
0 NULL NULL NULL NULL NULL the ability of lrp-1 to regulate expression of the factors identified here suggests a role for 
0 NULL NULL NULL NULL the ability of lrp-1 to regulate expression of the factors identified here suggests a role for lrp-1 
16 to regulate expression of the factors identified here suggests a role for lrp-1 in determining blood vessel structure and in angiogenesis 
3 role for lrp-1 in determining blood vessel structure and in angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL pericytes limit tumor cell metastasis . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL pericytes limit tumor cell metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL pericytes limit tumor cell metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL previously we observed that neural cell adhesion molecule ( ncam ) deficiency in 
0 NULL NULL NULL NULL previously we observed that neural cell adhesion molecule ( ncam ) deficiency in beta tumor cells facilitates 
9 we observed that neural cell adhesion molecule ( ncam ) deficiency in beta tumor cells facilitates metastasis into distant organs and 
0 neural cell adhesion molecule ( ncam ) deficiency in beta tumor cells facilitates metastasis into distant organs and local lymph nodes 
17 adhesion molecule ( ncam ) deficiency in beta tumor cells facilitates metastasis into distant organs and local lymph nodes . NULL 
14 molecule ( ncam ) deficiency in beta tumor cells facilitates metastasis into distant organs and local lymph nodes . NULL NULL 
0 NULL NULL NULL NULL NULL here , we show that deficient beta cell tumors grew leaky blood vessels with perturbed pericyte-endothelial 
2 NULL here , we show that ncam-deficient beta cell tumors grew leaky blood vessels with perturbed pericyte-endothelial cell-cell interactions and deficient 
15 beta cell tumors grew leaky blood vessels with perturbed pericyte-endothelial cell-cell interactions and deficient perivascular deposition of ecm components . NULL 
15 cell tumors grew leaky blood vessels with perturbed pericyte-endothelial cell-cell interactions and deficient perivascular deposition of ecm components . NULL NULL 
0 grew leaky blood vessels with perturbed pericyte-endothelial cell-cell interactions and deficient perivascular deposition of ecm components . NULL NULL NULL NULL 
14 blood vessels with perturbed pericyte-endothelial cell-cell interactions and deficient perivascular deposition of ecm components . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL conversely , tumor cell expression of ncam in a fibrosarcoma model ( t241 
9 NULL NULL NULL NULL NULL NULL conversely , tumor cell expression of ncam in a fibrosarcoma model ( t241 ) improved 
17 expression of ncam in a fibrosarcoma model ( t241 ) improved pericyte recruitment and increased perivascular deposition of ecm molecules . 
14 ncam in a fibrosarcoma model ( t241 ) improved pericyte recruitment and increased perivascular deposition of ecm molecules . NULL NULL 
17 a fibrosarcoma model ( t241 ) improved pericyte recruitment and increased perivascular deposition of ecm molecules . NULL NULL NULL NULL 
14 model ( t241 ) improved pericyte recruitment and increased perivascular deposition of ecm molecules . NULL NULL NULL NULL NULL NULL 
18 NULL NULL together , these findings suggest that ncam may limit tumor cell metastasis by stabilizing the microvessel wall . NULL 
0 NULL together , these findings suggest that ncam may limit tumor cell metastasis by stabilizing the microvessel wall . NULL NULL 
14 , these findings suggest that ncam may limit tumor cell metastasis by stabilizing the microvessel wall . NULL NULL NULL NULL 
17 findings suggest that ncam may limit tumor cell metastasis by stabilizing the microvessel wall . NULL NULL NULL NULL NULL NULL 
5 NULL NULL NULL NULL NULL to directly address whether pericyte dysfunction increases the metastatic potential of solid tumors , we studied 
17 NULL NULL NULL NULL to directly address whether pericyte dysfunction increases the metastatic potential of solid tumors , we studied beta 
14 NULL NULL to directly address whether pericyte dysfunction increases the metastatic potential of solid tumors , we studied beta cell tumorigenesis 
0 NULL to directly address whether pericyte dysfunction increases the metastatic potential of solid tumors , we studied beta cell tumorigenesis in 
0 solid tumors , we studied beta cell tumorigenesis in primary deficient pdgfb ( ret/ret ) mice . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL this resulted in beta tumor cell metastases in distant organs and local 
0 NULL NULL NULL NULL NULL NULL this resulted in beta tumor cell metastases in distant organs and local lymph nodes , 
14 NULL NULL NULL NULL this resulted in beta tumor cell metastases in distant organs and local lymph nodes , demonstrating a 
16 in distant organs and local lymph nodes , demonstrating a role for pericytes in limiting tumor cell metastasis . NULL NULL 
18 local lymph nodes , demonstrating a role for pericytes in limiting tumor cell metastasis . NULL NULL NULL NULL NULL NULL 
0 lymph nodes , demonstrating a role for pericytes in limiting tumor cell metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 , demonstrating a role for pericytes in limiting tumor cell metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL these data support a new model for how tumor cells trigger metastasis by 
0 NULL NULL these data support a new model for how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions . NULL 
17 these data support a new model for how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions . NULL NULL NULL 
14 data support a new model for how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions . NULL NULL NULL NULL 
16 a new model for how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions . NULL NULL NULL NULL NULL NULL 
15 model for how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions . NULL NULL NULL NULL NULL NULL NULL NULL 
15 for how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL nf-kappab and ikk as therapeutic targets in cancer . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the transcription factor nf-kappab and associated regulatory factors ( including ikappab kinase 
15 NULL NULL NULL NULL NULL the transcription factor nf-kappab and associated regulatory factors ( including ikappab kinase subunits and the ikappab 
0 NULL NULL NULL NULL the transcription factor nf-kappab and associated regulatory factors ( including ikappab kinase subunits and the ikappab family 
0 subunits and the ikappab family member bcl-3 ) are strongly implicated in a variety of hematologic and solid tumor malignancies . 
0 are strongly implicated in a variety of hematologic and solid tumor malignancies . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL a role for nf-kappab in cancer cells appears to involve regulation of 
0 NULL a role for nf-kappab in cancer cells appears to involve regulation of cell proliferation , control of apoptosis , promotion 
16 a role for nf-kappab in cancer cells appears to involve regulation of cell proliferation , control of apoptosis , promotion of 
1 nf-kappab in cancer cells appears to involve regulation of cell proliferation , control of apoptosis , promotion of angiogenesis , and 
16 cancer cells appears to involve regulation of cell proliferation , control of apoptosis , promotion of angiogenesis , and stimulation of 
5 appears to involve regulation of cell proliferation , control of apoptosis , promotion of angiogenesis , and stimulation of invasion/metastasis . 
17 involve regulation of cell proliferation , control of apoptosis , promotion of angiogenesis , and stimulation of invasion/metastasis . NULL NULL 
3 of cell proliferation , control of apoptosis , promotion of angiogenesis , and stimulation of invasion/metastasis . NULL NULL NULL NULL 
17 , control of apoptosis , promotion of angiogenesis , and stimulation of invasion/metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 of apoptosis , promotion of angiogenesis , and stimulation of invasion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 of apoptosis , promotion of angiogenesis , and stimulation of metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL consistent with a role for nf-kappab in oncogenesis are observations that inhibition of nf-kappab 
18 with a role for nf-kappab in oncogenesis are observations that inhibition of nf-kappab alone or in combination with cancer therapies leads 
19 that inhibition of nf-kappab alone or in combination with cancer therapies leads to tumor cell death or growth inhibition . NULL 
17 inhibition of nf-kappab alone or in combination with cancer therapies leads to tumor cell death or growth inhibition . NULL NULL 
0 nf-kappab alone or in combination with cancer therapies leads to tumor cell death or growth inhibition . NULL NULL NULL NULL 
5 or in combination with cancer therapies leads to tumor cell death or growth inhibition . NULL NULL NULL NULL NULL NULL 
4 combination with cancer therapies leads to tumor cell death or growth inhibition . NULL NULL NULL NULL NULL NULL NULL NULL 
18 with cancer therapies leads to tumor cell death or growth inhibition . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL however , other experimental data indicate that nf-kappab can play a tumor suppressor role in certain settings and that it 
0 , other experimental data indicate that nf-kappab can play a tumor suppressor role in certain settings and that it can be 
0 other experimental data indicate that nf-kappab can play a tumor suppressor role in certain settings and that it can be important 
0 experimental data indicate that nf-kappab can play a tumor suppressor role in certain settings and that it can be important in 
0 suppressor role in certain settings and that it can be important in promoting an apoptotic signal downstream of certain cancer therapy 
0 in certain settings and that it can be important in promoting an apoptotic signal downstream of certain cancer therapy regimens . 
0 that it can be important in promoting an apoptotic signal downstream of certain cancer therapy regimens . NULL NULL NULL NULL 
0 important in promoting an apoptotic signal downstream of certain cancer therapy regimens . NULL NULL NULL NULL NULL NULL NULL NULL 
0 nf-kappab inhibitors in the clinic , thorough approaches must be initiated to determine the molecular mechanisms that dictate the complexity of 
0 dictate the complexity of oncologic and therapeutic outcomes that are controlled by nf-kappab . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL circulating endothelial cells in malignant disease . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL circulating endothelial cells in malignant disease . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL cancer is a disease largely dependent on neoangiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL cancer is a disease largely dependent on angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL cancer angiogenesis is often disordered and abnormal , with evidence of coexisting 
6 disordered and abnormal , with evidence of coexisting vascular endothelial dysfunction . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL a novel method of assessing vascular endothelial function in cancer is via the quantification of circulating endothelial cells 
0 vascular endothelial function in cancer is via the quantification of circulating endothelial cells ( cec ) . NULL NULL NULL NULL 
0 NULL NULL NULL NULL unusual in healthy individuals , their presence in elevated numbers often indicates substantial vascular endothelial perturbation . 
0 NULL NULL unusual in healthy individuals , their presence in elevated numbers often indicates substantial vascular endothelial perturbation . NULL NULL 
17 the endothelial progenitor cell ( epc ) , whose numbers increase in the presence of vascular damage . NULL NULL NULL 
0 cell ( epc ) , whose numbers increase in the presence of vascular damage . NULL NULL NULL NULL NULL NULL 
6 ) , whose numbers increase in the presence of vascular damage . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL recent research suggests that epcs have an important role in tumor vasculogenesis . NULL NULL NULL NULL NULL 
16 NULL NULL recent research suggests that epcs have an important role in tumor vasculogenesis . NULL NULL NULL NULL NULL NULL 
0 recent research suggests that epcs have an important role in tumor vasculogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 research suggests that epcs have an important role in tumor vasculogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
6 NULL another marker being investigated in the context of vascular dysfunction and coagulopathy is the endothelial microparticle ( emp ) . 
0 biology terms , with particular emphasis on their relationship to malignant disease . NULL NULL NULL NULL NULL NULL NULL NULL 
6 NULL NULL gdp and age receptors : mechanisms of peritoneal damage . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL long-term peritoneal dialysis ( pd ) is limited by morphological changes of the peritoneal membrane . NULL NULL 
7 NULL long-term peritoneal dialysis ( pd ) is limited by morphological changes of the peritoneal membrane . NULL NULL NULL NULL 
7 long-term peritoneal dialysis ( pd ) is limited by morphological changes of the peritoneal membrane . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL structural changes were promoted by toxicity of glucose degradation products ( 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL structural changes were promoted by toxicity of glucose degradation products ( gdps 
17 NULL NULL NULL NULL NULL NULL NULL structural changes were promoted by toxicity of glucose degradation products ( gdps ) which 
0 NULL NULL structural changes were promoted by toxicity of glucose degradation products ( gdps ) which are generated during heat sterilization 
0 NULL NULL NULL NULL NULL NULL NULL NULL besides their direct toxicity gdps promote formation of advanced glycation endproducts ( ages 
17 NULL NULL NULL NULL NULL besides their direct toxicity gdps promote formation of advanced glycation endproducts ( ages ) . NULL 
8 NULL NULL NULL NULL besides their direct toxicity gdps promote formation of advanced glycation endproducts ( ages ) . NULL NULL 
9 the best characterized signal transduction receptor for ages and is expressed on mesothelial cells . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effects of pdfs with different amounts of gdps were compared on 
7 of pdfs with different amounts of gdps were compared on morphological changes in the peritoneal membrane in a rage -/- mouse 
7 pdfs with different amounts of gdps were compared on morphological changes in the peritoneal membrane in a rage -/- mouse model 
16 NULL NULL NULL NULL it could be demonstrated that rage plays a pivotal role in structural damage ( e.g. inflammation , 
16 NULL NULL it could be demonstrated that rage plays a pivotal role in structural damage ( e.g. inflammation , neoangiogenesis and 
16 NULL it could be demonstrated that rage plays a pivotal role in structural damage ( e.g. inflammation , neoangiogenesis and fibrosis 
6 could be demonstrated that rage plays a pivotal role in structural damage ( e.g. inflammation , neoangiogenesis and fibrosis ) of 
6 be demonstrated that rage plays a pivotal role in structural damage ( e.g. inflammation , neoangiogenesis and fibrosis ) of the 
3 a pivotal role in structural damage ( e.g. inflammation , angiogenesis and fibrosis ) of the peritoneal membrane . NULL NULL 
0 NULL NULL further investigations of this pathway with regard to preventing peritoneal fibrosis should be performed to maintain the integrity of 
19 bone marrow stem cell or peripheral blood endothelial progenitor cell therapy in patients with peripheral limb ischaemia ] NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL no effective medical therapies have been developed sofar to enhance blood flow 
0 NULL NULL NULL NULL NULL NULL NULL no effective medical therapies have been developed sofar to enhance blood flow in the 
0 NULL NULL NULL NULL no effective medical therapies have been developed sofar to enhance blood flow in the legs of patients 
0 NULL no effective medical therapies have been developed sofar to enhance blood flow in the legs of patients with peripheral arterial 
0 enhance blood flow in the legs of patients with peripheral arterial disease ( pad ) . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL there is evidence in experimental and clinical studies that adult bone marrow-derived stem cells and endothelial progenitor 
0 is evidence in experimental and clinical studies that adult bone derived stem cells and endothelial progenitor cells participate in the development 
0 that adult bone marrow-derived stem cells and endothelial progenitor cells participate in the development of new blood vessels , called neoangiogenesis 
2 marrow-derived stem cells and endothelial progenitor cells participate in the development of new blood vessels , called neoangiogenesis or neovascularization . 
3 participate in the development of new blood vessels , called angiogenesis or neovascularization . NULL NULL NULL NULL NULL NULL NULL 
3 the development of new blood vessels , called neoangiogenesis or neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical results induced by autologous bone marrow stem cells or angiogenic 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical results induced by autologous bone marrow stem cells or angiogenic growth/differentiation 
0 NULL NULL NULL NULL NULL NULL NULL NULL clinical results induced by autologous bone marrow stem cells or angiogenic growth/differentiation factors 
3 clinical results induced by autologous bone marrow stem cells or angiogenic growth/differentiation factors in end-stage patients with pad are summarized . 
0 results induced by autologous bone marrow stem cells or angiogenic growth factors in end-stage patients with pad are summarized . NULL 
0 results induced by autologous bone marrow stem cells or angiogenic differentiation factors in end-stage patients with pad are summarized . NULL 
19 NULL NULL NULL considering the relatively few number of patients treated by angiogenic therapy , the interpretation of clinical results needs 
3 NULL considering the relatively few number of patients treated by angiogenic therapy , the interpretation of clinical results needs cautiousness . 
0 considering the relatively few number of patients treated by angiogenic therapy , the interpretation of clinical results needs cautiousness . NULL 
0 of patients treated by angiogenic therapy , the interpretation of clinical results needs cautiousness . NULL NULL NULL NULL NULL NULL 
0 patients treated by angiogenic therapy , the interpretation of clinical results needs cautiousness . NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL formation of new bone during vertical distraction osteogenesis of the human 
19 NULL NULL NULL NULL NULL formation of new bone during vertical distraction osteogenesis of the human mandible is related to the 
19 NULL NULL NULL NULL formation of new bone during vertical distraction osteogenesis of the human mandible is related to the presence 
19 NULL NULL NULL formation of new bone during vertical distraction osteogenesis of the human mandible is related to the presence of 
0 distraction osteogenesis of the human mandible is related to the presence of blood vessels . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL we examined the effect of distraction rate on blood vessel growth in intramembraneous ossification 
0 NULL NULL NULL NULL NULL we examined the effect of distraction rate on blood vessel growth in intramembraneous ossification after vertical 
4 we examined the effect of distraction rate on blood vessel growth in intramembraneous ossification after vertical distraction osteogenesis in the human 
19 distraction rate on blood vessel growth in intramembraneous ossification after vertical distraction osteogenesis in the human mandible . NULL NULL NULL 
19 rate on blood vessel growth in intramembraneous ossification after vertical distraction osteogenesis in the human mandible . NULL NULL NULL NULL 
19 on blood vessel growth in intramembraneous ossification after vertical distraction osteogenesis in the human mandible . NULL NULL NULL NULL NULL 
0 ( aged 60+/-9 years ) with a severely atrophic mandible underwent bone augmentation with distraction osteogenesis . NULL NULL NULL NULL 
0 ) with a severely atrophic mandible underwent bone augmentation with distraction osteogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
0 with a severely atrophic mandible underwent bone augmentation with distraction osteogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL two distraction rates ( 0.5 and 1 mm/day ) were compared and 
0 histomorphometry was carried out in two different areas in the distraction gap : ( 1 ) in the first and ( 
2 between blood vessel parameters and the amount of new bone formed during distraction . NULL NULL NULL NULL NULL NULL NULL 
0 vessel parameters and the amount of new bone formed during distraction . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL histological analysis demonstrated the presence of blood vessels throughout the soft connective tissue in the 
0 of blood vessels throughout the soft connective tissue in the distraction gap . NULL NULL NULL NULL NULL NULL NULL NULL 
18 significantly lower in the 1 mm/day groups , suggesting a delay in angiogenesis in this group of patients . NULL NULL 
3 in the 1 mm/day groups , suggesting a delay in angiogenesis in this group of patients . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL a positive correlation between blood vessel volume and bone volume density was 
0 blood vessel density found in the patients with 1 mm/day distraction rate may be related to disruption of angiogenesis in the 
18 patients with 1 mm/day distraction rate may be related to disruption of angiogenesis in the soft connective tissue of the gap 
3 1 mm/day distraction rate may be related to disruption of angiogenesis in the soft connective tissue of the gap or to 
17 tissue of the gap or to a less optimal mechanical stimulation of cells involved in angiogenesis . NULL NULL NULL NULL 
0 gap or to a less optimal mechanical stimulation of cells involved in angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 to a less optimal mechanical stimulation of cells involved in angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL this probably results in the slower rate of osteogenesis seen at the 1 
0 NULL NULL this probably results in the slower rate of osteogenesis seen at the 1 mm/day distraction rate compared with the 
0 the slower rate of osteogenesis seen at the 1 mm/day distraction rate compared with the 0.5 mm/day distraction rate . NULL 
0 the 1 mm/day distraction rate compared with the 0.5 mm/day distraction rate . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the data support the concept that a positive relationship exists between the density 
0 NULL NULL NULL the data support the concept that a positive relationship exists between the density of blood vessels and the 
2 relationship exists between the density of blood vessels and the formation of bone . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL for distraction of the human mandible in elderly patients , a distraction 
0 distraction of the human mandible in elderly patients , a distraction rate of 0.5 mm/day seems beneficial . NULL NULL NULL 
0 elderly patients , a distraction rate of 0.5 mm/day seems beneficial . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 high-dose celecoxib and metronomic `` low-dose '' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive 
19 metronomic `` low-dose '' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-hodgkin 's 
3 NULL NULL NULL NULL NULL NULL NULL NULL purpose : angiogenesis is increased in aggressive histology non-hodgkin 's lymphoma and may 
17 NULL NULL NULL NULL NULL NULL purpose : angiogenesis is increased in aggressive histology non-hodgkin 's lymphoma and may be a 
0 in aggressive histology non-hodgkin 's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy . NULL NULL 
18 's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy . NULL NULL NULL NULL NULL NULL 
19 may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL experimental design : we assessed response , toxicity , and biomarkers of angiogenesis to low-dose cyclophosphamide 
3 : we assessed response , toxicity , and biomarkers of angiogenesis to low-dose cyclophosphamide ( 50 mg p.o . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : thirty-two of 35 patients ( median age , 62 
0 ( median age , 62 years ) are evaluable for response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 diffuse large b-cell lymphoma ( 63 % ) were heavily pretreated ( median of three regimens ) and high risk ( 
19 ) and 34 % were relapsed after autologous stem cell transplant . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 a median follow-up of 8.4 months , the overall best response rate is 37 % ( 2 complete clinical response/complete clinical 
0 overall best response rate is 37 % ( 2 complete clinical response/complete clinical response unconfirmed and 9 partial response ) , 
0 best response rate is 37 % ( 2 complete clinical response clinical response unconfirmed and 9 partial response ) , with 
0 response rate is 37 % ( 2 complete clinical response/complete clinical response unconfirmed and 9 partial response ) , with 22 
0 rate is 37 % ( 2 complete clinical response/complete clinical response unconfirmed and 9 partial response ) , with 22 % 
0 2 complete clinical response/complete clinical response unconfirmed and 9 partial response ) , with 22 % achieving stable disease . NULL 
0 NULL NULL NULL NULL NULL NULL NULL median overall and progression survivals are 14.4 and 4.7 months , respectively . NULL 
0 NULL NULL NULL NULL NULL NULL NULL median overall and free survivals are 14.4 and 4.7 months , respectively . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the median response duration was 8.2 months . NULL NULL NULL NULL NULL 
0 rash ( 40 % ) ; myelosuppression and gastrointestinal side effects were uncommon . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL three patients developed deep vein thromboses and two heavily pretreated patients developed treatment-related 
19 NULL three patients developed deep vein thromboses and two heavily pretreated patients developed treatment-related acute myelogenous leukemia or myelodysplasia after 3.7 
0 patients developed deep vein thromboses and two heavily pretreated patients developed treatment-related acute myelogenous leukemia or myelodysplasia after 3.7 and 12 
19 developed deep vein thromboses and two heavily pretreated patients developed treatment acute myelogenous leukemia or myelodysplasia after 3.7 and 12 months 
19 myelogenous leukemia or myelodysplasia after 3.7 and 12 months of therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL circulating endothelial cells and their precursors declined and remained low in 
0 NULL NULL NULL NULL circulating endothelial cells and their precursors declined and remained low in responders , whereas plasma vascular endothelial 
0 and remained low in responders , whereas plasma vascular endothelial growth factor trended to decline in responding patients but increase in 
18 responders , whereas plasma vascular endothelial growth factor trended to decline in responding patients but increase in nonresponders . NULL NULL 
17 endothelial growth factor trended to decline in responding patients but increase in nonresponders . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL trough celecoxib levels achieved targeted `` antiangiogenic '' levels . NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL trough celecoxib levels achieved targeted `` antiangiogenic '' levels . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL trough celecoxib levels achieved targeted `` angiogenic '' levels . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL trough celecoxib levels achieved targeted `` antiangiogenic '' levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 : low-dose cyclophosphamide and high-dose celecoxib is well tolerated and active in pretreated aggressive non-hodgkin 's lymphoma . NULL NULL NULL 
19 cyclophosphamide and high-dose celecoxib is well tolerated and active in pretreated aggressive non-hodgkin 's lymphoma . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL close surveillance for arterial and venous thrombotic events is recommended . NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL the decline in circulating endothelial cells and their precursors suggests that this 
0 NULL NULL NULL NULL NULL NULL NULL the decline in circulating endothelial cells and their precursors suggests that this combination may 
18 their precursors suggests that this combination may be working by inhibiting angiogenesis but should be validated in a larger patient sample 
3 precursors suggests that this combination may be working by inhibiting angiogenesis but should be validated in a larger patient sample . 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia 
3 NULL NULL NULL photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia : long-term study . NULL NULL 
0 NULL NULL NULL purpose : to assess the safety and effectiveness of photodynamic therapy ( pdt ) with verteporfin for subfoveal 
19 NULL purpose : to assess the safety and effectiveness of photodynamic therapy ( pdt ) with verteporfin for subfoveal choroidal neovascularization 
19 purpose : to assess the safety and effectiveness of photodynamic therapy ( pdt ) with verteporfin for subfoveal choroidal neovascularization ( 
0 to assess the safety and effectiveness of photodynamic therapy ( pdt ) with verteporfin for subfoveal choroidal neovascularization ( cnv ) 
3 photodynamic therapy ( pdt ) with verteporfin for subfoveal choroidal neovascularization ( cnv ) secondary to pathologic myopia ( pm ) 
3 ( pdt ) with verteporfin for subfoveal choroidal neovascularization ( cnv ) secondary to pathologic myopia ( pm ) . NULL 
0 methods : sixty-two patients ( 62 eyes ) with pm underwent pdt according to the guidelines of the verteporfin in photodynamic 
19 : sixty-two patients ( 62 eyes ) with pm underwent pdt according to the guidelines of the verteporfin in photodynamic therapy 
19 underwent pdt according to the guidelines of the verteporfin in photodynamic therapy study . NULL NULL NULL NULL NULL NULL NULL 
19 pdt according to the guidelines of the verteporfin in photodynamic therapy study . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical evaluations performed at all study visits included measurement of best-corrected 
19 snellen visual acuity , slit-lamp biomicroscopy , and fundus fluorescein angiography . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 were followed up at 1 month and 3 months after treatment and thereafter at 3-month intervals . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the final visual acuity of the study patients , 
0 patients , after a median follow-up of 31 months , improved by greater than or=1 snellen lines in 8 patients ( 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL cnv size did not affect visual outcomes . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL cnv size did not affect visual outcomes . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL conclusion : pdt preserves vision in patients with cnv associated with pm . 
3 NULL NULL conclusion : pdt preserves vision in patients with cnv associated with pm . NULL NULL NULL NULL NULL NULL 
0 NULL conclusion : pdt preserves vision in patients with cnv associated with pm . NULL NULL NULL NULL NULL NULL NULL 
19 with higher refractive error appear more likely to benefit from pdt with verteporfin . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL imaging tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL imaging tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL since the discovery of vascular-specific growth factors with angiogenic activity , there has been a significant 
0 NULL NULL since the discovery of vascular-specific growth factors with angiogenic activity , there has been a significant effort to develop 
0 NULL since the discovery of vascular-specific growth factors with angiogenic activity , there has been a significant effort to develop cancer 
0 growth factors with angiogenic activity , there has been a significant effort to develop cancer drugs that restrict tumorigenesis by targeting 
0 has been a significant effort to develop cancer drugs that restrict tumorigenesis by targeting the blood supply . NULL NULL NULL 
0 significant effort to develop cancer drugs that restrict tumorigenesis by targeting the blood supply . NULL NULL NULL NULL NULL NULL 
0 in this issue of the jci , mancuso et al. use mouse models to better understand the plasticity of the tumor 
0 use mouse models to better understand the plasticity of the tumor vasculature in the face of antiangiogenic therapy ( see the 
3 the plasticity of the tumor vasculature in the face of angiogenic therapy ( see the related article beginning on page 2610 
0 plasticity of the tumor vasculature in the face of antiangiogenic therapy ( see the related article beginning on page 2610 ) 
4 NULL NULL NULL NULL NULL NULL they describe a rapid regrowth of the tumor vasculature following withdrawal of vegfr inhibitors , 
0 NULL NULL NULL they describe a rapid regrowth of the tumor vasculature following withdrawal of vegfr inhibitors , emphasizing the importance 
0 vegfr inhibitors , emphasizing the importance of fully understanding the function of these and similar treatments used in the clinic at 
0 importance of fully understanding the function of these and similar treatments used in the clinic at the cellular and molecular level 
0 of fully understanding the function of these and similar treatments used in the clinic at the cellular and molecular level . 
0 NULL NULL NULL NULL NULL NULL collagen-poly glycolic acid hybrid matrix with basic fibroblast growth factor accelerated angiogenesis and granulation tissue 
0 NULL NULL collagen-poly glycolic acid hybrid matrix with basic fibroblast growth factor accelerated angiogenesis and granulation tissue formation in diabetic mice 
17 collagen-poly glycolic acid hybrid matrix with basic fibroblast growth factor accelerated angiogenesis and granulation tissue formation in diabetic mice . NULL 
3 glycolic acid hybrid matrix with basic fibroblast growth factor accelerated angiogenesis and granulation tissue formation in diabetic mice . NULL NULL 
2 with basic fibroblast growth factor accelerated angiogenesis and granulation tissue formation in diabetic mice . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL because poor skin wound healing associated with diabetes is thought to be partly a result from 
18 with diabetes is thought to be partly a result from impaired angiogenesis , treatments that improve angiogenesis could have important clinical 
3 diabetes is thought to be partly a result from impaired angiogenesis , treatments that improve angiogenesis could have important clinical applications 
0 thought to be partly a result from impaired angiogenesis , treatments that improve angiogenesis could have important clinical applications . NULL 
17 be partly a result from impaired angiogenesis , treatments that improve angiogenesis could have important clinical applications . NULL NULL NULL 
3 partly a result from impaired angiogenesis , treatments that improve angiogenesis could have important clinical applications . NULL NULL NULL NULL 
0 from impaired angiogenesis , treatments that improve angiogenesis could have important clinical applications . NULL NULL NULL NULL NULL NULL NULL 
0 impaired angiogenesis , treatments that improve angiogenesis could have important clinical applications . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL we herein report the effects of novel developed material , collagen-poly glycolic acid fiber hybrid 
0 NULL NULL NULL we herein report the effects of novel developed material , collagen-poly glycolic acid fiber hybrid matrix , being 
0 of novel developed material , collagen-poly glycolic acid fiber hybrid matrix , being used together with basic fibroblast growth factor to 
0 material , collagen-poly glycolic acid fiber hybrid matrix , being used together with basic fibroblast growth factor to promote wound healing 
0 fiber hybrid matrix , being used together with basic fibroblast growth factor to promote wound healing of full-thickness skin defects on 
0 , being used together with basic fibroblast growth factor to promote wound healing of full-thickness skin defects on the back of 
0 fibroblast growth factor to promote wound healing of full-thickness skin defects on the back of type 2 diabetic lepr ( db 
17 NULL NULL our data indicates that this therapeutic approach markedly promotes angiogenesis and granulation tissue formation in comparison with other conditions 
3 NULL our data indicates that this therapeutic approach markedly promotes angiogenesis and granulation tissue formation in comparison with other conditions 14 
2 that this therapeutic approach markedly promotes angiogenesis and granulation tissue formation in comparison with other conditions 14 days after wounding . 
0 NULL NULL NULL punica granatum ( pomegranate ) and its potential for prevention and treatment of inflammation and cancer . NULL 
0 NULL punica granatum ( pomegranate ) and its potential for prevention and treatment of inflammation and cancer . NULL NULL NULL 
0 granatum ( pomegranate ) and its potential for prevention and treatment of inflammation and cancer . NULL NULL NULL NULL NULL 
0 7 ) roots , each of which has interesting pharmacologic activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 juice and peels , for example , possess potent antioxidant properties , while juice , peel and oil are all weakly 
0 are all weakly estrogenic and heuristically of interest for the treatment of menopausal symptoms and sequellae . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the use of juice , peel and oil have also been shown 
0 peel and oil have also been shown to possess anticancer activities , including interference with tumor cell proliferation , cell cycle 
0 have also been shown to possess anticancer activities , including interference with tumor cell proliferation , cell cycle , invasion and 
0 been shown to possess anticancer activities , including interference with tumor cell proliferation , cell cycle , invasion and angiogenesis . 
1 to possess anticancer activities , including interference with tumor cell proliferation , cell cycle , invasion and angiogenesis . NULL NULL 
14 including interference with tumor cell proliferation , cell cycle , invasion and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 with tumor cell proliferation , cell cycle , invasion and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL these may be associated with plant based anti-inflammatory effects , the phytochemistry and pharmacological 
0 NULL NULL these may be associated with plant based anti-inflammatory effects , the phytochemistry and pharmacological actions of all punica granatum 
0 of all punica granatum components suggest a wide range of clinical applications for the treatment and prevention of cancer , as 
0 components suggest a wide range of clinical applications for the treatment and prevention of cancer , as well as other diseases 
0 a wide range of clinical applications for the treatment and prevention of cancer , as well as other diseases where chronic 
0 well as other diseases where chronic inflammation is believed to play an essential etiologic role . NULL NULL NULL NULL NULL 
0 other diseases where chronic inflammation is believed to play an essential etiologic role . NULL NULL NULL NULL NULL NULL NULL 
0 where chronic inflammation is believed to play an essential etiologic role . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL angiotensin ii induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in 
16 NULL NULL NULL NULL NULL NULL NULL NULL angiotensin ii induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in 
14 NULL NULL NULL angiotensin ii induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy . NULL NULL NULL 
6 NULL NULL NULL NULL NULL NULL NULL NULL maternal endothelial dysfunction in preeclampsia is associated with increased soluble fms-like tyrosine kinase-1 
0 NULL NULL NULL NULL maternal endothelial dysfunction in preeclampsia is associated with increased soluble fms-like tyrosine kinase-1 ( sflt-1 ) , 
17 NULL NULL maternal endothelial dysfunction in preeclampsia is associated with increased soluble fms-like tyrosine kinase-1 ( sflt-1 ) , a circulating 
14 increased soluble fms-like tyrosine kinase-1 ( sflt-1 ) , a circulating antagonist of vascular endothelial growth factor and placental growth factor 
0 ( sflt-1 ) , a circulating antagonist of vascular endothelial growth factor and placental growth factor . NULL NULL NULL NULL 
0 a circulating antagonist of vascular endothelial growth factor and placental growth factor . NULL NULL NULL NULL NULL NULL NULL NULL 
17 ii ( ang ii ) is a potent vasoconstrictor that increases concomitant with sflt-1 during pregnancy . NULL NULL NULL NULL 
17 NULL NULL therefore , we speculated that ang ii may promote the expression of sflt-1 in pregnancy . NULL NULL NULL 
9 therefore , we speculated that ang ii may promote the expression of sflt-1 in pregnancy . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL here we report that infusion of ang ii significantly increases circulating levels of sflt-1 in 
17 NULL here we report that infusion of ang ii significantly increases circulating levels of sflt-1 in pregnant mice , thereby demonstrating 
14 here we report that infusion of ang ii significantly increases circulating levels of sflt-1 in pregnant mice , thereby demonstrating that 
0 we report that infusion of ang ii significantly increases circulating levels of sflt-1 in pregnant mice , thereby demonstrating that ang 
0 pregnant mice , thereby demonstrating that ang ii is a regulator of sflt-1 secretion in vivo . NULL NULL NULL NULL 
14 thereby demonstrating that ang ii is a regulator of sflt-1 secretion in vivo . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL furthermore , ang ii stimulated sflt-1 production in a dose- and time-dependent manner from human 
9 NULL NULL NULL NULL furthermore , ang ii stimulated sflt-1 production in a dose- and time-dependent manner from human villous explants 
0 , ang ii stimulated sflt-1 production in a dose- and dependent manner from human villous explants and cultured trophoblasts but not 
0 a dose- and time-dependent manner from human villous explants and cultured trophoblasts but not from endothelial cells , suggesting that trophoblasts 
17 NULL NULL NULL NULL NULL NULL as expected , ang induced sflt-1 secretion resulted in the inhibition of endothelial cell migration 
14 NULL NULL NULL NULL as expected , ang ii-induced sflt-1 secretion resulted in the inhibition of endothelial cell migration and in 
0 NULL NULL NULL as expected , ang ii-induced sflt-1 secretion resulted in the inhibition of endothelial cell migration and in vitro 
17 as expected , ang ii-induced sflt-1 secretion resulted in the inhibition of endothelial cell migration and in vitro tube formation . 
14 ii-induced sflt-1 secretion resulted in the inhibition of endothelial cell migration and in vitro tube formation . NULL NULL NULL NULL 
2 the inhibition of endothelial cell migration and in vitro tube formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 interfering rna specific for calcineurin and fk506 demonstrated that ang mediated sflt-1 release was via ang ii type 1 receptor activation 
16 interfering rna specific for calcineurin and fk506 demonstrated that ang mediated sflt-1 release was via ang ii type 1 receptor activation 
14 specific for calcineurin and fk506 demonstrated that ang ii-mediated sflt-1 release was via ang ii type 1 receptor activation and calcineurin 
17 ii-mediated sflt-1 release was via ang ii type 1 receptor activation and calcineurin signaling , respectively . NULL NULL NULL NULL 
16 NULL NULL NULL NULL these findings reveal a previously unrecognized regulatory role for ang ii on sflt-1 expression in murine and 
16 NULL NULL NULL these findings reveal a previously unrecognized regulatory role for ang ii on sflt-1 expression in murine and human 
9 a previously unrecognized regulatory role for ang ii on sflt-1 expression in murine and human pregnancy and suggest that elevated sflt-1 
17 sflt-1 expression in murine and human pregnancy and suggest that elevated sflt-1 levels in preeclampsia may be caused by a dysregulation 
0 in murine and human pregnancy and suggest that elevated sflt-1 levels in preeclampsia may be caused by a dysregulation of the 
17 and suggest that elevated sflt-1 levels in preeclampsia may be caused by a dysregulation of the local renin/angiotensin system . NULL 
18 elevated sflt-1 levels in preeclampsia may be caused by a dysregulation of the local renin/angiotensin system . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL activation of vascular endothelial growth factor through reactive oxygen species mediates 
0 NULL NULL NULL NULL NULL NULL activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell 
16 activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation . NULL NULL NULL NULL 
17 vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic induced endothelial cell proliferation . NULL NULL NULL NULL NULL NULL 
1 factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
8 NULL NULL NULL NULL 20-hydroxyeicosatetraenoic acid ( 20-hete ) is formed by the omega-hydroxylation of arachidonic acid by cytochrome p450 4a 
17 by cytochrome p450 4a and 4f enzymes , and it induces angiogenic responses in vivo . NULL NULL NULL NULL NULL 
3 cytochrome p450 4a and 4f enzymes , and it induces angiogenic responses in vivo . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL to test the hypothesis that 20-hete increases endothelial cell ( ec ) proliferation via vascular endothelial growth 
1 the hypothesis that 20-hete increases endothelial cell ( ec ) proliferation via vascular endothelial growth factor ( vegf ) , we 
0 increases endothelial cell ( ec ) proliferation via vascular endothelial growth factor ( vegf ) , we studied the effects of 
16 endothelial growth factor ( vegf ) , we studied the effects of wit003 [ 20-hydroxyeicosa-5 ( z ) , 14 ( 
17 NULL NULL wit003 , as well as pure 20-hete , stimulated ec proliferation by approximately 40 % . NULL NULL NULL 
1 wit003 , as well as pure 20-hete , stimulated ec proliferation by approximately 40 % . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these proliferative effects were accompanied by increased vegf expression and release that 
0 NULL NULL NULL NULL NULL NULL NULL NULL these proliferative effects were accompanied by increased vegf expression and release that were 
17 NULL NULL NULL NULL these proliferative effects were accompanied by increased vegf expression and release that were observed as early as 
9 NULL NULL these proliferative effects were accompanied by increased vegf expression and release that were observed as early as 4 h 
14 these proliferative effects were accompanied by increased vegf expression and release that were observed as early as 4 h after 20-hete 
0 were accompanied by increased vegf expression and release that were observed as early as 4 h after 20-hete agonist addition . 
0 were observed as early as 4 h after 20-hete agonist addition . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL this was accompanied by increased phosphorylation of the vegf receptor 2 . NULL NULL NULL 
12 NULL NULL NULL NULL NULL this was accompanied by increased phosphorylation of the vegf receptor 2 . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the proliferative effects of 20-hete were markedly inhibited by a vegf-neutralizing antibody 
0 NULL NULL NULL NULL NULL NULL NULL NULL the proliferative effects of 20-hete were markedly inhibited by a vegf-neutralizing antibody . 
18 NULL NULL NULL the proliferative effects of 20-hete were markedly inhibited by a vegf-neutralizing antibody . NULL NULL NULL NULL NULL 
18 NULL NULL NULL polyethylene glycol-superoxide dismutase ( peg-sod ) markedly inhibited both the increases in vegf expression and the proliferative effects 
17 polyethylene glycol-superoxide dismutase ( peg-sod ) markedly inhibited both the increases in vegf expression and the proliferative effects of 20-hete . 
9 ( peg-sod ) markedly inhibited both the increases in vegf expression and the proliferative effects of 20-hete . NULL NULL NULL 
0 markedly inhibited both the increases in vegf expression and the proliferative effects of 20-hete . NULL NULL NULL NULL NULL NULL 
0 inhibited both the increases in vegf expression and the proliferative effects of 20-hete . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL in contrast , administration of the nad ( p ) h oxidase inhibitor apocynin 
0 , administration of the nad ( p ) h oxidase inhibitor apocynin had no effect to the proliferative response to 20-hete 
16 nad ( p ) h oxidase inhibitor apocynin had no effect to the proliferative response to 20-hete . NULL NULL NULL 
0 ) h oxidase inhibitor apocynin had no effect to the proliferative response to 20-hete . NULL NULL NULL NULL NULL NULL 
0 h oxidase inhibitor apocynin had no effect to the proliferative response to 20-hete . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL the 20-hete agonist markedly increased superoxide formation as reflected by an increase in dihydroethidium staining 
8 NULL NULL NULL NULL the 20-hete agonist markedly increased superoxide formation as reflected by an increase in dihydroethidium staining of ec 
0 20-hete agonist markedly increased superoxide formation as reflected by an increase in dihydroethidium staining of ec , and this increase was 
19 increased superoxide formation as reflected by an increase in dihydroethidium staining of ec , and this increase was inhibited by peg-sod 
0 an increase in dihydroethidium staining of ec , and this increase was inhibited by peg-sod but not by apocynin . NULL 
18 in dihydroethidium staining of ec , and this increase was inhibited by peg-sod but not by apocynin . NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL 20-hete also increased the phosphorylation of p42/p44 mitogen-activated protein kinase ( mapk ) 
12 NULL NULL NULL NULL NULL NULL 20-hete also increased the phosphorylation of p42/p44 mitogen-activated protein kinase ( mapk ) in ec 
0 NULL NULL NULL 20-hete also increased the phosphorylation of p42/p44 activated protein kinase ( mapk ) in ec , whereas an 
0 NULL NULL 20-hete also increased the phosphorylation of p42/p44 mitogen-activated protein kinase ( mapk ) in ec , whereas an inhibitor 
0 protein kinase ( mapk ) in ec , whereas an inhibitor of mapk [ u0126 , 1 , 4-diamino-2 , 3-dicyano-1 
18 4-diamino-2 , 3-dicyano-1 , 4-bis ( 2-aminophenylthio ) butadiene ] suppressed the proliferative and the vegf changes but not the pro-oxidant 
0 3-dicyano-1 , 4-bis ( 2-aminophenylthio ) butadiene ] suppressed the proliferative and the vegf changes but not the pro-oxidant effects of 
16 2-aminophenylthio ) butadiene ] suppressed the proliferative and the vegf changes but not the pro-oxidant effects of 20-hete . NULL NULL 
0 the proliferative and the vegf changes but not the pro-oxidant effects of 20-hete . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL these data suggest that 20-hete stimulates superoxide formation by pathways other than apocynin-sensitive nad ( p 
8 NULL NULL NULL these data suggest that 20-hete stimulates superoxide formation by pathways other than apocynin-sensitive nad ( p ) h 
0 NULL these data suggest that 20-hete stimulates superoxide formation by pathways other than apocynin-sensitive nad ( p ) h oxidase , 
0 suggest that 20-hete stimulates superoxide formation by pathways other than sensitive nad ( p ) h oxidase , thereby activating mapk 
17 than apocynin-sensitive nad ( p ) h oxidase , thereby activating mapk and then enhancing vegf synthesis that drives ec proliferation 
17 p ) h oxidase , thereby activating mapk and then enhancing vegf synthesis that drives ec proliferation . NULL NULL NULL 
9 h oxidase , thereby activating mapk and then enhancing vegf synthesis that drives ec proliferation . NULL NULL NULL NULL NULL 
16 , thereby activating mapk and then enhancing vegf synthesis that drives ec proliferation . NULL NULL NULL NULL NULL NULL NULL 
1 activating mapk and then enhancing vegf synthesis that drives ec proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL thus , 20-hete may be involved in the regulation of ec functions , such as angiogenesis 
16 NULL NULL thus , 20-hete may be involved in the regulation of ec functions , such as angiogenesis . NULL NULL 
0 , 20-hete may be involved in the regulation of ec functions , such as angiogenesis . NULL NULL NULL NULL NULL 
3 involved in the regulation of ec functions , such as angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL hyperforin blocks neutrophil activation of matrix metalloproteinase-9 , motility and recruitment , 
17 NULL NULL NULL NULL NULL NULL NULL hyperforin blocks neutrophil activation of matrix metalloproteinase-9 , motility and recruitment , and restrains 
0 NULL NULL NULL NULL NULL hyperforin blocks neutrophil activation of matrix metalloproteinase-9 , motility and recruitment , and restrains inflammation-triggered angiogenesis 
14 NULL NULL hyperforin blocks neutrophil activation of matrix metalloproteinase-9 , motility and recruitment , and restrains inflammation-triggered angiogenesis and lung fibrosis 
14 hyperforin blocks neutrophil activation of matrix metalloproteinase-9 , motility and recruitment , and restrains inflammation-triggered angiogenesis and lung fibrosis . NULL 
17 of matrix metalloproteinase-9 , motility and recruitment , and restrains triggered angiogenesis and lung fibrosis . NULL NULL NULL NULL NULL 
3 matrix metalloproteinase-9 , motility and recruitment , and restrains inflammation-triggered angiogenesis and lung fibrosis . NULL NULL NULL NULL NULL NULL 
0 's wort ( hypericum perforatum ) , has emerged as key player not only in the antidepressant activity of the plant 
0 has emerged as key player not only in the antidepressant activity of the plant but also as an inhibitor of bacteria 
0 the antidepressant activity of the plant but also as an inhibitor of bacteria lymphocyte and tumor cell proliferation , and matrix 
0 plant but also as an inhibitor of bacteria lymphocyte and tumor cell proliferation , and matrix proteinases . NULL NULL NULL 
1 also as an inhibitor of bacteria lymphocyte and tumor cell proliferation , and matrix proteinases . NULL NULL NULL NULL NULL 
0 inhibitor of bacteria lymphocyte and tumor cell proliferation , and matrix proteinases . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL we tested whether as well as inhibiting leukocyte elastase ( le ) activity , hyp might be 
0 whether as well as inhibiting leukocyte elastase ( le ) activity , hyp might be effective in containing both polymorphonuclear neutrophil 
16 leukocyte elastase ( le ) activity , hyp might be effective in containing both polymorphonuclear neutrophil ( pmn ) leukocyte recruitment 
14 effective in containing both polymorphonuclear neutrophil ( pmn ) leukocyte recruitment and unfavorable eventual tissue responses . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results show that , without affecting in vitro human pmn viability 
0 NULL NULL NULL NULL the results show that , without affecting in vitro human pmn viability and chemokine-receptor expression , hyp 
0 , without affecting in vitro human pmn viability and chemokine-receptor expression , hyp ( as stable dicyclohexylammonium salt ) was able 
18 hyp ( as stable dicyclohexylammonium salt ) was able to inhibit in a dose-dependent manner their chemotaxis and chemoinvasion ( ic50=1 
0 stable dicyclohexylammonium salt ) was able to inhibit in a dependent manner their chemotaxis and chemoinvasion ( ic50=1 microm for both 
14 ) was able to inhibit in a dose-dependent manner their chemotaxis and chemoinvasion ( ic50=1 microm for both ) ; this 
14 able to inhibit in a dose-dependent manner their chemotaxis and chemoinvasion ( ic50=1 microm for both ) ; this effect was 
0 and chemoinvasion ( ic50=1 microm for both ) ; this effect was associated with a reduced expression of the adhesion molecule 
0 ( ic50=1 microm for both ) ; this effect was associated with a reduced expression of the adhesion molecule cd11b by 
18 for both ) ; this effect was associated with a reduced expression of the adhesion molecule cd11b by formyl-met-leu-phe-stimulated neutrophils and 
9 both ) ; this effect was associated with a reduced expression of the adhesion molecule cd11b by formyl-met-leu-phe-stimulated neutrophils and block 
0 this effect was associated with a reduced expression of the adhesion molecule cd11b by formyl-met-leu-phe-stimulated neutrophils and block of le-triggered activation 
17 with a reduced expression of the adhesion molecule cd11b by stimulated neutrophils and block of le-triggered activation of the gelatinase matrix 
18 expression of the adhesion molecule cd11b by formyl-met-leu-phe-stimulated neutrophils and block of le-triggered activation of the gelatinase matrix metalloproteinase-9 . NULL 
17 the adhesion molecule cd11b by formyl-met-leu-phe-stimulated neutrophils and block of triggered activation of the gelatinase matrix metalloproteinase-9 . NULL NULL NULL 
17 adhesion molecule cd11b by formyl-met-leu-phe-stimulated neutrophils and block of le-triggered activation of the gelatinase matrix metalloproteinase-9 . NULL NULL NULL NULL 
0 formyl-met-leu-phe-stimulated neutrophils and block of le-triggered activation of the gelatinase matrix metalloproteinase-9 . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL triggered angiogenesis is also blocked by both local injection and daily 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL pmn-triggered angiogenesis is also blocked by both local injection and daily i.p 
18 NULL NULL NULL NULL NULL NULL pmn-triggered angiogenesis is also blocked by both local injection and daily i.p . NULL NULL 
19 NULL NULL pmn-triggered angiogenesis is also blocked by both local injection and daily i.p . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL administration of the hyp salt in an interleukin-8-induced murine model . 
17 NULL NULL NULL administration of the hyp salt in an induced murine model . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment with hyp reduces acute pmn recruitment and enhances resolution in 
18 NULL NULL NULL NULL NULL NULL NULL treatment with hyp reduces acute pmn recruitment and enhances resolution in a pulmonary bleomycin-induced 
14 NULL NULL NULL NULL treatment with hyp reduces acute pmn recruitment and enhances resolution in a pulmonary bleomycin-induced inflammation model , 
0 NULL NULL treatment with hyp reduces acute pmn recruitment and enhances resolution in a pulmonary bleomycin-induced inflammation model , significantly reducing 
0 reduces acute pmn recruitment and enhances resolution in a pulmonary induced inflammation model , significantly reducing consequent fibrosis . NULL NULL 
0 enhances resolution in a pulmonary bleomycin-induced inflammation model , significantly reducing consequent fibrosis . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate that hyp is a powerful anti-inflammatory compound with therapeutic 
0 indicate that hyp is a powerful anti-inflammatory compound with therapeutic potential , and they elucidate mechanistic keys . NULL NULL NULL 
0 NULL NULL NULL new vectors and strategies for cardiovascular gene therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL cardiovascular diseases are the major cause of morbidity and mortality in both men and women 
0 morbidity and mortality in both men and women in industrially developed countries . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL these disorders may result from impaired angiogenesis , particularly in response to hypoxia . NULL NULL 
3 NULL NULL NULL NULL these disorders may result from impaired angiogenesis , particularly in response to hypoxia . NULL NULL NULL 
0 these disorders may result from impaired angiogenesis , particularly in response to hypoxia . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL despite many limitations , gene therapy is still emerging as a potential alternative for patients who 
0 many limitations , gene therapy is still emerging as a potential alternative for patients who are not candidates for traditional revascularization 
3 potential alternative for patients who are not candidates for traditional revascularization procedures , like angioplasty or vein grafts . NULL NULL 
0 NULL NULL this review focuses on recent approaches in the development of new gene delivery vectors , with great respect to 
0 focuses on recent approaches in the development of new gene delivery vectors , with great respect to newly discovered aav serotypes 
0 NULL NULL NULL NULL moreover , some new cardiovascular gene therapy strategies have been highlighted , such as combination of different 
3 strategies have been highlighted , such as combination of different angiogenic growth factors or simultaneous application of genes and progenitor cells 
0 have been highlighted , such as combination of different angiogenic growth factors or simultaneous application of genes and progenitor cells in 
0 such as combination of different angiogenic growth factors or simultaneous application of genes and progenitor cells in order to obtain stable 
2 simultaneous application of genes and progenitor cells in order to obtain stable and functional blood vessels in ischemic tissue . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation 
5 NULL NULL NULL NULL NULL NULL NULL NULL NULL impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and 
0 NULL NULL NULL impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital 
4 impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease . 
0 basis of irreversible pulmonary hypertension ( pht ) in the clinical setting of congenital heart disease ( chd ) . NULL 
0 it is unclear why this complication is reversible after complete repair in some cases but irreversible in others . NULL NULL 
5 NULL NULL NULL NULL NULL because failure of endothelial cell apoptosis might lead to intimal proliferation and lack of reversibility of 
0 NULL NULL NULL because failure of endothelial cell apoptosis might lead to intimal proliferation and lack of reversibility of pht , 
4 because failure of endothelial cell apoptosis might lead to intimal proliferation and lack of reversibility of pht , we investigated this 
0 of reversibility of pht , we investigated this and other key markers of vasoactivity and angiogenesis in subjects with pht and 
3 we investigated this and other key markers of vasoactivity and angiogenesis in subjects with pht and chd . NULL NULL NULL 
0 with reversible and 11 with irreversible pht , and 6 control patients . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL immunostaining for endothelial nitric oxide synthase , vascular endothelial growth factor , and cd34 ( markers of vasoactivity and neoangiogenesis 
3 growth factor , and cd34 ( markers of vasoactivity and angiogenesis ) was also performed . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the antiapoptotic protein bcl-2 was highly expressed by pulmonary 
0 NULL NULL NULL NULL NULL NULL results : the antiapoptotic protein bcl-2 was highly expressed by pulmonary endothelial cells in all 
9 NULL NULL results : the antiapoptotic protein bcl-2 was highly expressed by pulmonary endothelial cells in all cases of irreversible pht 
0 but in no cases of reversible pht , nor in control patients ( p less than 0.001 ) . NULL NULL 
4 NULL NULL NULL NULL NULL NULL NULL NULL NULL intimal proliferation was present in 10 of 11 irreversible pht cases , 
0 NULL NULL NULL NULL NULL NULL NULL intimal proliferation was present in 10 of 11 irreversible pht cases , but never 
0 in 10 of 11 irreversible pht cases , but never observed in reversible pht ( p less than 0.001 ) . 
0 NULL NULL NULL NULL NULL similarly , perivascular inflammatory t-cells expressed more antiapoptotic proteins in irreversible pht ( p less than 
17 irreversible pht cases were also more likely to show compensatory upregulation of vascular endothelial growth factor and new small vessel formation 
0 also more likely to show compensatory upregulation of vascular endothelial growth factor and new small vessel formation at the sites of 
2 upregulation of vascular endothelial growth factor and new small vessel formation at the sites of native vessel stenosis or occlusion ( 
0 NULL NULL NULL NULL conclusions : irreversible pht is strongly associated with impaired endothelial cell apoptosis and antiapoptotic signaling from perivascular 
18 NULL NULL conclusions : irreversible pht is strongly associated with impaired endothelial cell apoptosis and antiapoptotic signaling from perivascular inflammatory cells 
5 : irreversible pht is strongly associated with impaired endothelial cell apoptosis and antiapoptotic signaling from perivascular inflammatory cells . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these changes are associated with intimal proliferation and vessel narrowing , and 
0 NULL NULL NULL NULL NULL NULL NULL these changes are associated with intimal proliferation and vessel narrowing , and thereby may 
4 NULL NULL NULL NULL these changes are associated with intimal proliferation and vessel narrowing , and thereby may contribute to clinical 
0 with intimal proliferation and vessel narrowing , and thereby may contribute to clinical outcomes associated with pulmonary hypertension . NULL NULL 
0 proliferation and vessel narrowing , and thereby may contribute to clinical outcomes associated with pulmonary hypertension . NULL NULL NULL NULL 
0 vessel narrowing , and thereby may contribute to clinical outcomes associated with pulmonary hypertension . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of dll4-mediated signaling induces proliferation of immature vessels and results 
17 NULL NULL NULL NULL NULL NULL NULL NULL inhibition of mediated signaling induces proliferation of immature vessels and results in poor 
17 NULL NULL NULL NULL NULL NULL inhibition of dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion 
4 NULL NULL NULL NULL NULL inhibition of dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion . 
0 inhibition of dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion . NULL NULL NULL NULL NULL 
0 induces proliferation of immature vessels and results in poor tissue perfusion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL vascular development is dependent on various growth factors and certain modifiers critical 
17 NULL NULL NULL NULL NULL NULL NULL vascular development is dependent on various growth factors and certain modifiers critical for providing 
0 NULL NULL NULL NULL vascular development is dependent on various growth factors and certain modifiers critical for providing arterial or venous 
0 development is dependent on various growth factors and certain modifiers critical for providing arterial or venous identity , interaction with the 
0 on various growth factors and certain modifiers critical for providing arterial or venous identity , interaction with the surrounding stroma and 
15 certain modifiers critical for providing arterial or venous identity , interaction with the surrounding stroma and tissues , hierarchic network formation 
2 interaction with the surrounding stroma and tissues , hierarchic network formation , and recruitment of pericytes . NULL NULL NULL NULL 
14 surrounding stroma and tissues , hierarchic network formation , and recruitment of pericytes . NULL NULL NULL NULL NULL NULL NULL 
16 NULL notch receptors and ligands ( jagged and delta-like ) play a critical role in this process in addition to vegf 
16 receptors and ligands ( jagged and delta-like ) play a critical role in this process in addition to vegf . NULL 
16 and ligands ( jagged and delta-like ) play a critical role in this process in addition to vegf . NULL NULL 
0 delta-like ) play a critical role in this process in addition to vegf . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL dll4 is one of the notch ligands that regulates arterial specification and maturation events . NULL NULL NULL NULL 
0 NULL dll4 is one of the notch ligands that regulates arterial specification and maturation events . NULL NULL NULL NULL NULL 
2 dll4 is one of the notch ligands that regulates arterial specification and maturation events . NULL NULL NULL NULL NULL NULL 
2 one of the notch ligands that regulates arterial specification and maturation events . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL in the current study , we have shown that loss of function by either targeted allele deletion or use of 
0 the current study , we have shown that loss of function by either targeted allele deletion or use of a soluble 
0 , we have shown that loss of function by either targeted allele deletion or use of a soluble form of dll4 
0 have shown that loss of function by either targeted allele deletion or use of a soluble form of dll4 extracellular domain 
0 that loss of function by either targeted allele deletion or use of a soluble form of dll4 extracellular domain leads to 
0 by either targeted allele deletion or use of a soluble form of dll4 extracellular domain leads to inhibition of notch signaling 
17 or use of a soluble form of dll4 extracellular domain leads to inhibition of notch signaling , resulting in increased vascular 
18 of a soluble form of dll4 extracellular domain leads to inhibition of notch signaling , resulting in increased vascular proliferation but 
0 dll4 extracellular domain leads to inhibition of notch signaling , resulting in increased vascular proliferation but defective maturation . NULL NULL 
17 domain leads to inhibition of notch signaling , resulting in increased vascular proliferation but defective maturation . NULL NULL NULL NULL 
4 to inhibition of notch signaling , resulting in increased vascular proliferation but defective maturation . NULL NULL NULL NULL NULL NULL 
18 of notch signaling , resulting in increased vascular proliferation but defective maturation . NULL NULL NULL NULL NULL NULL NULL NULL 
2 notch signaling , resulting in increased vascular proliferation but defective maturation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL newly forming vessels have thin caliber , a markedly reduced vessel lumen 
18 NULL newly forming vessels have thin caliber , a markedly reduced vessel lumen , markedly reduced pericyte recruitment , and deficient 
18 thin caliber , a markedly reduced vessel lumen , markedly reduced pericyte recruitment , and deficient vascular perfusion . NULL NULL 
14 , a markedly reduced vessel lumen , markedly reduced pericyte recruitment , and deficient vascular perfusion . NULL NULL NULL NULL 
0 reduced vessel lumen , markedly reduced pericyte recruitment , and deficient vascular perfusion . NULL NULL NULL NULL NULL NULL NULL 
0 lumen , markedly reduced pericyte recruitment , and deficient vascular perfusion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL sdll4 similarly induced defective vascular response in tumor implants leading to reduced tumor 
18 NULL NULL NULL NULL NULL NULL NULL sdll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth 
2 NULL NULL NULL NULL NULL sdll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth . NULL 
0 NULL NULL NULL sdll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth . NULL NULL NULL 
17 NULL sdll4 similarly induced defective vascular response in tumor implants leading to reduced tumor growth . NULL NULL NULL NULL NULL 
18 similarly induced defective vascular response in tumor implants leading to reduced tumor growth . NULL NULL NULL NULL NULL NULL NULL 
0 induced defective vascular response in tumor implants leading to reduced tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL 
4 defective vascular response in tumor implants leading to reduced tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL interference with dll4-notch signaling may be particularly desirable in tumors that 
17 signaling may be particularly desirable in tumors that have highly induced dll4-notch pathway . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL an antibody directed against pdgf receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-vegf receptor 
3 directed against pdgf receptor beta enhances the antitumor and the angiogenic activities of an anti-vegf receptor 2 antibody . NULL NULL 
18 against pdgf receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-vegf receptor 2 antibody . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL derived growth factor ( pdgf ) and its receptors ( pdgfr 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL platelet-derived growth factor ( pdgf ) and its receptors ( pdgfr ) 
0 factor ( pdgf ) and its receptors ( pdgfr ) play important roles in tumorigenesis through stimulating tumor growth and promoting 
0 ( pdgf ) and its receptors ( pdgfr ) play important roles in tumorigenesis through stimulating tumor growth and promoting angiogenesis 
0 pdgf ) and its receptors ( pdgfr ) play important roles in tumorigenesis through stimulating tumor growth and promoting angiogenesis via 
17 receptors ( pdgfr ) play important roles in tumorigenesis through stimulating tumor growth and promoting angiogenesis via enhancing pericyte recruitment and 
0 ( pdgfr ) play important roles in tumorigenesis through stimulating tumor growth and promoting angiogenesis via enhancing pericyte recruitment and vessel 
4 pdgfr ) play important roles in tumorigenesis through stimulating tumor growth and promoting angiogenesis via enhancing pericyte recruitment and vessel maturation 
17 play important roles in tumorigenesis through stimulating tumor growth and promoting angiogenesis via enhancing pericyte recruitment and vessel maturation . NULL 
3 important roles in tumorigenesis through stimulating tumor growth and promoting angiogenesis via enhancing pericyte recruitment and vessel maturation . NULL NULL 
17 in tumorigenesis through stimulating tumor growth and promoting angiogenesis via enhancing pericyte recruitment and vessel maturation . NULL NULL NULL NULL 
14 through stimulating tumor growth and promoting angiogenesis via enhancing pericyte recruitment and vessel maturation . NULL NULL NULL NULL NULL NULL 
2 growth and promoting angiogenesis via enhancing pericyte recruitment and vessel maturation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL here we produced a neutralizing antibody , 1b3 , directed against mouse pdgfrbeta 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL 1b3 binds to pdgfrbeta with high affinity ( 9x10 ( -11 ) 
0 NULL NULL NULL NULL 1b3 binds to pdgfrbeta with high affinity ( 9x10 ( -11 ) m ) and blocks pdgf-bb 
18 high affinity ( 9x10 ( -11 ) m ) and blocks pdgf-bb from binding to the receptor with an ic ( 
15 9x10 ( -11 ) m ) and blocks pdgf-bb from binding to the receptor with an ic ( 50 ) of 
18 NULL NULL NULL NULL NULL NULL NULL the antibody also blocks ligand-stimulated activation of pdgfrbeta and downstream signaling molecules , including 
0 NULL NULL NULL NULL NULL NULL the antibody also blocks stimulated activation of pdgfrbeta and downstream signaling molecules , including akt 
17 NULL NULL NULL NULL NULL the antibody also blocks ligand-stimulated activation of pdgfrbeta and downstream signaling molecules , including akt and 
0 NULL the antibody also blocks ligand-stimulated activation of pdgfrbeta and downstream signaling molecules , including akt and mapk p42/44 , in 
0 signaling molecules , including akt and mapk p42/44 , in tumor cells . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL in animal studies , 1b3 significantly enhanced the antitumor and the anti-angiogenic activities of dc101 , an 
3 animal studies , 1b3 significantly enhanced the antitumor and the angiogenic activities of dc101 , an antibody directed against mouse vascular 
18 studies , 1b3 significantly enhanced the antitumor and the anti-angiogenic activities of dc101 , an antibody directed against mouse vascular endothelial 
0 of dc101 , an antibody directed against mouse vascular endothelial growth factor receptor 2 , in a pancreatic ( bxpc-3 ) 
0 bxpc-3 ) and a non-small cell lung ( nci-h460 ) tumor xenograft models . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment with the combination of 1b3 and dc101 in bxpc-3 xenograft-bearing 
17 the combination of 1b3 and dc101 in bxpc-3 xenograft-bearing mice resulted in tumor regression in 58 % of mice compared to 
0 of 1b3 and dc101 in bxpc-3 xenograft-bearing mice resulted in tumor regression in 58 % of mice compared to that in 
18 1b3 and dc101 in bxpc-3 xenograft-bearing mice resulted in tumor regression in 58 % of mice compared to that in 18 
19 of mice compared to that in 18 % of mice treated with dc101 alone . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL taken together , these results lend great support to use pdgfrbeta antagonists in combinations with 
0 NULL NULL NULL taken together , these results lend great support to use pdgfrbeta antagonists in combinations with other antitumor and/or 
0 NULL taken together , these results lend great support to use pdgfrbeta antagonists in combinations with other antitumor and/or anti-angiogenic agents 
3 to use pdgfrbeta antagonists in combinations with other antitumor and/or angiogenic agents in the treatment of a variety of cancers . 
19 in combinations with other antitumor and/or anti-angiogenic agents in the treatment of a variety of cancers . NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha , vascular endothelial growth factor 
0 NULL NULL NULL NULL NULL NULL NULL NULL caffeine inhibits induced accumulation of hypoxia-inducible factor-1alpha , vascular endothelial growth factor , 
17 NULL NULL NULL NULL NULL NULL NULL caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha , vascular endothelial growth factor , and 
0 NULL NULL NULL NULL NULL caffeine inhibits adenosine-induced accumulation of inducible factor-1alpha , vascular endothelial growth factor , and interleukin-8 expression 
0 caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha , vascular endothelial growth factor , and interleukin-8 expression in hypoxic human colon cancer 
9 hypoxia-inducible factor-1alpha , vascular endothelial growth factor , and interleukin-8 expression in hypoxic human colon cancer cells . NULL NULL NULL 
0 NULL NULL NULL NULL NULL frequent coffee consumption has been associated with a reduced risk of colorectal cancer in a number 
0 NULL NULL frequent coffee consumption has been associated with a reduced risk of colorectal cancer in a number of case-control studies 
0 a reduced risk of colorectal cancer in a number of control studies . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL coffee is a leading source of methylxanthines , such as caffeine . NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the induction of vascular endothelial growth factor ( vegf ) and interleukin-8 
0 NULL NULL NULL NULL NULL the induction of vascular endothelial growth factor ( vegf ) and interleukin-8 ( il-8 ) is 
17 ( vegf ) and interleukin-8 ( il-8 ) is an essential feature of tumor angiogenesis , and the hypoxia-inducible factor-1 ( 
0 and interleukin-8 ( il-8 ) is an essential feature of tumor angiogenesis , and the hypoxia-inducible factor-1 ( hif-1 ) transcription 
3 interleukin-8 ( il-8 ) is an essential feature of tumor angiogenesis , and the hypoxia-inducible factor-1 ( hif-1 ) transcription factor 
0 is an essential feature of tumor angiogenesis , and the inducible factor-1 ( hif-1 ) transcription factor is known to be 
0 tumor angiogenesis , and the hypoxia-inducible factor-1 ( hif-1 ) transcription factor is known to be a key regulator of this 
0 ( hif-1 ) transcription factor is known to be a key regulator of this process . NULL NULL NULL NULL NULL 
0 hif-1 ) transcription factor is known to be a key regulator of this process . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL in this study , we investigated the effects of caffeine on hif-1 protein accumulation and on vegf and 
0 study , we investigated the effects of caffeine on hif-1 protein accumulation and on vegf and il-8 expression in the human 
17 , we investigated the effects of caffeine on hif-1 protein accumulation and on vegf and il-8 expression in the human colon 
9 caffeine on hif-1 protein accumulation and on vegf and il-8 expression in the human colon cancer cell line ht29 under hypoxic 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL our results show that caffeine significantly inhibits adenosine-induced hif-1alpha protein accumulation in 
18 NULL NULL NULL NULL our results show that caffeine significantly inhibits adenosine-induced hif-1alpha protein accumulation in cancer cells . NULL NULL 
17 NULL NULL NULL our results show that caffeine significantly inhibits induced hif-1alpha protein accumulation in cancer cells . NULL NULL NULL 
0 NULL our results show that caffeine significantly inhibits adenosine-induced hif-1alpha protein accumulation in cancer cells . NULL NULL NULL NULL NULL 
17 our results show that caffeine significantly inhibits adenosine-induced hif-1alpha protein accumulation in cancer cells . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL we show that hif-1alpha and vegf are increased through a3 adenosine receptor stimulation , whereas the effects on 
17 that hif-1alpha and vegf are increased through a3 adenosine receptor stimulation , whereas the effects on il-8 are mediated via the 
16 are increased through a3 adenosine receptor stimulation , whereas the effects on il-8 are mediated via the a2b subtype . NULL 
16 adenosine receptor stimulation , whereas the effects on il-8 are mediated via the a2b subtype . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL pretreatment of cells with caffeine significantly reduces adenosine-induced vegf promoter activity 
18 NULL NULL NULL NULL pretreatment of cells with caffeine significantly reduces adenosine-induced vegf promoter activity and vegf and il-8 expression . 
17 NULL NULL NULL pretreatment of cells with caffeine significantly reduces induced vegf promoter activity and vegf and il-8 expression . NULL 
0 pretreatment of cells with caffeine significantly reduces adenosine-induced vegf promoter activity and vegf and il-8 expression . NULL NULL NULL NULL 
9 significantly reduces adenosine-induced vegf promoter activity and vegf and il-8 expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the mechanism of caffeine seems to involve the inhibition of the extracellular 
16 NULL NULL NULL NULL the mechanism of caffeine seems to involve the inhibition of the extracellular signal-regulated kinase 1/2 ( erk1/2 
18 NULL NULL the mechanism of caffeine seems to involve the inhibition of the extracellular signal-regulated kinase 1/2 ( erk1/2 ) , 
0 of caffeine seems to involve the inhibition of the extracellular regulated kinase 1/2 ( erk1/2 ) , p38 , and akt 
17 1/2 ( erk1/2 ) , p38 , and akt , leading to a marked decrease in adenosine-induced hif-1alpha accumulation , vegf 
18 , p38 , and akt , leading to a marked decrease in adenosine-induced hif-1alpha accumulation , vegf transcriptional activation , and 
17 , and akt , leading to a marked decrease in induced hif-1alpha accumulation , vegf transcriptional activation , and vegf and 
17 akt , leading to a marked decrease in adenosine-induced hif-1alpha accumulation , vegf transcriptional activation , and vegf and il-8 protein 
10 to a marked decrease in adenosine-induced hif-1alpha accumulation , vegf transcriptional activation , and vegf and il-8 protein accumulation . NULL 
17 a marked decrease in adenosine-induced hif-1alpha accumulation , vegf transcriptional activation , and vegf and il-8 protein accumulation . NULL NULL 
0 accumulation , vegf transcriptional activation , and vegf and il-8 protein accumulation . NULL NULL NULL NULL NULL NULL NULL NULL 
17 , vegf transcriptional activation , and vegf and il-8 protein accumulation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 a functional perspective , we observe that caffeine also significantly inhibits the a3 receptor-stimulated cell migration of colon cancer cells . 
17 , we observe that caffeine also significantly inhibits the a3 stimulated cell migration of colon cancer cells . NULL NULL NULL 
14 observe that caffeine also significantly inhibits the a3 receptor-stimulated cell migration of colon cancer cells . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL conditioned media prepared from colon cells treated with an adenosine analog increased human umbilical vein endothelial cell 
17 media prepared from colon cells treated with an adenosine analog increased human umbilical vein endothelial cell migration . NULL NULL NULL 
14 with an adenosine analog increased human umbilical vein endothelial cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL these data provide evidence that adenosine could modulate the migration of colon cancer cells by an hif-1alpha/vegf/il-8-dependent mechanism 
14 NULL these data provide evidence that adenosine could modulate the migration of colon cancer cells by an hif-1alpha/vegf/il-8-dependent mechanism and that 
17 could modulate the migration of colon cancer cells by an dependent mechanism and that caffeine has the potential to inhibit colon 
0 modulate the migration of colon cancer cells by an hif-1alpha/vegf/il-8-dependent mechanism and that caffeine has the potential to inhibit colon cancer 
0 cells by an hif-1alpha/vegf/il-8-dependent mechanism and that caffeine has the potential to inhibit colon cancer cell growth . NULL NULL NULL 
18 an hif-1alpha/vegf/il-8-dependent mechanism and that caffeine has the potential to inhibit colon cancer cell growth . NULL NULL NULL NULL NULL 
1 that caffeine has the potential to inhibit colon cancer cell growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL medical therapy for intermittent claudication . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL medical therapy to improve symptoms , stabilise the underlying vascular disease and 
0 NULL NULL NULL NULL NULL NULL NULL medical therapy to improve symptoms , stabilise the underlying vascular disease and improve lower 
0 to improve symptoms , stabilise the underlying vascular disease and improve lower limb outcomes is an important and effective adjunct to 
0 underlying vascular disease and improve lower limb outcomes is an important and effective adjunct to lifestyle modification and surgical or endovascular 
0 disease and improve lower limb outcomes is an important and effective adjunct to lifestyle modification and surgical or endovascular interventions in 
0 is an important and effective adjunct to lifestyle modification and surgical or endovascular interventions in patients with ic . NULL NULL 
0 and effective adjunct to lifestyle modification and surgical or endovascular interventions in patients with ic . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL randomised placebo controlled trials have shown that the phosphodiesterase iii inhibitor 
0 NULL NULL NULL NULL NULL NULL NULL NULL randomised placebo controlled trials have shown that the phosphodiesterase iii inhibitor cilostazol 100mg 
0 NULL NULL NULL NULL NULL NULL NULL randomised placebo controlled trials have shown that the phosphodiesterase iii inhibitor cilostazol 100mg bid 
0 randomised placebo controlled trials have shown that the phosphodiesterase iii inhibitor cilostazol 100mg bid improves pain-free and maximum walking distance , 
0 have shown that the phosphodiesterase iii inhibitor cilostazol 100mg bid improves pain-free and maximum walking distance , as well as quality 
0 shown that the phosphodiesterase iii inhibitor cilostazol 100mg bid improves free and maximum walking distance , as well as quality of 
5 intermittent claudication in whom there is no evidence of tissue necrosis or rest pain . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL this review summarises the evidence from 8 pivotal trials of cilostazol involving over 2000 patients with intermittent claudication 
0 NULL NULL this review summarises the evidence from 8 pivotal trials of cilostazol involving over 2000 patients with intermittent claudication treated 
0 review summarises the evidence from 8 pivotal trials of cilostazol involving over 2000 patients with intermittent claudication treated for up to 
19 trials of cilostazol involving over 2000 patients with intermittent claudication treated for up to 6 months . NULL NULL NULL NULL 
0 NULL NULL NULL NULL there is comparatively less evidence to support the use of other treatment modalities for relief of symptoms 
0 NULL NULL there is comparatively less evidence to support the use of other treatment modalities for relief of symptoms in intermittent 
0 is comparatively less evidence to support the use of other treatment modalities for relief of symptoms in intermittent claudication , but 
3 intermittent claudication , but there is considerable interest in therapeutic angiogenesis to promote new vessel formation and enhance collateralisation of the 
17 , but there is considerable interest in therapeutic angiogenesis to promote new vessel formation and enhance collateralisation of the lower limb 
2 is considerable interest in therapeutic angiogenesis to promote new vessel formation and enhance collateralisation of the lower limb using recombinant growth 
17 interest in therapeutic angiogenesis to promote new vessel formation and enhance collateralisation of the lower limb using recombinant growth factor proteins 
3 in therapeutic angiogenesis to promote new vessel formation and enhance collateralisation of the lower limb using recombinant growth factor proteins or 
0 formation and enhance collateralisation of the lower limb using recombinant growth factor proteins or gene transfer strategies . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL the rationale for therapeutic angiogenesis is discussed , together with the most recent results from 
0 therapeutic angiogenesis is discussed , together with the most recent results from randomised trials in patients with peripheral arterial disease . 
19 is discussed , together with the most recent results from randomised trials in patients with peripheral arterial disease . NULL NULL 
19 discussed , together with the most recent results from randomised trials in patients with peripheral arterial disease . NULL NULL NULL 
0 most recent results from randomised trials in patients with peripheral arterial disease . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL an assay to measure angiogenesis in human fat tissue . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL background : inhibition of angiogenesis reverses rodent obesity . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL background : inhibition of angiogenesis reverses rodent obesity . NULL NULL NULL NULL NULL NULL 
16 assay in human fat tissue is needed to study the role of angiogenesis in human obesity . NULL NULL NULL NULL 
3 human fat tissue is needed to study the role of angiogenesis in human obesity . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL methods : human fat tissue fragments from surgery were placed in 96-well plates , embedded in fibrin thrombin 
19 NULL methods : human fat tissue fragments from surgery were placed in 96-well plates , embedded in fibrin thrombin clot and 
19 tissue fragments from surgery were placed in 96-well plates , embedded in fibrin thrombin clot and overlaid with cell culture media 
19 in 96-well plates , embedded in fibrin thrombin clot and overlaid with cell culture media containing 20 % fetal bovine serum 
19 , embedded in fibrin thrombin clot and overlaid with cell culture media containing 20 % fetal bovine serum . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effect of taxol , cobalt chloride and a heparin-steroid combination was 
3 tissue assay and compared to the validated human placental vein angiogenesis model ( hpvam ) . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : blood vessels initiated growth and elongated from the fat 
17 NULL NULL NULL NULL NULL NULL results : blood vessels initiated growth and elongated from the fat tissue fragments over 15 
4 NULL NULL NULL NULL NULL results : blood vessels initiated growth and elongated from the fat tissue fragments over 15 days 
4 NULL NULL NULL results : blood vessels initiated growth and elongated from the fat tissue fragments over 15 days . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL presence of blood vessels was confirmed with histology and electron microscopy 
18 ( -6 ) and 10 ( -7 ) m completely inhibited angiogenesis , while taxol 10 ( -8 ) and 10 
3 -6 ) and 10 ( -7 ) m completely inhibited angiogenesis , while taxol 10 ( -8 ) and 10 ( 
18 and 10 ( -9 ) m and the heparin-steroid partially inhibited angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 10 ( -9 ) m and the heparin-steroid partially inhibited angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the response to taxol and heparin-steroid was similar to that of the 
3 was similar to that of the hpvam , a validated angiogenesis assay . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL cobalt chloride , a stimulator of vascular endothelial growth factor ( vegf ) stimulated angiogenesis initiation at 10 ( 
17 a stimulator of vascular endothelial growth factor ( vegf ) stimulated angiogenesis initiation at 10 ( -9 ) m in fat 
3 stimulator of vascular endothelial growth factor ( vegf ) stimulated angiogenesis initiation at 10 ( -9 ) m in fat tissue 
17 of vascular endothelial growth factor ( vegf ) stimulated angiogenesis initiation at 10 ( -9 ) m in fat tissue and 
4 , but at 10 ( -10 ) m blood vessel growth was stimulated only in the fat assay . NULL NULL 
17 at 10 ( -10 ) m blood vessel growth was stimulated only in the fat assay . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL conclusion : this angiogenesis assay based on human fat tissue uses three-dimensionally intact human 
0 NULL NULL NULL NULL NULL NULL NULL the vessels are derived from quiescient vessels within the fat . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these properties allow the angiogenic switch to be evaluated in an in 
3 NULL NULL NULL NULL NULL NULL these properties allow the angiogenic switch to be evaluated in an in vitro setting . 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic response of fat tissue is not identical to placental tissue 
0 NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic response of fat tissue is not identical to placental tissue . 
17 NULL NULL NULL NULL NULL NULL NULL this assay allows exploration of angiogenesis in fat tissue . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL this assay allows exploration of angiogenesis in fat tissue . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL ovarian cancers overexpress the antimicrobial protein hcap-18 and its derivative ll-37 increases ovarian 
0 NULL NULL NULL NULL NULL ovarian cancers overexpress the antimicrobial protein hcap-18 and its derivative ll-37 increases ovarian cancer cell proliferation 
17 cancers overexpress the antimicrobial protein hcap-18 and its derivative ll-37 increases ovarian cancer cell proliferation and invasion . NULL NULL NULL 
1 protein hcap-18 and its derivative ll-37 increases ovarian cancer cell proliferation and invasion . NULL NULL NULL NULL NULL NULL NULL 
14 and its derivative ll-37 increases ovarian cancer cell proliferation and invasion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the role of the pro-inflammatory peptide , ll-37 , and its pro-form 
0 role of the pro-inflammatory peptide , ll-37 , and its form , human cationic antimicrobial protein 18 ( hcap-18 ) , 
0 , ll-37 , and its pro-form , human cationic antimicrobial protein 18 ( hcap-18 ) , in cancer development and progression 
2 cationic antimicrobial protein 18 ( hcap-18 ) , in cancer development and progression is poorly understood . NULL NULL NULL NULL 
2 protein 18 ( hcap-18 ) , in cancer development and progression is poorly understood . NULL NULL NULL NULL NULL NULL 
6 NULL NULL NULL NULL NULL NULL NULL NULL NULL in damaged and inflamed tissue , ll-37 functions as a chemoattractant , 
0 NULL NULL NULL in damaged and inflamed tissue , ll-37 functions as a chemoattractant , mitogen and pro-angiogenic factor suggesting that 
3 tissue , ll-37 functions as a chemoattractant , mitogen and angiogenic factor suggesting that the peptide may potentiate tumor progression . 
0 mitogen and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 and pro-angiogenic factor suggesting that the peptide may potentiate tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL the aim of this study was to characterize the distribution of hcap-18/ll-37 in normal and cancerous ovarian tissue and to 
16 in normal and cancerous ovarian tissue and to examine the effects of ll-37 on ovarian cancer cells . NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of hcap-18/ll-37 was localized to immune and granulosa cells of 
14 NULL NULL NULL NULL NULL NULL expression of hcap-18/ll-37 was localized to immune and granulosa cells of normal ovarian tissue . 
0 NULL NULL by contrast , ovarian tumors displayed significantly higher levels of hcap-18/ll-37 where expression was observed in tumor and stromal 
9 , ovarian tumors displayed significantly higher levels of hcap-18/ll-37 where expression was observed in tumor and stromal cells . NULL NULL 
0 tumors displayed significantly higher levels of hcap-18/ll-37 where expression was observed in tumor and stromal cells . NULL NULL NULL NULL 
0 significantly higher levels of hcap-18/ll-37 where expression was observed in tumor and stromal cells . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL protein expression was statistically compared to the degree of immune cell 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL protein expression was statistically compared to the degree of immune cell infiltration 
14 expression was statistically compared to the degree of immune cell infiltration and microvessel density in epithelial-derived ovarian tumors and a significant 
0 the degree of immune cell infiltration and microvessel density in derived ovarian tumors and a significant correlation was observed for both 
0 infiltration and microvessel density in epithelial-derived ovarian tumors and a significant correlation was observed for both . NULL NULL NULL NULL 
0 density in epithelial-derived ovarian tumors and a significant correlation was observed for both . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL it was demonstrated that ovarian tumor tissue lysates and ovarian cancer cell lines express hcap-18/ll-37 . 
9 that ovarian tumor tissue lysates and ovarian cancer cell lines express hcap-18/ll-37 . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment of ovarian cancer cell lines with recombinant ll-37 stimulated proliferation 
17 NULL treatment of ovarian cancer cell lines with recombinant ll-37 stimulated proliferation , chemotaxis , invasion and matrix metalloproteinase expression . 
1 treatment of ovarian cancer cell lines with recombinant ll-37 stimulated proliferation , chemotaxis , invasion and matrix metalloproteinase expression . NULL 
14 ovarian cancer cell lines with recombinant ll-37 stimulated proliferation , chemotaxis , invasion and matrix metalloproteinase expression . NULL NULL NULL 
14 cell lines with recombinant ll-37 stimulated proliferation , chemotaxis , invasion and matrix metalloproteinase expression . NULL NULL NULL NULL NULL 
0 with recombinant ll-37 stimulated proliferation , chemotaxis , invasion and matrix metalloproteinase expression . NULL NULL NULL NULL NULL NULL NULL 
9 ll-37 stimulated proliferation , chemotaxis , invasion and matrix metalloproteinase expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 data demonstrate for the first time that hcap-18/ll-37 is significantly overexpressed in ovarian tumors and suggest ll-37 may contribute to ovarian 
16 is significantly overexpressed in ovarian tumors and suggest ll-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells , 
0 tumors and suggest ll-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells , initiation of angiogenesis and recruitment 
17 and suggest ll-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells , initiation of angiogenesis and recruitment of 
0 ll-37 may contribute to ovarian tumorigenesis through direct stimulation of tumor cells , initiation of angiogenesis and recruitment of immune cells 
17 to ovarian tumorigenesis through direct stimulation of tumor cells , initiation of angiogenesis and recruitment of immune cells . NULL NULL 
3 tumorigenesis through direct stimulation of tumor cells , initiation of angiogenesis and recruitment of immune cells . NULL NULL NULL NULL 
14 direct stimulation of tumor cells , initiation of angiogenesis and recruitment of immune cells . NULL NULL NULL NULL NULL NULL 
2 of the existing relationship between pro-inflammatory molecules and ovarian cancer progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL role of telomeres in vascular senescence . NULL NULL NULL NULL 
0 NULL NULL NULL specific proteins associate with the telomeres and form non-nucleosomal dna-protein complexes that serve as protective caps for the 
0 NULL specific proteins associate with the telomeres and form non-nucleosomal protein complexes that serve as protective caps for the chromosome ends 
0 been reported to occur in human atherosclerotic lesions and this change is associated with telomere shortening . NULL NULL NULL NULL 
0 to occur in human atherosclerotic lesions and this change is associated with telomere shortening . NULL NULL NULL NULL NULL NULL 
6 NULL NULL NULL NULL impairment of telomere integrity causes vascular dysfunction , which is prevented by the activation of telomerase . 
18 impairment of telomere integrity causes vascular dysfunction , which is prevented by the activation of telomerase . NULL NULL NULL NULL 
17 integrity causes vascular dysfunction , which is prevented by the activation of telomerase . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL mice with short telomeres develop hypertension and exhibit impaired neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL mice with short telomeres develop hypertension and exhibit impaired neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 remains unclear whether short telomeres directly cause cardiovascular disease , manipulation of telomere function is potentially an attractive strategy for the 
0 short telomeres directly cause cardiovascular disease , manipulation of telomere function is potentially an attractive strategy for the treatment of vascular 
0 of telomere function is potentially an attractive strategy for the treatment of vascular senescence . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL ectopic decorin expression up-regulates vegf expression in mouse cerebral endothelial cells via activation 
17 NULL NULL NULL NULL NULL NULL NULL ectopic decorin expression up-regulates vegf expression in mouse cerebral endothelial cells via activation of 
9 NULL NULL NULL NULL NULL ectopic decorin expression up-regulates vegf expression in mouse cerebral endothelial cells via activation of the transcription 
17 expression up-regulates vegf expression in mouse cerebral endothelial cells via activation of the transcription factors sp1 , hif1alpha , and stat3 
0 expression in mouse cerebral endothelial cells via activation of the transcription factors sp1 , hif1alpha , and stat3 . NULL NULL 
17 NULL we demonstrate that a proteoglycan decorin ( dcn ) up-regulates the vascular endothelial growth factor ( vegf ) expression with 
16 NULL we demonstrate that a proteoglycan decorin ( dcn ) up-regulates the vascular endothelial growth factor ( vegf ) expression with 
0 a proteoglycan decorin ( dcn ) up-regulates the vascular endothelial growth factor ( vegf ) expression with activation of vegf regulating 
9 ) up-regulates the vascular endothelial growth factor ( vegf ) expression with activation of vegf regulating transcription factors sp1 , hypoxia-inducible 
17 the vascular endothelial growth factor ( vegf ) expression with activation of vegf regulating transcription factors sp1 , hypoxia-inducible factor 1alpha 
16 the vascular endothelial growth factor ( vegf ) expression with activation of vegf regulating transcription factors sp1 , hypoxia-inducible factor 1alpha 
16 growth factor ( vegf ) expression with activation of vegf regulating transcription factors sp1 , hypoxia-inducible factor 1alpha ( hif1alpha ) 
0 factor ( vegf ) expression with activation of vegf regulating transcription factors sp1 , hypoxia-inducible factor 1alpha ( hif1alpha ) , 
0 expression with activation of vegf regulating transcription factors sp1 , inducible factor 1alpha ( hif1alpha ) , and signal transducer and 
0 factor 1alpha ( hif1alpha ) , and signal transducer and activator of transcription 3 ( stat3 ) via epidermal growth factor 
0 ( hif1alpha ) , and signal transducer and activator of transcription 3 ( stat3 ) via epidermal growth factor receptor ( 
0 and activator of transcription 3 ( stat3 ) via epidermal growth factor receptor ( egfr ) , mitogen-activated protein kinase extracellular 
0 ) via epidermal growth factor receptor ( egfr ) , activated protein kinase extracellular signal-regulated kinase 1/2 ( erk1/2 ) , 
0 via epidermal growth factor receptor ( egfr ) , mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 ( erk1/2 ) , and 
0 factor receptor ( egfr ) , mitogen-activated protein kinase extracellular regulated kinase 1/2 ( erk1/2 ) , and protein kinase b 
0 kinase extracellular signal-regulated kinase 1/2 ( erk1/2 ) , and protein kinase b ( akt ) pathways in dcn transfected mouse 
0 erk1/2 ) , and protein kinase b ( akt ) pathways in dcn transfected mouse cerebral endothelial ( mce ) cells 
19 and protein kinase b ( akt ) pathways in dcn transfected mouse cerebral endothelial ( mce ) cells . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment with pharmacological inhibitors and small interfering rnas reveal that induction 
17 treatment with pharmacological inhibitors and small interfering rnas reveal that induction and activation of sp1 , hif1alpha , and stat3 facilitate 
17 pharmacological inhibitors and small interfering rnas reveal that induction and activation of sp1 , hif1alpha , and stat3 facilitate their nuclear 
14 of sp1 , hif1alpha , and stat3 facilitate their nuclear localization and binding to their specific motifs of the vegf promoter 
15 , hif1alpha , and stat3 facilitate their nuclear localization and binding to their specific motifs of the vegf promoter and induce 
17 binding to their specific motifs of the vegf promoter and induce vegf expression via two independent pathways , dcn/egfr/phosphoinositide-3 kinase/akt and 
9 their specific motifs of the vegf promoter and induce vegf expression via two independent pathways , dcn/egfr/phosphoinositide-3 kinase/akt and dcn/egfr/erk1/2 , 
0 of the vegf promoter and induce vegf expression via two independent pathways , dcn/egfr/phosphoinositide-3 kinase/akt and dcn/egfr/erk1/2 , respectively , in 
0 the vegf promoter and induce vegf expression via two independent pathways , dcn/egfr/phosphoinositide-3 kinase/akt and dcn/egfr/erk1/2 , respectively , in dcn 
9 , dcn/egfr/phosphoinositide-3 kinase/akt and dcn/egfr/erk1/2 , respectively , in dcn synthesizing mce cells . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL the cell type specific glycosylation protects sp1 and hif1alpha from proteosome degradation and plays an important 
11 cell type specific glycosylation protects sp1 and hif1alpha from proteosome degradation and plays an important and novel role in the regulation 
0 specific glycosylation protects sp1 and hif1alpha from proteosome degradation and plays an important and novel role in the regulation of vegf 
0 protects sp1 and hif1alpha from proteosome degradation and plays an important and novel role in the regulation of vegf in dcn 
0 hif1alpha from proteosome degradation and plays an important and novel role in the regulation of vegf in dcn transfected mce cells 
16 degradation and plays an important and novel role in the regulation of vegf in dcn transfected mce cells . NULL NULL 
19 and novel role in the regulation of vegf in dcn transfected mce cells . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL induction of gelatinases ( matrix metalloproteinase 2 and 9 ) , 
0 NULL NULL NULL NULL NULL NULL induction of gelatinases ( matrix metalloproteinase 2 and 9 ) , the serine protease tissue 
0 2 and 9 ) , the serine protease tissue plasminogen activator and plasmin by dcn transfection in mce cells leads to 
19 the serine protease tissue plasminogen activator and plasmin by dcn transfection in mce cells leads to extracellular proteolysis and to release 
17 plasminogen activator and plasmin by dcn transfection in mce cells leads to extracellular proteolysis and to release of matrix-bound vegf and 
0 plasmin by dcn transfection in mce cells leads to extracellular proteolysis and to release of matrix-bound vegf and activation of angiogenesis 
0 transfection in mce cells leads to extracellular proteolysis and to release of matrix-bound vegf and activation of angiogenesis . NULL NULL 
15 mce cells leads to extracellular proteolysis and to release of matrix vegf and activation of angiogenesis . NULL NULL NULL NULL 
15 mce cells leads to extracellular proteolysis and to release of bound vegf and activation of angiogenesis . NULL NULL NULL NULL 
17 to extracellular proteolysis and to release of matrix-bound vegf and activation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 proteolysis and to release of matrix-bound vegf and activation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in this study , we demonstrate that two independent downstream signal pathways , dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate 
0 NULL in this study , we demonstrate that two independent downstream signal pathways , dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation 
0 this study , we demonstrate that two independent downstream signal pathways , dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation and activation 
17 independent downstream signal pathways , dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation and activation of transcription factors of vegf such as 
17 downstream signal pathways , dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation and activation of transcription factors of vegf such as hif1alpha 
17 pathways , dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation and activation of transcription factors of vegf such as hif1alpha , stat3 
0 dcn/egfr/erk1/2 and dcn/egfr/phosphoinositide-3 kinase/akt , mediate up-regulation and activation of transcription factors of vegf such as hif1alpha , stat3 , and 
17 vegf such as hif1alpha , stat3 , and sp1 and increase vegf transcription and angiogenesis in mce cells . NULL NULL 
10 as hif1alpha , stat3 , and sp1 and increase vegf transcription and angiogenesis in mce cells . NULL NULL NULL NULL 
3 , stat3 , and sp1 and increase vegf transcription and angiogenesis in mce cells . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor microenvironment , a dangerous society leading to cancer metastasis . 
0 NULL NULL NULL NULL tumor microenvironment , a dangerous society leading to cancer metastasis . NULL NULL NULL NULL NULL NULL 
14 NULL tumor microenvironment , a dangerous society leading to cancer metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL from mechanisms to therapy and prevention . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL from mechanisms to therapy and prevention . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL NULL NULL NULL NULL NULL to grow , invade and metastasize , a treacherous society between cancer 
14 NULL NULL NULL NULL NULL NULL NULL to grow , invade and metastasize , a treacherous society between cancer and host 
14 NULL NULL NULL NULL NULL to grow , invade and metastasize , a treacherous society between cancer and host cells must 
0 a treacherous society between cancer and host cells must be formed , and this association provides novel and effective clinical targets 
0 cancer and host cells must be formed , and this association provides novel and effective clinical targets for cancer control and 
0 must be formed , and this association provides novel and effective clinical targets for cancer control and prevention . NULL NULL 
0 be formed , and this association provides novel and effective clinical targets for cancer control and prevention . NULL NULL NULL 
0 formed , and this association provides novel and effective clinical targets for cancer control and prevention . NULL NULL NULL NULL 
16 this association provides novel and effective clinical targets for cancer control and prevention . NULL NULL NULL NULL NULL NULL NULL 
18 provides novel and effective clinical targets for cancer control and prevention . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 of reviews at the front-edge of scientific knowledge focuses on tumor cell interactions , the disastrous consequences they can produce and 
15 at the front-edge of scientific knowledge focuses on host-tumor cell interactions , the disastrous consequences they can produce and approaches the 
0 on host-tumor cell interactions , the disastrous consequences they can produce and approaches the ways to break up these cellular conspiracies 
0 to break up these cellular conspiracies , to leave the tumor cells unattended and vulnerable . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effects of spironolactone on corneal allograft survival in the rat . 
5 NULL NULL NULL NULL effects of spironolactone on corneal allograft survival in the rat . NULL NULL NULL NULL NULL NULL 
0 purpose : spironolactone has recently been shown to have suppressive effects on several immunoactive and proinflammatory cytokines . NULL NULL NULL 
16 NULL NULL NULL in this study , we investigated the effects of spironolactone on the prevention of corneal allograft rejection in 
18 study , we investigated the effects of spironolactone on the prevention of corneal allograft rejection in a mhc class i/ii mismatch 
5 the effects of spironolactone on the prevention of corneal allograft rejection in a mhc class i/ii mismatch rat corneal transplant model 
19 allograft rejection in a mhc class i/ii mismatch rat corneal transplant model . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL methods : grafted animals for corneal survival analysis were assigned to receive either 
5 NULL NULL NULL NULL methods : grafted animals for corneal survival analysis were assigned to receive either spironolactone suspension ( orally 
0 volume as spironolactone , n = 9 ) or remained untreated ( n = 16 ) . NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL additional grafted rats treated with spironolactone ( n = 6 ) or 
19 NULL NULL NULL NULL NULL NULL NULL additional grafted rats treated with spironolactone ( n = 6 ) or pbs ( 
19 6 ) or pbs ( n = 8 ) were sacrificed on day 12 for quantitative rt-pcr analysis for mechanistic studies 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : mean ( +/-sem ) graft survival was significantly prolonged 
5 NULL NULL NULL results : mean ( +/-sem ) graft survival was significantly prolonged in animals receiving spironolactone ( 14.9 +/- 
17 results : mean ( +/-sem ) graft survival was significantly prolonged in animals receiving spironolactone ( 14.9 +/- 2.0 days ) 
19 ( +/-sem ) graft survival was significantly prolonged in animals receiving spironolactone ( 14.9 +/- 2.0 days ) compared with both 
19 spironolactone ( 14.9 +/- 2.0 days ) compared with both treated ( 12.3 +/- 1.2 days , p = 0.007 ) 
19 12.3 +/- 1.2 days , p = 0.007 ) and untreated controls ( 13.0 +/- 1.0 days , p = 0.01 
0 +/- 1.2 days , p = 0.007 ) and untreated controls ( 13.0 +/- 1.0 days , p = 0.01 ) 
18 NULL NULL NULL NULL NULL NULL NULL we found a decrease in corneal neovascularization in spironolactone-treated rats compared with the pbs-treated 
3 NULL NULL NULL NULL we found a decrease in corneal neovascularization in spironolactone-treated rats compared with the pbs-treated group , although 
19 NULL NULL we found a decrease in corneal neovascularization in treated rats compared with the pbs-treated group , although the difference 
19 decrease in corneal neovascularization in spironolactone-treated rats compared with the treated group , although the difference was not statistically significant . 
0 the pbs-treated group , although the difference was not statistically significant . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL spironolactone affected both systemic ( down-regulation of cd25+ cells in spleen ) 
18 NULL NULL NULL NULL NULL spironolactone affected both systemic ( down-regulation of cd25+ cells in spleen ) and local immune response 
0 down-regulation of cd25+ cells in spleen ) and local immune response ( up-regulation of il-10 in cornea ) . NULL NULL 
17 cd25+ cells in spleen ) and local immune response ( up-regulation of il-10 in cornea ) . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusion : we present initial results demonstrating anti-inflammatory effects of spironolactone . NULL NULL 
0 NULL NULL NULL NULL NULL conclusion : we present initial results demonstrating anti-inflammatory effects of spironolactone . NULL NULL NULL NULL 
0 NULL NULL conclusion : we present initial results demonstrating anti-inflammatory effects of spironolactone . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL [ photodynamic therapy in severe chronic central serous chorioretinopaty ] NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL [ photodynamic therapy in severe chronic central serous chorioretinopaty ] NULL NULL NULL 
0 NULL NULL NULL NULL [ photodynamic therapy in severe chronic central serous chorioretinopaty ] NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL objective : to determine the efficacy of photodynamic therapy ( pdt ) in chronic central serous 
0 NULL NULL NULL objective : to determine the efficacy of photodynamic therapy ( pdt ) in chronic central serous chorioretinopathy ( 
0 NULL NULL objective : to determine the efficacy of photodynamic therapy ( pdt ) in chronic central serous chorioretinopathy ( csc 
0 objective : to determine the efficacy of photodynamic therapy ( pdt ) in chronic central serous chorioretinopathy ( csc ) . 
0 the efficacy of photodynamic therapy ( pdt ) in chronic central serous chorioretinopathy ( csc ) . NULL NULL NULL NULL 
0 NULL methods : patients diagnosed with chronic csc , with clinical evidence of activity and treated with photodynamic therapy , are 
0 patients diagnosed with chronic csc , with clinical evidence of activity and treated with photodynamic therapy , are included in this 
19 with chronic csc , with clinical evidence of activity and treated with photodynamic therapy , are included in this report . 
0 csc , with clinical evidence of activity and treated with photodynamic therapy , are included in this report . NULL NULL 
0 , with clinical evidence of activity and treated with photodynamic therapy , are included in this report . NULL NULL NULL 
0 bcva ) using an etdrs chart , fluorescein and indocyanine angiography and optical coherence tomography ( oct ) . NULL NULL 
0 of the study was to determine the mean visual acuity change . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : 11 eyes of 11 patients were included in the 
0 NULL NULL NULL NULL NULL NULL NULL the mean bcva increased from 20/76 to 20/64 . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL 35 % of eyes improved their bcva by 2 lines or more , 45 % 
0 NULL NULL NULL NULL NULL NULL NULL choroidal hyperpermeability was reduced in every case . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL neurosensorial retinal detachment decreased in 80 % of cases . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL neurosensorial retinal detachment decreased in 80 % of cases . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL only one eye received a second pdt treatment due to choroidal neovascularization . NULL 
19 NULL NULL NULL NULL only one eye received a second pdt treatment due to choroidal neovascularization . NULL NULL NULL NULL 
19 NULL NULL NULL only one eye received a second pdt treatment due to choroidal neovascularization . NULL NULL NULL NULL NULL 
3 one eye received a second pdt treatment due to choroidal neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL an increase of atrophy over the retinal pigment epithelium ( rpe ) 
0 atrophy over the retinal pigment epithelium ( rpe ) was observed in another patient . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL conclusions : pdt can reduce the clinical signs of activity , such as 
0 NULL NULL NULL NULL NULL NULL conclusions : pdt can reduce the clinical signs of activity , such as choroidal hyperpermeability 
0 NULL NULL NULL NULL conclusions : pdt can reduce the clinical signs of activity , such as choroidal hyperpermeability or neurosensorial 
0 NULL conclusions : pdt can reduce the clinical signs of activity , such as choroidal hyperpermeability or neurosensorial retinal detachment , 
0 of activity , such as choroidal hyperpermeability or neurosensorial retinal detachment , in patients affected by chronic csc . NULL NULL 
0 as choroidal hyperpermeability or neurosensorial retinal detachment , in patients affected by chronic csc . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL however , the increase in visual acuity is variable , probably due to the 
0 is variable , probably due to the extent of rpe damage . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiopoietin-1 prevents vegf-induced endothelial permeability by sequestering src through mdia . NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL angiopoietin-1 prevents induced endothelial permeability by sequestering src through mdia . NULL NULL 
18 NULL NULL NULL NULL angiopoietin-1 prevents vegf-induced endothelial permeability by sequestering src through mdia . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL angiopoietin-1 prevents vegf-induced endothelial permeability by sequestering src through mdia . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) and angiopoietin 1 ( ang1 ) 
3 ) and angiopoietin 1 ( ang1 ) are both potent angiogenic factors , but , whereas vegf causes vascular permeability , 
16 , but , whereas vegf causes vascular permeability , ang1 stabilizes blood vessels and protects them from vegf-induced plasma leakage . 
18 vegf causes vascular permeability , ang1 stabilizes blood vessels and protects them from vegf-induced plasma leakage . NULL NULL NULL NULL 
17 permeability , ang1 stabilizes blood vessels and protects them from induced plasma leakage . NULL NULL NULL NULL NULL NULL NULL 
14 ang1 stabilizes blood vessels and protects them from vegf-induced plasma leakage . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL here , we demonstrate that ang1 halts the ability of vegf to induce the phosphorylation-dependent redistribution of 
0 NULL NULL here , we demonstrate that ang1 halts the ability of vegf to induce the phosphorylation-dependent redistribution of the adhesion 
17 we demonstrate that ang1 halts the ability of vegf to induce the phosphorylation-dependent redistribution of the adhesion molecule ve-cadherin , thereby 
12 that ang1 halts the ability of vegf to induce the phosphorylation redistribution of the adhesion molecule ve-cadherin , thereby rescuing the 
17 that ang1 halts the ability of vegf to induce the dependent redistribution of the adhesion molecule ve-cadherin , thereby rescuing the 
14 ang1 halts the ability of vegf to induce the phosphorylation-dependent redistribution of the adhesion molecule ve-cadherin , thereby rescuing the endothelial 
0 ability of vegf to induce the phosphorylation-dependent redistribution of the adhesion molecule ve-cadherin , thereby rescuing the endothelial barrier function . 
0 the adhesion molecule ve-cadherin , thereby rescuing the endothelial barrier function . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL ang1 inhibits the activation of src by vegf , the most upstream 
17 NULL NULL NULL NULL NULL NULL NULL ang1 inhibits the activation of src by vegf , the most upstream component of 
14 upstream component of the pathway linking vegf receptors to ve-cadherin internalization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL indeed , ang1 promotes the activation of mdia through rhoa , resulting in the 
16 NULL NULL NULL NULL NULL NULL NULL indeed , ang1 promotes the activation of mdia through rhoa , resulting in the 
17 NULL NULL NULL NULL NULL indeed , ang1 promotes the activation of mdia through rhoa , resulting in the association of 
17 , ang1 promotes the activation of mdia through rhoa , resulting in the association of mdia with src . NULL NULL 
15 the activation of mdia through rhoa , resulting in the association of mdia with src . NULL NULL NULL NULL NULL 
0 NULL NULL NULL this ultimately deprives vegf receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts 
17 NULL this ultimately deprives vegf receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular 
17 ultimately deprives vegf receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability . 
18 vegf receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability . NULL NULL 
15 an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability . NULL NULL NULL NULL NULL 
15 essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the retinopathy is often associated with migraine , raynaud 's phenomenon and mental changes , 
0 often associated with migraine , raynaud 's phenomenon and mental changes , mainly forgetfulness , aggression and depression . NULL NULL 
0 NULL NULL NULL NULL NULL to define this syndrome we collected medical data on 110 family members . NULL NULL NULL 
19 NULL NULL NULL NULL NULL general ophthalmological examination and fluorescein angiography were performed in 61 persons . NULL NULL NULL NULL 
0 , as diagnosed in 22 persons , is characterized by central and peripheral microangiopathy , areas of capillary non-perfusion , haemorrhages 
0 characterized by central and peripheral microangiopathy , areas of capillary perfusion , haemorrhages , cotton wool spots and , in a 
17 stage , occlusion of large retinal vessels , which can induce a neovascular response . NULL NULL NULL NULL NULL NULL 
3 occlusion of large retinal vessels , which can induce a neovascular response . NULL NULL NULL NULL NULL NULL NULL NULL 
3 of large retinal vessels , which can induce a neovascular response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL suppression of lung tumor growth and metastasis in mice by adeno-associated 
0 NULL NULL NULL NULL NULL NULL NULL suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of 
4 NULL NULL NULL NULL NULL NULL suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin 
14 NULL NULL NULL NULL suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin . NULL 
0 suppression of lung tumor growth and metastasis in mice by associated virus-mediated expression of vasostatin . NULL NULL NULL NULL NULL 
17 of lung tumor growth and metastasis in mice by adeno-associated mediated expression of vasostatin . NULL NULL NULL NULL NULL NULL 
9 lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL purpose : angiogenesis inhibitors have strong therapeutic potential as antitumor agents in suppressing 
0 NULL NULL NULL purpose : angiogenesis inhibitors have strong therapeutic potential as antitumor agents in suppressing tumor growth and metastatic progression 
18 angiogenesis inhibitors have strong therapeutic potential as antitumor agents in suppressing tumor growth and metastatic progression . NULL NULL NULL NULL 
0 inhibitors have strong therapeutic potential as antitumor agents in suppressing tumor growth and metastatic progression . NULL NULL NULL NULL NULL 
4 have strong therapeutic potential as antitumor agents in suppressing tumor growth and metastatic progression . NULL NULL NULL NULL NULL NULL 
2 therapeutic potential as antitumor agents in suppressing tumor growth and metastatic progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 potential as antitumor agents in suppressing tumor growth and metastatic progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 , the n-terminal domain of calreticulin , is a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 the n-terminal domain of calreticulin , is a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL in this study , we determined the effectiveness of vasostatin delivered by recombinant pseudotype adeno-associated virus 2/5 ( 
19 in this study , we determined the effectiveness of vasostatin delivered by recombinant pseudotype adeno-associated virus 2/5 ( raav2/5-vas ) as 
0 we determined the effectiveness of vasostatin delivered by recombinant pseudotype associated virus 2/5 ( raav2/5-vas ) as a gene therapy approach 
19 pseudotype adeno-associated virus 2/5 ( raav2/5-vas ) as a gene therapy approach for lung cancer treatment . NULL NULL NULL NULL 
0 raav2/5-vas ) as a gene therapy approach for lung cancer treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL experimental design : we used raav2/5 to deliver vasostatin intratumorally or systemically in different mouse 
19 NULL NULL NULL experimental design : we used raav2/5 to deliver vasostatin intratumorally or systemically in different mouse lung tumor models 
0 to deliver vasostatin intratumorally or systemically in different mouse lung tumor models -- subcutaneous , orthotopic xenograft , and spontaneous metastasis 
0 tumor models -- subcutaneous , orthotopic xenograft , and spontaneous metastasis lung tumor models . NULL NULL NULL NULL NULL NULL 
0 -- subcutaneous , orthotopic xenograft , and spontaneous metastasis lung tumor models . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the therapeutic efficacy of raav2/5-vas was determined by monitoring tumor volume , survival 
0 NULL the therapeutic efficacy of raav2/5-vas was determined by monitoring tumor volume , survival rate , and degree of neovascularization after 
0 efficacy of raav2/5-vas was determined by monitoring tumor volume , survival rate , and degree of neovascularization after treatment in these 
3 monitoring tumor volume , survival rate , and degree of neovascularization after treatment in these models . NULL NULL NULL NULL 
0 volume , survival rate , and degree of neovascularization after treatment in these models . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : mice bearing subcutaneous tumor of raav2/5-vas pretreated lewis lung 
0 NULL NULL NULL NULL NULL results : mice bearing subcutaneous tumor of raav2/5-vas pretreated lewis lung carcinoma cells showed > 50 
19 NULL NULL results : mice bearing subcutaneous tumor of raav2/5-vas pretreated lewis lung carcinoma cells showed > 50 % reduction in 
0 bearing subcutaneous tumor of raav2/5-vas pretreated lewis lung carcinoma cells showed > 50 % reduction in primary tumor volume and reduced 
18 raav2/5-vas pretreated lewis lung carcinoma cells showed > 50 % reduction in primary tumor volume and reduced spontaneous pulmonary metastases . 
0 lung carcinoma cells showed > 50 % reduction in primary tumor volume and reduced spontaneous pulmonary metastases . NULL NULL NULL 
18 showed > 50 % reduction in primary tumor volume and reduced spontaneous pulmonary metastases . NULL NULL NULL NULL NULL NULL 
14 % reduction in primary tumor volume and reduced spontaneous pulmonary metastases . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL the tumor-suppressive action of raav2/5-vas in subcutaneous human lung tumor a549 xenograft 
18 NULL NULL NULL NULL NULL NULL NULL NULL the tumor-suppressive action of raav2/5-vas in subcutaneous human lung tumor a549 xenograft correlated 
0 NULL the tumor-suppressive action of raav2/5-vas in subcutaneous human lung tumor a549 xenograft correlated with a reduced number of capillary vessels 
18 in subcutaneous human lung tumor a549 xenograft correlated with a reduced number of capillary vessels in tumors . NULL NULL NULL 
18 NULL NULL NULL in the orthotopic xenograft model , raav2/5-vas suppressed metastasis of a549 tumors to mediastinal lymph nodes and contralateral 
14 NULL NULL in the orthotopic xenograft model , raav2/5-vas suppressed metastasis of a549 tumors to mediastinal lymph nodes and contralateral lung 
19 NULL NULL NULL NULL NULL NULL NULL NULL furthermore , treatment of immunocompetent mice in the spontaneous lung metastases model with 
0 furthermore , treatment of immunocompetent mice in the spontaneous lung metastases model with raav2/5-vas after primary tumor excision prolonged their median 
0 in the spontaneous lung metastases model with raav2/5-vas after primary tumor excision prolonged their median survival from 21 to 51.5 days 
19 the spontaneous lung metastases model with raav2/5-vas after primary tumor excision prolonged their median survival from 21 to 51.5 days . 
0 spontaneous lung metastases model with raav2/5-vas after primary tumor excision prolonged their median survival from 21 to 51.5 days . NULL 
0 model with raav2/5-vas after primary tumor excision prolonged their median survival from 21 to 51.5 days . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusion : our results show the effectiveness of raav2/5-vas as an angiogenesis inhibitor in 
18 NULL NULL NULL NULL conclusion : our results show the effectiveness of raav2/5-vas as an angiogenesis inhibitor in suppressing tumor growth 
3 : our results show the effectiveness of raav2/5-vas as an angiogenesis inhibitor in suppressing tumor growth during different stages of tumor 
0 our results show the effectiveness of raav2/5-vas as an angiogenesis inhibitor in suppressing tumor growth during different stages of tumor progression 
18 show the effectiveness of raav2/5-vas as an angiogenesis inhibitor in suppressing tumor growth during different stages of tumor progression , validating 
0 the effectiveness of raav2/5-vas as an angiogenesis inhibitor in suppressing tumor growth during different stages of tumor progression , validating the 
4 effectiveness of raav2/5-vas as an angiogenesis inhibitor in suppressing tumor growth during different stages of tumor progression , validating the application 
0 angiogenesis inhibitor in suppressing tumor growth during different stages of tumor progression , validating the application of raav2/5-vas gene therapy in 
2 inhibitor in suppressing tumor growth during different stages of tumor progression , validating the application of raav2/5-vas gene therapy in treatment 
0 growth during different stages of tumor progression , validating the application of raav2/5-vas gene therapy in treatment against lung cancer . 
19 of tumor progression , validating the application of raav2/5-vas gene therapy in treatment against lung cancer . NULL NULL NULL NULL 
0 progression , validating the application of raav2/5-vas gene therapy in treatment against lung cancer . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab ( 
0 NULL NULL NULL radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab ( avastin ) . NULL NULL NULL NULL 
19 NULL NULL NULL NULL purpose : to report on bevacizumab treatment for radiation retinopathy affecting the macula . NULL NULL NULL 
0 NULL NULL purpose : to report on bevacizumab treatment for radiation retinopathy affecting the macula . NULL NULL NULL NULL NULL 
16 purpose : to report on bevacizumab treatment for radiation retinopathy affecting the macula . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL patients and methods : twenty-one patients with radiation retinopathy ( edema , hemorrhages , capillary dropout , and 
3 retinopathy ( edema , hemorrhages , capillary dropout , and neovascularization ) and a subjective or objective loss of vision were 
0 dropout , and neovascularization ) and a subjective or objective loss of vision were treated . NULL NULL NULL NULL NULL 
0 ) and a subjective or objective loss of vision were treated . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment involved intravitreal injection of bevacizumab ( 1.25 mg in 0.05 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment involved intravitreal injection of bevacizumab ( 1.25 mg in 0.05 ml 
19 NULL NULL NULL NULL NULL NULL NULL NULL treatment involved intravitreal injection of bevacizumab ( 1.25 mg in 0.05 ml ) 
19 NULL NULL NULL NULL NULL NULL NULL treatment involved intravitreal injection of bevacizumab ( 1.25 mg in 0.05 ml ) every 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment was discontinued at patient request or if there was no 
0 NULL NULL NULL NULL NULL NULL NULL NULL treatment was discontinued at patient request or if there was no measurable response 
0 discontinued at patient request or if there was no measurable response to therapy . NULL NULL NULL NULL NULL NULL NULL 
0 patient request or if there was no measurable response to therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 visual acuity , ophthalmic examination , retinal photography , and angiography . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : bevacizumab treatment was followed by reductions in retinal hemorrhage 
19 NULL NULL NULL NULL NULL NULL NULL results : bevacizumab treatment was followed by reductions in retinal hemorrhage , exudation , 
0 NULL NULL NULL NULL NULL visual acuities were stable or improved in 86 % ( n=18 ) . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL three patients discontinued therapy . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL three patients discontinued therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL each was legally blind before treatment ( n=1 ) , experienced little to no subjective improvement 
0 NULL NULL NULL NULL no ocular or systemic bevacizumab-related side effects were observed . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL no ocular or systemic bevacizumab-related side effects were observed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL conclusions : intravitreal bevacizumab can be used to treat radiation retinopathy . NULL 
0 NULL NULL NULL NULL conclusions : intravitreal bevacizumab can be used to treat radiation retinopathy . NULL NULL NULL NULL NULL 
0 NULL NULL conclusions : intravitreal bevacizumab can be used to treat radiation retinopathy . NULL NULL NULL NULL NULL NULL NULL 
0 NULL conclusions : intravitreal bevacizumab can be used to treat radiation retinopathy . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL in most cases treatment was associated with decreased vascular leakage , stabilization , or 
0 NULL NULL NULL NULL NULL in most cases treatment was associated with decreased vascular leakage , stabilization , or improved vision 
0 NULL NULL NULL in most cases treatment was associated with decreased vascular leakage , stabilization , or improved vision . NULL 
0 NULL in most cases treatment was associated with decreased vascular leakage , stabilization , or improved vision . NULL NULL NULL 
0 most cases treatment was associated with decreased vascular leakage , stabilization , or improved vision . NULL NULL NULL NULL NULL 
0 was associated with decreased vascular leakage , stabilization , or improved vision . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL an anti-vascular endothelial growth factor strategy may reduce tissue damage associated with radiation vasculopathy 
18 NULL NULL NULL an anti-vascular endothelial growth factor strategy may reduce tissue damage associated with radiation vasculopathy and neuropathy . NULL 
6 NULL an anti-vascular endothelial growth factor strategy may reduce tissue damage associated with radiation vasculopathy and neuropathy . NULL NULL NULL 
0 an anti-vascular endothelial growth factor strategy may reduce tissue damage associated with radiation vasculopathy and neuropathy . NULL NULL NULL NULL 
0 endothelial growth factor strategy may reduce tissue damage associated with radiation vasculopathy and neuropathy . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma . 
17 NULL NULL NULL NULL NULL mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma . NULL NULL NULL NULL 
4 NULL NULL NULL NULL mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma . NULL NULL NULL NULL NULL 
3 NULL NULL mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL we hypothesized that signaling through multiple activated protein kinase ( mapk ) kinase ( mkk ) pathways 
0 NULL NULL NULL we hypothesized that signaling through multiple mitogen-activated protein kinase ( mapk ) kinase ( mkk ) pathways is 
0 mitogen-activated protein kinase ( mapk ) kinase ( mkk ) pathways is essential for the growth and vascularization of soft-tissue sarcomas 
17 kinase ( mapk ) kinase ( mkk ) pathways is essential for the growth and vascularization of soft-tissue sarcomas , which 
4 ) kinase ( mkk ) pathways is essential for the growth and vascularization of soft-tissue sarcomas , which are malignant tumors 
3 ( mkk ) pathways is essential for the growth and vascularization of soft-tissue sarcomas , which are malignant tumors derived from 
0 the growth and vascularization of soft-tissue sarcomas , which are malignant tumors derived from mesenchymal tissues . NULL NULL NULL NULL 
0 and vascularization of soft-tissue sarcomas , which are malignant tumors derived from mesenchymal tissues . NULL NULL NULL NULL NULL NULL 
0 we tested this using ht-1080 , nci , and shac derived cell lines and anthrax lethal toxin ( letx ) , 
18 lethal toxin ( letx ) , a bacterial toxin that inactivates mkks . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL western blots confirmed that letx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 
18 NULL NULL NULL NULL western blots confirmed that letx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 mapk 
0 NULL NULL western blots confirmed that letx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 mapk in vitro 
12 western blots confirmed that letx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 mapk in vitro . NULL 
0 confirmed that letx treatment reduced the levels of phosphorylated extracellular regulated kinase and p38 mapk in vitro . NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL although short treatments with letx only modestly affected cell proliferation , sustained treatment 
16 NULL NULL NULL although short treatments with letx only modestly affected cell proliferation , sustained treatment markedly reduced cell numbers . 
1 NULL although short treatments with letx only modestly affected cell proliferation , sustained treatment markedly reduced cell numbers . NULL NULL 
0 treatments with letx only modestly affected cell proliferation , sustained treatment markedly reduced cell numbers . NULL NULL NULL NULL NULL 
0 letx only modestly affected cell proliferation , sustained treatment markedly reduced cell numbers . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL letx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth 
14 NULL NULL NULL NULL letx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor , interleukin-8 
3 NULL NULL letx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor , interleukin-8 , and 
0 inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor , interleukin-8 , and basic fibroblast growth factor . 
0 vascular endothelial growth factor , interleukin-8 , and basic fibroblast growth factor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL similar results were obtained with cell lines derived from malignant fibrous histiocytomas 
0 NULL NULL NULL NULL NULL NULL NULL similar results were obtained with cell lines derived from malignant fibrous histiocytomas , leiomyosarcomas 
0 NULL NULL NULL similar results were obtained with cell lines derived from malignant fibrous histiocytomas , leiomyosarcomas , and liposarcomas . 
0 NULL similar results were obtained with cell lines derived from malignant fibrous histiocytomas , leiomyosarcomas , and liposarcomas . NULL NULL 
18 NULL NULL NULL NULL NULL NULL in vivo , letx decreased mapk activity and blocked fibrosarcoma growth . NULL NULL NULL 
0 NULL NULL NULL NULL in vivo , letx decreased mapk activity and blocked fibrosarcoma growth . NULL NULL NULL NULL NULL 
18 NULL NULL in vivo , letx decreased mapk activity and blocked fibrosarcoma growth . NULL NULL NULL NULL NULL NULL NULL 
4 in vivo , letx decreased mapk activity and blocked fibrosarcoma growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL growth inhibition correlated with decreased cellular proliferation and extensive necrosis , 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL growth inhibition correlated with decreased cellular proliferation and extensive necrosis , and 
0 NULL NULL NULL NULL NULL NULL growth inhibition correlated with decreased cellular proliferation and extensive necrosis , and it was accompanied 
1 NULL NULL NULL NULL growth inhibition correlated with decreased cellular proliferation and extensive necrosis , and it was accompanied by a 
0 NULL growth inhibition correlated with decreased cellular proliferation and extensive necrosis , and it was accompanied by a decrease in tumor 
18 and extensive necrosis , and it was accompanied by a decrease in tumor mean vessel density as well as a reduction 
0 necrosis , and it was accompanied by a decrease in tumor mean vessel density as well as a reduction in serum 
18 decrease in tumor mean vessel density as well as a reduction in serum expression of angioproliferative cytokines . NULL NULL NULL 
0 mean vessel density as well as a reduction in serum expression of angioproliferative cytokines . NULL NULL NULL NULL NULL NULL 
3 density as well as a reduction in serum expression of angioproliferative cytokines . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL vital imaging using high-resolution ultrasound enhanced with contrast microbubbles revealed that the effects of letx on 
16 using high-resolution ultrasound enhanced with contrast microbubbles revealed that the effects of letx on tumor perfusion were remarkably rapid ( less 
0 with contrast microbubbles revealed that the effects of letx on tumor perfusion were remarkably rapid ( less than 24 h ) 
2 contrast microbubbles revealed that the effects of letx on tumor perfusion were remarkably rapid ( less than 24 h ) and 
17 were remarkably rapid ( less than 24 h ) and resulted in a marked reduction of perfusion within the tumor but 
18 less than 24 h ) and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues 
2 24 h ) and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues . NULL 
0 and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results are consistent with our initial hypothesis and lead us to 
0 NULL these results are consistent with our initial hypothesis and lead us to propose that mkk inhibition by letx is a 
18 our initial hypothesis and lead us to propose that mkk inhibition by letx is a broadly effective strategy for targeting neovascularization 
0 to propose that mkk inhibition by letx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative 
16 mkk inhibition by letx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions . NULL 
3 inhibition by letx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions . NULL NULL 
0 effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL acute ethanol exposure disrupts vegf receptor cell signaling in endothelial cells . NULL 
18 NULL NULL NULL NULL NULL NULL NULL acute ethanol exposure disrupts vegf receptor cell signaling in endothelial cells . NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL physiological angiogenesis is regulated by various factors , including signaling through vascular 
16 NULL NULL NULL NULL NULL NULL NULL physiological angiogenesis is regulated by various factors , including signaling through vascular endothelial growth 
0 regulated by various factors , including signaling through vascular endothelial growth factor ( vegf ) receptors . NULL NULL NULL NULL 
18 yielding a blood alcohol concentration of 100 mg/dl , significantly impairs angiogenesis in murine wounds , despite adequate levels of vegf 
3 a blood alcohol concentration of 100 mg/dl , significantly impairs angiogenesis in murine wounds , despite adequate levels of vegf , 
0 , significantly impairs angiogenesis in murine wounds , despite adequate levels of vegf , suggesting direct effects of ethanol on endothelial 
0 murine wounds , despite adequate levels of vegf , suggesting direct effects of ethanol on endothelial cell signaling ( 40 ) 
16 wounds , despite adequate levels of vegf , suggesting direct effects of ethanol on endothelial cell signaling ( 40 ) . 
0 NULL NULL NULL NULL NULL NULL NULL to examine the mechanism by which ethanol influences angiogenesis in wounds , we employed 
16 NULL NULL NULL to examine the mechanism by which ethanol influences angiogenesis in wounds , we employed two different in vitro 
3 NULL NULL to examine the mechanism by which ethanol influences angiogenesis in wounds , we employed two different in vitro angiogenesis 
3 angiogenesis in wounds , we employed two different in vitro angiogenesis assays to determine whether acute ethanol exposure ( 100 mg/dl 
19 different in vitro angiogenesis assays to determine whether acute ethanol exposure ( 100 mg/dl ) would have long-lasting effects on vegf-induced 
16 acute ethanol exposure ( 100 mg/dl ) would have long-lasting effects on vegf-induced capillary network formation . NULL NULL NULL NULL 
17 exposure ( 100 mg/dl ) would have long-lasting effects on induced capillary network formation . NULL NULL NULL NULL NULL NULL 
2 mg/dl ) would have long-lasting effects on vegf-induced capillary network formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL ethanol exposure resulted in reduced vegf-induced cord formation on collagen and reduced 
17 NULL NULL NULL NULL NULL NULL NULL NULL ethanol exposure resulted in reduced vegf-induced cord formation on collagen and reduced capillary 
18 NULL NULL NULL NULL NULL NULL ethanol exposure resulted in reduced vegf-induced cord formation on collagen and reduced capillary network structure 
17 NULL NULL NULL NULL NULL ethanol exposure resulted in reduced induced cord formation on collagen and reduced capillary network structure on 
2 NULL NULL NULL ethanol exposure resulted in reduced vegf-induced cord formation on collagen and reduced capillary network structure on matrigel in 
18 exposure resulted in reduced vegf-induced cord formation on collagen and reduced capillary network structure on matrigel in vitro . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , ethanol exposure decreased expression of endothelial vegf receptor-2 , 
19 NULL NULL NULL NULL NULL NULL in addition , ethanol exposure decreased expression of endothelial vegf receptor-2 , as well as 
18 NULL NULL NULL NULL NULL in addition , ethanol exposure decreased expression of endothelial vegf receptor-2 , as well as vegf 
9 NULL NULL NULL NULL in addition , ethanol exposure decreased expression of endothelial vegf receptor-2 , as well as vegf receptor-2 
12 of endothelial vegf receptor-2 , as well as vegf receptor-2 phosphorylation in vitro . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of ethanol metabolism by 4-methylpyrazole partially abrogated the effect of 
18 NULL NULL NULL inhibition of ethanol metabolism by 4-methylpyrazole partially abrogated the effect of ethanol on endothelial cell cord formation . 
16 NULL inhibition of ethanol metabolism by 4-methylpyrazole partially abrogated the effect of ethanol on endothelial cell cord formation . NULL NULL 
2 partially abrogated the effect of ethanol on endothelial cell cord formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL however , mice treated with t-butanol , an alcohol not metabolized by alcohol dehydrogenase 
17 however , mice treated with t-butanol , an alcohol not metabolized by alcohol dehydrogenase , exhibited no change in wound vascularity 
0 t-butanol , an alcohol not metabolized by alcohol dehydrogenase , exhibited no change in wound vascularity . NULL NULL NULL NULL 
0 an alcohol not metabolized by alcohol dehydrogenase , exhibited no change in wound vascularity . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest that products of ethanol metabolism are important factors in 
16 NULL these results suggest that products of ethanol metabolism are important factors in the development of ethanol-induced changes in endothelial cell 
0 that products of ethanol metabolism are important factors in the development of ethanol-induced changes in endothelial cell responsiveness to vegf . 
17 of ethanol metabolism are important factors in the development of induced changes in endothelial cell responsiveness to vegf . NULL NULL 
16 ethanol metabolism are important factors in the development of ethanol-induced changes in endothelial cell responsiveness to vegf . NULL NULL NULL 
16 factors in the development of ethanol-induced changes in endothelial cell responsiveness to vegf . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL in vivo , ethanol exposure caused both decreased angiogenesis and increased hypoxia in wounds . 
0 NULL NULL NULL NULL NULL in vivo , ethanol exposure caused both decreased angiogenesis and increased hypoxia in wounds . NULL 
18 NULL NULL NULL in vivo , ethanol exposure caused both decreased angiogenesis and increased hypoxia in wounds . NULL NULL NULL 
3 NULL NULL in vivo , ethanol exposure caused both decreased angiogenesis and increased hypoxia in wounds . NULL NULL NULL NULL 
0 in vivo , ethanol exposure caused both decreased angiogenesis and increased hypoxia in wounds . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL moreover , in vitro experiments demonstrated a direct effect of ethanol on the response to hypoxia in endothelial 
0 NULL NULL moreover , in vitro experiments demonstrated a direct effect of ethanol on the response to hypoxia in endothelial cells 
0 vitro experiments demonstrated a direct effect of ethanol on the response to hypoxia in endothelial cells , as ethanol diminished nuclear 
18 the response to hypoxia in endothelial cells , as ethanol diminished nuclear hypoxia-inducible factor-1alpha protein levels . NULL NULL NULL NULL 
0 to hypoxia in endothelial cells , as ethanol diminished nuclear inducible factor-1alpha protein levels . NULL NULL NULL NULL NULL NULL 
0 in endothelial cells , as ethanol diminished nuclear hypoxia-inducible factor-1alpha protein levels . NULL NULL NULL NULL NULL NULL NULL NULL 
0 endothelial cells , as ethanol diminished nuclear hypoxia-inducible factor-1alpha protein levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL together , the data establish that acute ethanol exposure significantly impairs angiogenesis and suggest that this effect is mediated 
18 together , the data establish that acute ethanol exposure significantly impairs angiogenesis and suggest that this effect is mediated by changes 
3 , the data establish that acute ethanol exposure significantly impairs angiogenesis and suggest that this effect is mediated by changes in 
0 acute ethanol exposure significantly impairs angiogenesis and suggest that this effect is mediated by changes in endothelial cell responsiveness to both 
16 exposure significantly impairs angiogenesis and suggest that this effect is mediated by changes in endothelial cell responsiveness to both vegf and 
16 impairs angiogenesis and suggest that this effect is mediated by changes in endothelial cell responsiveness to both vegf and hypoxia . 
16 that this effect is mediated by changes in endothelial cell responsiveness to both vegf and hypoxia . NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL hepatectomy was performed , and the patient is alive and free 
0 hepatectomy was performed , and the patient is alive and free of disease 1 year postsurgery . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL grossly , the tumour showed a haemorrhagic cut surface with numerous microcystic structures . NULL 
3 NULL NULL NULL NULL NULL histological examination revealed cystic or angiomatoid spaces of various sizes lined by cuboidal , low-columnar , 
19 of various sizes lined by cuboidal , low-columnar , or flattened epithelioid cells with vacuolated cytoplasm and round to oval nuclei 
0 NULL NULL NULL NULL NULL the epithelioid cells were entirely supported by proliferated capillaries and arteries together with collagenous stroma . 
4 NULL NULL NULL the epithelioid cells were entirely supported by proliferated capillaries and arteries together with collagenous stroma . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL immunohistochemical studies showed that the epithelioid cells were strongly positive for 
0 NULL NULL NULL NULL NULL NULL NULL NULL immunohistochemical studies showed that the epithelioid cells were strongly positive for a broad 
0 NULL immunohistochemical studies showed that the epithelioid cells were strongly positive for a broad spectrum of cytokeratins ( ae1/ae3 , cam5.2 
0 NULL NULL NULL NULL NULL NULL NULL these cells were negative for hep par-1 , carcinoembryonic antigen , neural cell adhesion 
0 negative for hep par-1 , carcinoembryonic antigen , neural cell adhesion molecule , cd34 , cd31 and hmb45 . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL atypically , abundant capillaries were observed ; however , the cystic proliferation of 
0 NULL NULL NULL NULL NULL atypically , abundant capillaries were observed ; however , the cystic proliferation of epithelioid cells with 
1 , abundant capillaries were observed ; however , the cystic proliferation of epithelioid cells with vacuoles and immunohistochemical profile of the 
0 , the cystic proliferation of epithelioid cells with vacuoles and immunohistochemical profile of the epithelioid element were consistent with hepatic adenomatoid 
3 the c-terminal fragment of collagen xviii , is a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 c-terminal fragment of collagen xviii , is a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL at present , there are a large number of research papers on 
0 NULL NULL NULL NULL NULL NULL NULL however , the action mechanism of endostatin is still a matter of ongoing discussion 
0 NULL NULL NULL NULL NULL NULL however , the action mechanism of endostatin is still a matter of ongoing discussion . 
0 elementary structure , and to discuss its structure basis of activity and action mechanisms based on the latest research . NULL 
0 , and to discuss its structure basis of activity and action mechanisms based on the latest research . NULL NULL NULL 
3 NULL NULL NULL furthermore , some published studies reporting the angiogenic effects of endostatin-derived peptides were also reviewed . NULL NULL 
18 NULL NULL furthermore , some published studies reporting the antiangiogenic effects of endostatin-derived peptides were also reviewed . NULL NULL NULL 
0 furthermore , some published studies reporting the antiangiogenic effects of derived peptides were also reviewed . NULL NULL NULL NULL NULL 
3 proposed that the amino acid sequence of endostatin contains both angiosuppressive and angiostimulatory domains . NULL NULL NULL NULL NULL NULL 
3 the amino acid sequence of endostatin contains both angiosuppressive and angiostimulatory domains . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL short endostatin fragments may be exploited as a new angiogenesis inhibitor for therapeutic applications , in substitution of the full 
0 short endostatin fragments may be exploited as a new angiogenesis inhibitor for therapeutic applications , in substitution of the full length 
0 fragments also shed light on our understanding of the molecular action mechanisms of endostatin . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and 
18 NULL NULL NULL NULL NULL the tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis . 
17 NULL NULL NULL NULL the tyrosine kinase inhibitor cediranib blocks induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis . NULL 
0 NULL the tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis . NULL NULL NULL NULL 
0 kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis . NULL NULL NULL NULL NULL NULL NULL 
0 cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL solid tumors express a range of factors required to sustain their growth and 
0 NULL NULL NULL solid tumors express a range of factors required to sustain their growth and promote their dissemination . NULL 
0 tumors express a range of factors required to sustain their growth and promote their dissemination . NULL NULL NULL NULL NULL 
0 a range of factors required to sustain their growth and promote their dissemination . NULL NULL NULL NULL NULL NULL NULL 
0 of factors required to sustain their growth and promote their dissemination . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL among these are vascular endothelial growth factor-a ( vegf-a ) , the key angiogenic stimulant , 
0 are vascular endothelial growth factor-a ( vegf-a ) , the key angiogenic stimulant , and vegf-c , a primary mediator of 
3 vascular endothelial growth factor-a ( vegf-a ) , the key angiogenic stimulant , and vegf-c , a primary mediator of lymphangiogenesis 
0 the key angiogenic stimulant , and vegf-c , a primary mediator of lymphangiogenesis . NULL NULL NULL NULL NULL NULL NULL 
0 angiogenic stimulant , and vegf-c , a primary mediator of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL small molecule tyrosine kinase inhibitors offer the potential to inhibit more than one kinase and impede tumor growth 
0 NULL small molecule tyrosine kinase inhibitors offer the potential to inhibit more than one kinase and impede tumor growth by multiple 
18 offer the potential to inhibit more than one kinase and impede tumor growth by multiple mechanisms . NULL NULL NULL NULL 
0 the potential to inhibit more than one kinase and impede tumor growth by multiple mechanisms . NULL NULL NULL NULL NULL 
4 potential to inhibit more than one kinase and impede tumor growth by multiple mechanisms . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL however , their potency toward individual targets can vary . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL cediranib ( recentin ; azd2171 ) is an inhibitor of vegf signaling that has been shown in experimental models 
18 vegf signaling that has been shown in experimental models to prevent vegf-a-induced angiogenesis and primary tumor growth , yet the effects 
17 signaling that has been shown in experimental models to prevent induced angiogenesis and primary tumor growth , yet the effects of 
3 that has been shown in experimental models to prevent vegf-a-induced angiogenesis and primary tumor growth , yet the effects of cediranib 
0 shown in experimental models to prevent vegf-a-induced angiogenesis and primary tumor growth , yet the effects of cediranib on vegf receptor 
4 in experimental models to prevent vegf-a-induced angiogenesis and primary tumor growth , yet the effects of cediranib on vegf receptor ( 
16 prevent vegf-a-induced angiogenesis and primary tumor growth , yet the effects of cediranib on vegf receptor ( vegfr ) -3-mediated endothelial 
16 the effects of cediranib on vegf receptor ( vegfr ) mediated endothelial cell function and lymphangiogenesis are unknown . NULL NULL 
0 cediranib on vegf receptor ( vegfr ) -3-mediated endothelial cell function and lymphangiogenesis are unknown . NULL NULL NULL NULL NULL 
0 vegf receptor ( vegfr ) -3-mediated endothelial cell function and angiogenesis are unknown . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL to better understand the activity of cediranib against vegfr-3 and its associated signaling events compared 
0 better understand the activity of cediranib against vegfr-3 and its associated signaling events compared with its activity against vegfr-2 , we 
0 against vegfr-3 and its associated signaling events compared with its activity against vegfr-2 , we used the receptor-specific ligands vegf-e and 
0 signaling events compared with its activity against vegfr-2 , we used the receptor-specific ligands vegf-e and vegf-c156s . NULL NULL NULL 
18 NULL NULL NULL NULL in human endothelial cells , cediranib inhibited vegf-e-induced phosphorylation of vegfr-2 and vegf-c156s-induced phosphorylation of vegfr-3 at 
17 NULL NULL NULL in human endothelial cells , cediranib inhibited induced phosphorylation of vegfr-2 and vegf-c156s-induced phosphorylation of vegfr-3 at concentrations 
12 NULL NULL in human endothelial cells , cediranib inhibited vegf-e-induced phosphorylation of vegfr-2 and vegf-c156s-induced phosphorylation of vegfr-3 at concentrations of 
17 endothelial cells , cediranib inhibited vegf-e-induced phosphorylation of vegfr-2 and induced phosphorylation of vegfr-3 at concentrations of less than /=1nmol/l and 
12 cells , cediranib inhibited vegf-e-induced phosphorylation of vegfr-2 and vegf-c156s-induced phosphorylation of vegfr-3 at concentrations of less than /=1nmol/l and inhibited 
0 phosphorylation of vegfr-3 at concentrations of less than /=1nmol/l and inhibited activation of downstream signaling molecules . NULL NULL NULL NULL 
0 of vegfr-3 at concentrations of less than /=1nmol/l and inhibited activation of downstream signaling molecules . NULL NULL NULL NULL NULL 
0 at concentrations of less than /=1nmol/l and inhibited activation of downstream signaling molecules . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL additionally , cediranib blocked vegf-c156s-induced and vegf-e-induced proliferation , survival , and migration of 
17 NULL NULL NULL NULL NULL NULL additionally , cediranib blocked induced and vegf-e-induced proliferation , survival , and migration of lymphatic 
17 NULL NULL NULL NULL additionally , cediranib blocked vegf-c156s-induced and induced proliferation , survival , and migration of lymphatic and blood 
1 NULL NULL NULL additionally , cediranib blocked vegf-c156s-induced and vegf-e-induced proliferation , survival , and migration of lymphatic and blood vascular 
5 NULL additionally , cediranib blocked vegf-c156s-induced and vegf-e-induced proliferation , survival , and migration of lymphatic and blood vascular endothelial cells 
14 cediranib blocked vegf-c156s-induced and vegf-e-induced proliferation , survival , and migration of lymphatic and blood vascular endothelial cells . NULL NULL 
18 NULL NULL in vivo , cediranib ( 6 mg/kg/d ) prevented angiogenesis and lymphangiogenesis induced by vegf-e-expressing and vegf-c156s-expressing adenoviruses , 
3 NULL in vivo , cediranib ( 6 mg/kg/d ) prevented angiogenesis and lymphangiogenesis induced by vegf-e-expressing and vegf-c156s-expressing adenoviruses , respectively 
0 vivo , cediranib ( 6 mg/kg/d ) prevented angiogenesis and angiogenesis induced by vegf-e-expressing and vegf-c156s-expressing adenoviruses , respectively . NULL 
17 , cediranib ( 6 mg/kg/d ) prevented angiogenesis and lymphangiogenesis induced by vegf-e-expressing and vegf-c156s-expressing adenoviruses , respectively . NULL NULL 
9 ( 6 mg/kg/d ) prevented angiogenesis and lymphangiogenesis induced by expressing and vegf-c156s-expressing adenoviruses , respectively . NULL NULL NULL NULL 
9 mg/kg/d ) prevented angiogenesis and lymphangiogenesis induced by vegf-e-expressing and expressing adenoviruses , respectively . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL cediranib ( 6 mg/kg/day ) also blocked angiogenesis and lymphangiogenesis induced by adenoviruses expressing vegf-a or vegf-c 
3 NULL NULL NULL cediranib ( 6 mg/kg/day ) also blocked angiogenesis and lymphangiogenesis induced by adenoviruses expressing vegf-a or vegf-c and 
0 NULL cediranib ( 6 mg/kg/day ) also blocked angiogenesis and angiogenesis induced by adenoviruses expressing vegf-a or vegf-c and compromised the 
0 cediranib ( 6 mg/kg/day ) also blocked angiogenesis and lymphangiogenesis induced by adenoviruses expressing vegf-a or vegf-c and compromised the blood 
9 mg/kg/day ) also blocked angiogenesis and lymphangiogenesis induced by adenoviruses expressing vegf-a or vegf-c and compromised the blood and lymphatic vasculatures 
9 or vegf-c and compromised the blood and lymphatic vasculatures of expressing tumors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL cediranib may , therefore , be an effective means of preventing tumor progression , not only by inhibiting 
18 cediranib may , therefore , be an effective means of preventing tumor progression , not only by inhibiting vegfr-2 activity and 
0 may , therefore , be an effective means of preventing tumor progression , not only by inhibiting vegfr-2 activity and angiogenesis 
2 , therefore , be an effective means of preventing tumor progression , not only by inhibiting vegfr-2 activity and angiogenesis , 
18 effective means of preventing tumor progression , not only by inhibiting vegfr-2 activity and angiogenesis , but also by concomitantly inhibiting 
0 of preventing tumor progression , not only by inhibiting vegfr-2 activity and angiogenesis , but also by concomitantly inhibiting vegfr-3 activity 
3 tumor progression , not only by inhibiting vegfr-2 activity and angiogenesis , but also by concomitantly inhibiting vegfr-3 activity and lymphangiogenesis 
18 inhibiting vegfr-2 activity and angiogenesis , but also by concomitantly inhibiting vegfr-3 activity and lymphangiogenesis . NULL NULL NULL NULL NULL 
0 activity and angiogenesis , but also by concomitantly inhibiting vegfr-3 activity and lymphangiogenesis . NULL NULL NULL NULL NULL NULL NULL 
0 angiogenesis , but also by concomitantly inhibiting vegfr-3 activity and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL contemporary perspectives on vital pulp therapy : views from the endodontists and pediatric dentists . NULL 
19 of agreement between pediatric dentists and endodontists at a pulp therapy symposium conjointly sponsored by the american association of endodontists ( 
0 at a pulp therapy symposium conjointly sponsored by the american association of endodontists ( aae ) and the american academy of 
0 NULL NULL NULL NULL NULL presymposium and postsymposium tests were administered , and respondent answers were compared between pediatric dentists and 
19 NULL NULL opinions on 3 areas were sought : pulp therapy for cariously involved primary teeth ; indirect pulp treatment ( 
0 on 3 areas were sought : pulp therapy for cariously involved primary teeth ; indirect pulp treatment ( ipt ) for 
19 pulp therapy for cariously involved primary teeth ; indirect pulp treatment ( ipt ) for cariously involved immature permanent teeth ; 
0 teeth ; indirect pulp treatment ( ipt ) for cariously involved immature permanent teeth ; and innovative treatment options including pulpal 
0 ) for cariously involved immature permanent teeth ; and innovative treatment options including pulpal revascularization and regeneration . NULL NULL NULL 
3 immature permanent teeth ; and innovative treatment options including pulpal revascularization and regeneration . NULL NULL NULL NULL NULL NULL NULL 
2 teeth ; and innovative treatment options including pulpal revascularization and regeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results were analyzed with chi2 tests . NULL NULL NULL NULL 
19 for pulpotomy , and that ipt is an acceptable pulp therapy technique for cariously involved young permanent teeth . NULL NULL 
0 that ipt is an acceptable pulp therapy technique for cariously involved young permanent teeth . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL both groups believe that pulp revascularization and regeneration will be viable treatment modalities in the future 
2 NULL NULL NULL both groups believe that pulp revascularization and regeneration will be viable treatment modalities in the future . NULL 
0 groups believe that pulp revascularization and regeneration will be viable treatment modalities in the future . NULL NULL NULL NULL NULL 
0 preparation of best practice guidelines that share common language and treatment recommendations for pulp therapies performed by both specialties . NULL 
19 guidelines that share common language and treatment recommendations for pulp therapies performed by both specialties . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior 
0 NULL NULL NULL NULL NULL NULL NULL the role of derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior . NULL 
0 NULL NULL NULL NULL the role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior . NULL NULL NULL NULL 
0 the role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL derived endothelial cell growth-factor ( pd-ecgf ) is similar to the 
0 NULL NULL NULL NULL NULL NULL NULL platelet-derived endothelial cell growth ( pd-ecgf ) is similar to the pyrimidine enzyme thymidine 
9 NULL NULL NULL NULL NULL NULL NULL a high tp expression at tumor sites is correlated with tumor growth , induction 
0 NULL NULL NULL NULL NULL a high tp expression at tumor sites is correlated with tumor growth , induction of angiogenesis 
0 a high tp expression at tumor sites is correlated with tumor growth , induction of angiogenesis , and metastasis . NULL 
4 high tp expression at tumor sites is correlated with tumor growth , induction of angiogenesis , and metastasis . NULL NULL 
17 expression at tumor sites is correlated with tumor growth , induction of angiogenesis , and metastasis . NULL NULL NULL NULL 
3 tumor sites is correlated with tumor growth , induction of angiogenesis , and metastasis . NULL NULL NULL NULL NULL NULL 
0 correlated with tumor growth , induction of angiogenesis , and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL therefore , high tp is most likely associated with a poor prognosis . NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL tp is not only expressed in tumor cells but also in tumor surrounding tissues , 
0 NULL NULL NULL NULL tp is not only expressed in tumor cells but also in tumor surrounding tissues , such as 
0 is not only expressed in tumor cells but also in tumor surrounding tissues , such as tumor infiltrating macrophages . NULL 
0 cells but also in tumor surrounding tissues , such as tumor infiltrating macrophages . NULL NULL NULL NULL NULL NULL NULL 
0 but also in tumor surrounding tissues , such as tumor infiltrating macrophages . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL tp catalyzes the conversion of thymidine to thymine and doxyribose-1-phosphate ( dr-1-p 
0 NULL NULL NULL NULL NULL the latter in its parent form or in its sugar form , deoxyribose ( dr ) 
0 the latter in its parent form or in its sugar form , deoxyribose ( dr ) may play a role in 
16 in its sugar form , deoxyribose ( dr ) may play a role in the induction of angiogenesis . NULL NULL 
16 sugar form , deoxyribose ( dr ) may play a role in the induction of angiogenesis . NULL NULL NULL NULL 
17 deoxyribose ( dr ) may play a role in the induction of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 dr ) may play a role in the induction of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL it may modulate cellular energy metabolism or be a substrate in a chemical 
0 energy metabolism or be a substrate in a chemical reaction generating reactive oxygen species . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL l-deoxyribose ( l-dr ) and thymidine phosphorylase inhibitor ( tpi ) can reverse these effects . NULL NULL 
0 and thymidine phosphorylase inhibitor ( tpi ) can reverse these effects . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the mechanism of tp induction is not yet completely clear , but 
17 NULL NULL NULL NULL NULL NULL the mechanism of tp induction is not yet completely clear , but tnf , il10 
17 , il10 and other cytokines have been clearly shown to induce its expression . NULL NULL NULL NULL NULL NULL NULL 
9 and other cytokines have been clearly shown to induce its expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the various complex interactions of tp give it an essential role in cellular functioning 
0 NULL the various complex interactions of tp give it an essential role in cellular functioning and , hence , it is 
0 the various complex interactions of tp give it an essential role in cellular functioning and , hence , it is an 
0 cellular functioning and , hence , it is an ideal target in cancer therapy . NULL NULL NULL NULL NULL NULL 
0 , hence , it is an ideal target in cancer therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in 
0 NULL NULL NULL NULL NULL NULL allogeneic injection of fetal derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model 
17 NULL NULL allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia 
3 allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL bone derived mesenchymal stem cells ( bm-msc ) have been demonstrated to 
2 demonstrated to be an attractive therapeutic cell source for tissue regeneration and repair . NULL NULL NULL NULL NULL NULL NULL 
2 be an attractive therapeutic cell source for tissue regeneration and repair . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL however , it remains unknown whether or not allogeneic transplantation of mesenchymal stem cells ( msc ) derived from fetal 
0 not allogeneic transplantation of mesenchymal stem cells ( msc ) derived from fetal membranes ( fm ) , which are generally 
0 ) , which are generally discarded as medical waste after delivery , has therapeutic potential . NULL NULL NULL NULL NULL 
0 generally discarded as medical waste after delivery , has therapeutic potential . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL fm-msc were obtained from lewis rats and had surface antigen expression and multipotent 
0 fm-msc were obtained from lewis rats and had surface antigen expression and multipotent potential partly similar to those of bm-msc . 
0 from lewis rats and had surface antigen expression and multipotent potential partly similar to those of bm-msc . NULL NULL NULL 
14 NULL NULL NULL NULL NULL compared with bm-msc , fm-msc secreted a comparable amount of hepatocyte growth factor despite a small 
0 with bm-msc , fm-msc secreted a comparable amount of hepatocyte growth factor despite a small amount of vascular endothelial growth factor 
0 hepatocyte growth factor despite a small amount of vascular endothelial growth factor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL fm-msc and bm-msc both expressed major histocompatibility complex ( mhc ) class i but not 
0 NULL NULL NULL NULL NULL fm-msc and bm-msc both expressed major histocompatibility complex ( mhc ) class i but not mhc 
0 i but not mhc class ii antigens and did not elicit allogeneic lymphocyte proliferation in mixed lymphocyte culture . NULL NULL 
1 mhc class ii antigens and did not elicit allogeneic lymphocyte proliferation in mixed lymphocyte culture . NULL NULL NULL NULL NULL 
0 and did not elicit allogeneic lymphocyte proliferation in mixed lymphocyte culture . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL fm-msc or bm-msc obtained from lewis rats were injected into a mhc-mismatched august-copenhagen-irish rat 
19 NULL NULL fm-msc or bm-msc obtained from lewis rats were injected into a mhc-mismatched august-copenhagen-irish rat model of hind limb ischemia 
0 NULL NULL NULL NULL NULL NULL NULL three weeks after injection , blood perfusion and capillary density were significantly higher in 
0 NULL NULL NULL NULL three weeks after injection , blood perfusion and capillary density were significantly higher in the fm-msc and 
19 saline group , and allogeneic fm-msc and bm-msc were still observed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 in nonischemic hind limb tissues , allogeneic fm-msc and bm-msc injection were associated with a comparatively small amount of t lymphocyte 
0 hind limb tissues , allogeneic fm-msc and bm-msc injection were associated with a comparatively small amount of t lymphocyte infiltration , 
14 were associated with a comparatively small amount of t lymphocyte infiltration , compared with the injection of allogeneic splenic lymphocytes . 
19 small amount of t lymphocyte infiltration , compared with the injection of allogeneic splenic lymphocytes . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL in conclusion , allogeneic fm-msc injection did not elicit a lymphocyte proliferative response and provided significant 
17 NULL NULL in conclusion , allogeneic fm-msc injection did not elicit a lymphocyte proliferative response and provided significant improvement in a 
1 conclusion , allogeneic fm-msc injection did not elicit a lymphocyte proliferative response and provided significant improvement in a rat model of 
1 , allogeneic fm-msc injection did not elicit a lymphocyte proliferative response and provided significant improvement in a rat model of hind 
0 injection did not elicit a lymphocyte proliferative response and provided significant improvement in a rat model of hind limb ischemia , 
0 rat model of hind limb ischemia , comparable to the response to bm-msc . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL thus , allogeneic injection of fm-msc may be a new therapeutic strategy for the 
0 of fm-msc may be a new therapeutic strategy for the treatment of severe peripheral vascular disease . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL disclosure of potential conflicts of interest is found at the end of this 
19 NULL NULL NULL NULL NULL NULL NULL bevacizumab and irinotecan therapy in glioblastoma multiforme : a series of 13 cases . 
1 NULL NULL NULL NULL NULL NULL NULL object : endothelial proliferation has been recognized as a marker of high-grade or aggressive 
0 is a humanized immunoglobulin g1 monoclonal antibody to vascular endothelial growth factor that has been shown to have activity in malignant 
16 vascular endothelial growth factor that has been shown to have activity in malignant gliomas when combined with irinotecan . NULL NULL 
0 growth factor that has been shown to have activity in malignant gliomas when combined with irinotecan . NULL NULL NULL NULL 
19 on a case series of 13 patients with recurrent heavily pretreated malignant glioma that was treated with the combination of bevacizumab 
0 a case series of 13 patients with recurrent heavily pretreated malignant glioma that was treated with the combination of bevacizumab and 
19 13 patients with recurrent heavily pretreated malignant glioma that was treated with the combination of bevacizumab and irinotecan . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL methods : standard therapy with primary resection followed by adjuvant chemotherapy and radiation had 
0 NULL NULL NULL NULL methods : standard therapy with primary resection followed by adjuvant chemotherapy and radiation had failed in all 
19 methods : standard therapy with primary resection followed by adjuvant chemotherapy and radiation had failed in all patients . NULL NULL 
19 standard therapy with primary resection followed by adjuvant chemotherapy and radiation had failed in all patients . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the median number of therapies applied , including initial surgery , was 5 ( range 
0 NULL the median number of therapies applied , including initial surgery , was 5 ( range 3-7 therapies ) . NULL 
0 , including initial surgery , was 5 ( range 3-7 therapies ) . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL nine patients were started on bevacizumab at a dose of 5 mg/m2 every 2 
19 NULL NULL NULL NULL NULL NULL NULL NULL four patients received bevacizumab at a dose of 10 mg/m2 ; irinotecan was 
19 bevacizumab at a dose of 10 mg/m2 ; irinotecan was given at a dose of 125 mg/m2 every week for 3 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : of the 13 treated patients , 10 ( 77 
19 NULL NULL NULL NULL NULL results : of the 13 treated patients , 10 ( 77 % ) had a radiologically 
0 10 ( 77 % ) had a radiologically demonstrated partial response and 3 ( 23 % ) had stable disease . 
0 NULL NULL six patients ( 46 % ) had a clinical response . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL six patients ( 46 % ) had a clinical response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the median time to disease progression while on treatment was 24 weeks . NULL NULL NULL 
0 NULL NULL the median time to disease progression while on treatment was 24 weeks . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the median overall survival was 27 weeks . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the disease progressed in 8 patients , despite an initial response . NULL 
0 the disease progressed in 8 patients , despite an initial response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL five patients are still responding to therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL six of the 8 patients whose disease progressed have died . NULL NULL NULL NULL NULL NULL NULL 
5 NULL six of the 8 patients whose disease progressed have died . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL bevacizumab was discontinued in 2 patients because of nonfatal intracranial bleeding . NULL 
0 combination of bevacizumab and irinotecan is safe and has excellent activity even in this relapsed , heavily pretreated population of patients 
19 and has excellent activity even in this relapsed , heavily pretreated population of patients with high-grade malignant glioma , most of 
0 this relapsed , heavily pretreated population of patients with high-grade malignant glioma , most of whom would not be candidates for 
0 glioma , most of whom would not be candidates for clinical trials . NULL NULL NULL NULL NULL NULL NULL NULL 
0 , most of whom would not be candidates for clinical trials . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL intracerebral grafting of cultured autologous skin fibroblasts into the rat striatum 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL intracerebral grafting of cultured autologous skin fibroblasts into the rat striatum : 
0 NULL NULL NULL NULL NULL NULL NULL intracerebral grafting of cultured autologous skin fibroblasts into the rat striatum : an assessment 
0 NULL to identify a suitable donor cell population for gene therapy applications to the central nervous system , primary fibroblasts isolated 
0 suitable donor cell population for gene therapy applications to the central nervous system , primary fibroblasts isolated from skin biopsies and 
19 therapy applications to the central nervous system , primary fibroblasts isolated from skin biopsies and maintained in culture are employed as 
0 nervous system , primary fibroblasts isolated from skin biopsies and maintained in culture are employed as autologous cells for intracerebral grafting 
0 , primary fibroblasts isolated from skin biopsies and maintained in culture are employed as autologous cells for intracerebral grafting within the 
19 and maintained in culture are employed as autologous cells for intracerebral grafting within the adult rat striatum . NULL NULL NULL 
19 maintained in culture are employed as autologous cells for intracerebral grafting within the adult rat striatum . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results from the present investigation reveal that cultured primary skin fibroblasts 
0 NULL NULL NULL NULL NULL NULL NULL results from the present investigation reveal that cultured primary skin fibroblasts cease to proliferate 
19 NULL NULL NULL results from the present investigation reveal that cultured primary skin fibroblasts cease to proliferate once they reach confluence 
1 present investigation reveal that cultured primary skin fibroblasts cease to proliferate once they reach confluence ; these cells are thus contact 
0 that cultured primary skin fibroblasts cease to proliferate once they reach confluence ; these cells are thus contact inhibited in vitro 
15 proliferate once they reach confluence ; these cells are thus contact inhibited in vitro . NULL NULL NULL NULL NULL NULL 
18 once they reach confluence ; these cells are thus contact inhibited in vitro . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL following implantation within the striatum , the volume of the primary fibroblast 
0 NULL NULL NULL NULL NULL NULL the graft size is dependent on the density of the cell suspension , but not 
0 on the density of the cell suspension , but not dependent on either the number of passages the cells are taken 
19 suspension , but not dependent on either the number of passages the cells are taken through in culture prior to grafting 
19 the number of passages the cells are taken through in culture prior to grafting or on the postoperative survival period . 
19 passages the cells are taken through in culture prior to grafting or on the postoperative survival period . NULL NULL NULL 
0 through in culture prior to grafting or on the postoperative survival period . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL reactive astrocytic processes and phagocytic cells are also present in the grafts . 
0 NULL NULL reactive astrocytic processes and phagocytic cells are also present in the grafts . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the grafts are extensively vascularized with capillaries composed of nonfenestrated endothelium ; intercellular junctions are 
5 it is concluded that primary skin fibroblasts are able to survive for at least 8 weeks following intracerebral implantation and continue 
0 are able to survive for at least 8 weeks following intracerebral implantation and continue to synthesize collagen and fibronectin in vivo 
0 able to survive for at least 8 weeks following intracerebral implantation and continue to synthesize collagen and fibronectin in vivo . 
9 at least 8 weeks following intracerebral implantation and continue to synthesize collagen and fibronectin in vivo . NULL NULL NULL NULL 
2 weeks , thereby indicating that primary skin fibroblasts do not produce tumors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL finally , dynamic host-to-graft interactions -- including phagocytic migration , astrocytic hypertrophy and infiltration within 
0 NULL NULL finally , dynamic host-to-graft interactions -- including phagocytic migration , astrocytic hypertrophy and infiltration within the grafts , and 
0 host-to-graft interactions -- including phagocytic migration , astrocytic hypertrophy and infiltration within the grafts , and angiogenesis -- are features that 
3 , astrocytic hypertrophy and infiltration within the grafts , and angiogenesis -- are features that constitute the structural integration of primary 
0 grafts , and angiogenesis -- are features that constitute the structural integration of primary skin fibroblasts grafted within the adult rat 
19 features that constitute the structural integration of primary skin fibroblasts grafted within the adult rat central nervous system . NULL NULL 
0 integration of primary skin fibroblasts grafted within the adult rat central nervous system . NULL NULL NULL NULL NULL NULL NULL 
0 NULL endosialin/tem 1/cd248 is a pericyte marker of embryonic and tumor neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL 
3 endosialin/tem 1/cd248 is a pericyte marker of embryonic and tumor neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL the formation of functional , mature blood vessels depends on the interaction 
17 NULL NULL the formation of functional , mature blood vessels depends on the interaction between endothelial cells and pericytes . NULL 
15 formation of functional , mature blood vessels depends on the interaction between endothelial cells and pericytes . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL commonality exists in the processes involved in vasculature development between tissues whether healthy or diseased 
0 NULL NULL NULL NULL NULL commonality exists in the processes involved in vasculature development between tissues whether healthy or diseased . 
2 NULL NULL commonality exists in the processes involved in vasculature development between tissues whether healthy or diseased . NULL NULL NULL 
0 NULL NULL NULL NULL endosialin/tem 1 is a cell membrane protein that is expressed in blood vessels during embryogenesis and tumorigenesis 
9 NULL endosialin/tem 1 is a cell membrane protein that is expressed in blood vessels during embryogenesis and tumorigenesis but not in 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL antibodies developed to human endosialin were used to investigate endosialin expression and 
0 NULL NULL NULL NULL antibodies developed to human endosialin were used to investigate endosialin expression and function in human prenatal brain 
9 antibodies developed to human endosialin were used to investigate endosialin expression and function in human prenatal brain pericytes and pericytes residing 
0 to human endosialin were used to investigate endosialin expression and function in human prenatal brain pericytes and pericytes residing in tumors 
18 NULL NULL NULL NULL NULL NULL anti-endosialin was capable of preventing pericyte tube formation in culture and inhibited migration . NULL 
2 NULL NULL NULL anti-endosialin was capable of preventing pericyte tube formation in culture and inhibited migration . NULL NULL NULL NULL 
0 NULL anti-endosialin was capable of preventing pericyte tube formation in culture and inhibited migration . NULL NULL NULL NULL NULL NULL 
0 was capable of preventing pericyte tube formation in culture and inhibited migration . NULL NULL NULL NULL NULL NULL NULL NULL 
0 capable of preventing pericyte tube formation in culture and inhibited migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL brain pericytes in culture had higher levels of endosialin/tem 1 than tems-2 , -3 
0 NULL NULL NULL NULL brain pericytes in culture had higher levels of endosialin/tem 1 than tems-2 , -3 , -4 , 
14 NULL NULL NULL NULL NULL immunocytochemistry revealed that endosialin was present in the cytoplasmic body and in the elongated extensions essential 
0 endosialin was present in the cytoplasmic body and in the elongated extensions essential to pericyte function . NULL NULL NULL NULL 
0 present in the cytoplasmic body and in the elongated extensions essential to pericyte function . NULL NULL NULL NULL NULL NULL 
0 cytoplasmic body and in the elongated extensions essential to pericyte function . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL transgenic mice engineered to express human endosialin bred on an immunocompromised 
9 NULL NULL NULL NULL NULL NULL transgenic mice engineered to express human endosialin bred on an immunocompromised background allowed the growth 
4 express human endosialin bred on an immunocompromised background allowed the growth of human tumor xenografts . NULL NULL NULL NULL NULL 
0 bred on an immunocompromised background allowed the growth of human tumor xenografts . NULL NULL NULL NULL NULL NULL NULL NULL 
4 NULL NULL in human colon carcinoma colo205 and ht29 xenografts grown in human endosialin-transgenic mice , endosialin expression was largely confined 
19 human colon carcinoma colo205 and ht29 xenografts grown in human transgenic mice , endosialin expression was largely confined to ng2-expressing perivascular 
9 and ht29 xenografts grown in human endosialin-transgenic mice , endosialin expression was largely confined to ng2-expressing perivascular cells and not cd31-positive 
9 human endosialin-transgenic mice , endosialin expression was largely confined to expressing perivascular cells and not cd31-positive endothelial cells . NULL NULL 
9 expression was largely confined to ng2-expressing perivascular cells and not positive endothelial cells . NULL NULL NULL NULL NULL NULL NULL 
9 methods applied to human ovarian and colon tumors confirmed endosialin expression by pericytes . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL the data indicate that endosialin is strongly expressed by pericytes during periods of active angiogenesis during embryonic and 
0 that endosialin is strongly expressed by pericytes during periods of active angiogenesis during embryonic and tumor development . NULL NULL NULL 
3 endosialin is strongly expressed by pericytes during periods of active angiogenesis during embryonic and tumor development . NULL NULL NULL NULL 
0 by pericytes during periods of active angiogenesis during embryonic and tumor development . NULL NULL NULL NULL NULL NULL NULL NULL 
2 pericytes during periods of active angiogenesis during embryonic and tumor development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL anti-endosialin antibodies may have value in identifying vasculature in malignant tissues . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL with the appropriate agent , targeting endosialin may interfere with blood vessel growth during tumor development 
18 NULL NULL with the appropriate agent , targeting endosialin may interfere with blood vessel growth during tumor development . NULL NULL 
4 appropriate agent , targeting endosialin may interfere with blood vessel growth during tumor development . NULL NULL NULL NULL NULL NULL 
0 , targeting endosialin may interfere with blood vessel growth during tumor development . NULL NULL NULL NULL NULL NULL NULL NULL 
2 targeting endosialin may interfere with blood vessel growth during tumor development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL efficient inhibition of ovarian cancer growth and prolonged survival by transfection with 
4 NULL NULL NULL NULL NULL efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene 
0 NULL NULL NULL efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene , hpnas-4 
5 NULL NULL efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene , hpnas-4 , 
19 efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene , hpnas-4 , in a 
0 NULL NULL NULL NULL NULL in vivo and in vitro results . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL objective : we transfected ovarian cancer cells and administered recombinant plasmid encoding hpnas-4 to 
19 NULL NULL objective : we transfected ovarian cancer cells and administered recombinant plasmid encoding hpnas-4 to nude mice bearing ovarian cancer 
16 nude mice bearing ovarian cancer , aiming to evaluate the effect of hpnas-4 against ovarian cancer in vitro and in vivo 
19 NULL NULL NULL methods : ovarian cancer skov3 cells were transfected with hpnas-4-plasmid , and cell proliferation was evaluated by mtt 
1 cancer skov3 cells were transfected with hpnas-4-plasmid , and cell proliferation was evaluated by mtt assay ; apoptosis was examined by 
5 , and cell proliferation was evaluated by mtt assay ; apoptosis was examined by dna ladder , hoechst33258 staining and flow-cytometric 
0 assay ; apoptosis was examined by dna ladder , hoechst33258 staining and flow-cytometric assays . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL nude mice bearing ovarian cancers were treated with hpnas-4-p/liposome . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor growth was determined and survival was recorded . NULL NULL 
4 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor growth was determined and survival was recorded . NULL NULL NULL 
0 NULL NULL NULL NULL NULL tumor growth was determined and survival was recorded . NULL NULL NULL NULL NULL NULL NULL 
0 NULL tunel assay and microvessel density was assessed to evaluate apoptosis and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 assay and microvessel density was assessed to evaluate apoptosis and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : both inhibition of proliferation ( p < 0.05 ) 
18 NULL NULL NULL NULL NULL NULL NULL results : both inhibition of proliferation ( p < 0.05 ) and induction of 
1 NULL NULL NULL NULL NULL results : both inhibition of proliferation ( p < 0.05 ) and induction of apoptosis ( 
17 both inhibition of proliferation ( p < 0.05 ) and induction of apoptosis ( p < 0.05 ) were observed in 
5 of proliferation ( p < 0.05 ) and induction of apoptosis ( p < 0.05 ) were observed in skov3 cells 
0 and induction of apoptosis ( p < 0.05 ) were observed in skov3 cells transfected with hpnas-4-p in vitro . NULL 
19 ( p < 0.05 ) were observed in skov3 cells transfected with hpnas-4-p in vitro . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL in treated tumor cells in vivo , tumor growth significantly decreased , 
0 NULL NULL NULL NULL NULL NULL NULL NULL in hpnas-4-p-treated tumor cells in vivo , tumor growth significantly decreased , while 
0 NULL NULL NULL in hpnas-4-p-treated tumor cells in vivo , tumor growth significantly decreased , while the survival time of tumor-bearing 
4 NULL NULL in hpnas-4-p-treated tumor cells in vivo , tumor growth significantly decreased , while the survival time of tumor-bearing mice 
18 in hpnas-4-p-treated tumor cells in vivo , tumor growth significantly decreased , while the survival time of tumor-bearing mice was prolonged 
5 in vivo , tumor growth significantly decreased , while the survival time of tumor-bearing mice was prolonged compared with control groups 
17 decreased , while the survival time of tumor-bearing mice was prolonged compared with control groups ( p < 0.05 ) . 
0 the survival time of tumor-bearing mice was prolonged compared with control groups ( p < 0.05 ) . NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL increased apoptosis of tumor cells and decreased angiogenesis in tumor tissue 
5 NULL NULL NULL NULL NULL NULL NULL NULL NULL increased apoptosis of tumor cells and decreased angiogenesis in tumor tissue were 
0 NULL NULL NULL NULL NULL NULL NULL increased apoptosis of tumor cells and decreased angiogenesis in tumor tissue were also observed 
18 NULL NULL NULL NULL increased apoptosis of tumor cells and decreased angiogenesis in tumor tissue were also observed . NULL NULL 
3 NULL NULL NULL increased apoptosis of tumor cells and decreased angiogenesis in tumor tissue were also observed . NULL NULL NULL 
0 NULL increased apoptosis of tumor cells and decreased angiogenesis in tumor tissue were also observed . NULL NULL NULL NULL NULL 
0 tumor cells and decreased angiogenesis in tumor tissue were also observed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL conclusions : our promising results on the potential antitumor effects of hpnas-4 on ovarian cancer 
0 NULL NULL NULL conclusions : our promising results on the potential antitumor effects of hpnas-4 on ovarian cancer in vitro and 
18 NULL conclusions : our promising results on the potential antitumor effects of hpnas-4 on ovarian cancer in vitro and in vivo 
17 vivo may be explained , in part , by the induction of apoptosis and inhibition of angiogenesis . NULL NULL NULL 
5 be explained , in part , by the induction of apoptosis and inhibition of angiogenesis . NULL NULL NULL NULL NULL 
18 , in part , by the induction of apoptosis and inhibition of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 part , by the induction of apoptosis and inhibition of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL consequently , hpnas-4 has potential as a new gene therapy for human ovarian cancer . 
19 NULL consequently , hpnas-4 has potential as a new gene therapy for human ovarian cancer . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis associated with visceral and subcutaneous adipose tissue in severe human 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity 
2 NULL NULL NULL NULL NULL NULL NULL objective : the expansion of adipose tissue is linked to the development of its 
16 NULL NULL objective : the expansion of adipose tissue is linked to the development of its vasculature . NULL NULL NULL 
2 : the expansion of adipose tissue is linked to the development of its vasculature . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL however , the regulation of adipose tissue angiogenesis in humans has not been extensively 
3 NULL NULL NULL however , the regulation of adipose tissue angiogenesis in humans has not been extensively studied . NULL NULL 
3 NULL NULL NULL NULL our aim was to compare the angiogenesis associated with subcutaneous adipose tissue ( sat ) and visceral 
0 NULL NULL NULL our aim was to compare the angiogenesis associated with subcutaneous adipose tissue ( sat ) and visceral adipose 
19 ( vat ) and subcutaneous ( sat ) sites , obtained from 36 obese patients ( mean bmi 46.5 kg/m ( 
0 mean bmi 46.5 kg/m ( 2 ) ) during bariatric surgery , were layered on chick chorioallantoic membrane ( cam ) 
19 kg/m ( 2 ) ) during bariatric surgery , were layered on chick chorioallantoic membrane ( cam ) . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : both sat and vat expressed angiogenic factors without significant 
0 NULL NULL NULL NULL results : both sat and vat expressed angiogenic factors without significant difference for vascular endothelial growth factor 
3 NULL NULL NULL results : both sat and vat expressed angiogenic factors without significant difference for vascular endothelial growth factor ( 
0 results : both sat and vat expressed angiogenic factors without significant difference for vascular endothelial growth factor ( vegf ) expression 
0 vat expressed angiogenic factors without significant difference for vascular endothelial growth factor ( vegf ) expression . NULL NULL NULL NULL 
9 significant difference for vascular endothelial growth factor ( vegf ) expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL adipose tissue layered on cam stimulated angiogenesis . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL adipose tissue layered on cam stimulated angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL adipose tissue layered on cam stimulated angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic stimulation was macroscopically detectable , with engulfment of the samples 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic stimulation was macroscopically detectable , with engulfment of the samples , 
0 NULL NULL NULL NULL NULL NULL angiogenic stimulation was macroscopically detectable , with engulfment of the samples , in 39 % 
0 the samples , in 39 % and was evidenced by angiography in 59 % of the samples . NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL NULL a connection between cam and adipose tissue vessels was evidenced by immunohistochemistry 
14 and adipose tissue vessels was evidenced by immunohistochemistry , with recruitment of both avian and human endothelial cells . NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic potency of adipose tissue was not related to its localization 
14 angiogenic potency of adipose tissue was not related to its localization ( with an angiogenic stimulation in 60 % of sat 
3 tissue was not related to its localization ( with an angiogenic stimulation in 60 % of sat samples and 61 % 
17 was not related to its localization ( with an angiogenic stimulation in 60 % of sat samples and 61 % of 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulation of angiogenesis by adipose tissue was nearly abolished by bevacizumab 
3 NULL NULL NULL NULL NULL NULL NULL NULL stimulation of angiogenesis by adipose tissue was nearly abolished by bevacizumab , which 
18 NULL NULL stimulation of angiogenesis by adipose tissue was nearly abolished by bevacizumab , which specifically targets human vegf . NULL 
16 adipose tissue was nearly abolished by bevacizumab , which specifically targets human vegf . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL conclusions : we have established a model to study the regulation of angiogenesis by human 
16 conclusions : we have established a model to study the regulation of angiogenesis by human adipose tissue . NULL NULL NULL 
3 we have established a model to study the regulation of angiogenesis by human adipose tissue . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL this model highlighted the role of vegf in angiogenesis in both sat and vat . 
3 NULL NULL this model highlighted the role of vegf in angiogenesis in both sat and vat . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the in vivo properties of stx243 : a potent angiogenesis inhibitor in breast cancer 
3 NULL the in vivo properties of stx243 : a potent angiogenesis inhibitor in breast cancer . NULL NULL NULL NULL NULL 
0 the in vivo properties of stx243 : a potent angiogenesis inhibitor in breast cancer . NULL NULL NULL NULL NULL NULL 
0 2-ethyloestradiol-3 , 17-o , o-bis-sulphamate ( stx243 ) has been developed as a potent antiangiogenic and antitumour compound . NULL NULL 
3 o-bis-sulphamate ( stx243 ) has been developed as a potent angiogenic and antitumour compound . NULL NULL NULL NULL NULL NULL 
0 of this study was to ascertain whether stx243 is more active in vivo than the clinically relevant drug 2-methoxyoestradiol ( 2-meoe2 
4 NULL NULL NULL NULL NULL NULL NULL NULL the tumour growth inhibition efficacy , antiangiogenic potential and pharmacokinetics of stx243 were 
18 NULL NULL NULL NULL NULL NULL NULL the tumour growth inhibition efficacy , antiangiogenic potential and pharmacokinetics of stx243 were examined 
0 NULL NULL NULL NULL NULL NULL the tumour growth inhibition efficacy , antiangiogenic potential and pharmacokinetics of stx243 were examined using 
3 NULL NULL NULL NULL the tumour growth inhibition efficacy , angiogenic potential and pharmacokinetics of stx243 were examined using four in 
18 NULL NULL NULL the tumour growth inhibition efficacy , antiangiogenic potential and pharmacokinetics of stx243 were examined using four in vivo 
18 NULL NULL NULL both stx243 and stx140 were capable of retarding the growth of mda-mb-231 xenograft tumours ( 72 and 63 
4 NULL both stx243 and stx140 were capable of retarding the growth of mda-mb-231 xenograft tumours ( 72 and 63 % , 
0 72 and 63 % , respectively ) , whereas no inhibition was observed for animals treated with 2-meoe2 . NULL NULL 
0 63 % , respectively ) , whereas no inhibition was observed for animals treated with 2-meoe2 . NULL NULL NULL NULL 
19 respectively ) , whereas no inhibition was observed for animals treated with 2-meoe2 . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL further tumour inhibition studies showed that stx243 was also active against mcf-7 paclitaxel-resistant 
0 NULL NULL NULL NULL NULL NULL further tumour inhibition studies showed that stx243 was also active against mcf-7 paclitaxel-resistant tumours . 
16 NULL further tumour inhibition studies showed that stx243 was also active against mcf-7 paclitaxel-resistant tumours . NULL NULL NULL NULL NULL 
3 NULL NULL using a matrigel plug-based model , in vivo angiogenesis was restricted with stx243 and stx140 ( 50 and 72 
18 using a matrigel plug-based model , in vivo angiogenesis was restricted with stx243 and stx140 ( 50 and 72 % , 
3 ( -1 ) oral dose ) , thereby showing the angiogenic activity of both compounds . NULL NULL NULL NULL NULL 
18 -1 ) oral dose ) , thereby showing the antiangiogenic activity of both compounds . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results show that stx243 is a potent in vivo drug and 
0 is a potent in vivo drug and could be clinically effective at treating a number of oncological conditions . NULL NULL 
0 potent in vivo drug and could be clinically effective at treating a number of oncological conditions . NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL m-csf signals through the mapk/erk pathway via sp1 to induce vegf production 
17 NULL m-csf signals through the mapk/erk pathway via sp1 to induce vegf production and induces angiogenesis in vivo . NULL NULL 
9 signals through the mapk/erk pathway via sp1 to induce vegf production and induces angiogenesis in vivo . NULL NULL NULL NULL 
0 the mapk/erk pathway via sp1 to induce vegf production and induces angiogenesis in vivo . NULL NULL NULL NULL NULL NULL 
3 mapk/erk pathway via sp1 to induce vegf production and induces angiogenesis in vivo . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL background : m-csf recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases 
16 NULL NULL NULL background : m-csf recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors . NULL 
0 NULL NULL background : m-csf recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors . NULL NULL 
3 : m-csf recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors . NULL NULL NULL NULL NULL 
14 recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in tumors . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL vegf is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new 
3 NULL NULL NULL NULL vegf is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel 
17 NULL vegf is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation . NULL 
1 a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel formation . NULL NULL NULL NULL 
2 as it promotes endothelial cell proliferation and new blood vessel formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL previously , we reported that in vitro m-csf induces the expression of biologically-active vegf from human monocytes . NULL 
9 previously , we reported that in vitro m-csf induces the expression of biologically-active vegf from human monocytes . NULL NULL NULL 
0 we reported that in vitro m-csf induces the expression of active vegf from human monocytes . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL methodology and results : in this study , we demonstrate the molecular mechanism 
0 results : in this study , we demonstrate the molecular mechanism of m-csf-induced vegf production . NULL NULL NULL NULL NULL 
17 in this study , we demonstrate the molecular mechanism of induced vegf production . NULL NULL NULL NULL NULL NULL NULL 
9 study , we demonstrate the molecular mechanism of m-csf-induced vegf production . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL using a construct containing the vegf promoter linked to a luciferase reporter , we found that a mutation 
18 to a luciferase reporter , we found that a mutation reducing hif binding to the vegf promoter had no significant effect 
15 luciferase reporter , we found that a mutation reducing hif binding to the vegf promoter had no significant effect on luciferase 
0 mutation reducing hif binding to the vegf promoter had no significant effect on luciferase production induced by m-csf stimulation . NULL 
16 reducing hif binding to the vegf promoter had no significant effect on luciferase production induced by m-csf stimulation . NULL NULL 
9 to the vegf promoter had no significant effect on luciferase production induced by m-csf stimulation . NULL NULL NULL NULL NULL 
17 the vegf promoter had no significant effect on luciferase production induced by m-csf stimulation . NULL NULL NULL NULL NULL NULL 
17 had no significant effect on luciferase production induced by m-csf stimulation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL further analysis revealed that m-csf induced vegf through the mapk/erk signaling pathway via the transcription factor 
16 NULL NULL NULL NULL NULL further analysis revealed that m-csf induced vegf through the mapk/erk signaling pathway via the transcription factor 
0 m-csf induced vegf through the mapk/erk signaling pathway via the transcription factor , sp1 . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL thus , inhibition of either erk or sp1 suppressed m-csf-induced vegf at the 
18 NULL NULL thus , inhibition of either erk or sp1 suppressed m-csf-induced vegf at the mrna and protein level . NULL 
17 NULL thus , inhibition of either erk or sp1 suppressed induced vegf at the mrna and protein level . NULL NULL 
0 of either erk or sp1 suppressed m-csf-induced vegf at the mrna and protein level . NULL NULL NULL NULL NULL NULL 
0 erk or sp1 suppressed m-csf-induced vegf at the mrna and protein level . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL m-csf also induced the nuclear localization of sp1 , which was blocked by 
14 NULL NULL NULL NULL NULL m-csf also induced the nuclear localization of sp1 , which was blocked by erk inhibition . 
18 also induced the nuclear localization of sp1 , which was blocked by erk inhibition . NULL NULL NULL NULL NULL NULL 
18 nuclear localization of sp1 , which was blocked by erk inhibition . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL finally , mutating the sp1 binding sites within the vegf promoter or inhibiting 
0 NULL NULL NULL NULL NULL finally , mutating the sp1 binding sites within the vegf promoter or inhibiting erk decreased vegf 
18 mutating the sp1 binding sites within the vegf promoter or inhibiting erk decreased vegf promoter activity in m-csf-treated human monocytes . 
18 sp1 binding sites within the vegf promoter or inhibiting erk decreased vegf promoter activity in m-csf-treated human monocytes . NULL NULL 
0 within the vegf promoter or inhibiting erk decreased vegf promoter activity in m-csf-treated human monocytes . NULL NULL NULL NULL NULL 
19 vegf promoter or inhibiting erk decreased vegf promoter activity in treated human monocytes . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL to evaluate the biological significance of m-csf induced vegf production , we used an in vivo angiogenesis model 
9 NULL to evaluate the biological significance of m-csf induced vegf production , we used an in vivo angiogenesis model to illustrate 
0 the biological significance of m-csf induced vegf production , we used an in vivo angiogenesis model to illustrate the ability of 
3 m-csf induced vegf production , we used an in vivo angiogenesis model to illustrate the ability of m-csf to recruit mononuclear 
16 we used an in vivo angiogenesis model to illustrate the ability of m-csf to recruit mononuclear phagocytes , increase vegf levels 
14 vivo angiogenesis model to illustrate the ability of m-csf to recruit mononuclear phagocytes , increase vegf levels , and enhance angiogenesis 
17 illustrate the ability of m-csf to recruit mononuclear phagocytes , increase vegf levels , and enhance angiogenesis . NULL NULL NULL 
0 ability of m-csf to recruit mononuclear phagocytes , increase vegf levels , and enhance angiogenesis . NULL NULL NULL NULL NULL 
17 to recruit mononuclear phagocytes , increase vegf levels , and enhance angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 recruit mononuclear phagocytes , increase vegf levels , and enhance angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL importantly , the addition of a neutralizing vegf antibody abolished m-csf-induced blood vessel formation 
18 NULL importantly , the addition of a neutralizing vegf antibody abolished m-csf-induced blood vessel formation . NULL NULL NULL NULL NULL 
17 importantly , the addition of a neutralizing vegf antibody abolished induced blood vessel formation . NULL NULL NULL NULL NULL NULL 
2 addition of a neutralizing vegf antibody abolished m-csf-induced blood vessel formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL conclusion : these data delineate an erk- and dependent mechanism of m-csf induced vegf production and demonstrate for the 
0 NULL conclusion : these data delineate an erk- and sp1-dependent mechanism of m-csf induced vegf production and demonstrate for the first 
17 these data delineate an erk- and sp1-dependent mechanism of m-csf induced vegf production and demonstrate for the first time the ability 
9 delineate an erk- and sp1-dependent mechanism of m-csf induced vegf production and demonstrate for the first time the ability of m-csf 
0 induced vegf production and demonstrate for the first time the ability of m-csf to induce angiogenesis via vegf in vivo . 
17 demonstrate for the first time the ability of m-csf to induce angiogenesis via vegf in vivo . NULL NULL NULL NULL 
16 demonstrate for the first time the ability of m-csf to induce angiogenesis via vegf in vivo . NULL NULL NULL NULL 
3 for the first time the ability of m-csf to induce angiogenesis via vegf in vivo . NULL NULL NULL NULL NULL 
0 novel integrin alpha5beta1 antagonistic peptide , a5-1 , screened by protein chip system as a potent angiogenesis inhibitor . NULL NULL 
3 a5-1 , screened by protein chip system as a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 , screened by protein chip system as a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL integrin alpha5beta1 immobilized on a proteochip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of 
15 NULL NULL NULL NULL NULL NULL NULL the integrin alpha5beta1-fibronectin interaction was demonstrated on the chip . NULL NULL NULL NULL 
0 peptide ligand , a5-1 ( vilvlf ) , with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with 
0 this chip-based screening method on the basis of a competitive inhibition assay . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL a5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner ( ic ( 
15 NULL NULL NULL NULL NULL NULL a5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner ( ic ( 50 ) ; 
0 NULL NULL NULL a5-1 inhibits the integrin-fibronectin interaction in a dependent manner ( ic ( 50 ) ; 1.56+/-0.28 microm . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , it inhibits human umbilical vein endothelial cell proliferation , 
18 NULL NULL NULL NULL NULL NULL in addition , it inhibits human umbilical vein endothelial cell proliferation , migration , adhesion 
1 in addition , it inhibits human umbilical vein endothelial cell proliferation , migration , adhesion , tubular network formation , and 
14 , it inhibits human umbilical vein endothelial cell proliferation , migration , adhesion , tubular network formation , and bfgf-induced neovascularization 
15 inhibits human umbilical vein endothelial cell proliferation , migration , adhesion , tubular network formation , and bfgf-induced neovascularization in a 
2 endothelial cell proliferation , migration , adhesion , tubular network formation , and bfgf-induced neovascularization in a chick chorioallantoic membrane . 
17 , migration , adhesion , tubular network formation , and induced neovascularization in a chick chorioallantoic membrane . NULL NULL NULL 
3 migration , adhesion , tubular network formation , and bfgf-induced neovascularization in a chick chorioallantoic membrane . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest that a5-1 will be a potent inhibitor of neovascularization 
0 NULL these results suggest that a5-1 will be a potent inhibitor of neovascularization . NULL NULL NULL NULL NULL NULL NULL 
3 results suggest that a5-1 will be a potent inhibitor of neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL evaluation of electrical stimulation for ischemic wound therapy : a feasibility study using the 
0 NULL NULL NULL evaluation of electrical stimulation for ischemic wound therapy : a feasibility study using the lapine wound model . 
0 NULL NULL NULL NULL NULL NULL chronic wounds are a major secondary complication for many people with impaired mobility . NULL 
0 wounds are a major secondary complication for many people with impaired mobility . NULL NULL NULL NULL NULL NULL NULL NULL 
0 are a major secondary complication for many people with impaired mobility . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL electrical stimulation ( es ) has been recommended as a adjunctive therapy 
0 stimulation ( es ) has been recommended as a adjunctive therapy , however optimal treatment paradigms have not been established . 
0 has been recommended as a adjunctive therapy , however optimal treatment paradigms have not been established . NULL NULL NULL NULL 
0 adjunctive therapy , however optimal treatment paradigms have not been established . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 group seeks to determine the basic mechanisms underlying es wound therapy , an area where understanding is currently limited . NULL 
0 es wound therapy , an area where understanding is currently limited . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 the ahn/mustoe lapine wound model for systematic investigation of the effects of electrical stimulation on ischemic wound therapy . NULL NULL 
0 wound model for systematic investigation of the effects of electrical stimulation on ischemic wound therapy . NULL NULL NULL NULL NULL 
0 investigation of the effects of electrical stimulation on ischemic wound therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL a standardized surgical procedure incorporated a hybrid stimulation system comprising an implantable mini-stimulator 
0 NULL NULL NULL a standardized surgical procedure incorporated a hybrid stimulation system comprising an implantable mini-stimulator and surface electrodes , with 
0 ( 3 kg weight ) were employed to evaluate the effects of two empirically selected stimulation paradigms applied continuously for 7-21 
0 were employed to evaluate the effects of two empirically selected stimulation paradigms applied continuously for 7-21 days , using each animal 
0 for 7-21 days , using each animal as its own control . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL outcomes measures included transcutaneous blood gas levels , histology , total rna content and analysis of alpha2 
0 v ) collagen ( col-v ) , and vascular endothelial growth factor ( vegf ) expression using real-time quantitative pcr . 
9 ) , and vascular endothelial growth factor ( vegf ) expression using real-time quantitative pcr . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL all markers for stimulated wounds showed increased activity relative to non-stimulated control wounds between 
0 NULL NULL NULL NULL NULL all markers for stimulated wounds showed increased activity relative to non-stimulated control wounds between 7 and 
0 NULL NULL NULL NULL all markers for stimulated wounds showed increased activity relative to non-stimulated control wounds between 7 and 14 
0 NULL NULL NULL all markers for stimulated wounds showed increased activity relative to non-stimulated control wounds between 7 and 14 days 
0 all markers for stimulated wounds showed increased activity relative to stimulated control wounds between 7 and 14 days following injury , 
0 markers for stimulated wounds showed increased activity relative to non-stimulated control wounds between 7 and 14 days following injury , with 
0 between 7 and 14 days following injury , with peak activity at 14 days . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL by 21 days post-injury , all activity had returned to near baseline level . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL vegf and col-iv levels were found to be significantly higher for pattern a ( 
0 14 days , implying that pattern a may be more effective at promoting angiogenesis . NULL NULL NULL NULL NULL NULL 
17 , implying that pattern a may be more effective at promoting angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 implying that pattern a may be more effective at promoting angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL both col-i and col-v showed statistically significant ( p less than 0.05 ) increased activity 
0 NULL NULL NULL NULL both col-i and col-v showed statistically significant ( p less than 0.05 ) increased activity between day 
0 col-v showed statistically significant ( p less than 0.05 ) increased activity between day 7 and day 14 for pattern a 
17 showed statistically significant ( p less than 0.05 ) increased activity between day 7 and day 14 for pattern a , 
16 day 14 for pattern a , potentially indicating a continued effect on matrix remodeling . NULL NULL NULL NULL NULL NULL 
0 for pattern a , potentially indicating a continued effect on matrix remodeling . NULL NULL NULL NULL NULL NULL NULL NULL 
7 pattern a , potentially indicating a continued effect on matrix remodeling . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the early closure of all wounds implies that the rabbit ear model may 
0 , angiopoietin-1 and -2 in bronchial asthma : new molecular targets in airway angiogenesis and microvascular remodeling . NULL NULL NULL 
3 -2 in bronchial asthma : new molecular targets in airway angiogenesis and microvascular remodeling . NULL NULL NULL NULL NULL NULL 
7 asthma : new molecular targets in airway angiogenesis and microvascular remodeling . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL airway angiogenesis and microvascular remodeling are known features of bronchial asthma , 
7 NULL NULL NULL NULL NULL NULL airway angiogenesis and microvascular remodeling are known features of bronchial asthma , but the mechanisms 
0 features of bronchial asthma , but the mechanisms of these structural alterations are just beginning to be elucidated . NULL NULL 
0 of bronchial asthma , but the mechanisms of these structural alterations are just beginning to be elucidated . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) , one of the most potent 
3 factor ( vegf ) , one of the most potent angiogenic factors , stimulates endothelial cell proliferation and induces the angiogenesis 
17 ) , one of the most potent angiogenic factors , stimulates endothelial cell proliferation and induces the angiogenesis . NULL NULL 
1 of the most potent angiogenic factors , stimulates endothelial cell proliferation and induces the angiogenesis . NULL NULL NULL NULL NULL 
17 most potent angiogenic factors , stimulates endothelial cell proliferation and induces the angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 angiogenic factors , stimulates endothelial cell proliferation and induces the angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 recently , considerable attentions have been devoted to the physiological roles of angiopoietin ( ang ) -1 and -2 as regulatory 
0 roles of angiopoietin ( ang ) -1 and -2 as regulatory factors of vegf . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL ang-1 has been shown to induce the migration and sprouting of endothelial cells , and coexpression 
14 NULL NULL NULL ang-1 has been shown to induce the migration and sprouting of endothelial cells , and coexpression of ang-1 
2 NULL ang-1 has been shown to induce the migration and sprouting of endothelial cells , and coexpression of ang-1 and vegf 
9 induce the migration and sprouting of endothelial cells , and coexpression of ang-1 and vegf enhanced angiogenesis . NULL NULL NULL 
17 of endothelial cells , and coexpression of ang-1 and vegf enhanced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 endothelial cells , and coexpression of ang-1 and vegf enhanced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL in the presence of high levels of vegf , ang-2 also promotes rapid 
0 NULL NULL NULL NULL NULL in the presence of high levels of vegf , ang-2 also promotes rapid increase in capillary 
17 the presence of high levels of vegf , ang-2 also promotes rapid increase in capillary diameter , remodeling of the basal 
0 of high levels of vegf , ang-2 also promotes rapid increase in capillary diameter , remodeling of the basal lamina , 
7 , ang-2 also promotes rapid increase in capillary diameter , remodeling of the basal lamina , proliferation and migration of endothelial 
1 in capillary diameter , remodeling of the basal lamina , proliferation and migration of endothelial cells , and stimulates sprouting of 
14 diameter , remodeling of the basal lamina , proliferation and migration of endothelial cells , and stimulates sprouting of new blood 
17 lamina , proliferation and migration of endothelial cells , and stimulates sprouting of new blood vessels . NULL NULL NULL NULL 
2 , proliferation and migration of endothelial cells , and stimulates sprouting of new blood vessels . NULL NULL NULL NULL NULL 
16 NULL NULL thus , vegf , ang-1 and -2 may play complementary and coordinated roles in airway angiogenesis and microvascular remodeling 
16 NULL thus , vegf , ang-1 and -2 may play complementary and coordinated roles in airway angiogenesis and microvascular remodeling , 
16 , vegf , ang-1 and -2 may play complementary and coordinated roles in airway angiogenesis and microvascular remodeling , and these 
16 vegf , ang-1 and -2 may play complementary and coordinated roles in airway angiogenesis and microvascular remodeling , and these structural 
3 and -2 may play complementary and coordinated roles in airway angiogenesis and microvascular remodeling , and these structural changes are potentially 
7 play complementary and coordinated roles in airway angiogenesis and microvascular remodeling , and these structural changes are potentially reversible by therapeutic 
0 roles in airway angiogenesis and microvascular remodeling , and these structural changes are potentially reversible by therapeutic intervention . NULL NULL 
0 in airway angiogenesis and microvascular remodeling , and these structural changes are potentially reversible by therapeutic intervention . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the scope of the present review is to discuss from a clinical point of view 
0 scope of the present review is to discuss from a clinical point of view the potential interactions between vegf and angiopoietins 
0 is to discuss from a clinical point of view the potential interactions between vegf and angiopoietins in the asthmatic airways , 
15 to discuss from a clinical point of view the potential interactions between vegf and angiopoietins in the asthmatic airways , and 
0 the asthmatic airways , and focus on the therapeutic implications targeting for these angiogenic factors . NULL NULL NULL NULL NULL 
3 , and focus on the therapeutic implications targeting for these angiogenic factors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL recently , there is an increasing number of patents which have been focused on the inhibitors 
0 patents which have been focused on the inhibitors of vegf action . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 we will also discuss several patents regarding inhibitors of vegf action in the present review . NULL NULL NULL NULL NULL 
0 discuss several patents regarding inhibitors of vegf action in the present review . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effect of transplanted mesenchymal stem cells from rats of different ages 
19 NULL NULL NULL NULL NULL NULL NULL NULL effect of transplanted mesenchymal stem cells from rats of different ages on the 
0 from rats of different ages on the improvement of heart function after acute myocardial infarction . NULL NULL NULL NULL NULL 
19 NULL NULL background : mesenchymal stem cells ( mscs ) transplantation is of therapeutic potential after ischemic injury in both experimental 
0 mesenchymal stem cells ( mscs ) transplantation is of therapeutic potential after ischemic injury in both experimental and clinical studies . 
0 of therapeutic potential after ischemic injury in both experimental and clinical studies . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL but little is known about the characteristics of young derived mscs transplanted to old patients with ami . NULL NULL 
19 little is known about the characteristics of young donor-derived mscs transplanted to old patients with ami . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the present study was designed to investigate the effect of transplanted mscs 
0 NULL NULL the present study was designed to investigate the effect of transplanted mscs from rats of different ages on the 
19 the present study was designed to investigate the effect of transplanted mscs from rats of different ages on the improvement of 
0 from rats of different ages on the improvement of heart function after ami . NULL NULL NULL NULL NULL NULL NULL 
19 methods : mscs from sprague-dawley ( sd ) rats were isolated and cultured in vitro . NULL NULL NULL NULL NULL 
19 mscs from sprague-dawley ( sd ) rats were isolated and cultured in vitro . NULL NULL NULL NULL NULL NULL NULL 
5 NULL NULL NULL NULL NULL NULL NULL NULL NULL the apoptosis characteristics of mscs were observed under conditions of ischemia and 
0 NULL NULL NULL NULL the apoptosis characteristics of mscs were observed under conditions of ischemia and anoxia . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL sd rats underwent mi received intramyocardial injection of mscs from young donor rats 
0 NULL NULL NULL NULL NULL NULL sd rats underwent mi received intramyocardial injection of mscs from young donor rats ( n 
19 NULL NULL NULL NULL sd rats underwent mi received intramyocardial injection of mscs from young donor rats ( n = 8 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL ami control group received equal volume physiological saline . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL ami control group received equal volume physiological saline . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL immunofluorescence was used to observe the differentiation of the grafted cells into cardiomyocytes 
2 NULL NULL NULL NULL immunofluorescence was used to observe the differentiation of the grafted cells into cardiomyocytes . NULL NULL NULL 
19 NULL immunofluorescence was used to observe the differentiation of the grafted cells into cardiomyocytes . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL four weeks after cell transplantation , reverse transcriptase-polymerase chain reaction ( rt-pcr ) and immunohistochemistry 
0 chain reaction ( rt-pcr ) and immunohistochemistry for vascular endothelial growth factor ( vegf ) , viii-factor immunohistochemistry for vessel density 
5 immunohistochemistry for vessel density , tunel , caspase-3 for cardiomyocyte apoptosis , echocardiography and hemodynamic detection for heart function were performed 
0 for cardiomyocyte apoptosis , echocardiography and hemodynamic detection for heart function were performed . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the apoptosis rate of the old donor-derived mscs group 
5 NULL NULL NULL NULL NULL NULL NULL results : the apoptosis rate of the old donor-derived mscs group was significantly higher 
0 NULL NULL results : the apoptosis rate of the old derived mscs group was significantly higher than that of the young 
0 mscs group was significantly higher than that of the young derived mscs group under conditions of ischemia and anoxia ( p 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL engrafted mscs survived , proliferated and differentiated into myocardium-like cells . 
5 NULL NULL NULL NULL NULL NULL NULL NULL engrafted mscs survived , proliferated and differentiated into myocardium-like cells . NULL NULL 
1 NULL NULL NULL NULL NULL NULL engrafted mscs survived , proliferated and differentiated into myocardium-like cells . NULL NULL NULL NULL 
2 NULL NULL NULL NULL engrafted mscs survived , proliferated and differentiated into myocardium-like cells . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL vegf gene expression and capillary density in the old donor-derived group were lower 
0 NULL vegf gene expression and capillary density in the old derived group were lower than those in the young donor-derived group 
0 old donor-derived group were lower than those in the young derived group but higher than those in the control group ( 
0 the young donor-derived group but higher than those in the control group ( p less than 0.05 ) . NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL the transplantation of old donor-derived mscs attenuated apoptosis of cardiomyocytes in the 
0 NULL NULL NULL NULL NULL NULL the transplantation of old derived mscs attenuated apoptosis of cardiomyocytes in the peri-infarct region compared 
18 NULL NULL NULL NULL the transplantation of old donor-derived mscs attenuated apoptosis of cardiomyocytes in the peri-infarct region compared with the 
5 NULL NULL NULL the transplantation of old donor-derived mscs attenuated apoptosis of cardiomyocytes in the peri-infarct region compared with the control 
0 apoptosis of cardiomyocytes in the peri-infarct region compared with the control group and the effect was elevated in young donor-derived mscs 
16 the peri-infarct region compared with the control group and the effect was elevated in young donor-derived mscs ( p less than 
17 region compared with the control group and the effect was elevated in young donor-derived mscs ( p less than 0.05 ) 
0 the control group and the effect was elevated in young derived mscs ( p less than 0.05 ) . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the heart functions ( left ventricle ejection fraction ( lvef ) , left 
0 , left ventricle fractional shortening ( lvfs ) ) were improved more significantly in the old donor-derived mscs group than in 
0 lvfs ) ) were improved more significantly in the old derived mscs group than in the control group and the heart 
0 significantly in the old donor-derived mscs group than in the control group and the heart function in the young donor-derived mscs 
0 mscs group than in the control group and the heart function in the young donor-derived mscs group further improved ( p 
0 the control group and the heart function in the young derived mscs group further improved ( p less than 0.05 ) 
17 the heart function in the young donor-derived mscs group further improved ( p less than 0.05 ) . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusions : young derived mscs can improve heart function significantly through angiogenesis and decreasing 
17 NULL NULL NULL NULL conclusions : young donor-derived mscs can improve heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis when 
16 NULL NULL NULL NULL conclusions : young donor-derived mscs can improve heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis when 
0 NULL NULL conclusions : young donor-derived mscs can improve heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis when transplanted to 
3 : young donor-derived mscs can improve heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis when transplanted to the infarcted area 
18 donor-derived mscs can improve heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis when transplanted to the infarcted area . NULL 
5 can improve heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis when transplanted to the infarcted area . NULL NULL NULL 
19 heart function significantly through angiogenesis and decreasing cardiomyocyte apoptosis when transplanted to the infarcted area . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical significance of chicken ovalbumin upstream promoter-transcription factor ii expression in 
0 NULL NULL NULL NULL clinical significance of chicken ovalbumin upstream transcription factor ii expression in human colorectal cancer . NULL NULL 
9 NULL clinical significance of chicken ovalbumin upstream promoter-transcription factor ii expression in human colorectal cancer . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL chicken ovalbumin upstream transcription factor ii ( coup-tfii ) plays an essential role in 
16 NULL chicken ovalbumin upstream promoter-transcription factor ii ( coup-tfii ) plays an essential role in angiogenesis and development . NULL NULL 
16 ovalbumin upstream promoter-transcription factor ii ( coup-tfii ) plays an essential role in angiogenesis and development . NULL NULL NULL NULL 
16 upstream promoter-transcription factor ii ( coup-tfii ) plays an essential role in angiogenesis and development . NULL NULL NULL NULL NULL 
3 factor ii ( coup-tfii ) plays an essential role in angiogenesis and development . NULL NULL NULL NULL NULL NULL NULL 
0 ( coup-tfii ) plays an essential role in angiogenesis and development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL a previous study showed that the expression of coup-tfii enhanced invasiveness of human lung 
9 NULL NULL NULL NULL a previous study showed that the expression of coup-tfii enhanced invasiveness of human lung carcinoma cells . 
17 NULL a previous study showed that the expression of coup-tfii enhanced invasiveness of human lung carcinoma cells . NULL NULL NULL 
14 a previous study showed that the expression of coup-tfii enhanced invasiveness of human lung carcinoma cells . NULL NULL NULL NULL 
0 , no published data are available concerning the biological and clinical significance of coup-tfii expression in colorectal cancer . NULL NULL 
9 are available concerning the biological and clinical significance of coup-tfii expression in colorectal cancer . NULL NULL NULL NULL NULL NULL 
9 NULL NULL thus , our objective was to explore the expression of coup-tfii in colorectal cancer as well as its association 
0 expression of coup-tfii in colorectal cancer as well as its association with clinicopathological features , and to evaluate the role of 
16 its association with clinicopathological features , and to evaluate the role of coup-tfii as a prognostic indicator in colorectal cancer . 
14 NULL NULL NULL NULL NULL NULL NULL we investigated the presence of coup-tfii in human colorectal cancer tissues and adjacent normal 
9 NULL NULL NULL NULL NULL NULL the correlation between the expression of coup-tfii and clinicopathologic features was investigated . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the 3-year free survival ( dfs ) and overall survival ( os ) 
0 NULL NULL NULL NULL NULL NULL NULL the 3-year disease-free survival ( dfs ) and overall survival ( os ) of 
0 NULL the 3-year disease-free survival ( dfs ) and overall survival ( os ) of patients with tumors expressing different levels 
9 and overall survival ( os ) of patients with tumors expressing different levels of coup-tfii were evaluated by the kaplan-meier method 
0 survival ( os ) of patients with tumors expressing different levels of coup-tfii were evaluated by the kaplan-meier method . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL no significant correlation was found between coup-tfii expression and age at surgery 
9 NULL NULL NULL no significant correlation was found between coup-tfii expression and age at surgery , gender , histopathologic differentiation , 
0 significant correlation was found between coup-tfii expression and age at surgery , gender , histopathologic differentiation , vessel invasion , carcinoembryonic 
0 coup-tfii expression and age at surgery , gender , histopathologic differentiation , vessel invasion , carcinoembryonic antigen ( cea ) , 
14 age at surgery , gender , histopathologic differentiation , vessel invasion , carcinoembryonic antigen ( cea ) , or nodal involvement 
0 invasion , carcinoembryonic antigen ( cea ) , or nodal involvement . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL however , survival analysis showed that the coup-tfii-positive group had a significantly better 
0 NULL NULL NULL NULL NULL NULL however , survival analysis showed that the coup-tfii-positive group had a significantly better os compared 
9 NULL NULL NULL however , survival analysis showed that the positive group had a significantly better os compared to coup-tfii-negative group 
9 the coup-tfii-positive group had a significantly better os compared to negative group ( 80.4 % vs. 57.7 % , p=0.0491 ) 
0 NULL NULL NULL NULL NULL NULL NULL based on our results , coup-tfii may represent a biomarker for good prognosis in 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL involvement of pten promoter methylation in cerebral cavernous malformations . NULL 
0 cavernous malformations ( ccms ) are prevalent cerebral vascular lesions involving aberrant angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
0 malformations ( ccms ) are prevalent cerebral vascular lesions involving aberrant angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 ( ccms ) are prevalent cerebral vascular lesions involving aberrant angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL however , the underlying mechanism is poorly understood . NULL NULL NULL NULL NULL NULL 
0 homolog deleted on chromosome 10 ( pten ) , a tumor suppressor , is frequently deficient in various pathologies due to 
0 deleted on chromosome 10 ( pten ) , a tumor suppressor , is frequently deficient in various pathologies due to mutation 
9 ( pten ) , a tumor suppressor , is frequently deficient in various pathologies due to mutation or epigenetic alterations . 
0 frequently deficient in various pathologies due to mutation or epigenetic alterations . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL pten promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors 
0 NULL NULL pten promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors . NULL NULL 
17 NULL pten promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors . NULL NULL NULL 
17 promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors . NULL NULL NULL NULL NULL 
3 is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the present study aimed to investigate whether pten promoter methylation was involved 
0 present study aimed to investigate whether pten promoter methylation was involved in ccms . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL methods : pten promoter methylation was detected in surgical specimens of ccms ( n=69 ) by methylation-specific 
0 NULL NULL methods : pten promoter methylation was detected in surgical specimens of ccms ( n=69 ) by methylation-specific polymerase chain 
0 NULL NULL NULL the methylation status was correlated to the clinical manifestations and to pten expression , which was analyzed by 
9 status was correlated to the clinical manifestations and to pten expression , which was analyzed by both western blot and immunohistochemistry 
1 NULL NULL NULL NULL NULL NULL to investigate the endothelial proliferation and the potential signaling pathways affected by pten methylation , 
0 NULL NULL NULL to investigate the endothelial proliferation and the potential signaling pathways affected by pten methylation , proliferating cell nuclear 
0 NULL to investigate the endothelial proliferation and the potential signaling pathways affected by pten methylation , proliferating cell nuclear antigen as 
16 to investigate the endothelial proliferation and the potential signaling pathways affected by pten methylation , proliferating cell nuclear antigen as well 
0 and the potential signaling pathways affected by pten methylation , proliferating cell nuclear antigen as well as phosphor-akt and phosphor-erk1 , 
0 antigen as well as phosphor-akt and phosphor-erk1 , 2 were detected by immunofluorescence and western blot , respectively , in ccm 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : methylation-specific polymerase chain reaction revealed pten promoter methylation in 
0 NULL NULL NULL strikingly , 5 of 6 familial ccms showed pten promoter methylation ( 83.3 % ) , which was 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , pten promoter methylation appeared more frequently in multiple ccms 
0 NULL NULL NULL immunostaining and western blot revealed a more significant pten downregulation in pten-methylated ccms in comparison to pten-unmethylated ccms 
18 NULL immunostaining and western blot revealed a more significant pten downregulation in pten-methylated ccms in comparison to pten-unmethylated ccms . NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL reduced pten expression was inversely correlated to the expression of proliferating 
9 NULL NULL NULL NULL NULL NULL NULL NULL reduced pten expression was inversely correlated to the expression of proliferating cell nuclear 
9 NULL NULL reduced pten expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of 
0 reduced pten expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of erk1 , 
17 the expression of proliferating cell nuclear antigen and to the activation of erk1 , 2 , but not of akt . 
0 conclusions : we reported here for the first time the involvement of pten promoter methylation in ccms , particularly in familial 
0 in familial ccms , suggesting this epigenetic alteration as a potential pathomechanism of ccms . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL the identification of erk1 , 2 as triggered signaling in the lesions may be valuable for the development 
0 triggered signaling in the lesions may be valuable for the development of effective therapy for this disease . NULL NULL NULL 
0 in the lesions may be valuable for the development of effective therapy for this disease . NULL NULL NULL NULL NULL 
0 the lesions may be valuable for the development of effective therapy for this disease . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor 
3 NULL NULL NULL NULL NULL NULL grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling 
18 NULL NULL NULL NULL grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway . 
0 seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL blockade of angiogenesis is an important approach for cancer treatment and 
3 NULL NULL NULL NULL NULL NULL NULL NULL blockade of angiogenesis is an important approach for cancer treatment and prevention . 
0 NULL NULL NULL NULL NULL blockade of angiogenesis is an important approach for cancer treatment and prevention . NULL NULL NULL 
19 NULL blockade of angiogenesis is an important approach for cancer treatment and prevention . NULL NULL NULL NULL NULL NULL NULL 
18 of angiogenesis is an important approach for cancer treatment and prevention . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) is one of the most critical 
0 growth factor ( vegf ) is one of the most critical factors that induce angiogenesis and has thus become an attractive 
17 vegf ) is one of the most critical factors that induce angiogenesis and has thus become an attractive target for antiangiogenesis 
3 ) is one of the most critical factors that induce angiogenesis and has thus become an attractive target for antiangiogenesis treatment 
0 factors that induce angiogenesis and has thus become an attractive target for antiangiogenesis treatment . NULL NULL NULL NULL NULL NULL 
3 induce angiogenesis and has thus become an attractive target for angiogenesis treatment . NULL NULL NULL NULL NULL NULL NULL NULL 
18 angiogenesis and has thus become an attractive target for antiangiogenesis treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 however , most current anti-vegf agents often cause some side effects when given chronically . NULL NULL NULL NULL NULL NULL 
0 most current anti-vegf agents often cause some side effects when given chronically . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL identification of naturally occurring vegf inhibitors derived from diet would be one alternative approach with an advantage 
0 NULL grape seed extract ( gse ) , a widely used dietary supplement , is known to have antitumor activity . 
18 widely used dietary supplement , is known to have antitumor activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in this study , we have explored the activity of gse on vegf receptor and angiogenesis . NULL NULL 
3 have explored the activity of gse on vegf receptor and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL we found that gse could directly inhibit the kinase activity of purified vegf receptor 2 , a 
0 NULL we found that gse could directly inhibit the kinase activity of purified vegf receptor 2 , a novel activity of 
0 found that gse could directly inhibit the kinase activity of purified vegf receptor 2 , a novel activity of gse that 
0 kinase activity of purified vegf receptor 2 , a novel activity of gse that has not been characterized . NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL gse could also inhibit the vegf receptor/mitogen-activated protein kinase-mediated signaling pathway in endothelial cells 
0 NULL NULL NULL NULL gse could also inhibit the vegf activated protein kinase-mediated signaling pathway in endothelial cells . NULL NULL 
0 NULL NULL NULL gse could also inhibit the vegf receptor/mitogen-activated protein kinase-mediated signaling pathway in endothelial cells . NULL NULL NULL 
17 NULL NULL gse could also inhibit the vegf receptor/mitogen-activated protein mediated signaling pathway in endothelial cells . NULL NULL NULL NULL 
18 NULL NULL NULL NULL as a result , gse could inhibit vegf-induced endothelial cell proliferation and migration as well as sprout 
17 NULL NULL NULL as a result , gse could inhibit induced endothelial cell proliferation and migration as well as sprout formation 
1 as a result , gse could inhibit vegf-induced endothelial cell proliferation and migration as well as sprout formation from aorta ring 
14 result , gse could inhibit vegf-induced endothelial cell proliferation and migration as well as sprout formation from aorta ring . NULL 
2 vegf-induced endothelial cell proliferation and migration as well as sprout formation from aorta ring . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL in vivo assay further showed that gse could inhibit tumor growth and tumor angiogenesis of 
18 NULL NULL in vivo assay further showed that gse could inhibit tumor growth and tumor angiogenesis of mda-mb-231 breast cancer cells 
0 NULL in vivo assay further showed that gse could inhibit tumor growth and tumor angiogenesis of mda-mb-231 breast cancer cells in 
4 in vivo assay further showed that gse could inhibit tumor growth and tumor angiogenesis of mda-mb-231 breast cancer cells in mice 
0 assay further showed that gse could inhibit tumor growth and tumor angiogenesis of mda-mb-231 breast cancer cells in mice . NULL 
3 further showed that gse could inhibit tumor growth and tumor angiogenesis of mda-mb-231 breast cancer cells in mice . NULL NULL 
19 NULL NULL consistent with the in vitro data , gse treatment of tumor-bearing mice led to concomitant reduction of blood vessel 
17 the in vitro data , gse treatment of tumor-bearing mice led to concomitant reduction of blood vessel density and phosphorylation of 
18 data , gse treatment of tumor-bearing mice led to concomitant reduction of blood vessel density and phosphorylation of mitogen-activated protein kinase 
12 mice led to concomitant reduction of blood vessel density and phosphorylation of mitogen-activated protein kinase . NULL NULL NULL NULL NULL 
0 to concomitant reduction of blood vessel density and phosphorylation of activated protein kinase . NULL NULL NULL NULL NULL NULL NULL 
0 concomitant reduction of blood vessel density and phosphorylation of mitogen-activated protein kinase . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL depletion of polyphenol with polyvinylpyrrolidone abolished the antiangiogenic activity of gse 
18 NULL NULL NULL NULL NULL depletion of polyphenol with polyvinylpyrrolidone abolished the antiangiogenic activity of gse , suggesting a water-soluble fraction 
3 NULL NULL NULL depletion of polyphenol with polyvinylpyrrolidone abolished the angiogenic activity of gse , suggesting a water-soluble fraction of polyphenol 
18 NULL NULL depletion of polyphenol with polyvinylpyrrolidone abolished the antiangiogenic activity of gse , suggesting a water-soluble fraction of polyphenol in 
17 , suggesting a water-soluble fraction of polyphenol in gse is responsible for the antiangiogenic activity . NULL NULL NULL NULL NULL 
3 water-soluble fraction of polyphenol in gse is responsible for the angiogenic activity . NULL NULL NULL NULL NULL NULL NULL NULL 
18 fraction of polyphenol in gse is responsible for the antiangiogenic activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 indicates that gse is a well-tolerated and inexpensive natural vegf inhibitor and could potentially be useful in cancer prevention or treatment 
18 natural vegf inhibitor and could potentially be useful in cancer prevention or treatment . NULL NULL NULL NULL NULL NULL NULL 
19 inhibitor and could potentially be useful in cancer prevention or treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL aflibercept ( ave0005 ) : an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors . NULL NULL 
3 ( ave0005 ) : an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors . NULL NULL NULL NULL 
0 an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL background : aberrant angiogenesis is a landmark feature in cancer , which is 
3 NULL NULL NULL NULL NULL NULL NULL background : aberrant angiogenesis is a landmark feature in cancer , which is important 
0 angiogenesis is a landmark feature in cancer , which is important for proliferation , growth and metastasis , and is mediated 
0 a landmark feature in cancer , which is important for proliferation , growth and metastasis , and is mediated by various 
0 feature in cancer , which is important for proliferation , growth and metastasis , and is mediated by various pro-angiogenic factors 
0 cancer , which is important for proliferation , growth and metastasis , and is mediated by various pro-angiogenic factors . NULL 
16 important for proliferation , growth and metastasis , and is mediated by various pro-angiogenic factors . NULL NULL NULL NULL NULL 
3 , growth and metastasis , and is mediated by various angiogenic factors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL the vegf pathway is one of the most important and best-studied angiogenic pathways . NULL NULL NULL NULL NULL 
3 vegf pathway is one of the most important and best-studied angiogenic pathways . NULL NULL NULL NULL NULL NULL NULL NULL 
0 pathway is one of the most important and best-studied angiogenic pathways . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of this pathway may provide clinical benefits to cancer patients 
0 NULL NULL NULL NULL inhibition of this pathway may provide clinical benefits to cancer patients . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL objectives : strategies to inhibit the vegf pathway , including antibodies to vegf , antibodies 
0 NULL methods : this review outlines and compares the latest development of these strategies , with emphasis on aflibercept , a 
0 strategies , with emphasis on aflibercept , a novel decoy fusion protein of domain 2 of vegfr-1 and domain 3 of 
0 , with emphasis on aflibercept , a novel decoy fusion protein of domain 2 of vegfr-1 and domain 3 of vegfr-2 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : aflibercept was shown to have early clinical activity . 
0 NULL NULL results : aflibercept was shown to have early clinical activity . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL results : aflibercept was shown to have early clinical activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL multiple studies are ongoing to determine the clinical benefits of aflibercept in cancer patients . NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effect of perfluorocarbon-based artificial oxygen carriers on tissue-engineered trachea . NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL the biological effect of the perfluorocarbon-based artificial oxygen carrier ( oxygent ) was 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL media supplemented with and without 10 % oxygent were compared in all 
0 NULL NULL NULL NULL NULL NULL NULL chondrocyte-degrapol constructs were cultured for 1 month with the medium before glycosaminoglycan assessment and 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL oxygent perfusion medium increased the tet epithelial pto ( 2 ) ( 
0 NULL NULL NULL NULL NULL NULL NULL oxygent perfusion medium increased the tet epithelial pto ( 2 ) ( 51.2 +/- 
0 400 microm thickness , p less than 0.01 ) and decreased the lactate concentration ( 0.63 +/- 0.08 vs. 0.80 +/- 
0 0.00 , p less than 0.05 ) ; histology slides showed poor acid mucopolysaccharides formation . NULL NULL NULL NULL NULL 
8 than 0.05 ) ; histology slides showed poor acid mucopolysaccharides formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL orthogonal polarization spectral imaging showed no difference in functional capillary density between the scaffolds cultured 
19 showed no difference in functional capillary density between the scaffolds cultured on chorioallantoic membranes . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL we conclude that oxygent increases tet epithelial pto ( 2 ) , improves epithelial metabolism 
0 that oxygent increases tet epithelial pto ( 2 ) , improves epithelial metabolism , does not impair angiogenesis , and tends 
18 ( 2 ) , improves epithelial metabolism , does not impair angiogenesis , and tends to slow cartilage tissue formation . 
3 2 ) , improves epithelial metabolism , does not impair angiogenesis , and tends to slow cartilage tissue formation . NULL 
18 metabolism , does not impair angiogenesis , and tends to slow cartilage tissue formation . NULL NULL NULL NULL NULL NULL 
2 not impair angiogenesis , and tends to slow cartilage tissue formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 the semaphorin 7a receptor plexin c1 is lost during melanoma metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL the transformation of normal melanocytes , or melanocyte stem cells , to 
0 stem cells , to melanoma , is a complex process involving multiple mechanisms . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL loss of tumor suppressor proteins , which function as brakes on 
0 NULL NULL NULL NULL NULL NULL NULL NULL loss of tumor suppressor proteins , which function as brakes on cell growth 
0 NULL NULL NULL NULL NULL NULL NULL loss of tumor suppressor proteins , which function as brakes on cell growth , 
0 NULL NULL NULL loss of tumor suppressor proteins , which function as brakes on cell growth , migration , or cell 
18 NULL loss of tumor suppressor proteins , which function as brakes on cell growth , migration , or cell survival , 
1 tumor suppressor proteins , which function as brakes on cell growth , migration , or cell survival , was recognized early 
14 proteins , which function as brakes on cell growth , migration , or cell survival , was recognized early on as 
5 as brakes on cell growth , migration , or cell survival , was recognized early on as an important mechanism for 
0 or cell survival , was recognized early on as an important mechanism for initiation and progression of melanoma . NULL NULL 
0 cell survival , was recognized early on as an important mechanism for initiation and progression of melanoma . NULL NULL NULL 
0 , was recognized early on as an important mechanism for initiation and progression of melanoma . NULL NULL NULL NULL NULL 
0 recognized early on as an important mechanism for initiation and progression of melanoma . NULL NULL NULL NULL NULL NULL NULL 
0 and their cognate receptors , plexins and neuropilins , are involved in neuronal pathfinding , immune function , and tumor progression 
0 and neuropilins , are involved in neuronal pathfinding , immune function , and tumor progression through effects on blood vessel growth 
0 are involved in neuronal pathfinding , immune function , and tumor progression through effects on blood vessel growth and cell migration 
2 involved in neuronal pathfinding , immune function , and tumor progression through effects on blood vessel growth and cell migration . 
16 neuronal pathfinding , immune function , and tumor progression through effects on blood vessel growth and cell migration . NULL NULL 
4 function , and tumor progression through effects on blood vessel growth and cell migration . NULL NULL NULL NULL NULL NULL 
14 tumor progression through effects on blood vessel growth and cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL semaphorin 7a ( sema7a ) is a linked semaphorin that is expressed by human keratinocytes , and we 
9 7a ( sema7a ) is a membrane-linked semaphorin that is expressed by human keratinocytes , and we have shown that sema7a 
15 by human keratinocytes , and we have shown that sema7a binds to human melanocytes through beta1-integrins and the plexin c1 receptor 
0 NULL NULL NULL NULL NULL NULL NULL NULL functional studies showed that sema7a stimulates cytoskeletal reorganization in human melanocytes , resulting 
17 NULL NULL NULL NULL NULL functional studies showed that sema7a stimulates cytoskeletal reorganization in human melanocytes , resulting in adhesion and 
0 NULL NULL NULL NULL functional studies showed that sema7a stimulates cytoskeletal reorganization in human melanocytes , resulting in adhesion and dendrite 
16 NULL NULL NULL functional studies showed that sema7a stimulates cytoskeletal reorganization in human melanocytes , resulting in adhesion and dendrite formation 
17 showed that sema7a stimulates cytoskeletal reorganization in human melanocytes , resulting in adhesion and dendrite formation . NULL NULL NULL NULL 
15 sema7a stimulates cytoskeletal reorganization in human melanocytes , resulting in adhesion and dendrite formation . NULL NULL NULL NULL NULL NULL 
2 cytoskeletal reorganization in human melanocytes , resulting in adhesion and dendrite formation . NULL NULL NULL NULL NULL NULL NULL NULL 
2 reorganization in human melanocytes , resulting in adhesion and dendrite formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL downstream targets of plexin c1 signaling in human melanocytes include cofilin 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL downstream targets of plexin c1 signaling in human melanocytes include cofilin and 
0 cofilin and lim kinase ii , both of which are critical mediators of cell adhesion and migration . NULL NULL NULL 
15 ii , both of which are critical mediators of cell adhesion and migration . NULL NULL NULL NULL NULL NULL NULL 
14 both of which are critical mediators of cell adhesion and migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL in this report , we analyzed the expression of plexin c1 using immunohistochemistry on sections of primary and 
0 plexin c1 using immunohistochemistry on sections of primary and matched metastatic lesions from 19 subjects and in a large melanoma tumor 
0 metastatic lesions from 19 subjects and in a large melanoma tumor microarray . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL our data show a significant loss of plexin c1 in metastatic melanoma compared with primary 
0 NULL NULL NULL NULL NULL our data show a significant loss of plexin c1 in metastatic melanoma compared with primary melanoma 
0 our data show a significant loss of plexin c1 in metastatic melanoma compared with primary melanoma , suggesting the possibility that 
0 suggesting the possibility that the plexin c1 receptor is a tumor suppressor protein for melanoma . NULL NULL NULL NULL NULL 
0 the possibility that the plexin c1 receptor is a tumor suppressor protein for melanoma . NULL NULL NULL NULL NULL NULL 
0 possibility that the plexin c1 receptor is a tumor suppressor protein for melanoma . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL role of the interferon-inducible ifi16 gene in the induction of icam-1 
17 NULL NULL NULL NULL NULL NULL NULL role of the inducible ifi16 gene in the induction of icam-1 by tnf-alpha . 
17 NULL NULL role of the interferon-inducible ifi16 gene in the induction of icam-1 by tnf-alpha . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the inducible gene ifi16 , a member of the hin200 family , 
17 ifi16 , a member of the hin200 family , is activated by oxidative stress and cell density , in addition to 
0 is activated by oxidative stress and cell density , in addition to interferons , and it is implicated in the regulation 
0 density , in addition to interferons , and it is implicated in the regulation of endothelial cell proliferation and vessel formation 
16 addition to interferons , and it is implicated in the regulation of endothelial cell proliferation and vessel formation in vitro . 
1 and it is implicated in the regulation of endothelial cell proliferation and vessel formation in vitro . NULL NULL NULL NULL 
2 implicated in the regulation of endothelial cell proliferation and vessel formation in vitro . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL we have previously shown that ifi16 is required for proinflammatory gene stimulation by ifn-gamma through the nf-kappab complex 
0 have previously shown that ifi16 is required for proinflammatory gene stimulation by ifn-gamma through the nf-kappab complex . NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL to examine whether ifi16 induction might be extended to other proinflammatory cytokines such as tumor 
17 NULL NULL NULL to examine whether ifi16 induction might be extended to other proinflammatory cytokines such as tumor necrosis factor ( 
0 induction might be extended to other proinflammatory cytokines such as tumor necrosis factor ( tnf ) -alpha , we used the 
0 might be extended to other proinflammatory cytokines such as tumor necrosis factor ( tnf ) -alpha , we used the strategy 
0 as tumor necrosis factor ( tnf ) -alpha , we used the strategy of the rna interference to knock down ifi16 
0 ) -alpha , we used the strategy of the rna interference to knock down ifi16 expression , and analyze the capability 
19 , we used the strategy of the rna interference to knock down ifi16 expression , and analyze the capability of tnf-alpha 
9 the strategy of the rna interference to knock down ifi16 expression , and analyze the capability of tnf-alpha to stimulate intercellular 
17 ifi16 expression , and analyze the capability of tnf-alpha to stimulate intercellular adhesion molecule-1 ( icam-1 or cd54 ) expression in 
0 , and analyze the capability of tnf-alpha to stimulate intercellular adhesion molecule-1 ( icam-1 or cd54 ) expression in the absence 
9 to stimulate intercellular adhesion molecule-1 ( icam-1 or cd54 ) expression in the absence of functional ifi16 . NULL NULL NULL 
16 NULL NULL NULL NULL NULL our studies demonstrate that ifi16 mediates icam-1 stimulation by tnf-alpha through the nf-kappab pathway , thus 
17 NULL NULL NULL our studies demonstrate that ifi16 mediates icam-1 stimulation by tnf-alpha through the nf-kappab pathway , thus reinforcing the 
0 by tnf-alpha through the nf-kappab pathway , thus reinforcing the role of the ifi16 molecule in the inflammation process . NULL 
0 NULL NULL NULL NULL NULL NULL characterization of the metabolic changes underlying growth factor angiogenic activation : identification of new potential 
0 NULL NULL NULL NULL characterization of the metabolic changes underlying growth factor angiogenic activation : identification of new potential therapeutic targets 
3 NULL NULL characterization of the metabolic changes underlying growth factor angiogenic activation : identification of new potential therapeutic targets . NULL 
17 NULL characterization of the metabolic changes underlying growth factor angiogenic activation : identification of new potential therapeutic targets . NULL NULL 
0 changes underlying growth factor angiogenic activation : identification of new potential therapeutic targets . NULL NULL NULL NULL NULL NULL NULL 
0 growth factor angiogenic activation : identification of new potential therapeutic targets . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis is a fundamental process to normal and abnormal tissue growth 
4 angiogenesis is a fundamental process to normal and abnormal tissue growth and repair , which consists of recruiting endothelial cells toward 
2 a fundamental process to normal and abnormal tissue growth and repair , which consists of recruiting endothelial cells toward an angiogenic 
14 and abnormal tissue growth and repair , which consists of recruiting endothelial cells toward an angiogenic stimulus . NULL NULL NULL 
3 repair , which consists of recruiting endothelial cells toward an angiogenic stimulus . NULL NULL NULL NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL the cells subsequently proliferate and differentiate to form endothelial tubes and capillary-like structures . 
2 NULL NULL NULL NULL NULL the cells subsequently proliferate and differentiate to form endothelial tubes and capillary-like structures . NULL NULL 
2 NULL NULL NULL the cells subsequently proliferate and differentiate to form endothelial tubes and capillary-like structures . NULL NULL NULL NULL 
2 about the metabolic adaptation of endothelial cells through such a transformation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL we studied the metabolic changes of endothelial cell activation by growth factors using human umbilical 
17 NULL NULL we studied the metabolic changes of endothelial cell activation by growth factors using human umbilical vein endothelial cells ( 
0 we studied the metabolic changes of endothelial cell activation by growth factors using human umbilical vein endothelial cells ( huvecs ) 
0 ) c ( 2 ) ] -glucose and mass isotopomer distribution analysis . NULL NULL NULL NULL NULL NULL NULL NULL 
0 allows us to trace many of the main glucose metabolic pathways , including glycogen synthesis , the pentose cycle and the 
8 many of the main glucose metabolic pathways , including glycogen synthesis , the pentose cycle and the glycolytic pathways . NULL 
0 including glycogen synthesis , the pentose cycle and the glycolytic pathways . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL so we established that these pathways were crucial to endothelial cell proliferation under 
0 NULL NULL NULL NULL NULL so we established that these pathways were crucial to endothelial cell proliferation under vascular endothelial growth 
0 NULL NULL NULL so we established that these pathways were crucial to endothelial cell proliferation under vascular endothelial growth factor ( 
1 we established that these pathways were crucial to endothelial cell proliferation under vascular endothelial growth factor ( vegf ) and fibroblast 
0 pathways were crucial to endothelial cell proliferation under vascular endothelial growth factor ( vegf ) and fibroblast growth factor ( fgf 
0 under vascular endothelial growth factor ( vegf ) and fibroblast growth factor ( fgf ) stimulation . NULL NULL NULL NULL 
17 ( vegf ) and fibroblast growth factor ( fgf ) stimulation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL a specific vegf receptor-2 inhibitor demonstrated the importance of glycogen metabolism and pentose cycle pathway 
0 NULL NULL NULL NULL NULL NULL NULL furthermore , we showed that glycogen was depleted in a low glucose medium , 
11 NULL NULL NULL furthermore , we showed that glycogen was depleted in a low glucose medium , but conserved under hypoxic 
0 NULL NULL NULL NULL NULL finally , we demonstrated that direct inhibition of key enzymes to glycogen metabolism and pentose phosphate 
0 NULL NULL NULL NULL finally , we demonstrated that direct inhibition of key enzymes to glycogen metabolism and pentose phosphate pathways 
0 NULL NULL finally , we demonstrated that direct inhibition of key enzymes to glycogen metabolism and pentose phosphate pathways reduced huvec 
0 inhibition of key enzymes to glycogen metabolism and pentose phosphate pathways reduced huvec viability and migration . NULL NULL NULL NULL 
18 of key enzymes to glycogen metabolism and pentose phosphate pathways reduced huvec viability and migration . NULL NULL NULL NULL NULL 
14 glycogen metabolism and pentose phosphate pathways reduced huvec viability and migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL in this regard , inhibitors of these pathways have been shown to be effective antitumoral agents . NULL 
0 , inhibitors of these pathways have been shown to be effective antitumoral agents . NULL NULL NULL NULL NULL NULL NULL 
0 NULL to sum up , our data suggest that the inhibition of metabolic pathways offers a novel and powerful therapeutic approach 
0 up , our data suggest that the inhibition of metabolic pathways offers a novel and powerful therapeutic approach , which simultaneously 
18 offers a novel and powerful therapeutic approach , which simultaneously inhibits tumor cell proliferation and tumor-induced angiogenesis . NULL NULL NULL 
0 a novel and powerful therapeutic approach , which simultaneously inhibits tumor cell proliferation and tumor-induced angiogenesis . NULL NULL NULL NULL 
1 and powerful therapeutic approach , which simultaneously inhibits tumor cell proliferation and tumor-induced angiogenesis . NULL NULL NULL NULL NULL NULL 
17 therapeutic approach , which simultaneously inhibits tumor cell proliferation and induced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 approach , which simultaneously inhibits tumor cell proliferation and tumor-induced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL rab gtpase regulation of vegfr2 trafficking and signaling in endothelial cells . NULL 
14 NULL NULL NULL NULL NULL rab gtpase regulation of vegfr2 trafficking and signaling in endothelial cells . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL objective : vascular endothelial growth factor receptor 2 ( vegfr2 ) is a receptor tyrosine 
16 2 ( vegfr2 ) is a receptor tyrosine kinase that regulates vascular physiology . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL however , mechanism ( s ) by which vegfr2 signaling and trafficking is 
14 , mechanism ( s ) by which vegfr2 signaling and trafficking is coordinated are not clear . NULL NULL NULL NULL 
0 ( s ) by which vegfr2 signaling and trafficking is coordinated are not clear . NULL NULL NULL NULL NULL NULL 
16 NULL here , we have tested endocytic rab gtpases for regulation of vegfr2 trafficking and signaling linked to endothelial cell migration 
14 we have tested endocytic rab gtpases for regulation of vegfr2 trafficking and signaling linked to endothelial cell migration . NULL NULL 
16 endocytic rab gtpases for regulation of vegfr2 trafficking and signaling linked to endothelial cell migration . NULL NULL NULL NULL NULL 
14 regulation of vegfr2 trafficking and signaling linked to endothelial cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL methods and results : quiescent vegfr2 displays endosomal localization and colocalization with the 
14 NULL NULL methods and results : quiescent vegfr2 displays endosomal localization and colocalization with the rab5a gtpase , an early endosome 
14 methods and results : quiescent vegfr2 displays endosomal localization and colocalization with the rab5a gtpase , an early endosome fusion regulator 
0 and colocalization with the rab5a gtpase , an early endosome fusion regulator . NULL NULL NULL NULL NULL NULL NULL NULL 
0 colocalization with the rab5a gtpase , an early endosome fusion regulator . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of gtp or gdp-bound rab5a mutants block activated vegfr2 trafficking 
15 NULL NULL NULL NULL NULL NULL expression of gtp or bound rab5a mutants block activated vegfr2 trafficking and degradation . NULL 
18 NULL NULL NULL expression of gtp or gdp-bound rab5a mutants block activated vegfr2 trafficking and degradation . NULL NULL NULL NULL 
17 NULL NULL expression of gtp or gdp-bound rab5a mutants block activated vegfr2 trafficking and degradation . NULL NULL NULL NULL NULL 
14 expression of gtp or gdp-bound rab5a mutants block activated vegfr2 trafficking and degradation . NULL NULL NULL NULL NULL NULL NULL 
11 gtp or gdp-bound rab5a mutants block activated vegfr2 trafficking and degradation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL manipulation of rab7a gtpase activity associated with late endosomes using overexpression 
0 NULL NULL NULL NULL NULL NULL manipulation of rab7a gtpase activity associated with late endosomes using overexpression of wild-type or mutant 
0 NULL NULL NULL NULL NULL manipulation of rab7a gtpase activity associated with late endosomes using overexpression of wild-type or mutant proteins 
9 manipulation of rab7a gtpase activity associated with late endosomes using overexpression of wild-type or mutant proteins blocks activated vegfr2 trafficking and 
18 with late endosomes using overexpression of wild-type or mutant proteins blocks activated vegfr2 trafficking and degradation . NULL NULL NULL NULL 
17 late endosomes using overexpression of wild-type or mutant proteins blocks activated vegfr2 trafficking and degradation . NULL NULL NULL NULL NULL 
14 using overexpression of wild-type or mutant proteins blocks activated vegfr2 trafficking and degradation . NULL NULL NULL NULL NULL NULL NULL 
11 of wild-type or mutant proteins blocks activated vegfr2 trafficking and degradation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL depletion of rab7a decreased vegfr2 y1175 phosphorylation but increased p42/44 ( 
18 NULL NULL NULL NULL NULL NULL NULL depletion of rab7a decreased vegfr2 y1175 phosphorylation but increased p42/44 ( perk1/2 ) mapk 
12 NULL NULL NULL NULL depletion of rab7a decreased vegfr2 y1175 phosphorylation but increased p42/44 ( perk1/2 ) mapk phosphorylation . NULL 
17 NULL NULL depletion of rab7a decreased vegfr2 y1175 phosphorylation but increased p42/44 ( perk1/2 ) mapk phosphorylation . NULL NULL NULL 
12 vegfr2 y1175 phosphorylation but increased p42/44 ( perk1/2 ) mapk phosphorylation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell migration was increased by rab5a depletion but decreased by rab7a depletion 
17 NULL NULL NULL NULL NULL NULL endothelial cell migration was increased by rab5a depletion but decreased by rab7a depletion . NULL 
18 NULL NULL NULL endothelial cell migration was increased by rab5a depletion but decreased by rab7a depletion . NULL NULL NULL NULL 
18 NULL endothelial cell migration was increased by rab5a depletion but decreased by rab7a depletion . NULL NULL NULL NULL NULL NULL 
18 migration was increased by rab5a depletion but decreased by rab7a depletion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL conclusions : rab5a and rab7a regulate vegfr2 trafficking toward early and late endosomes . NULL NULL 
14 NULL NULL NULL conclusions : rab5a and rab7a regulate vegfr2 trafficking toward early and late endosomes . NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL our data suggest that mediated regulation of endothelial function is dependent on different but specific 
16 NULL NULL NULL NULL NULL our data suggest that vegfr2-mediated regulation of endothelial function is dependent on different but specific rab-mediated 
0 NULL NULL our data suggest that vegfr2-mediated regulation of endothelial function is dependent on different but specific rab-mediated gtp hydrolysis activity 
17 our data suggest that vegfr2-mediated regulation of endothelial function is dependent on different but specific rab-mediated gtp hydrolysis activity required for 
16 regulation of endothelial function is dependent on different but specific mediated gtp hydrolysis activity required for endosomal trafficking . NULL NULL 
11 endothelial function is dependent on different but specific rab-mediated gtp hydrolysis activity required for endosomal trafficking . NULL NULL NULL NULL 
0 function is dependent on different but specific rab-mediated gtp hydrolysis activity required for endosomal trafficking . NULL NULL NULL NULL NULL 
0 is dependent on different but specific rab-mediated gtp hydrolysis activity required for endosomal trafficking . NULL NULL NULL NULL NULL NULL 
0 different but specific rab-mediated gtp hydrolysis activity required for endosomal trafficking . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL angiomirs -- key regulators of angiogenesis . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL angiomirs -- key regulators of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL the formation of new blood vessels through the process of angiogenesis is 
3 the formation of new blood vessels through the process of angiogenesis is critical in vascular development and homeostasis . NULL NULL 
17 of new blood vessels through the process of angiogenesis is critical in vascular development and homeostasis . NULL NULL NULL NULL 
2 vessels through the process of angiogenesis is critical in vascular development and homeostasis . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL aberrant angiogenesis leads to a variety of diseases , such as 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL aberrant angiogenesis leads to a variety of diseases , such as ischemia 
17 NULL NULL NULL NULL NULL NULL NULL NULL aberrant angiogenesis leads to a variety of diseases , such as ischemia and 
0 NULL NULL NULL NULL NULL NULL recent studies have revealed important roles for mirnas in regulating endothelial cell ( ec ) 
0 NULL NULL NULL NULL NULL recent studies have revealed important roles for mirnas in regulating endothelial cell ( ec ) function 
16 NULL recent studies have revealed important roles for mirnas in regulating endothelial cell ( ec ) function , especially angiogenesis . 
0 roles for mirnas in regulating endothelial cell ( ec ) function , especially angiogenesis . NULL NULL NULL NULL NULL NULL 
3 in regulating endothelial cell ( ec ) function , especially angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL mice with ec-specific deletion of dicer , a key enzyme for generating mirnas , 
0 NULL NULL mice with ec-specific deletion of dicer , a key enzyme for generating mirnas , display defective postnatal angiogenesis . 
0 with ec-specific deletion of dicer , a key enzyme for generating mirnas , display defective postnatal angiogenesis . NULL NULL NULL 
0 dicer , a key enzyme for generating mirnas , display defective postnatal angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 a key enzyme for generating mirnas , display defective postnatal angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 specific mirnas ( angiomirs ) have recently been shown to regulate angiogenesis in vivo . NULL NULL NULL NULL NULL NULL 
3 mirnas ( angiomirs ) have recently been shown to regulate angiogenesis in vivo . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL mirna-126 , an restricted mirna , regulates vascular integrity and developmental angiogenesis . NULL 
16 NULL NULL NULL NULL mirna-126 , an ec-restricted mirna , regulates vascular integrity and developmental angiogenesis . NULL NULL NULL NULL 
3 , an ec-restricted mirna , regulates vascular integrity and developmental angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL mir-378 , mir-296 , and the mir-17-92 cluster contribute to tumor angiogenesis . NULL NULL NULL NULL NULL NULL 
0 mir-378 , mir-296 , and the mir-17-92 cluster contribute to tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 , mir-296 , and the mir-17-92 cluster contribute to tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL manipulating angiomirs in the settings of pathological vascularization represents a new therapeutic approach . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL promoting angiogenesis via manipulation of vegf responsiveness with notch signaling . 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL promoting angiogenesis via manipulation of vegf responsiveness with notch signaling . NULL 
16 NULL NULL NULL NULL NULL NULL NULL promoting angiogenesis via manipulation of vegf responsiveness with notch signaling . NULL NULL NULL 
0 NULL NULL NULL NULL promoting angiogenesis via manipulation of vegf responsiveness with notch signaling . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL promoting angiogenesis via delivery of vascular endothelial growth factor ( vegf 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL promoting angiogenesis via delivery of vascular endothelial growth factor ( vegf ) 
14 NULL NULL NULL NULL NULL NULL NULL promoting angiogenesis via delivery of vascular endothelial growth factor ( vegf ) and other 
0 NULL NULL NULL promoting angiogenesis via delivery of vascular endothelial growth factor ( vegf ) and other angiogenic factors is both 
3 of vascular endothelial growth factor ( vegf ) and other angiogenic factors is both a potential therapy for cardiovascular diseases and 
0 ( vegf ) and other angiogenic factors is both a potential therapy for cardiovascular diseases and a critical aspect for tissue 
0 vegf ) and other angiogenic factors is both a potential therapy for cardiovascular diseases and a critical aspect for tissue regeneration 
0 is both a potential therapy for cardiovascular diseases and a critical aspect for tissue regeneration . NULL NULL NULL NULL NULL 
2 therapy for cardiovascular diseases and a critical aspect for tissue regeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL the recent demonstration that vegf signaling is modulated by the notch signaling pathway , however , suggests that 
18 by the notch signaling pathway , however , suggests that inhibiting notch signaling may enhance regional neovascularization , by altering the 
17 pathway , however , suggests that inhibiting notch signaling may enhance regional neovascularization , by altering the responsiveness of local endothelial 
3 however , suggests that inhibiting notch signaling may enhance regional neovascularization , by altering the responsiveness of local endothelial cells to 
16 notch signaling may enhance regional neovascularization , by altering the responsiveness of local endothelial cells to angiogenic stimuli . NULL NULL 
3 , by altering the responsiveness of local endothelial cells to angiogenic stimuli . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment of cultured human endothelial cells with dapt , a gamma 
19 NULL NULL NULL NULL NULL NULL NULL NULL treatment of cultured human endothelial cells with dapt , a gamma secretase inhibitor 
0 cultured human endothelial cells with dapt , a gamma secretase inhibitor , increased cell migration and sprout formation in response to 
17 endothelial cells with dapt , a gamma secretase inhibitor , increased cell migration and sprout formation in response to vegf stimulation 
14 with dapt , a gamma secretase inhibitor , increased cell migration and sprout formation in response to vegf stimulation with a 
2 a gamma secretase inhibitor , increased cell migration and sprout formation in response to vegf stimulation with a biphasic dependence on 
0 secretase inhibitor , increased cell migration and sprout formation in response to vegf stimulation with a biphasic dependence on dapt concentration 
17 increased cell migration and sprout formation in response to vegf stimulation with a biphasic dependence on dapt concentration . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL further , delivery of an appropriate combination of dapt and vegf from an 
0 vegf from an injectable alginate hydrogel system into ischemic hindlimbs led to a faster recovery of blood flow than vegf or 
0 recovery of blood flow than vegf or dapt alone ; perfusion levels reached 80 % of the normal level by week 
0 of blood flow than vegf or dapt alone ; perfusion levels reached 80 % of the normal level by week 4 
14 normal level by week 4 with combined dapt and vegf delivery . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL direct intramuscular or intraperitoneal injection of dapt did not result in 
19 NULL NULL NULL NULL NULL NULL direct intramuscular or intraperitoneal injection of dapt did not result in the same level of 
0 improvement , suggesting that appropriate presentation of dapt ( gel delivery ) is important for its activity . NULL NULL NULL 
0 that appropriate presentation of dapt ( gel delivery ) is important for its activity . NULL NULL NULL NULL NULL NULL 
0 of dapt ( gel delivery ) is important for its activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL dapt delivery from the hydrogels also did not lead to any adverse 
0 NULL NULL dapt delivery from the hydrogels also did not lead to any adverse side effects , in contrast to systemic 
0 the hydrogels also did not lead to any adverse side effects , in contrast to systemic introduction of dapt . NULL 
17 to any adverse side effects , in contrast to systemic introduction of dapt . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL altogether , these results suggest a new approach to promote angiogenesis by controlling notch 
17 NULL altogether , these results suggest a new approach to promote angiogenesis by controlling notch signaling , and may provide new 
3 altogether , these results suggest a new approach to promote angiogenesis by controlling notch signaling , and may provide new options 
16 these results suggest a new approach to promote angiogenesis by controlling notch signaling , and may provide new options to treat 
19 controlling notch signaling , and may provide new options to treat patients with diseases that diminish angiogenic responsiveness . NULL NULL 
18 may provide new options to treat patients with diseases that diminish angiogenic responsiveness . NULL NULL NULL NULL NULL NULL NULL 
3 provide new options to treat patients with diseases that diminish angiogenic responsiveness . NULL NULL NULL NULL NULL NULL NULL NULL 
0 new options to treat patients with diseases that diminish angiogenic responsiveness . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL [ activation of sterol regulatory element binding protein and its involvement in 
0 NULL NULL NULL NULL NULL NULL [ activation of sterol regulatory element binding protein and its involvement in endothelial cell migration 
0 NULL NULL NULL NULL [ activation of sterol regulatory element binding protein and its involvement in endothelial cell migration ] NULL 
0 NULL NULL NULL [ activation of sterol regulatory element binding protein and its involvement in endothelial cell migration ] NULL NULL 
16 [ activation of sterol regulatory element binding protein and its involvement in endothelial cell migration ] NULL NULL NULL NULL NULL 
14 regulatory element binding protein and its involvement in endothelial cell migration ] NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL objective : to study the activation of sterol regulatory element binding protein ( srebp ) and 
0 NULL NULL objective : to study the activation of sterol regulatory element binding protein ( srebp ) and its critical role 
0 objective : to study the activation of sterol regulatory element binding protein ( srebp ) and its critical role in endothelial 
0 : to study the activation of sterol regulatory element binding protein ( srebp ) and its critical role in endothelial cell 
16 sterol regulatory element binding protein ( srebp ) and its critical role in endothelial cell migration . NULL NULL NULL NULL 
16 regulatory element binding protein ( srebp ) and its critical role in endothelial cell migration . NULL NULL NULL NULL NULL 
14 ( srebp ) and its critical role in endothelial cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 methods : bovine aortic endothelial cells ( ecs ) were cultured . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL the expression of srebp and cdc42 were determined by western blot and 
0 NULL NULL NULL NULL NULL NULL NULL moreover , outward growth migration model and transwell chamber assay were used to detect 
0 NULL NULL NULL NULL NULL NULL moreover , outward growth migration model and transwell chamber assay were used to detect ecs 
0 , outward growth migration model and transwell chamber assay were used to detect ecs migration . NULL NULL NULL NULL NULL 
14 model and transwell chamber assay were used to detect ecs migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : ( 1 ) srebp was activated during ecs migration 
17 NULL NULL NULL results : ( 1 ) srebp was activated during ecs migration . NULL NULL NULL NULL NULL NULL 
14 results : ( 1 ) srebp was activated during ecs migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL western blot analysis demonstrated increased active form srebp in migrating as compared to non-migrating ecs 
0 NULL NULL NULL NULL NULL western blot analysis demonstrated increased active form srebp in migrating as compared to non-migrating ecs population 
0 NULL NULL NULL NULL western blot analysis demonstrated increased active form srebp in migrating as compared to non-migrating ecs population . 
14 NULL western blot analysis demonstrated increased active form srebp in migrating as compared to non-migrating ecs population . NULL NULL NULL 
14 demonstrated increased active form srebp in migrating as compared to non-migrating ecs population . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL srebp activation decreased as ecs migration slowed ; ( 2 ) coincidental 
18 NULL NULL NULL NULL NULL NULL NULL NULL srebp activation decreased as ecs migration slowed ; ( 2 ) coincidental with 
14 NULL NULL NULL NULL NULL srebp activation decreased as ecs migration slowed ; ( 2 ) coincidental with srebp activation , 
18 NULL NULL NULL NULL srebp activation decreased as ecs migration slowed ; ( 2 ) coincidental with srebp activation , mrna 
17 ecs migration slowed ; ( 2 ) coincidental with srebp activation , mrna expression of its target genes such as low 
10 slowed ; ( 2 ) coincidental with srebp activation , mrna expression of its target genes such as low density lipoprotein 
10 ; ( 2 ) coincidental with srebp activation , mrna expression of its target genes such as low density lipoprotein receptor 
0 ) coincidental with srebp activation , mrna expression of its target genes such as low density lipoprotein receptor , hmg-coa reductase 
17 receptor , hmg-coa reductase , and fatty acid synthase also increased in migrating ecs population as detected by real-time pcr ; 
14 hmg-coa reductase , and fatty acid synthase also increased in migrating ecs population as detected by real-time pcr ; ( 3 
0 fatty acid synthase also increased in migrating ecs population as detected by real-time pcr ; ( 3 ) migration induced srebp 
14 population as detected by real-time pcr ; ( 3 ) migration induced srebp activation in ecs was inhibited by srebp-acting protein 
17 as detected by real-time pcr ; ( 3 ) migration induced srebp activation in ecs was inhibited by srebp-acting protein rnai 
17 by real-time pcr ; ( 3 ) migration induced srebp activation in ecs was inhibited by srebp-acting protein rnai and pharmacologically 
18 ( 3 ) migration induced srebp activation in ecs was inhibited by srebp-acting protein rnai and pharmacologically by 25-hydroxycholesterol ; ( 
0 migration induced srebp activation in ecs was inhibited by srebp-acting protein rnai and pharmacologically by 25-hydroxycholesterol ; ( 4 ) inhibition 
18 protein rnai and pharmacologically by 25-hydroxycholesterol ; ( 4 ) inhibition of srebp led to decreased ecs migration in various models 
17 pharmacologically by 25-hydroxycholesterol ; ( 4 ) inhibition of srebp led to decreased ecs migration in various models ; ( 5 
18 25-hydroxycholesterol ; ( 4 ) inhibition of srebp led to decreased ecs migration in various models ; ( 5 ) cells 
14 ( 4 ) inhibition of srebp led to decreased ecs migration in various models ; ( 5 ) cells genetically deficient 
9 migration in various models ; ( 5 ) cells genetically deficient in srebp-acting protein , s1p , or s2p , phenotypically 
0 models ; ( 5 ) cells genetically deficient in srebp-acting protein , s1p , or s2p , phenotypically exhibited impaired migration 
0 in srebp-acting protein , s1p , or s2p , phenotypically exhibited impaired migration ; ( 6 ) srebp inhibition in ecs 
0 srebp-acting protein , s1p , or s2p , phenotypically exhibited impaired migration ; ( 6 ) srebp inhibition in ecs suppressed 
0 protein , s1p , or s2p , phenotypically exhibited impaired migration ; ( 6 ) srebp inhibition in ecs suppressed the 
18 , phenotypically exhibited impaired migration ; ( 6 ) srebp inhibition in ecs suppressed the activity of small gtpase cdc42 , 
18 impaired migration ; ( 6 ) srebp inhibition in ecs suppressed the activity of small gtpase cdc42 , a key molecule 
0 ; ( 6 ) srebp inhibition in ecs suppressed the activity of small gtpase cdc42 , a key molecule for ecs 
0 ecs suppressed the activity of small gtpase cdc42 , a key molecule for ecs motility . NULL NULL NULL NULL NULL 
14 of small gtpase cdc42 , a key molecule for ecs motility . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL conclusions : srebp is activated during and plays a critical role in ecs migration . 
16 NULL NULL NULL conclusions : srebp is activated during and plays a critical role in ecs migration . NULL NULL NULL 
16 NULL conclusions : srebp is activated during and plays a critical role in ecs migration . NULL NULL NULL NULL NULL 
16 conclusions : srebp is activated during and plays a critical role in ecs migration . NULL NULL NULL NULL NULL NULL 
14 is activated during and plays a critical role in ecs migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL targeting srebp could become a novel approach in fighting diseases involving 
0 targeting srebp could become a novel approach in fighting diseases involving abnormal ecs migration . NULL NULL NULL NULL NULL NULL 
14 become a novel approach in fighting diseases involving abnormal ecs migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor 
0 NULL NULL NULL NULL NULL NULL fibroblast growth factor receptor positive fibroblasts provide a suitable microenvironment for tumor development and progression 
0 growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma . NULL NULL NULL 
2 factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma . NULL NULL NULL NULL 
2 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL purpose : tumor fibroblasts ( tf ) have been suggested to play an 
16 : tumor fibroblasts ( tf ) have been suggested to play an essential role in the complex process of tumor-stroma interactions 
16 fibroblasts ( tf ) have been suggested to play an essential role in the complex process of tumor-stroma interactions and tumorigenesis 
16 ( tf ) have been suggested to play an essential role in the complex process of tumor-stroma interactions and tumorigenesis . 
0 to play an essential role in the complex process of tumor interactions and tumorigenesis . NULL NULL NULL NULL NULL NULL 
15 play an essential role in the complex process of tumor-stroma interactions and tumorigenesis . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the aim of the present study was to investigate the specific role of tf in 
0 aim of the present study was to investigate the specific role of tf in the esophageal cancer microenvironment . NULL NULL 
0 NULL NULL NULL NULL NULL experimental design : an affymetrix expression microarray was used to compare gene expression profiles between six 
0 NULL NULL experimental design : an affymetrix expression microarray was used to compare gene expression profiles between six pairs of tfs 
0 : an affymetrix expression microarray was used to compare gene expression profiles between six pairs of tfs and normal fibroblasts from 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL differentially expressed genes were identified , and a subset was evaluated by 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : about 43 % ( 126 of 292 ) of 
0 of 292 ) of known deregulated genes in tfs were associated with cell proliferation , extracellular matrix remodeling , and immune 
1 of known deregulated genes in tfs were associated with cell proliferation , extracellular matrix remodeling , and immune response . NULL 
0 genes in tfs were associated with cell proliferation , extracellular matrix remodeling , and immune response . NULL NULL NULL NULL 
7 in tfs were associated with cell proliferation , extracellular matrix remodeling , and immune response . NULL NULL NULL NULL NULL 
0 with cell proliferation , extracellular matrix remodeling , and immune response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL up-regulation of fibroblast growth factor receptor 2 ( fgfr2 ) , 
0 NULL NULL NULL NULL NULL NULL NULL up-regulation of fibroblast growth factor receptor 2 ( fgfr2 ) , which showed the 
0 fibroblast growth factor receptor 2 ( fgfr2 ) , which showed the most significant change , was detected in all six 
0 receptor 2 ( fgfr2 ) , which showed the most significant change , was detected in all six tested tfs compared 
0 2 ( fgfr2 ) , which showed the most significant change , was detected in all six tested tfs compared with 
0 ) , which showed the most significant change , was detected in all six tested tfs compared with their paired normal 
0 NULL NULL NULL NULL NULL a further study found that positive fibroblasts were only observed inside the tumor tissues and not 
0 NULL a further study found that fgfr2-positive fibroblasts were only observed inside the tumor tissues and not in tumor-surrounding stromal tissues 
0 study found that fgfr2-positive fibroblasts were only observed inside the tumor tissues and not in tumor-surrounding stromal tissues , suggesting that 
0 were only observed inside the tumor tissues and not in tumor stromal tissues , suggesting that fgfr2 could be used as 
0 in tumor-surrounding stromal tissues , suggesting that fgfr2 could be used as a tf-specific marker in escc . NULL NULL NULL 
0 conditioned medium from tfs was found to be able to promote escc tumor cell growth , migration , and invasion in 
0 from tfs was found to be able to promote escc tumor cell growth , migration , and invasion in vitro . 
1 was found to be able to promote escc tumor cell growth , migration , and invasion in vitro . NULL NULL 
14 to be able to promote escc tumor cell growth , migration , and invasion in vitro . NULL NULL NULL NULL 
14 to promote escc tumor cell growth , migration , and invasion in vitro . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL based on our results , we hypothesize that fgfr2 ( + ) -tfs might 
0 -tfs might provide cancer cells with a suitable microenvironment via secretion of proteins that could promote cancer development and progression through 
0 with a suitable microenvironment via secretion of proteins that could promote cancer development and progression through stimulation of cancer cell proliferation 
0 suitable microenvironment via secretion of proteins that could promote cancer development and progression through stimulation of cancer cell proliferation , induction 
0 via secretion of proteins that could promote cancer development and progression through stimulation of cancer cell proliferation , induction of angiogenesis 
17 of proteins that could promote cancer development and progression through stimulation of cancer cell proliferation , induction of angiogenesis , inhibition 
1 promote cancer development and progression through stimulation of cancer cell proliferation , induction of angiogenesis , inhibition of cell adhesion , 
17 development and progression through stimulation of cancer cell proliferation , induction of angiogenesis , inhibition of cell adhesion , enhancement of 
3 progression through stimulation of cancer cell proliferation , induction of angiogenesis , inhibition of cell adhesion , enhancement of cell mobility 
18 stimulation of cancer cell proliferation , induction of angiogenesis , inhibition of cell adhesion , enhancement of cell mobility , and 
15 cell proliferation , induction of angiogenesis , inhibition of cell adhesion , enhancement of cell mobility , and promotion of the 
17 , induction of angiogenesis , inhibition of cell adhesion , enhancement of cell mobility , and promotion of the epithelial-mesenchymal transition 
14 angiogenesis , inhibition of cell adhesion , enhancement of cell mobility , and promotion of the epithelial-mesenchymal transition . NULL NULL 
17 of cell adhesion , enhancement of cell mobility , and promotion of the epithelial-mesenchymal transition . NULL NULL NULL NULL NULL 
2 enhancement of cell mobility , and promotion of the epithelial-mesenchymal transition . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL [ role of the tumor suppressor arf in oncogenesis ] NULL NULL 
0 NULL NULL NULL NULL NULL NULL [ role of the tumor suppressor arf in oncogenesis ] NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL [ role of the tumor suppressor arf in oncogenesis ] NULL NULL NULL NULL NULL NULL 
0 paper reviews the data available in the literature on a role of the tumor suppressor arf in oncogenesis and considers the 
0 data available in the literature on a role of the tumor suppressor arf in oncogenesis and considers the structure of a 
0 available in the literature on a role of the tumor suppressor arf in oncogenesis and considers the structure of a gene 
0 oncogenesis and considers the structure of a gene encoding arf protein . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the dependent and p-53-independent functions of this protein are under many studies 
16 NULL NULL NULL NULL NULL NULL NULL the p53-dependent and independent functions of this protein are under many studies . NULL 
0 NULL NULL NULL NULL NULL NULL the p53-dependent and p-53-independent functions of this protein are under many studies . NULL NULL 
0 NULL NULL NULL the p53-dependent and p-53-independent functions of this protein are under many studies . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL there is evidence for the implication of arf in angiogenesis . NULL NULL NULL NULL NULL 
3 NULL there is evidence for the implication of arf in angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL there is more and more information on the role of arf in the regulation of a cell cycle , 
16 and more information on the role of arf in the regulation of a cell cycle , apoptosis , and autophagy . 
5 of arf in the regulation of a cell cycle , apoptosis , and autophagy . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the importance of this tumor suppressor in the mechanisms of carcinogenesis is beyond question as 
0 NULL NULL NULL NULL NULL the importance of this tumor suppressor in the mechanisms of carcinogenesis is beyond question as the 
0 the importance of this tumor suppressor in the mechanisms of carcinogenesis is beyond question as the inactivation of arf suppressor activity 
18 in the mechanisms of carcinogenesis is beyond question as the inactivation of arf suppressor activity leads to the rapid growth of 
0 of carcinogenesis is beyond question as the inactivation of arf suppressor activity leads to the rapid growth of neoplasia . NULL 
0 carcinogenesis is beyond question as the inactivation of arf suppressor activity leads to the rapid growth of neoplasia . NULL NULL 
17 is beyond question as the inactivation of arf suppressor activity leads to the rapid growth of neoplasia . NULL NULL NULL 
4 the inactivation of arf suppressor activity leads to the rapid growth of neoplasia . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL however , the exact mechanisms of arf action yet remain unclear and require further studies by different specialists 
0 the exact mechanisms of arf action yet remain unclear and require further studies by different specialists at both the molecular genetic 
0 by different specialists at both the molecular genetic and other levels of investigation . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL impact of tumor cell vegf expression on the in vivo efficacy 
0 NULL NULL NULL NULL NULL NULL NULL NULL impact of tumor cell vegf expression on the in vivo efficacy of vandetanib 
9 NULL NULL NULL NULL NULL impact of tumor cell vegf expression on the in vivo efficacy of vandetanib ( zactima ; 
0 impact of tumor cell vegf expression on the in vivo efficacy of vandetanib ( zactima ; zd6474 ) . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL vegf is the key player in tumor angiogenesis . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL vegf is the key player in tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL vegf is the key player in tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL in the current study , the impact of vegf expression on the response of tumors to the 
9 NULL in the current study , the impact of vegf expression on the response of tumors to the vegfr2 associated tyrosine 
16 current study , the impact of vegf expression on the response of tumors to the vegfr2 associated tyrosine kinase inhibitor vandetanib 
15 vegf expression on the response of tumors to the vegfr2 associated tyrosine kinase inhibitor vandetanib was evaluated . NULL NULL NULL 
0 the response of tumors to the vegfr2 associated tyrosine kinase inhibitor vandetanib was evaluated . NULL NULL NULL NULL NULL NULL 
9 and murine squamous carcinoma ( sccvii ) clonal cell lines expressing varying levels of vegf were established and their response to 
0 squamous carcinoma ( sccvii ) clonal cell lines expressing varying levels of vegf were established and their response to vandetanib was 
0 ) clonal cell lines expressing varying levels of vegf were established and their response to vandetanib was assessed in tissue culture 
16 lines expressing varying levels of vegf were established and their response to vandetanib was assessed in tissue culture and as solid 
0 established and their response to vandetanib was assessed in tissue culture and as solid tumors . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : vandetanib treatment had no effect on tumor cell clonogenic 
19 NULL NULL NULL NULL NULL NULL NULL results : vandetanib treatment had no effect on tumor cell clonogenic cell survival in 
16 NULL NULL NULL NULL results : vandetanib treatment had no effect on tumor cell clonogenic cell survival in vitro but doses 
0 NULL NULL results : vandetanib treatment had no effect on tumor cell clonogenic cell survival in vitro but doses > or=10 
5 vandetanib treatment had no effect on tumor cell clonogenic cell survival in vitro but doses > or=10 nm significantly reduced endothelial 
18 cell survival in vitro but doses > or=10 nm significantly reduced endothelial cell migration . NULL NULL NULL NULL NULL NULL 
14 vitro but doses > or=10 nm significantly reduced endothelial cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL in vivo , tumors derived from cell clones expressing high levels of vegf displayed significantly 
9 NULL NULL in vivo , tumors derived from cell clones expressing high levels of vegf displayed significantly enhanced angiogenesis and more 
0 in vivo , tumors derived from cell clones expressing high levels of vegf displayed significantly enhanced angiogenesis and more aggressive growth 
17 from cell clones expressing high levels of vegf displayed significantly enhanced angiogenesis and more aggressive growth . NULL NULL NULL NULL 
3 cell clones expressing high levels of vegf displayed significantly enhanced angiogenesis and more aggressive growth . NULL NULL NULL NULL NULL 
4 levels of vegf displayed significantly enhanced angiogenesis and more aggressive growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL an intradermal angiogenesis assay was used to demonstrate that a 4-day treatment with 
0 NULL NULL NULL NULL NULL an intradermal angiogenesis assay was used to demonstrate that a 4-day treatment with vandetanib ( 50 
19 intradermal angiogenesis assay was used to demonstrate that a 4-day treatment with vandetanib ( 50 mg/kg/day ) was able to significantly 
18 with vandetanib ( 50 mg/kg/day ) was able to significantly inhibit blood vessel growth induced by both parental and high vegf-expressing 
4 50 mg/kg/day ) was able to significantly inhibit blood vessel growth induced by both parental and high vegf-expressing tumor cell clones 
17 mg/kg/day ) was able to significantly inhibit blood vessel growth induced by both parental and high vegf-expressing tumor cell clones . 
9 inhibit blood vessel growth induced by both parental and high expressing tumor cell clones . NULL NULL NULL NULL NULL NULL 
0 blood vessel growth induced by both parental and high vegf-expressing tumor cell clones . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL in the ht29 tumor model , treatment response to vandetanib ( 50 mg/kg/day , 
19 NULL NULL NULL NULL in the ht29 tumor model , treatment response to vandetanib ( 50 mg/kg/day , monday-friday for 2 
16 NULL NULL NULL in the ht29 tumor model , treatment response to vandetanib ( 50 mg/kg/day , monday-friday for 2 weeks 
0 , monday-friday for 2 weeks ) was greatest in xenografts derived from the highest vegf-expressing cell clones . NULL NULL NULL 
9 weeks ) was greatest in xenografts derived from the highest expressing cell clones . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL a similar trend was noted in the sccvii tumor model . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the present findings indicate that vandetanib therapy effectively counteracted the aggressive feature 
19 NULL NULL NULL NULL the present findings indicate that vandetanib therapy effectively counteracted the aggressive feature of tumor growth resulting from 
18 NULL NULL the present findings indicate that vandetanib therapy effectively counteracted the aggressive feature of tumor growth resulting from vegf over-expressing 
0 indicate that vandetanib therapy effectively counteracted the aggressive feature of tumor growth resulting from vegf over-expressing tumor cells and suggest that 
4 that vandetanib therapy effectively counteracted the aggressive feature of tumor growth resulting from vegf over-expressing tumor cells and suggest that such 
0 vandetanib therapy effectively counteracted the aggressive feature of tumor growth resulting from vegf over-expressing tumor cells and suggest that such tumors 
9 counteracted the aggressive feature of tumor growth resulting from vegf over-expressing tumor cells and suggest that such tumors may be particularly 
0 the aggressive feature of tumor growth resulting from vegf over-expressing tumor cells and suggest that such tumors may be particularly well 
18 that such tumors may be particularly well suited for anti-vegf interventions . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL mechanical regulation of the proangiogenic factor ccn1/cyr61 gene requires the combined activities 
3 NULL NULL NULL NULL NULL NULL mechanical regulation of the angiogenic factor ccn1/cyr61 gene requires the combined activities of mrtf-a and 
17 NULL NULL mechanical regulation of the proangiogenic factor ccn1/cyr61 gene requires the combined activities of mrtf-a and creb-binding protein histone acetyltransferase 
0 regulation of the proangiogenic factor ccn1/cyr61 gene requires the combined activities of mrtf-a and creb-binding protein histone acetyltransferase . NULL NULL 
0 factor ccn1/cyr61 gene requires the combined activities of mrtf-a and binding protein histone acetyltransferase . NULL NULL NULL NULL NULL NULL 
0 ccn1/cyr61 gene requires the combined activities of mrtf-a and creb-binding protein histone acetyltransferase . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL smooth muscle-rich tissues respond to mechanical overload by an adaptive hypertrophic growth combined with 
0 muscle-rich tissues respond to mechanical overload by an adaptive hypertrophic growth combined with activation of angiogenesis , which potentiates their mechanical 
17 to mechanical overload by an adaptive hypertrophic growth combined with activation of angiogenesis , which potentiates their mechanical overload-bearing capabilities . 
3 overload by an adaptive hypertrophic growth combined with activation of angiogenesis , which potentiates their mechanical overload-bearing capabilities . NULL NULL 
0 adaptive hypertrophic growth combined with activation of angiogenesis , which potentiates their mechanical overload-bearing capabilities . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL neovascularization is associated with mechanical strain-dependent induction of angiogenic factors such 
0 NULL NULL NULL NULL NULL NULL NULL NULL neovascularization is associated with mechanical strain-dependent induction of angiogenic factors such as ccn1 
0 NULL NULL NULL NULL NULL neovascularization is associated with mechanical dependent induction of angiogenic factors such as ccn1 , an immediate-early 
17 NULL NULL NULL NULL neovascularization is associated with mechanical strain-dependent induction of angiogenic factors such as ccn1 , an immediate-early gene-encoded 
3 NULL NULL neovascularization is associated with mechanical strain-dependent induction of angiogenic factors such as ccn1 , an immediate-early gene-encoded matricellular molecule 
17 factors such as ccn1 , an immediate-early gene-encoded matricellular molecule critical for vascular development and repair . NULL NULL NULL NULL 
2 ccn1 , an immediate-early gene-encoded matricellular molecule critical for vascular development and repair . NULL NULL NULL NULL NULL NULL NULL 
2 an immediate-early gene-encoded matricellular molecule critical for vascular development and repair . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL here we have demonstrated that mechanical dependent induction of the ccn1 gene involves signaling cascades through rhoa-mediated 
17 NULL NULL NULL here we have demonstrated that mechanical strain-dependent induction of the ccn1 gene involves signaling cascades through rhoa-mediated actin 
0 have demonstrated that mechanical strain-dependent induction of the ccn1 gene involves signaling cascades through rhoa-mediated actin remodeling and the p38 stress-activated 
16 strain-dependent induction of the ccn1 gene involves signaling cascades through mediated actin remodeling and the p38 stress-activated protein kinase ( sapk 
0 of the ccn1 gene involves signaling cascades through rhoa-mediated actin remodeling and the p38 stress-activated protein kinase ( sapk ) . 
0 involves signaling cascades through rhoa-mediated actin remodeling and the p38 activated protein kinase ( sapk ) . NULL NULL NULL NULL 
0 signaling cascades through rhoa-mediated actin remodeling and the p38 stress-activated protein kinase ( sapk ) . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL actin signaling controls serum response factor ( srf ) activity via srf interaction 
0 NULL NULL NULL NULL NULL NULL actin signaling controls serum response factor ( srf ) activity via srf interaction with the 
0 NULL actin signaling controls serum response factor ( srf ) activity via srf interaction with the myocardin-related transcriptional activator ( mrtf 
15 controls serum response factor ( srf ) activity via srf interaction with the myocardin-related transcriptional activator ( mrtf ) -a and 
0 ( srf ) activity via srf interaction with the myocardin-related transcriptional activator ( mrtf ) -a and tethering to a single 
0 srf ) activity via srf interaction with the myocardin-related transcriptional activator ( mrtf ) -a and tethering to a single carg 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL such activity was abolished in mechanically stimulated mouse mrtf-a ( -/- ) 
0 NULL NULL NULL NULL NULL NULL NULL such activity was abolished in mechanically stimulated mouse mrtf-a ( -/- ) cells or 
17 NULL NULL NULL NULL such activity was abolished in mechanically stimulated mouse mrtf-a ( -/- ) cells or upon inhibition of 
18 mechanically stimulated mouse mrtf-a ( -/- ) cells or upon inhibition of creb-binding protein ( cbp ) histone acetyltransferase ( hat 
0 mouse mrtf-a ( -/- ) cells or upon inhibition of binding protein ( cbp ) histone acetyltransferase ( hat ) either 
0 mrtf-a ( -/- ) cells or upon inhibition of creb-binding protein ( cbp ) histone acetyltransferase ( hat ) either pharmacologically 
17 NULL NULL NULL NULL NULL NULL NULL NULL mechanical strain induced cbp-mediated acetylation of histones 3 and 4 at the srf-binding 
17 NULL NULL NULL NULL NULL NULL NULL mechanical strain induced mediated acetylation of histones 3 and 4 at the srf-binding site 
0 induced cbp-mediated acetylation of histones 3 and 4 at the binding site and within the ccn1 gene coding region . NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of p38 sapk reduced cbp hat activity and its recruitment 
18 NULL NULL NULL NULL NULL NULL inhibition of p38 sapk reduced cbp hat activity and its recruitment to the srf.mrtf-a complex 
0 NULL NULL NULL inhibition of p38 sapk reduced cbp hat activity and its recruitment to the srf.mrtf-a complex , whereas enforced 
15 inhibition of p38 sapk reduced cbp hat activity and its recruitment to the srf.mrtf-a complex , whereas enforced induction of p38 
0 activity and its recruitment to the srf.mrtf-a complex , whereas enforced induction of p38 by upstream activators ( e.g. mkk3 and 
17 and its recruitment to the srf.mrtf-a complex , whereas enforced induction of p38 by upstream activators ( e.g. mkk3 and mkk6 
17 p38 by upstream activators ( e.g. mkk3 and mkk6 ) enhanced both cbp hat and ccn1 promoter activities . NULL NULL 
0 and mkk6 ) enhanced both cbp hat and ccn1 promoter activities . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL similarly , mechanical induced ccn1 gene expression in vivo was associated with nuclear localization 
9 NULL NULL NULL NULL similarly , mechanical overload-induced ccn1 gene expression in vivo was associated with nuclear localization of mrtf-a and 
16 similarly , mechanical overload-induced ccn1 gene expression in vivo was associated with nuclear localization of mrtf-a and enrichment of the ccn1 
14 overload-induced ccn1 gene expression in vivo was associated with nuclear localization of mrtf-a and enrichment of the ccn1 promoter with both 
16 NULL NULL NULL taken together , these data suggest that controlled activation of srf , mrtf-a , and cbp provides a 
17 NULL NULL taken together , these data suggest that signal-controlled activation of srf , mrtf-a , and cbp provides a novel 
0 of srf , mrtf-a , and cbp provides a novel connection between mechanical stimuli and angiogenic gene expression . NULL NULL 
3 and cbp provides a novel connection between mechanical stimuli and angiogenic gene expression . NULL NULL NULL NULL NULL NULL NULL 
0 provides a novel connection between mechanical stimuli and angiogenic gene expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis in platelet endothelial cell adhesion molecule-1-null mice . NULL NULL 
0 NULL NULL NULL NULL NULL angiogenesis in platelet endothelial cell adhesion molecule-1-null mice . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL angiogenesis in platelet endothelial cell adhesion null mice . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL platelet endothelial cell adhesion molecule ( pecam ) -1 has been previously implicated in 
0 cell adhesion molecule ( pecam ) -1 has been previously implicated in endothelial cell migration ; additionally , anti-pecam-1 antibodies have 
14 pecam ) -1 has been previously implicated in endothelial cell migration ; additionally , anti-pecam-1 antibodies have been shown to inhibit 
18 migration ; additionally , anti-pecam-1 antibodies have been shown to inhibit in vivo angiogenesis . NULL NULL NULL NULL NULL NULL 
3 , anti-pecam-1 antibodies have been shown to inhibit in vivo angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL studies were therefore performed with null mice to further define the involvement of pecam-1 in blood 
16 were therefore performed with pecam-1-null mice to further define the involvement of pecam-1 in blood vessel formation . NULL NULL NULL 
2 to further define the involvement of pecam-1 in blood vessel formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL vascularization of subcutaneous matrigel implants as well as tumor angiogenesis were 
0 NULL NULL vascularization of subcutaneous matrigel implants as well as tumor angiogenesis were both inhibited in pecam-1-null mice . NULL NULL 
3 NULL vascularization of subcutaneous matrigel implants as well as tumor angiogenesis were both inhibited in pecam-1-null mice . NULL NULL NULL 
18 subcutaneous matrigel implants as well as tumor angiogenesis were both inhibited in pecam-1-null mice . NULL NULL NULL NULL NULL NULL 
9 implants as well as tumor angiogenesis were both inhibited in null mice . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL reciprocal bone marrow transplants that involved both wild-type and pecam-1-deficient mice revealed that the 
0 NULL NULL NULL NULL NULL reciprocal bone marrow transplants that involved both wild-type and pecam-1-deficient mice revealed that the impaired angiogenic 
9 NULL reciprocal bone marrow transplants that involved both wild-type and deficient mice revealed that the impaired angiogenic response resulted from a 
18 that involved both wild-type and pecam-1-deficient mice revealed that the impaired angiogenic response resulted from a loss of endothelial , but 
3 involved both wild-type and pecam-1-deficient mice revealed that the impaired angiogenic response resulted from a loss of endothelial , but not 
0 both wild-type and pecam-1-deficient mice revealed that the impaired angiogenic response resulted from a loss of endothelial , but not leukocyte 
0 wild-type and pecam-1-deficient mice revealed that the impaired angiogenic response resulted from a loss of endothelial , but not leukocyte , 
14 mice revealed that the impaired angiogenic response resulted from a loss of endothelial , but not leukocyte , pecam-1 . NULL 
0 NULL NULL NULL NULL NULL NULL NULL in vitro wound migration and single-cell motility by pecam-1-null endothelial cells were also compromised 
14 NULL NULL NULL NULL in vitro wound migration and single-cell motility by pecam-1-null endothelial cells were also compromised . NULL NULL 
0 NULL NULL in vitro wound migration and single-cell motility by null endothelial cells were also compromised . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , filopodia formation , a feature of motile cells , 
2 NULL NULL NULL NULL NULL NULL in addition , filopodia formation , a feature of motile cells , was inhibited in 
18 filopodia formation , a feature of motile cells , was inhibited in pecam-1-null endothelial cells as well as in human endothelial 
0 , a feature of motile cells , was inhibited in null endothelial cells as well as in human endothelial cells treated 
19 pecam-1-null endothelial cells as well as in human endothelial cells treated with either anti-pecam-1 antibody or pecam-1 sirna . NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL furthermore , the expression of pecam-1 promoted filopodia formation and increased the protein expression 
17 NULL NULL NULL NULL furthermore , the expression of pecam-1 promoted filopodia formation and increased the protein expression levels of cdc42 
2 NULL NULL furthermore , the expression of pecam-1 promoted filopodia formation and increased the protein expression levels of cdc42 , a 
17 furthermore , the expression of pecam-1 promoted filopodia formation and increased the protein expression levels of cdc42 , a rho gtpase 
0 the expression of pecam-1 promoted filopodia formation and increased the protein expression levels of cdc42 , a rho gtpase that is 
9 expression of pecam-1 promoted filopodia formation and increased the protein expression levels of cdc42 , a rho gtpase that is known 
0 of pecam-1 promoted filopodia formation and increased the protein expression levels of cdc42 , a rho gtpase that is known to 
17 of cdc42 , a rho gtpase that is known to promote the formation of filopodia . NULL NULL NULL NULL NULL 
2 , a rho gtpase that is known to promote the formation of filopodia . NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL in the developing retinal vasculature , numerous , long filamentous filopodia , emanating 
3 filopodia , emanating from endothelial cells at the tips of angiogenic sprouts , were observed in wild-type animals , but to 
0 endothelial cells at the tips of angiogenic sprouts , were observed in wild-type animals , but to a lesser extent in 
9 wild-type animals , but to a lesser extent in the null mice . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL together , these data further establish the involvement of endothelial pecam-1 in angiogenesis and suggest that , in 
3 these data further establish the involvement of endothelial pecam-1 in angiogenesis and suggest that , in vivo , pecam-1 may stimulate 
17 angiogenesis and suggest that , in vivo , pecam-1 may stimulate endothelial cell motility by promoting the formation of filopodia . 
14 that , in vivo , pecam-1 may stimulate endothelial cell motility by promoting the formation of filopodia . NULL NULL NULL 
17 in vivo , pecam-1 may stimulate endothelial cell motility by promoting the formation of filopodia . NULL NULL NULL NULL NULL 
2 , pecam-1 may stimulate endothelial cell motility by promoting the formation of filopodia . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL mek5/erk5 signaling modulates endothelial cell migration and focal contact turnover . NULL NULL 
14 NULL NULL NULL NULL NULL mek5/erk5 signaling modulates endothelial cell migration and focal contact turnover . NULL NULL NULL NULL NULL 
0 NULL NULL mek5/erk5 signaling modulates endothelial cell migration and focal contact turnover . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL mek5/erk5 signaling modulates endothelial cell migration and focal contact turnover . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL the formation of new blood vessels from pre-existing ones requires highly coordinated 
17 NULL the formation of new blood vessels from pre-existing ones requires highly coordinated restructuring of endothelial cells ( ec ) and 
0 formation of new blood vessels from pre-existing ones requires highly coordinated restructuring of endothelial cells ( ec ) and the surrounding 
7 of new blood vessels from pre-existing ones requires highly coordinated restructuring of endothelial cells ( ec ) and the surrounding extracellular 
0 of endothelial cells ( ec ) and the surrounding extracellular matrix . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL directed ec migration is a central step in this process and depends on 
0 NULL NULL NULL NULL NULL directed ec migration is a central step in this process and depends on cellular signaling cascades 
0 ec migration is a central step in this process and depends on cellular signaling cascades that initiate and control the structural 
0 in this process and depends on cellular signaling cascades that initiate and control the structural rearrangements . NULL NULL NULL NULL 
0 process and depends on cellular signaling cascades that initiate and control the structural rearrangements . NULL NULL NULL NULL NULL NULL 
0 depends on cellular signaling cascades that initiate and control the structural rearrangements . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL on the basis of earlier findings that erk5 deficiency in mouse ec results in massive defects in vessel architecture 
17 basis of earlier findings that erk5 deficiency in mouse ec results in massive defects in vessel architecture , we focused on 
18 findings that erk5 deficiency in mouse ec results in massive defects in vessel architecture , we focused on the impact of 
16 massive defects in vessel architecture , we focused on the impact of the mek5/erk5 signaling pathway on ec migration . NULL 
14 on the impact of the mek5/erk5 signaling pathway on ec migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 a retroviral gene transfer approach , we found that constitutive activation of mek5/erk5 signaling strongly inhibits ec migration and results in 
18 , we found that constitutive activation of mek5/erk5 signaling strongly inhibits ec migration and results in massive morphological changes . NULL 
14 found that constitutive activation of mek5/erk5 signaling strongly inhibits ec migration and results in massive morphological changes . NULL NULL NULL 
0 constitutive activation of mek5/erk5 signaling strongly inhibits ec migration and results in massive morphological changes . NULL NULL NULL NULL NULL 
0 mek5/erk5 signaling strongly inhibits ec migration and results in massive morphological changes . NULL NULL NULL NULL NULL NULL NULL NULL 
0 signaling strongly inhibits ec migration and results in massive morphological changes . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL the area covered by spread ec was dramatically enlarged , accompanied by an increase in 
0 by spread ec was dramatically enlarged , accompanied by an increase in focal contacts and altered organization of actin filaments . 
0 was dramatically enlarged , accompanied by an increase in focal contacts and altered organization of actin filaments . NULL NULL NULL 
0 enlarged , accompanied by an increase in focal contacts and altered organization of actin filaments . NULL NULL NULL NULL NULL 
7 , accompanied by an increase in focal contacts and altered organization of actin filaments . NULL NULL NULL NULL NULL NULL 
18 NULL NULL consequently , cells were more rigid and show reduced motility . NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL consequently , cells were more rigid and show reduced motility . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL this phenotype was most likely based on decreased focal contact turnover caused by reduced expression of p130cas , 
0 NULL this phenotype was most likely based on decreased focal contact turnover caused by reduced expression of p130cas , a key 
0 this phenotype was most likely based on decreased focal contact turnover caused by reduced expression of p130cas , a key player 
0 phenotype was most likely based on decreased focal contact turnover caused by reduced expression of p130cas , a key player in 
18 most likely based on decreased focal contact turnover caused by reduced expression of p130cas , a key player in directed cell 
9 likely based on decreased focal contact turnover caused by reduced expression of p130cas , a key player in directed cell migration 
0 contact turnover caused by reduced expression of p130cas , a key player in directed cell migration . NULL NULL NULL NULL 
14 expression of p130cas , a key player in directed cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 for the first time that erk5 signaling not only is involved in ec survival and stress response but also controls migration 
5 time that erk5 signaling not only is involved in ec survival and stress response but also controls migration and morphology of 
0 signaling not only is involved in ec survival and stress response but also controls migration and morphology of ec . NULL 
16 is involved in ec survival and stress response but also controls migration and morphology of ec . NULL NULL NULL NULL 
14 involved in ec survival and stress response but also controls migration and morphology of ec . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene 
0 the down syndrome critical region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice . NULL 
0 region gene 1 short variant promoters direct vascular bed-specific gene expression during inflammation in mice . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL down syndrome critical region gene 1 ( dscr-1 ) short variant ( dscr-1s 
0 ( dscr-1 ) short variant ( dscr-1s ) is an inhibitor of calcineurin/nfat signaling encoded by exons 4-7 of dscr1 . 
17 NULL NULL NULL NULL NULL we previously reported that vegf induces dscr-1s expression in endothelial cells , which in turn negatively 
9 NULL NULL NULL we previously reported that vegf induces dscr-1s expression in endothelial cells , which in turn negatively feeds back 
0 induces dscr-1s expression in endothelial cells , which in turn negatively feeds back to attenuate endothelial cell activation . NULL NULL 
18 endothelial cells , which in turn negatively feeds back to attenuate endothelial cell activation . NULL NULL NULL NULL NULL NULL 
17 which in turn negatively feeds back to attenuate endothelial cell activation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL here , in order to characterize the role of the promoter that drives dscr-1s expression in mediating inducible 
0 in order to characterize the role of the promoter that drives dscr-1s expression in mediating inducible expression in vivo and to 
9 to characterize the role of the promoter that drives dscr-1s expression in mediating inducible expression in vivo and to determine the 
0 the role of the promoter that drives dscr-1s expression in mediating inducible expression in vivo and to determine the functional relevance 
0 role of the promoter that drives dscr-1s expression in mediating inducible expression in vivo and to determine the functional relevance of 
0 of the promoter that drives dscr-1s expression in mediating inducible expression in vivo and to determine the functional relevance of dscr-1s 
19 determine the functional relevance of dscr-1s in inflammation , we targeted a dna construct containing 1.7 kb of the human dscr1s 
19 dna construct containing 1.7 kb of the human dscr1s promoter coupled to the lacz reporter to the hypoxanthine guanine phosphoribosyl transferase 
9 NULL NULL NULL NULL we determined that lacz was uniformly expressed in the endothelium of transgenic embryos but was markedly downregulated 
0 determined that lacz was uniformly expressed in the endothelium of transgenic embryos but was markedly downregulated postnatally . NULL NULL NULL 
18 expressed in the endothelium of transgenic embryos but was markedly downregulated postnatally . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL systemic administration of vegf or lps in adult mice resulted in cyclosporine 
17 NULL systemic administration of vegf or lps in adult mice resulted in cyclosporine a-sensitive reactivation of the dscr1s promoter and endogenous 
16 of vegf or lps in adult mice resulted in cyclosporine sensitive reactivation of the dscr1s promoter and endogenous gene expression in 
17 vegf or lps in adult mice resulted in cyclosporine a-sensitive reactivation of the dscr1s promoter and endogenous gene expression in a 
0 cyclosporine a-sensitive reactivation of the dscr1s promoter and endogenous gene expression in a subset of organs , including the heart and 
17 NULL NULL NULL NULL NULL the dscr1s promoter was similarly induced in the endothelium of tumor xenografts . NULL NULL NULL 
0 the dscr1s promoter was similarly induced in the endothelium of tumor xenografts . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL in a mouse model of endotoxemia , deficient mice demonstrated increased sepsis mortality , whereas adenovirus-mediated dscr-1s overexpression 
0 in a mouse model of endotoxemia , dscr-1s-deficient mice demonstrated increased sepsis mortality , whereas adenovirus-mediated dscr-1s overexpression protected against lps-induced 
17 endotoxemia , dscr-1s-deficient mice demonstrated increased sepsis mortality , whereas mediated dscr-1s overexpression protected against lps-induced lethality . NULL NULL NULL 
9 dscr-1s-deficient mice demonstrated increased sepsis mortality , whereas adenovirus-mediated dscr-1s overexpression protected against lps-induced lethality . NULL NULL NULL NULL NULL 
0 increased sepsis mortality , whereas adenovirus-mediated dscr-1s overexpression protected against induced lethality . NULL NULL NULL NULL NULL NULL NULL NULL 
9 these data suggest that the dscr1s promoter directs vascular bed-specific expression in activated endothelium and that dscr-1s serves to dampen the 
17 suggest that the dscr1s promoter directs vascular bed-specific expression in activated endothelium and that dscr-1s serves to dampen the host response 
0 activated endothelium and that dscr-1s serves to dampen the host response to infection . NULL NULL NULL NULL NULL NULL NULL 
0 and that dscr-1s serves to dampen the host response to infection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL epox inhibits angiogenesis by degradation of mcl-1 through erk inactivation . NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL epox inhibits angiogenesis by degradation of mcl-1 through erk inactivation . NULL NULL 
11 NULL NULL NULL NULL NULL NULL epox inhibits angiogenesis by degradation of mcl-1 through erk inactivation . NULL NULL NULL NULL 
18 NULL epox inhibits angiogenesis by degradation of mcl-1 through erk inactivation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL purpose : angiogenic therapy is considered as an effective strategy for controlling the 
18 NULL NULL NULL NULL NULL NULL NULL purpose : antiangiogenic therapy is considered as an effective strategy for controlling the growth 
0 NULL NULL purpose : antiangiogenic therapy is considered as an effective strategy for controlling the growth and metastasis of tumors . 
16 : antiangiogenic therapy is considered as an effective strategy for controlling the growth and metastasis of tumors . NULL NULL NULL 
4 therapy is considered as an effective strategy for controlling the growth and metastasis of tumors . NULL NULL NULL NULL NULL 
14 considered as an effective strategy for controlling the growth and metastasis of tumors . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL among a myriad of biological activities described for xanthone derivatives , the anticancer activity is quite 
18 of biological activities described for xanthone derivatives , the anticancer activity is quite remarkable , but the molecular mechanism is not 
0 the anticancer activity is quite remarkable , but the molecular mechanism is not clearly resolved . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the present study , we investigated the antiangiogenic mechanism of 3 , 
3 NULL NULL in the present study , we investigated the angiogenic mechanism of 3 , 6-di ( 2 , 3-epoxypropoxy ) 
18 NULL in the present study , we investigated the antiangiogenic mechanism of 3 , 6-di ( 2 , 3-epoxypropoxy ) xanthone 
16 3-epoxypropoxy ) xanthone ( epox ) , a novel mcl-1 targeting drug . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL experimental design : to evaluate the angiogenic activity of epox , we did cell viability , cell 
18 NULL NULL NULL experimental design : to evaluate the antiangiogenic activity of epox , we did cell viability , cell cycle 
2 , we did cell viability , cell cycle , tube formation assay in vitro , and matrigel plug assay in vivo 
16 NULL NULL NULL NULL NULL NULL NULL to evaluate the effect of epox on the endothelial signaling pathway , we did 
0 NULL NULL NULL NULL NULL NULL NULL NULL intracellular glutathione levels were determined with the use of monochlorobimane , a glutathione-specific 
0 NULL NULL NULL intracellular glutathione levels were determined with the use of monochlorobimane , a glutathione-specific probe . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : epox induced endothelial cell apoptosis in association with proteasome-dependent 
17 NULL NULL NULL NULL NULL NULL NULL results : epox induced endothelial cell apoptosis in association with proteasome-dependent mcl-1 degradation . 
5 NULL NULL NULL NULL results : epox induced endothelial cell apoptosis in association with proteasome-dependent mcl-1 degradation . NULL NULL NULL 
16 NULL NULL results : epox induced endothelial cell apoptosis in association with proteasome-dependent mcl-1 degradation . NULL NULL NULL NULL NULL 
17 results : epox induced endothelial cell apoptosis in association with dependent mcl-1 degradation . NULL NULL NULL NULL NULL NULL NULL 
11 epox induced endothelial cell apoptosis in association with proteasome-dependent mcl-1 degradation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL down-regulation of mcl-1 resulted in an increase in mcl-1-free bim , 
17 NULL NULL NULL NULL NULL NULL NULL down-regulation of mcl-1 resulted in an increase in mcl-1-free bim , activation of bax 
17 NULL NULL NULL NULL down-regulation of mcl-1 resulted in an increase in mcl-1-free bim , activation of bax , and then 
16 NULL NULL down-regulation of mcl-1 resulted in an increase in free bim , activation of bax , and then signaling of 
17 of mcl-1 resulted in an increase in mcl-1-free bim , activation of bax , and then signaling of mitochondria-mediated apoptosis . 
0 bim , activation of bax , and then signaling of mediated apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL 
0 , activation of bax , and then signaling of mitochondria-mediated apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL additionally , glutathione depletion and extracellular signal-regulated kinase ( erk ) inactivation was observed 
0 NULL NULL NULL NULL additionally , glutathione depletion and extracellular regulated kinase ( erk ) inactivation was observed in epox-treated cells 
18 , glutathione depletion and extracellular signal-regulated kinase ( erk ) inactivation was observed in epox-treated cells . NULL NULL NULL NULL 
0 depletion and extracellular signal-regulated kinase ( erk ) inactivation was observed in epox-treated cells . NULL NULL NULL NULL NULL NULL 
19 extracellular signal-regulated kinase ( erk ) inactivation was observed in treated cells . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL glutathione supplementation reversed the inhibitory effects of epox on erk , which 
18 NULL NULL NULL NULL NULL NULL NULL NULL glutathione supplementation reversed the inhibitory effects of epox on erk , which increases 
18 NULL NULL NULL NULL NULL NULL glutathione supplementation reversed the inhibitory effects of epox on erk , which increases the phosphorylation 
18 NULL NULL NULL NULL NULL glutathione supplementation reversed the inhibitory effects of epox on erk , which increases the phosphorylation of 
17 reversed the inhibitory effects of epox on erk , which increases the phosphorylation of mcl-1 at t ( 163. ) overexpression 
12 inhibitory effects of epox on erk , which increases the phosphorylation of mcl-1 at t ( 163. ) overexpression of mitogen-activated 
9 increases the phosphorylation of mcl-1 at t ( 163. ) overexpression of mitogen-activated protein/erk kinase ( mek ) partially reversed the 
0 phosphorylation of mcl-1 at t ( 163. ) overexpression of activated protein/erk kinase ( mek ) partially reversed the effect of 
0 of mcl-1 at t ( 163. ) overexpression of mitogen-activated protein kinase ( mek ) partially reversed the effect of epox 
18 ) overexpression of mitogen-activated protein/erk kinase ( mek ) partially reversed the effect of epox on mcl-1 dephosphorylation , ubiquitination , 
16 of mitogen-activated protein/erk kinase ( mek ) partially reversed the effect of epox on mcl-1 dephosphorylation , ubiquitination , and degradation 
13 mek ) partially reversed the effect of epox on mcl-1 dephosphorylation , ubiquitination , and degradation , further implicating erk in 
11 effect of epox on mcl-1 dephosphorylation , ubiquitination , and degradation , further implicating erk in the regulation of mcl-1 stability 
16 ubiquitination , and degradation , further implicating erk in the regulation of mcl-1 stability . NULL NULL NULL NULL NULL NULL 
17 NULL NULL conclusions : this study provides evidence that epox induces glutathione depletion , erk inactivation , and mcl-1 degradation on 
18 conclusions : this study provides evidence that epox induces glutathione depletion , erk inactivation , and mcl-1 degradation on endothelial cells 
18 study provides evidence that epox induces glutathione depletion , erk inactivation , and mcl-1 degradation on endothelial cells , which leads 
11 epox induces glutathione depletion , erk inactivation , and mcl-1 degradation on endothelial cells , which leads to inhibition of angiogenesis 
17 inactivation , and mcl-1 degradation on endothelial cells , which leads to inhibition of angiogenesis . NULL NULL NULL NULL NULL 
18 and mcl-1 degradation on endothelial cells , which leads to inhibition of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 degradation on endothelial cells , which leads to inhibition of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL our results suggest that epox is a novel antiangiogenic agent , making 
3 NULL NULL our results suggest that epox is a novel angiogenic agent , making it a promising lead compound for further 
0 is a novel antiangiogenic agent , making it a promising lead compound for further development in the treatment of angiogenesis-related pathologies 
0 agent , making it a promising lead compound for further development in the treatment of angiogenesis-related pathologies . NULL NULL NULL 
0 it a promising lead compound for further development in the treatment of angiogenesis-related pathologies . NULL NULL NULL NULL NULL NULL 
3 promising lead compound for further development in the treatment of angiogenesis pathologies . NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL nicked { beta } 2-glycoprotein i binds angiostatin 4.5 ( plasminogen kringle 1-5 ) and attenuates its 
18 i binds angiostatin 4.5 ( plasminogen kringle 1-5 ) and attenuates its antiangiogenic property . NULL NULL NULL NULL NULL NULL 
3 angiostatin 4.5 ( plasminogen kringle 1-5 ) and attenuates its angiogenic property . NULL NULL NULL NULL NULL NULL NULL NULL 
18 4.5 ( plasminogen kringle 1-5 ) and attenuates its antiangiogenic property . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 angiostatin was first discovered as a plasminogen fragment with antitumor/antiangiogenic property . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 4 and a most part of kringle 5 , is produced by autoproteolysis and present in human plasma . NULL NULL 
0 part of kringle 5 , is produced by autoproteolysis and present in human plasma . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL beta2-glycoprotein i ( beta2gpi ) is proteolytically cleaved by plasmin in its domain v ( nicked beta2gpi ) 
17 plasmin in its domain v ( nicked beta2gpi ) , resulting in binding to plasminogen . NULL NULL NULL NULL NULL 
15 its domain v ( nicked beta2gpi ) , resulting in binding to plasminogen . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic properties have been recently reported in nicked beta2gpi as well 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL antiangiogenic properties have been recently reported in nicked beta2gpi as well as 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the present study , we found significant binding of nicked beta2gpi to 
0 NULL NULL NULL in the present study , we found significant binding of nicked beta2gpi to as4.5 ( k ( d 
15 NULL NULL in the present study , we found significant binding of nicked beta2gpi to as4.5 ( k ( d ) 
15 NULL NULL NULL NULL NULL NULL NULL NULL via this binding , nicked beta2gpi attenuates the antiangiogenic functions of as4.5 in 
18 NULL NULL NULL NULL via this binding , nicked beta2gpi attenuates the antiangiogenic functions of as4.5 in the proliferation of arterial/venous 
3 NULL NULL via this binding , nicked beta2gpi attenuates the angiogenic functions of as4.5 in the proliferation of arterial/venous endothelial cells 
18 NULL via this binding , nicked beta2gpi attenuates the antiangiogenic functions of as4.5 in the proliferation of arterial/venous endothelial cells , 
1 nicked beta2gpi attenuates the antiangiogenic functions of as4.5 in the proliferation of arterial/venous endothelial cells , in the extracellular matrix invasion 
0 the proliferation of arterial/venous endothelial cells , in the extracellular matrix invasion and the tube formation of venous endothelial cells , 
14 proliferation of arterial/venous endothelial cells , in the extracellular matrix invasion and the tube formation of venous endothelial cells , and 
2 cells , in the extracellular matrix invasion and the tube formation of venous endothelial cells , and in vivo angiogenesis . 
3 tube formation of venous endothelial cells , and in vivo angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL in contrast , intact beta2gpi does not bind to as4.5 or inhibit its antiangiogenic activity . NULL NULL 
18 contrast , intact beta2gpi does not bind to as4.5 or inhibit its antiangiogenic activity . NULL NULL NULL NULL NULL NULL 
3 intact beta2gpi does not bind to as4.5 or inhibit its angiogenic activity . NULL NULL NULL NULL NULL NULL NULL NULL 
18 beta2gpi does not bind to as4.5 or inhibit its antiangiogenic activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL thus , nicked beta2gpi exerts dual effects on angiogenesis , that is , nicked beta2gpi promotes angiogenesis 
3 NULL NULL thus , nicked beta2gpi exerts dual effects on angiogenesis , that is , nicked beta2gpi promotes angiogenesis in the 
17 dual effects on angiogenesis , that is , nicked beta2gpi promotes angiogenesis in the presence of as4.5 , whereas nicked beta2gpi 
3 effects on angiogenesis , that is , nicked beta2gpi promotes angiogenesis in the presence of as4.5 , whereas nicked beta2gpi inhibits 
0 , that is , nicked beta2gpi promotes angiogenesis in the presence of as4.5 , whereas nicked beta2gpi inhibits angiogenesis at concentrations 
18 angiogenesis in the presence of as4.5 , whereas nicked beta2gpi inhibits angiogenesis at concentrations high enough to neutralize as4.5 . NULL 
3 in the presence of as4.5 , whereas nicked beta2gpi inhibits angiogenesis at concentrations high enough to neutralize as4.5 . NULL NULL 
0 whereas nicked beta2gpi inhibits angiogenesis at concentrations high enough to neutralize as4.5 . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL our data suggest that plasmin-nicked beta2gpi promotes angiogenesis by interacting with plasmin-generated as4.5 in sites of increased 
3 NULL NULL NULL our data suggest that plasmin-nicked beta2gpi promotes angiogenesis by interacting with plasmin-generated as4.5 in sites of increased fibrinolysis 
15 NULL our data suggest that plasmin-nicked beta2gpi promotes angiogenesis by interacting with plasmin-generated as4.5 in sites of increased fibrinolysis such as 
0 promotes angiogenesis by interacting with plasmin-generated as4.5 in sites of increased fibrinolysis such as thrombus . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL targeting angiogenesis : progress with anti-vegf treatment with large molecules . 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL targeting angiogenesis : progress with anti-vegf treatment with large molecules . NULL 
0 NULL NULL NULL NULL targeting angiogenesis : progress with anti-vegf treatment with large molecules . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis -- one of the hallmarks of cancer -- has emerged 
0 hallmarks of cancer -- has emerged as a valid therapeutic target in oncology . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the vegf system represents a key mediator of tumor-initiated angiogenesis and the first target of antiangiogenesis 
0 NULL NULL NULL NULL the vegf system represents a key mediator of tumor-initiated angiogenesis and the first target of antiangiogenesis agents 
17 NULL NULL the vegf system represents a key mediator of initiated angiogenesis and the first target of antiangiogenesis agents introduced in 
3 NULL the vegf system represents a key mediator of tumor-initiated angiogenesis and the first target of antiangiogenesis agents introduced in clinical 
0 represents a key mediator of tumor-initiated angiogenesis and the first target of antiangiogenesis agents introduced in clinical practice . NULL NULL 
3 key mediator of tumor-initiated angiogenesis and the first target of angiogenesis agents introduced in clinical practice . NULL NULL NULL NULL 
0 angiogenesis and the first target of antiangiogenesis agents introduced in clinical practice . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL although anti-vegf therapies have clearly demonstrated antitumor efficacy in various malignancies , especially 
18 NULL NULL NULL although anti-vegf therapies have clearly demonstrated antitumor efficacy in various malignancies , especially when combined with conventional cytotoxic 
0 in various malignancies , especially when combined with conventional cytotoxic chemotherapy , their mechanism of action is not fully understood . 
0 , especially when combined with conventional cytotoxic chemotherapy , their mechanism of action is not fully understood . NULL NULL NULL 
0 when combined with conventional cytotoxic chemotherapy , their mechanism of action is not fully understood . NULL NULL NULL NULL NULL 
3 NULL NULL this review will discuss the rationale for using angiogenic compounds and will focus on large molecules , such as 
0 focus on large molecules , such as antibodies , that target the vegf system . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical data on bevacizumab is discussed in detail . NULL NULL 
0 bevacizumab in the adjuvant setting as well as its continued use beyond progression remain unanswered , in spite of negative data 
0 the adjuvant setting as well as its continued use beyond progression remain unanswered , in spite of negative data on bevacizumab 
0 continued use beyond progression remain unanswered , in spite of negative data on bevacizumab in treating patients with adjuvant colon cancer 
19 unanswered , in spite of negative data on bevacizumab in treating patients with adjuvant colon cancer . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL nonetheless , anti-vegf therapy has enhanced the arsenal of anticancer therapies and has provided 
0 NULL NULL NULL NULL NULL nonetheless , anti-vegf therapy has enhanced the arsenal of anticancer therapies and has provided new insights 
0 nonetheless , anti-vegf therapy has enhanced the arsenal of anticancer therapies and has provided new insights into the biology of malignancy 
3 NULL NULL NULL NULL NULL [ an experimental study on angiogenesis of non-vascularized autogenous bone graft with vascular bundle implantation ] 
3 NULL NULL NULL [ an experimental study on angiogenesis of vascularized autogenous bone graft with vascular bundle implantation ] NULL NULL 
19 on angiogenesis of non-vascularized autogenous bone graft with vascular bundle implantation ] NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL objective : to investigate the effect of vascular bundle implantation in autogenous bone graft on angiogenesis 
19 NULL objective : to investigate the effect of vascular bundle implantation in autogenous bone graft on angiogenesis . NULL NULL NULL 
3 effect of vascular bundle implantation in autogenous bone graft on angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 a portion of bilateral radial bones of a rabbit were removed as free bone grafts , whose periostea were peeled off 
0 of bilateral radial bones of a rabbit were removed as free bone grafts , whose periostea were peeled off . NULL 
19 were removed as free bone grafts , whose periostea were peeled off . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in control group , there was no vascular bundle implantation . NULL 
19 NULL in control group , there was no vascular bundle implantation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL each bone was placed in masseter muscle separately . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL the rabbits were sacrificed and the specimens were procured at 3 days , 1 
0 , 2 , 3 , 4 and 6 weeks after surgery for histological observation , chinese ink perfusion and cd34 immunohistochemistry 
0 6 weeks after surgery for histological observation , chinese ink perfusion and cd34 immunohistochemistry . NULL NULL NULL NULL NULL NULL 
3 density ( mvd ) was assessed in order to evaluate angiogenesis of autogenous bone grafts . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the bone grafts were found revascularization in 3 days 
3 NULL NULL NULL results : the bone grafts were found revascularization in 3 days after surgery in the test group , 
0 the bone grafts were found revascularization in 3 days after surgery in the test group , whereas at 2 weeks in 
0 the test group , whereas at 2 weeks in the control group . NULL NULL NULL NULL NULL NULL NULL NULL 
0 , 2 weeks , 3 weeks and 4 weeks after surgery , the mvd of test group was significantly higher than 
0 mvd of test group was significantly higher than that of control group . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL in 4 weeks after surgery , angiogenesis of test group reached to peak . NULL 
3 NULL NULL NULL NULL in 4 weeks after surgery , angiogenesis of test group reached to peak . NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL conclusion : vascular bundle implantation improved angiogenesis in non-vascularized autogenous bone graft in this study 
17 NULL NULL NULL NULL NULL conclusion : vascular bundle implantation improved angiogenesis in non-vascularized autogenous bone graft in this study . 
3 NULL NULL NULL NULL conclusion : vascular bundle implantation improved angiogenesis in non-vascularized autogenous bone graft in this study . NULL 
3 NULL NULL conclusion : vascular bundle implantation improved angiogenesis in vascularized autogenous bone graft in this study . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL [ ambiguity role of neutrophils in oncogenesis ] NULL NULL NULL NULL NULL 
2 on the participation of polymorphonuclear granulocytes ( neutrophils ) in development and spreading of a tumor . NULL NULL NULL NULL 
14 participation of polymorphonuclear granulocytes ( neutrophils ) in development and spreading of a tumor . NULL NULL NULL NULL NULL NULL 
0 granulocytes ( neutrophils ) in development and spreading of a tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL we consider both the well known functions of neutrophils ( degranulation , production of reactive oxygen species 
8 both the well known functions of neutrophils ( degranulation , production of reactive oxygen species ( ros ) ) and the 
0 special attention is focused on the ambiguity of the neutrophil role in oncogenesis . NULL NULL NULL NULL NULL NULL NULL 
18 NULL the dominant view is that neutrophils display exclusively antitumor properties . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL the update information testifies about protumoral activity of neutrophils : they migrate to a tumor and promote 
14 update information testifies about protumoral activity of neutrophils : they migrate to a tumor and promote angiogenesis and metastasis at late 
0 about protumoral activity of neutrophils : they migrate to a tumor and promote angiogenesis and metastasis at late stages of the 
17 activity of neutrophils : they migrate to a tumor and promote angiogenesis and metastasis at late stages of the tumor . 
3 of neutrophils : they migrate to a tumor and promote angiogenesis and metastasis at late stages of the tumor . NULL 
14 : they migrate to a tumor and promote angiogenesis and metastasis at late stages of the tumor . NULL NULL NULL 
0 and promote angiogenesis and metastasis at late stages of the tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 cytotoxic arsenal ( ros , cytokines , specific enzymes ) participate both in antitumoral defenses of an organism and protumoral activity 
0 participate both in antitumoral defenses of an organism and protumoral activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell migration and vascular endothelial growth factor expression are the result of 
0 NULL NULL NULL NULL endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue 
9 NULL NULL endothelial cell migration and vascular endothelial growth factor expression are the result of loss of breast tissue polarity . 
0 and vascular endothelial growth factor expression are the result of loss of breast tissue polarity . NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL recruiting a new blood supply is a rate-limiting step in tumor 
0 NULL NULL NULL recruiting a new blood supply is a limiting step in tumor progression . NULL NULL NULL NULL NULL 
0 recruiting a new blood supply is a rate-limiting step in tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 a new blood supply is a rate-limiting step in tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL in a three-dimensional model of breast carcinogenesis , disorganized , proliferative transformed breast epithelial cells express significantly 
0 in a three-dimensional model of breast carcinogenesis , disorganized , proliferative transformed breast epithelial cells express significantly higher expression of angiogenic 
2 a three-dimensional model of breast carcinogenesis , disorganized , proliferative transformed breast epithelial cells express significantly higher expression of angiogenic genes 
0 breast carcinogenesis , disorganized , proliferative transformed breast epithelial cells express significantly higher expression of angiogenic genes compared with their polarized 
0 disorganized , proliferative transformed breast epithelial cells express significantly higher expression of angiogenic genes compared with their polarized , growth-arrested nonmalignant 
0 proliferative transformed breast epithelial cells express significantly higher expression of angiogenic genes compared with their polarized , growth-arrested nonmalignant counterparts . 
0 higher expression of angiogenic genes compared with their polarized , growth nonmalignant counterparts . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL elevated vascular endothelial growth factor ( vegf ) secretion by malignant 
0 NULL NULL NULL NULL NULL NULL NULL elevated vascular endothelial growth factor ( vegf ) secretion by malignant cells enhanced recruitment 
14 NULL NULL elevated vascular endothelial growth factor ( vegf ) secretion by malignant cells enhanced recruitment of endothelial cells ( ec 
0 elevated vascular endothelial growth factor ( vegf ) secretion by malignant cells enhanced recruitment of endothelial cells ( ec ) in 
17 endothelial growth factor ( vegf ) secretion by malignant cells enhanced recruitment of endothelial cells ( ec ) in heterotypic cocultures 
14 growth factor ( vegf ) secretion by malignant cells enhanced recruitment of endothelial cells ( ec ) in heterotypic cocultures . 
2 NULL NULL NULL NULL NULL NULL NULL NULL significantly , phenotypic reversion of malignant cells via reexpression of hoxd10 , which 
2 NULL NULL NULL NULL NULL NULL NULL significantly , phenotypic reversion of malignant cells via reexpression of hoxd10 , which is 
0 NULL NULL NULL NULL NULL significantly , phenotypic reversion of malignant cells via reexpression of hoxd10 , which is lost in 
9 NULL NULL significantly , phenotypic reversion of malignant cells via reexpression of hoxd10 , which is lost in malignant progression , 
0 cells via reexpression of hoxd10 , which is lost in malignant progression , significantly attenuated vegf expression in a hypoxia-inducible factor 
0 via reexpression of hoxd10 , which is lost in malignant progression , significantly attenuated vegf expression in a hypoxia-inducible factor 1alpha-independent 
18 hoxd10 , which is lost in malignant progression , significantly attenuated vegf expression in a hypoxia-inducible factor 1alpha-independent fashion and reduced 
9 which is lost in malignant progression , significantly attenuated vegf expression in a hypoxia-inducible factor 1alpha-independent fashion and reduced ec migration 
0 in malignant progression , significantly attenuated vegf expression in a inducible factor 1alpha-independent fashion and reduced ec migration . NULL NULL 
16 progression , significantly attenuated vegf expression in a hypoxia-inducible factor independent fashion and reduced ec migration . NULL NULL NULL NULL 
18 attenuated vegf expression in a hypoxia-inducible factor 1alpha-independent fashion and reduced ec migration . NULL NULL NULL NULL NULL NULL NULL 
14 expression in a hypoxia-inducible factor 1alpha-independent fashion and reduced ec migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL this was due primarily to restoring polarity : forced proliferation of polarized , nonmalignant cells did not induce vegf 
1 NULL this was due primarily to restoring polarity : forced proliferation of polarized , nonmalignant cells did not induce vegf expression 
17 : forced proliferation of polarized , nonmalignant cells did not induce vegf expression and ec recruitment , whereas disrupting the architecture 
9 proliferation of polarized , nonmalignant cells did not induce vegf expression and ec recruitment , whereas disrupting the architecture of growth-arrested 
14 , nonmalignant cells did not induce vegf expression and ec recruitment , whereas disrupting the architecture of growth-arrested , reverted cells 
0 did not induce vegf expression and ec recruitment , whereas disrupting the architecture of growth-arrested , reverted cells did . NULL 
0 expression and ec recruitment , whereas disrupting the architecture of growth , reverted cells did . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL these data show that disrupting cytostructure activates the angiogenic switch even in the absence of 
17 NULL NULL NULL NULL these data show that disrupting cytostructure activates the angiogenic switch even in the absence of proliferation and/or 
3 NULL NULL these data show that disrupting cytostructure activates the angiogenic switch even in the absence of proliferation and/or hypoxia and 
0 cytostructure activates the angiogenic switch even in the absence of proliferation and/or hypoxia and restoring organization of malignant clusters reduces vegf 
0 even in the absence of proliferation and/or hypoxia and restoring organization of malignant clusters reduces vegf expression and ec activation to 
0 the absence of proliferation and/or hypoxia and restoring organization of malignant clusters reduces vegf expression and ec activation to levels found 
18 of proliferation and/or hypoxia and restoring organization of malignant clusters reduces vegf expression and ec activation to levels found in quiescent 
9 and/or hypoxia and restoring organization of malignant clusters reduces vegf expression and ec activation to levels found in quiescent nonmalignant epithelium 
17 restoring organization of malignant clusters reduces vegf expression and ec activation to levels found in quiescent nonmalignant epithelium . NULL NULL 
0 of malignant clusters reduces vegf expression and ec activation to levels found in quiescent nonmalignant epithelium . NULL NULL NULL NULL 
0 data confirm the importance of tissue architecture and polarity in malignant progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 confirm the importance of tissue architecture and polarity in malignant progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL metronomic chemotherapy ( the frequent , long term , low dose administration 
0 chemotherapy ( the frequent , long term , low dose administration of chemotherapeutic drugs ) is a promising therapy because it 
0 low dose administration of chemotherapeutic drugs ) is a promising therapy because it enhances the anti-endothelial activity of conventional chemotherapeutics , 
17 of chemotherapeutic drugs ) is a promising therapy because it enhances the anti-endothelial activity of conventional chemotherapeutics , but with lower 
18 ) is a promising therapy because it enhances the anti-endothelial activity of conventional chemotherapeutics , but with lower or no toxic 
0 of conventional chemotherapeutics , but with lower or no toxic effects compared to maximum tolerated dose administration . NULL NULL NULL 
0 lower or no toxic effects compared to maximum tolerated dose administration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the aims of the present study were to compare , in vitro and in vivo 
3 to compare , in vitro and in vivo , the angiogenic and antitumor activities of metronomic irinotecan ( cpt-11 ) , 
18 in vitro and in vivo , the antiangiogenic and antitumor activities of metronomic irinotecan ( cpt-11 ) , oxaliplatin ( l-ohp 
1 NULL NULL NULL NULL NULL NULL NULL in vitro cell proliferation , combination studies and vascular endothelial growth factor ( vegf 
0 in vitro cell proliferation , combination studies and vascular endothelial growth factor ( vegf ) secretion analyses were performed on endothelial 
14 combination studies and vascular endothelial growth factor ( vegf ) secretion analyses were performed on endothelial ( hmvec-d ) and colorectal 
19 ( hmvec-d ) and colorectal cancer ( ht-29 ) cells exposed for 144 h to metronomic concentrations of sn-38 , the 
0 for 144 h to metronomic concentrations of sn-38 , the active metabolite of cpt-11 , l-ohp and 5-fu . NULL NULL 
0 NULL NULL NULL ht-29 human colorectal cancer xenograft model was used and tumour growth , microvessel density and vegf quantification were 
4 ht-29 human colorectal cancer xenograft model was used and tumour growth , microvessel density and vegf quantification were performed in tumours 
0 density and vegf quantification were performed in tumours after the administration of metronomic cpt-11 , l-ohp , 5-fu and their simultaneous 
18 of sn-38 , but not 5-fu and l-ohp , preferentially inhibited endothelial cell proliferation . NULL NULL NULL NULL NULL NULL 
1 but not 5-fu and l-ohp , preferentially inhibited endothelial cell proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL simultaneous and continuous exposure of ht-29 and hmvec-d cells to low concentrations sn-38+l-ohp+5-fu for 
0 and hmvec-d cells to low concentrations sn-38+l-ohp+5-fu for 144 h showed a strong antagonism and an unfavorable dose-reduction index . NULL 
0 to low concentrations sn-38+l-ohp+5-fu for 144 h showed a strong antagonism and an unfavorable dose-reduction index . NULL NULL NULL NULL 
0 for 144 h showed a strong antagonism and an unfavorable reduction index . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL moreover , the ternary combination resulted in a significant increase of vegf secretion in ht-29 cancer 
0 NULL NULL moreover , the ternary combination resulted in a significant increase of vegf secretion in ht-29 cancer cells . NULL 
17 NULL moreover , the ternary combination resulted in a significant increase of vegf secretion in ht-29 cancer cells . NULL NULL 
14 the ternary combination resulted in a significant increase of vegf secretion in ht-29 cancer cells . NULL NULL NULL NULL NULL 
18 metronomic cpt-11 , but not 5-fu and l-ohp , significantly inhibits ht-29 tumor growth and microvessel density in the absence of 
4 , but not 5-fu and l-ohp , significantly inhibits ht-29 tumor growth and microvessel density in the absence of toxicity . 
4 but not 5-fu and l-ohp , significantly inhibits ht-29 tumor growth and microvessel density in the absence of toxicity . NULL 
19 NULL NULL NULL NULL on the contrary , metronomic 5-fu+l-ohp+cpt-11 therapy did not affect the microvascular count . NULL NULL NULL 
16 NULL on the contrary , metronomic 5-fu+l-ohp+cpt-11 therapy did not affect the microvascular count . NULL NULL NULL NULL NULL NULL 
0 drug in colorectal cancer and metronomic combination regimens should be used with caution . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL a key role for the integrin alpha2beta1 in experimental and developmental angiogenesis 
0 NULL NULL NULL NULL NULL NULL NULL NULL a key role for the integrin alpha2beta1 in experimental and developmental angiogenesis . 
3 key role for the integrin alpha2beta1 in experimental and developmental angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL the alpha2beta1 integrin receptor plays a key role in angiogenesis . NULL NULL NULL NULL 
16 NULL NULL NULL NULL the alpha2beta1 integrin receptor plays a key role in angiogenesis . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL the alpha2beta1 integrin receptor plays a key role in angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 NULL the alpha2beta1 integrin receptor plays a key role in angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL here we investigated the effects of small molecule inhibitors ( smis ) designed to disrupt 
0 effects of small molecule inhibitors ( smis ) designed to disrupt integrin alpha2 i or beta1 i-like domain function on angiogenesis 
0 designed to disrupt integrin alpha2 i or beta1 i-like domain function on angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 disrupt integrin alpha2 i or beta1 i-like domain function on angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL in unchallenged endothelial cells , fibrillar collagen induced robust capillary morphogenesis . 
17 NULL NULL NULL in unchallenged endothelial cells , fibrillar collagen induced robust capillary morphogenesis . NULL NULL NULL NULL NULL NULL 
2 in unchallenged endothelial cells , fibrillar collagen induced robust capillary morphogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL in contrast , tube formation was significantly reduced by smi496 , a beta1 i-like domain 
18 NULL NULL NULL in contrast , tube formation was significantly reduced by smi496 , a beta1 i-like domain inhibitor and by 
0 was significantly reduced by smi496 , a beta1 i-like domain inhibitor and by function-blocking anti-alpha2beta1 but not -alpha1beta1 antibodies . NULL 
0 by smi496 , a beta1 i-like domain inhibitor and by function anti-alpha2beta1 but not -alpha1beta1 antibodies . NULL NULL NULL NULL 
0 by smi496 , a beta1 i-like domain inhibitor and by blocking anti-alpha2beta1 but not -alpha1beta1 antibodies . NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cells bound fluorescein-labeled collagen i fibrils , an interaction specifically inhibited by 
19 NULL NULL NULL NULL NULL NULL NULL endothelial cells bound labeled collagen i fibrils , an interaction specifically inhibited by smi496 
0 NULL endothelial cells bound fluorescein-labeled collagen i fibrils , an interaction specifically inhibited by smi496 . NULL NULL NULL NULL NULL 
18 cells bound fluorescein-labeled collagen i fibrils , an interaction specifically inhibited by smi496 . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL moreover , smi496 caused cell retraction and cytoskeletal collapse of endothelial cells as well 
5 NULL NULL NULL moreover , smi496 caused cell retraction and cytoskeletal collapse of endothelial cells as well as delayed endothelial cell 
5 NULL NULL moreover , smi496 caused cell retraction and cytoskeletal collapse of endothelial cells as well as delayed endothelial cell wound 
18 retraction and cytoskeletal collapse of endothelial cells as well as delayed endothelial cell wound healing . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL smi activities were examined in vivo by supplementing the growth medium of 
0 NULL smi activities were examined in vivo by supplementing the growth medium of zebrafish embryos expressing green fluorescent protein under the 
9 in vivo by supplementing the growth medium of zebrafish embryos expressing green fluorescent protein under the control of the vascular endothelial 
0 supplementing the growth medium of zebrafish embryos expressing green fluorescent protein under the control of the vascular endothelial growth factor receptor-2 
16 medium of zebrafish embryos expressing green fluorescent protein under the control of the vascular endothelial growth factor receptor-2 promoter . NULL 
0 green fluorescent protein under the control of the vascular endothelial growth factor receptor-2 promoter . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL smi496 , but not a control compound , interfered with angiogenesis in vivo by reversibly inhibiting 
18 NULL NULL smi496 , but not a control compound , interfered with angiogenesis in vivo by reversibly inhibiting sprouting from the 
3 smi496 , but not a control compound , interfered with angiogenesis in vivo by reversibly inhibiting sprouting from the axial vessels 
18 control compound , interfered with angiogenesis in vivo by reversibly inhibiting sprouting from the axial vessels . NULL NULL NULL NULL 
2 compound , interfered with angiogenesis in vivo by reversibly inhibiting sprouting from the axial vessels . NULL NULL NULL NULL NULL 
0 NULL NULL NULL notably , a similar vascular phenotype was induced by morpholino-mediated knockdown of the integrin alpha2 subunit . NULL 
0 NULL notably , a similar vascular phenotype was induced by mediated knockdown of the integrin alpha2 subunit . NULL NULL NULL 
19 notably , a similar vascular phenotype was induced by morpholino-mediated knockdown of the integrin alpha2 subunit . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL collectively , our results provide strong biochemical and genetic evidence of a central role 
16 our results provide strong biochemical and genetic evidence of a central role for alpha2beta1 integrin in experimental and developmental angiogenesis . 
16 results provide strong biochemical and genetic evidence of a central role for alpha2beta1 integrin in experimental and developmental angiogenesis . NULL 
3 a central role for alpha2beta1 integrin in experimental and developmental angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL dopamine regulates phosphorylation of vegf receptor 2 by engaging src-homology-2-domain-containing protein tyrosine 
12 NULL NULL NULL NULL NULL NULL NULL NULL dopamine regulates phosphorylation of vegf receptor 2 by engaging src-homology-2-domain-containing protein tyrosine phosphatase 
16 NULL NULL dopamine regulates phosphorylation of vegf receptor 2 by engaging src-homology-2-domain-containing protein tyrosine phosphatase 2 . NULL NULL NULL NULL 
0 dopamine regulates phosphorylation of vegf receptor 2 by engaging src-homology-2-domain-containing protein tyrosine phosphatase 2 . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) -induced receptor phosphorylation is the crucial 
0 NULL NULL NULL vascular endothelial growth factor ( vegf ) induced receptor phosphorylation is the crucial step for initiating downstream signaling 
0 NULL vascular endothelial growth factor ( vegf ) -induced receptor phosphorylation is the crucial step for initiating downstream signaling pathways that 
0 growth factor ( vegf ) -induced receptor phosphorylation is the crucial step for initiating downstream signaling pathways that lead to angiogenesis 
0 ) -induced receptor phosphorylation is the crucial step for initiating downstream signaling pathways that lead to angiogenesis or related pathophysiological outcomes 
0 receptor phosphorylation is the crucial step for initiating downstream signaling pathways that lead to angiogenesis or related pathophysiological outcomes . NULL 
17 is the crucial step for initiating downstream signaling pathways that lead to angiogenesis or related pathophysiological outcomes . NULL NULL NULL 
3 crucial step for initiating downstream signaling pathways that lead to angiogenesis or related pathophysiological outcomes . NULL NULL NULL NULL NULL 
18 our previous studies have shown that the neurotransmitter dopamine could inhibit vegf-induced phosphorylation of vegf receptor 2 ( vegfr-2 ) , 
17 previous studies have shown that the neurotransmitter dopamine could inhibit induced phosphorylation of vegf receptor 2 ( vegfr-2 ) , endothelial 
12 studies have shown that the neurotransmitter dopamine could inhibit vegf-induced phosphorylation of vegf receptor 2 ( vegfr-2 ) , endothelial cell 
1 of vegf receptor 2 ( vegfr-2 ) , endothelial cell proliferation , migration , microvascular permeability , and thus , angiogenesis 
14 receptor 2 ( vegfr-2 ) , endothelial cell proliferation , migration , microvascular permeability , and thus , angiogenesis . NULL 
3 proliferation , migration , microvascular permeability , and thus , angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL in this study , we address the mechanism by which vegfr-2 phosphorylation is regulated by dopamine . NULL 
12 this study , we address the mechanism by which vegfr-2 phosphorylation is regulated by dopamine . NULL NULL NULL NULL NULL 
16 , we address the mechanism by which vegfr-2 phosphorylation is regulated by dopamine . NULL NULL NULL NULL NULL NULL NULL 
14 , we demonstrate that d2 dopamine receptor ( d2dr ) colocalizes with vegfr-2 at the cell surface . NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL dopamine pretreatment increases the translocation and colocalization of src-homology-2-domain-containing protein tyrosine phosphatase 
17 NULL NULL NULL NULL NULL NULL NULL NULL dopamine pretreatment increases the translocation and colocalization of src-homology-2-domain-containing protein tyrosine phosphatase ( 
14 NULL NULL NULL NULL NULL NULL dopamine pretreatment increases the translocation and colocalization of src-homology-2-domain-containing protein tyrosine phosphatase ( shp-2 ) 
14 NULL NULL NULL NULL dopamine pretreatment increases the translocation and colocalization of src-homology-2-domain-containing protein tyrosine phosphatase ( shp-2 ) with d2dr 
0 NULL dopamine pretreatment increases the translocation and colocalization of src-homology-2-domain-containing protein tyrosine phosphatase ( shp-2 ) with d2dr at the cell 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL dopamine administration leads to increased vegf-induced phosphorylation of shp-2 and this increased 
17 NULL NULL NULL NULL NULL NULL NULL NULL dopamine administration leads to increased vegf-induced phosphorylation of shp-2 and this increased phosphorylation 
17 NULL NULL NULL NULL NULL NULL dopamine administration leads to increased vegf-induced phosphorylation of shp-2 and this increased phosphorylation parallels the 
17 NULL NULL NULL NULL NULL dopamine administration leads to increased induced phosphorylation of shp-2 and this increased phosphorylation parallels the increased 
12 NULL NULL NULL NULL dopamine administration leads to increased vegf-induced phosphorylation of shp-2 and this increased phosphorylation parallels the increased phosphatase 
17 administration leads to increased vegf-induced phosphorylation of shp-2 and this increased phosphorylation parallels the increased phosphatase activity of shp-2 . NULL 
12 leads to increased vegf-induced phosphorylation of shp-2 and this increased phosphorylation parallels the increased phosphatase activity of shp-2 . NULL NULL 
17 vegf-induced phosphorylation of shp-2 and this increased phosphorylation parallels the increased phosphatase activity of shp-2 . NULL NULL NULL NULL NULL 
0 of shp-2 and this increased phosphorylation parallels the increased phosphatase activity of shp-2 . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL active shp-2 then dephosphorylates vegfr-2 at y951 , y996 and y1059 
13 NULL NULL NULL NULL NULL NULL NULL active shp-2 then dephosphorylates vegfr-2 at y951 , y996 and y1059 , but not 
17 NULL NULL NULL NULL NULL NULL NULL active shp-2 then dephosphorylates vegfr-2 at y951 , y996 and y1059 , but not 
19 NULL NULL NULL NULL NULL we also observe that shp-2 knockdown impairs the dopamine-regulated inhibition of vegf-induced phosphorylation of vegfr-2 and 
18 NULL NULL NULL NULL we also observe that shp-2 knockdown impairs the dopamine-regulated inhibition of vegf-induced phosphorylation of vegfr-2 and , 
0 NULL NULL we also observe that shp-2 knockdown impairs the regulated inhibition of vegf-induced phosphorylation of vegfr-2 and , subsequently , 
18 NULL we also observe that shp-2 knockdown impairs the dopamine-regulated inhibition of vegf-induced phosphorylation of vegfr-2 and , subsequently , src 
17 also observe that shp-2 knockdown impairs the dopamine-regulated inhibition of induced phosphorylation of vegfr-2 and , subsequently , src phosphorylation and 
12 observe that shp-2 knockdown impairs the dopamine-regulated inhibition of vegf-induced phosphorylation of vegfr-2 and , subsequently , src phosphorylation and migration 
12 of vegf-induced phosphorylation of vegfr-2 and , subsequently , src phosphorylation and migration . NULL NULL NULL NULL NULL NULL NULL 
14 phosphorylation of vegfr-2 and , subsequently , src phosphorylation and migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL our data establish a novel role for shp-2 phosphatase in the dopamine-mediated regulation of vegfr-2 phosphorylation 
0 data establish a novel role for shp-2 phosphatase in the mediated regulation of vegfr-2 phosphorylation . NULL NULL NULL NULL NULL 
16 establish a novel role for shp-2 phosphatase in the dopamine-mediated regulation of vegfr-2 phosphorylation . NULL NULL NULL NULL NULL NULL 
12 role for shp-2 phosphatase in the dopamine-mediated regulation of vegfr-2 phosphorylation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial 
17 NULL NULL NULL NULL NULL NULL glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and 
16 NULL NULL NULL NULL NULL NULL glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and 
0 NULL NULL NULL NULL NULL glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived 
3 NULL NULL NULL NULL glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 
3 NULL NULL glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1 . 
0 stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1 . NULL NULL NULL NULL 
0 tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and derived factor 1 . NULL NULL NULL NULL NULL NULL NULL 
0 cancer stem cells ( csc ) are predicted to be critical drivers of tumor progression due to their self-renewal capacity and 
0 ( csc ) are predicted to be critical drivers of tumor progression due to their self-renewal capacity and limitless proliferative potential 
2 csc ) are predicted to be critical drivers of tumor progression due to their self-renewal capacity and limitless proliferative potential . 
1 of tumor progression due to their self-renewal capacity and limitless proliferative potential . NULL NULL NULL NULL NULL NULL NULL NULL 
0 tumor progression due to their self-renewal capacity and limitless proliferative potential . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 an emerging area of research suggests that csc may also support tumor progression by promoting tumor angiogenesis . NULL NULL NULL 
0 emerging area of research suggests that csc may also support tumor progression by promoting tumor angiogenesis . NULL NULL NULL NULL 
2 area of research suggests that csc may also support tumor progression by promoting tumor angiogenesis . NULL NULL NULL NULL NULL 
17 research suggests that csc may also support tumor progression by promoting tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
0 suggests that csc may also support tumor progression by promoting tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 that csc may also support tumor progression by promoting tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL to investigate how csc contribute to tumor vascular development , we used an approach comparing 
0 NULL NULL NULL NULL to investigate how csc contribute to tumor vascular development , we used an approach comparing tumor xenografts 
2 NULL NULL to investigate how csc contribute to tumor vascular development , we used an approach comparing tumor xenografts of the 
0 investigate how csc contribute to tumor vascular development , we used an approach comparing tumor xenografts of the c6 glioma cell 
0 to tumor vascular development , we used an approach comparing tumor xenografts of the c6 glioma cell line containing either a 
0 NULL NULL NULL compared with csc-low tumors , csc-high tumors exhibited increased microvessel density and blood perfusion and induced increased mobilization 
17 NULL NULL compared with csc-low tumors , csc-high tumors exhibited increased microvessel density and blood perfusion and induced increased mobilization and 
0 tumors , csc-high tumors exhibited increased microvessel density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow-derived 
17 csc-high tumors exhibited increased microvessel density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow-derived endothelial progenitor 
0 tumors exhibited increased microvessel density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow-derived endothelial progenitor cells 
14 exhibited increased microvessel density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow-derived endothelial progenitor cells ( 
0 microvessel density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow-derived endothelial progenitor cells ( epc ) 
14 density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow-derived endothelial progenitor cells ( epc ) . 
0 perfusion and induced increased mobilization and tumor recruitment of bone derived endothelial progenitor cells ( epc ) . NULL NULL NULL 
17 NULL NULL NULL NULL NULL csc-high c6 cell cultures also induced higher levels of endothelial cell proliferation and tubule organization in 
0 NULL NULL NULL csc-high c6 cell cultures also induced higher levels of endothelial cell proliferation and tubule organization in vitro compared 
1 c6 cell cultures also induced higher levels of endothelial cell proliferation and tubule organization in vitro compared with csc-low cultures . 
2 also induced higher levels of endothelial cell proliferation and tubule organization in vitro compared with csc-low cultures . NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL csc-high cultures and tumors expressed increased levels of the proangiogenic factors vascular endothelial growth factor 
17 NULL NULL NULL NULL NULL csc-high cultures and tumors expressed increased levels of the proangiogenic factors vascular endothelial growth factor and 
0 NULL NULL NULL NULL csc-high cultures and tumors expressed increased levels of the proangiogenic factors vascular endothelial growth factor and stromal-derived 
3 NULL csc-high cultures and tumors expressed increased levels of the angiogenic factors vascular endothelial growth factor and stromal-derived factor 1 , 
0 tumors expressed increased levels of the proangiogenic factors vascular endothelial growth factor and stromal-derived factor 1 , and when signaling by 
0 levels of the proangiogenic factors vascular endothelial growth factor and derived factor 1 , and when signaling by either factor was 
18 factor 1 , and when signaling by either factor was blocked , all aspects of angiogenesis observed in csc-high cultures and 
3 signaling by either factor was blocked , all aspects of angiogenesis observed in csc-high cultures and tumors , including microvessel density 
0 by either factor was blocked , all aspects of angiogenesis observed in csc-high cultures and tumors , including microvessel density , 
0 in csc-high cultures and tumors , including microvessel density , perfusion , epc mobilization/recruitment , and stimulation of endothelial cell activity 
14 and tumors , including microvessel density , perfusion , epc mobilization/recruitment , and stimulation of endothelial cell activity , were reduced 
17 including microvessel density , perfusion , epc mobilization/recruitment , and stimulation of endothelial cell activity , were reduced to levels comparable 
0 perfusion , epc mobilization/recruitment , and stimulation of endothelial cell activity , were reduced to levels comparable with those observed in 
18 mobilization/recruitment , and stimulation of endothelial cell activity , were reduced to levels comparable with those observed in csc-low cultures/tumors . 
0 and stimulation of endothelial cell activity , were reduced to levels comparable with those observed in csc-low cultures/tumors . NULL NULL 
0 cell activity , were reduced to levels comparable with those observed in csc-low cultures/tumors . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest that csc contribute to tumor angiogenesis by promoting both 
16 NULL NULL NULL NULL NULL these results suggest that csc contribute to tumor angiogenesis by promoting both local endothelial cell activity 
0 NULL NULL NULL these results suggest that csc contribute to tumor angiogenesis by promoting both local endothelial cell activity and systemic 
3 NULL NULL these results suggest that csc contribute to tumor angiogenesis by promoting both local endothelial cell activity and systemic angiogenic 
17 these results suggest that csc contribute to tumor angiogenesis by promoting both local endothelial cell activity and systemic angiogenic processes involving 
0 contribute to tumor angiogenesis by promoting both local endothelial cell activity and systemic angiogenic processes involving bone marrow-derived epc in a 
3 angiogenesis by promoting both local endothelial cell activity and systemic angiogenic processes involving bone marrow-derived epc in a vascular endothelial growth 
0 by promoting both local endothelial cell activity and systemic angiogenic processes involving bone marrow-derived epc in a vascular endothelial growth factor-dependent 
0 promoting both local endothelial cell activity and systemic angiogenic processes involving bone marrow-derived epc in a vascular endothelial growth factor-dependent and 
0 local endothelial cell activity and systemic angiogenic processes involving bone derived epc in a vascular endothelial growth factor-dependent and stromal-derived factor 
0 angiogenic processes involving bone marrow-derived epc in a vascular endothelial growth factor-dependent and stromal-derived factor 1-dependent manner . NULL NULL NULL 
17 processes involving bone marrow-derived epc in a vascular endothelial growth dependent and stromal-derived factor 1-dependent manner . NULL NULL NULL NULL 
0 bone marrow-derived epc in a vascular endothelial growth factor-dependent and derived factor 1-dependent manner . NULL NULL NULL NULL NULL NULL 
17 epc in a vascular endothelial growth factor-dependent and stromal-derived factor dependent manner . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL islet endothelial activation and oxidative stress gene expression is reduced by il-1ra treatment 
0 NULL NULL NULL islet endothelial activation and oxidative stress gene expression is reduced by il-1ra treatment in the type 2 diabetic 
18 NULL islet endothelial activation and oxidative stress gene expression is reduced by il-1ra treatment in the type 2 diabetic gk rat 
19 activation and oxidative stress gene expression is reduced by il-1ra treatment in the type 2 diabetic gk rat . NULL NULL 
6 : inflammation followed by fibrosis is a component of islet dysfunction in both rodent and human type 2 diabetes . NULL 
0 NULL NULL NULL NULL NULL NULL because islet inflammation may originate from endothelial cells , we assessed the expression of selected 
0 inflammation may originate from endothelial cells , we assessed the expression of selected genes involved in endothelial cell activation in islets 
0 endothelial cells , we assessed the expression of selected genes involved in endothelial cell activation in islets from a spontaneous model 
17 assessed the expression of selected genes involved in endothelial cell activation in islets from a spontaneous model of type 2 diabetes 
0 also examined islet endotheliuml/oxidative stress ( os ) /inflammation-related gene expression , islet vascularization and fibrosis after treatment with the interleukin-1 
3 endotheliuml/oxidative stress ( os ) /inflammation-related gene expression , islet vascularization and fibrosis after treatment with the interleukin-1 ( il-1 ) 
19 ) /inflammation-related gene expression , islet vascularization and fibrosis after treatment with the interleukin-1 ( il-1 ) receptor antagonist ( il-1ra 
0 NULL NULL NULL NULL NULL NULL methodology/principal findings : gene expression was analyzed by quantitative rt-pcr on islets isolated from 10-week-old 
19 : gene expression was analyzed by quantitative rt-pcr on islets isolated from 10-week-old diabetic gk and control wistar rats . NULL 
0 quantitative rt-pcr on islets isolated from 10-week-old diabetic gk and control wistar rats . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL furthermore , gk rats were treated s.c twice daily with il-1ra ( kineret , amgen , 
0 NULL NULL NULL NULL thirty-two genes were selected encoding molecules involved in endothelial cell activation , particularly fibrinolysis , vascular tone 
17 thirty-two genes were selected encoding molecules involved in endothelial cell activation , particularly fibrinolysis , vascular tone , os , angiogenesis 
3 activation , particularly fibrinolysis , vascular tone , os , angiogenesis and also inflammation . NULL NULL NULL NULL NULL NULL 
18 except those encoding angiotensinogen and epoxide hydrolase ( that were decreased ) , and 12-lipoxygenase and vascular endothelial growth factor ( 
0 that were decreased ) , and 12-lipoxygenase and vascular endothelial growth factor ( that showed no change ) , were significantly 
16 , and 12-lipoxygenase and vascular endothelial growth factor ( that showed no change ) , were significantly up-regulated in gk islets 
16 12-lipoxygenase and vascular endothelial growth factor ( that showed no change ) , were significantly up-regulated in gk islets . NULL 
17 factor ( that showed no change ) , were significantly up-regulated in gk islets . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL after il-1ra treatment of gk rats in vivo , most selected genes implied 
0 , most selected genes implied in endothelium/os/immune cells/fibrosis were significantly down-regulated . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL il-1ra also improved islet vascularization , reduced fibrosis and ameliorated glycemia . NULL 
3 NULL NULL NULL NULL NULL NULL il-1ra also improved islet vascularization , reduced fibrosis and ameliorated glycemia . NULL NULL NULL 
0 NULL NULL NULL NULL il-1ra also improved islet vascularization , reduced fibrosis and ameliorated glycemia . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL conclusions/significance : gk rat islets have increased mrna expression of markers of early islet endothelial cell activation 
0 NULL NULL NULL conclusions/significance : gk rat islets have increased mrna expression of markers of early islet endothelial cell activation , 
0 NULL NULL conclusions/significance : gk rat islets have increased mrna expression of markers of early islet endothelial cell activation , possibly 
17 increased mrna expression of markers of early islet endothelial cell activation , possibly triggered by several metabolic factors , and also 
0 of markers of early islet endothelial cell activation , possibly triggered by several metabolic factors , and also some defense mechanisms 
0 possibly triggered by several metabolic factors , and also some defense mechanisms . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the beneficial effect of il-1ra on most islet endothelial/os/immune cells/fibrosis parameters analyzed 
17 NULL NULL NULL NULL NULL NULL NULL NULL the beneficial effect of il-1ra on most islet endothelial/os/immune cells/fibrosis parameters analyzed highlights 
0 il-1ra on most islet endothelial/os/immune cells/fibrosis parameters analyzed highlights a major endothelial-related role for il-1 in gk islet alterations . NULL 
16 most islet endothelial/os/immune cells/fibrosis parameters analyzed highlights a major endothelial-related role for il-1 in gk islet alterations . NULL NULL NULL 
2 highlights a major endothelial-related role for il-1 in gk islet alterations . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL thus , altered islet endothelium might affect the beta-cell microenvironment and contribute to 
16 NULL NULL NULL NULL thus , metabolically-altered islet endothelium might affect the beta-cell microenvironment and contribute to progressive type 2 diabetic 
0 , metabolically-altered islet endothelium might affect the beta-cell microenvironment and contribute to progressive type 2 diabetic beta-cell dysfunction in gk rats 
0 beta-cell microenvironment and contribute to progressive type 2 diabetic beta-cell dysfunction in gk rats . NULL NULL NULL NULL NULL NULL 
0 counteracting islet endothelial cell inflammation might be one way to prevent beta-cell dysfunction in type 2 diabetes . NULL NULL NULL 
0 endothelial cell inflammation might be one way to ameliorate/prevent beta-cell dysfunction in type 2 diabetes . NULL NULL NULL NULL NULL 
6 NULL NULL NULL ave8062 : a new combretastatin derivative vascular disrupting agent . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis has an essential role in promoting and supporting tumor growth 
16 NULL NULL NULL NULL NULL NULL NULL angiogenesis has an essential role in promoting and supporting tumor growth and it is 
16 NULL NULL NULL NULL NULL NULL angiogenesis has an essential role in promoting and supporting tumor growth and it is an 
17 NULL NULL NULL NULL angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic 
17 NULL NULL angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target . 
0 NULL angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target . NULL 
4 angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target . NULL NULL 
0 in promoting and supporting tumor growth and it is an important therapeutic target . NULL NULL NULL NULL NULL NULL NULL 
0 and supporting tumor growth and it is an important therapeutic target . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the tumor vascular network is the result of pro-angiogenic and inhibitory factors 
3 NULL NULL the tumor vascular network is the result of angiogenic and inhibitory factors as well as of the interaction between 
0 the tumor vascular network is the result of pro-angiogenic and inhibitory factors as well as of the interaction between endothelial cells 
15 of pro-angiogenic and inhibitory factors as well as of the interaction between endothelial cells and extracellular matrix . NULL NULL NULL 
0 well as of the interaction between endothelial cells and extracellular matrix . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL different angiogenic therapeutics have been developed to improve tumor control through vascular-targeting 
0 NULL NULL NULL NULL NULL different antiangiogenic therapeutics have been developed to improve tumor control through vascular-targeting agents ( vta ) 
17 NULL NULL NULL different antiangiogenic therapeutics have been developed to improve tumor control through vascular-targeting agents ( vta ) . NULL 
0 NULL NULL different antiangiogenic therapeutics have been developed to improve tumor control through vascular-targeting agents ( vta ) . NULL NULL 
16 NULL different antiangiogenic therapeutics have been developed to improve tumor control through vascular-targeting agents ( vta ) . NULL NULL NULL 
0 antiangiogenic therapeutics have been developed to improve tumor control through targeting agents ( vta ) . NULL NULL NULL NULL NULL 
3 NULL NULL vtas can be divided into two groups : angiogenic agents and vascular-disrupting agents ( vdas ) . NULL NULL 
0 can be divided into two groups : antiangiogenic agents and disrupting agents ( vdas ) . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL vtas inhibit specific factors required to induce and direct the angiogenic process 
0 NULL NULL NULL NULL NULL NULL vtas inhibit specific factors required to induce and direct the angiogenic process , with major 
0 NULL NULL NULL NULL vtas inhibit specific factors required to induce and direct the angiogenic process , with major activity against 
0 NULL NULL vtas inhibit specific factors required to induce and direct the angiogenic process , with major activity against small tumor 
3 vtas inhibit specific factors required to induce and direct the angiogenic process , with major activity against small tumor masses and 
0 required to induce and direct the angiogenic process , with major activity against small tumor masses and at the tumor periphery 
0 to induce and direct the angiogenic process , with major activity against small tumor masses and at the tumor periphery , 
0 direct the angiogenic process , with major activity against small tumor masses and at the tumor periphery , encompassing monoclonal antibodies 
0 with major activity against small tumor masses and at the tumor periphery , encompassing monoclonal antibodies and small molecules inhibitors of 
16 NULL NULL NULL NULL NULL NULL NULL NULL vdas specifically target and destroy well-established tumor vessels with ischemia and destruction of 
18 NULL NULL NULL NULL NULL NULL vdas specifically target and destroy well-established tumor vessels with ischemia and destruction of large masses 
2 NULL NULL NULL NULL NULL vdas specifically target and destroy established tumor vessels with ischemia and destruction of large masses with 
0 NULL NULL NULL NULL vdas specifically target and destroy well-established tumor vessels with ischemia and destruction of large masses with central 
6 specifically target and destroy well-established tumor vessels with ischemia and destruction of large masses with central hemorrhagic necrosis and survival of 
0 tumor vessels with ischemia and destruction of large masses with central hemorrhagic necrosis and survival of a thin peripheral tumor layer 
5 with ischemia and destruction of large masses with central hemorrhagic necrosis and survival of a thin peripheral tumor layer . NULL 
5 and destruction of large masses with central hemorrhagic necrosis and survival of a thin peripheral tumor layer . NULL NULL NULL 
0 with central hemorrhagic necrosis and survival of a thin peripheral tumor layer . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL in this review we will discuss the mechanism of action , as well as the preclinical and clinical 
0 NULL in this review we will discuss the mechanism of action , as well as the preclinical and clinical results , 
0 mechanism of action , as well as the preclinical and clinical results , of one of the most promising antitubulin agents 
0 of action , as well as the preclinical and clinical results , of one of the most promising antitubulin agents : 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL targeting tnf for treatment of cancer and autoimmunity . NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL targeting tnf for treatment of cancer and autoimmunity . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor necrosis factor-alpha ( tnf-alpha ) was first isolated two decades 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor necrosis factor-alpha ( tnf-alpha ) was first isolated two decades ago 
0 NULL NULL tumor necrosis factor-alpha ( tnf-alpha ) was first isolated two decades ago as a macrophageproduced protein that can effectively 
0 ) was first isolated two decades ago as a macrophageproduced protein that can effectively kill tumor cells . NULL NULL NULL 
5 two decades ago as a macrophageproduced protein that can effectively kill tumor cells . NULL NULL NULL NULL NULL NULL NULL 
17 two decades ago as a macrophageproduced protein that can effectively kill tumor cells . NULL NULL NULL NULL NULL NULL NULL 
0 decades ago as a macrophageproduced protein that can effectively kill tumor cells . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL tnf-alpha is also an essential component of the immune system and is required for hematopoiesis 
0 also an essential component of the immune system and is required for hematopoiesis , for protection from bacterial infection and for 
0 the immune system and is required for hematopoiesis , for protection from bacterial infection and for immune cell-mediated cytotoxicity . NULL 
0 and is required for hematopoiesis , for protection from bacterial infection and for immune cell-mediated cytotoxicity . NULL NULL NULL NULL 
0 hematopoiesis , for protection from bacterial infection and for immune mediated cytotoxicity . NULL NULL NULL NULL NULL NULL NULL NULL 
16 however , has revealed that tnf-alpha is one of the major players in tumor initiation , proliferation , invasion , angiogenesis 
16 , has revealed that tnf-alpha is one of the major players in tumor initiation , proliferation , invasion , angiogenesis and 
0 revealed that tnf-alpha is one of the major players in tumor initiation , proliferation , invasion , angiogenesis and metastasis . 
17 that tnf-alpha is one of the major players in tumor initiation , proliferation , invasion , angiogenesis and metastasis . NULL 
4 is one of the major players in tumor initiation , proliferation , invasion , angiogenesis and metastasis . NULL NULL NULL 
14 of the major players in tumor initiation , proliferation , invasion , angiogenesis and metastasis . NULL NULL NULL NULL NULL 
3 major players in tumor initiation , proliferation , invasion , angiogenesis and metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 in tumor initiation , proliferation , invasion , angiogenesis and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the proinflammatory activities link tnf-alpha with a wide variety of autoimmune diseases , 
19 ) ( anti-tnf antibodies ) have been approved for the treatment inflammatory bowel disease , psoriasis and rheumatoid arthritis . NULL 
0 NULL NULL these drugs , however , exhibit severe side effects and are expensive . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL hence orally active blockers of tnf-alpha that are safe , efficacious and inexpensive 
18 vegetable and traditional medicinal plants have been described which can suppress tnf expression and tnf signaling but their clinical potential is 
9 traditional medicinal plants have been described which can suppress tnf expression and tnf signaling but their clinical potential is yet uncertain 
0 which can suppress tnf expression and tnf signaling but their clinical potential is yet uncertain . NULL NULL NULL NULL NULL 
0 can suppress tnf expression and tnf signaling but their clinical potential is yet uncertain . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inducible nitric oxide synthase modulates angiogenesis in ischemic hindlimb of rat 
16 NULL NULL NULL NULL NULL NULL inducible nitric oxide synthase modulates angiogenesis in ischemic hindlimb of rat . NULL NULL NULL 
3 NULL NULL NULL NULL NULL inducible nitric oxide synthase modulates angiogenesis in ischemic hindlimb of rat . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL background : angiogenesis plays an important role in maintaining adequate oxygen delivery , 
16 NULL NULL NULL NULL NULL NULL NULL background : angiogenesis plays an important role in maintaining adequate oxygen delivery , and 
16 NULL NULL NULL NULL NULL background : angiogenesis plays an important role in maintaining adequate oxygen delivery , and nitric oxide 
16 NULL NULL NULL NULL background : angiogenesis plays an important role in maintaining adequate oxygen delivery , and nitric oxide ( 
16 NULL NULL background : angiogenesis plays an important role in maintaining adequate oxygen delivery , and nitric oxide ( no ) 
14 : angiogenesis plays an important role in maintaining adequate oxygen delivery , and nitric oxide ( no ) is a potential 
0 delivery , and nitric oxide ( no ) is a potential regulator of angiogenesis . NULL NULL NULL NULL NULL NULL 
0 , and nitric oxide ( no ) is a potential regulator of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 nitric oxide ( no ) is a potential regulator of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
8 NULL NULL NULL NULL NULL NULL NULL NULL no is synthesized through three isoforms of no synthase ( nos ) . 
0 NULL NULL NULL NULL it is hypothesized that the no derived from inducible nos ( inos ) may promote survival of 
0 NULL NULL it is hypothesized that the no derived from inducible nos ( inos ) may promote survival of ischemic tissue 
17 the no derived from inducible nos ( inos ) may promote survival of ischemic tissue through angiogenesis . NULL NULL NULL 
16 the no derived from inducible nos ( inos ) may promote survival of ischemic tissue through angiogenesis . NULL NULL NULL 
5 no derived from inducible nos ( inos ) may promote survival of ischemic tissue through angiogenesis . NULL NULL NULL NULL 
3 ( inos ) may promote survival of ischemic tissue through angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL to test this hypothesis , we investigated the effect of inos deficiency ( by l-nil ) on angiogenesis in 
0 test this hypothesis , we investigated the effect of inos deficiency ( by l-nil ) on angiogenesis in a hindlimb ischemia 
3 the effect of inos deficiency ( by l-nil ) on angiogenesis in a hindlimb ischemia model . NULL NULL NULL NULL 
0 NULL in groups 1 & 2 , hindlimb ischemia was induced by ligation of femoral artery and they received l-nil and 
19 groups 1 & 2 , hindlimb ischemia was induced by ligation of femoral artery and they received l-nil and saline respectively 
19 ischemia was induced by ligation of femoral artery and they received l-nil and saline respectively . NULL NULL NULL NULL NULL 
19 NULL NULL the animals in groups 3 and 4 also received l-nil and saline respectively without surgical procedure . NULL NULL 
0 3 and 4 also received l-nil and saline respectively without surgical procedure . NULL NULL NULL NULL NULL NULL NULL NULL 
9 , the serum concentration of nitrite , capillary density and expression of hif1alpha were determined . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : serum nitrite levels were significantly lower in l-nil groups 
0 NULL NULL NULL NULL NULL NULL results : serum nitrite levels were significantly lower in l-nil groups ( p < 0.05 
0 2 : 549+/-81.85 /mm2 , p < 0.05 ) .in addition , expression of hif1alpha was significantly increased in ischemic groups 
9 549+/-81.85 /mm2 , p < 0.05 ) .in addition , expression of hif1alpha was significantly increased in ischemic groups ( p 
17 0.05 ) .in addition , expression of hif1alpha was significantly increased in ischemic groups ( p < 0.05 ) . NULL 
18 NULL NULL NULL NULL NULL NULL NULL conclusion : selective inhibition of inos by l-nil inhibits angiogenesis in a hindlimb ischemic 
18 NULL NULL conclusion : selective inhibition of inos by l-nil inhibits angiogenesis in a hindlimb ischemic rat model . NULL NULL 
3 NULL conclusion : selective inhibition of inos by l-nil inhibits angiogenesis in a hindlimb ischemic rat model . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , ischemia induces expression of hif1alpha in hypoxic tissue . 
17 NULL NULL NULL NULL NULL NULL in addition , ischemia induces expression of hif1alpha in hypoxic tissue . NULL NULL NULL 
9 NULL NULL NULL NULL NULL in addition , ischemia induces expression of hif1alpha in hypoxic tissue . NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of basic fibroblast growth factor in normal human tissues . 
0 NULL NULL NULL NULL NULL NULL expression of basic fibroblast growth factor in normal human tissues . NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL the distribution of basic fibroblast growth factor ( bfgf ) was studied 
0 NULL NULL NULL NULL NULL the distribution of basic fibroblast growth factor ( bfgf ) was studied immunohistochemically in fresh frozen 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL immunodetection was performed with a specific anti-bfgf mouse monoclonal antibody that 
18 human bfgf in western blot analysis , and to specifically neutralize the mitogenic activity of bfgf on bovine vascular endothelial cells 
0 western blot analysis , and to specifically neutralize the mitogenic activity of bfgf on bovine vascular endothelial cells . NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of bfgf on normal human tissues was ubiquitously detected in 
14 NULL NULL expression of bfgf on normal human tissues was ubiquitously detected in the basement membranes of all size blood vessels 
14 NULL expression of bfgf on normal human tissues was ubiquitously detected in the basement membranes of all size blood vessels , 
14 NULL NULL NULL NULL NULL NULL intensity and patterns of localization in blood vessels was consistent in various tissues , but 
0 NULL NULL NULL NULL whereas homogeneous and intense immunoreactivity were observed in large and intermediate size blood vessels , heterogeneity of 
9 in large and intermediate size blood vessels , heterogeneity of expression was found in capillaries . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the most intense immunoreactivity was observed in branching capillaries . NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL the most intense immunoreactivity was observed in branching capillaries . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell staining was heterogeneous and varied in different regions . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL strong staining for bfgf was also found in cardiac muscle fibers , 
0 blood vessels , the gut and the myometrium , in central nervous system neurons and cerebellar purkinje cells , and on 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL the presence of bfgf in the extracellular compartment of a diverse variety 
16 the extracellular compartment of a diverse variety of organs may play a role in angiogenesis . NULL NULL NULL NULL NULL 
16 compartment of a diverse variety of organs may play a role in angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 a diverse variety of organs may play a role in angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL however , the function of bfgf in parenchymal cells remains to be determined . 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL retinal revascularisation in diabetic retinopathy . NULL NULL NULL NULL NULL NULL 
0 NULL NULL when first seen in 1975 he had bilateral proliferative retinopathy with new vessels in the retinal periphery . NULL 
0 NULL NULL NULL NULL he had large areas of capillary perfusion lateral to the macula in the right eye associated with 
0 capillary non-perfusion lateral to the macula in the right eye associated with the new vessels . NULL NULL NULL NULL NULL 
0 NULL NULL NULL nine years later , after extensive repeated photocoagulation , revascularisation of large areas previously not perfused were seen 
3 NULL nine years later , after extensive repeated photocoagulation , revascularisation of large areas previously not perfused were seen . NULL 
2 the plane of the retina and do not have the appearance of new vessels . NULL NULL NULL NULL NULL NULL 
3 NULL NULL [ intraepithelial neoplasm of the uterine cervix and angiogenesis : morphologic study ] NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL thirty uterine cervix specimens sampled following conization or total hysterectomy were studied using histology , histoenzymology ( 
19 NULL thirty uterine cervix specimens sampled following conization or total hysterectomy were studied using histology , histoenzymology ( vessel phosphatase alkaline 
0 were studied using histology , histoenzymology ( vessel phosphatase alkaline activity ) , and immunohistochemistry ( demonstration of laminin and type 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results were compared to findings in a control group . NULL 
0 NULL NULL NULL results were compared to findings in a control group . NULL NULL NULL NULL NULL NULL NULL NULL 
0 histologic epithelial lesions ; this finding is consistent with colposcopic results . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL anarchic angiogenesis with large , moniliform , tortuous vessels was seen in 
0 NULL NULL NULL the vascular anomalies seem to precede the development of histologic lesions in some instances . NULL NULL NULL 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL histogenesis of the abnormal vessels may involve production of an angiogenic 
0 NULL NULL NULL NULL histogenesis of the abnormal vessels may involve production of an angiogenic factor by the cancerized epithelia . 
0 NULL NULL NULL histogenesis of the abnormal vessels may involve production of an angiogenic factor by the cancerized epithelia . NULL 
3 histogenesis of the abnormal vessels may involve production of an angiogenic factor by the cancerized epithelia . NULL NULL NULL NULL 
0 NULL NULL NULL NULL a frequently cited theory for the pathogenesis of neovascularization in diabetic retinopathy is that retinal hypoxia and/or 
3 NULL NULL a frequently cited theory for the pathogenesis of neovascularization in diabetic retinopathy is that retinal hypoxia and/or ischemia release 
0 neovascularization in diabetic retinopathy is that retinal hypoxia and/or ischemia release a factor which stimulates neovascularization . NULL NULL NULL NULL 
17 is that retinal hypoxia and/or ischemia release a factor which stimulates neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL 
3 that retinal hypoxia and/or ischemia release a factor which stimulates neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL to the authors ' knowledge , there is no direct in vivo evidence in the human proving this theory . 
0 diabetic subjects were studied to see whether worsening retinopathy was associated with changes in conjunctival oxygen tension ( po2 ) . 
16 were studied to see whether worsening retinopathy was associated with changes in conjunctival oxygen tension ( po2 ) . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL diabetics with proliferative retinopathy showed a conjunctival po2 that was significantly lower than 
0 NULL NULL NULL NULL NULL NULL diabetics with proliferative retinopathy showed a conjunctival po2 that was significantly lower than either of 
0 NULL NULL NULL NULL NULL NULL NULL NULL these findings support the hypoxic theory of diabetic neovascular retinopathy . NULL NULL 
3 NULL NULL these findings support the hypoxic theory of diabetic neovascular retinopathy . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL new functions of epidermal growth factor : stimulation of capillary endothelial cell 
0 NULL NULL NULL NULL NULL NULL new functions of epidermal growth factor : stimulation of capillary endothelial cell migration and matrix 
17 NULL NULL NULL new functions of epidermal growth factor : stimulation of capillary endothelial cell migration and matrix dependent proliferation . 
14 of epidermal growth factor : stimulation of capillary endothelial cell migration and matrix dependent proliferation . NULL NULL NULL NULL NULL 
0 growth factor : stimulation of capillary endothelial cell migration and matrix dependent proliferation . NULL NULL NULL NULL NULL NULL NULL 
17 factor : stimulation of capillary endothelial cell migration and matrix dependent proliferation . NULL NULL NULL NULL NULL NULL NULL NULL 
1 : stimulation of capillary endothelial cell migration and matrix dependent proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL NULL NULL the proliferative response of bovine retinal capillary endothelial cells to egf is 
16 NULL NULL NULL NULL NULL NULL NULL NULL the proliferative response of bovine retinal capillary endothelial cells to egf is dependent 
17 response of bovine retinal capillary endothelial cells to egf is dependent upon attaching the cells to a matrix of fibronectin . 
15 bovine retinal capillary endothelial cells to egf is dependent upon attaching the cells to a matrix of fibronectin . NULL NULL 
0 to egf is dependent upon attaching the cells to a matrix of fibronectin . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL bovine capillary endothelial cells are also stimulated to actively migrate when exposed to egf in vitro . 
14 NULL bovine capillary endothelial cells are also stimulated to actively migrate when exposed to egf in vitro . NULL NULL NULL 
19 capillary endothelial cells are also stimulated to actively migrate when exposed to egf in vitro . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these activities provide an explanation for the angiogenic properties of egf in 
3 NULL NULL NULL these activities provide an explanation for the angiogenic properties of egf in vivo . NULL NULL NULL NULL 
0 NULL NULL these activities provide an explanation for the angiogenic properties of egf in vivo . NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL capillary cell migration and proliferation are proposed as sensitive quantifiable bioassays to explore 
1 NULL NULL NULL NULL NULL NULL capillary cell migration and proliferation are proposed as sensitive quantifiable bioassays to explore the functional 
0 NULL NULL capillary cell migration and proliferation are proposed as sensitive quantifiable bioassays to explore the functional domains of the egf 
18 NULL NULL NULL NULL NULL NULL NULL studies on the inactivation of these properties of egf by specific cleavage of the 
0 NULL NULL NULL NULL studies on the inactivation of these properties of egf by specific cleavage of the molecule with cnbr 
11 on the inactivation of these properties of egf by specific cleavage of the molecule with cnbr or proteases suggest that an 
17 on the inactivation of these properties of egf by specific cleavage of the molecule with cnbr or proteases suggest that an 
0 in part by amino acid residues 20 to 31 is essential for at least some functions . NULL NULL NULL NULL 
0 residues 20 to 31 is essential for at least some functions . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL the specific enhancement of tumor proliferation in vitro . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the specific enhancement of tumor proliferation in vitro . NULL NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL NULL the specific enhancement of tumor proliferation in vitro . NULL NULL NULL NULL NULL NULL NULL 
17 among the peritoneal leukocytes by virtue of their capacity to enhance profoundly the proliferation of a variety of tumors in vitro 
4 leukocytes by virtue of their capacity to enhance profoundly the proliferation of a variety of tumors in vitro . NULL NULL 
0 NULL NULL this phenomenon occurs at mast cell/tumor ratios which reflect the stoichiometry of host cell/tumor relationships in vivo . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the growth factor was found to reside in mast cell granules and 
0 and was identified as heparin by sequential purification and enzymatic degradation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL this cellular interaction was tumor-specific , although isolated granules could enhance fibroblast proliferation 
0 NULL NULL NULL this cellular interaction was tumor-specific , although isolated granules could enhance fibroblast proliferation . NULL NULL NULL NULL 
17 this cellular interaction was tumor-specific , although isolated granules could enhance fibroblast proliferation . NULL NULL NULL NULL NULL NULL NULL 
1 interaction was tumor-specific , although isolated granules could enhance fibroblast proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 relation to previous morphologic studies , reports of in vitro mediated tumor cytotoxicity , and the role of mast cells in 
0 to previous morphologic studies , reports of in vitro mast-cell-mediated tumor cytotoxicity , and the role of mast cells in angiogenesis 
16 reports of in vitro mast-cell-mediated tumor cytotoxicity , and the role of mast cells in angiogenesis and connective tissue proliferation . 
3 tumor cytotoxicity , and the role of mast cells in angiogenesis and connective tissue proliferation . NULL NULL NULL NULL NULL 
4 the role of mast cells in angiogenesis and connective tissue proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis : initiation and control . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis : initiation and control . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL angiogenesis : initiation and control . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
4 rabbit cornea , it is now becoming clear that the growth of a capillary involves an ordered sequence of events that 
16 is now becoming clear that the growth of a capillary involves an ordered sequence of events that includes lysis of the 
6 a capillary involves an ordered sequence of events that includes lysis of the basement membrane of a parent venule , directional 
14 of the basement membrane of a parent venule , directional migration of capillary endothelial cells toward the angiogenic stimulus , lumen 
3 venule , directional migration of capillary endothelial cells toward the angiogenic stimulus , lumen formation , development of branches , and 
2 of capillary endothelial cells toward the angiogenic stimulus , lumen formation , development of branches , and anastomosis of the tip 
2 endothelial cells toward the angiogenic stimulus , lumen formation , development of branches , and anastomosis of the tip of one 
2 stimulus , lumen formation , development of branches , and anastomosis of the tip of one tube with another to form 
0 anastomosis of the tip of one tube with another to form a loop . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL it is also clear that diffusible angiogenic stimuli can be released not only from most solid tumors 
0 it is also clear that diffusible angiogenic stimuli can be released not only from most solid tumors , but also from 
17 NULL NULL NULL NULL NULL NULL NULL NULL these include activated macrophages , sensitized lymphocytes , and adipocytes . NULL NULL 
17 NULL NULL NULL NULL NULL other normal tissues can also stimulate angiogenesis , but the type of cell giving rise to 
3 NULL NULL NULL NULL other normal tissues can also stimulate angiogenesis , but the type of cell giving rise to the 
3 , but the type of cell giving rise to the angiogenic stimulus is unknown , and the period of angiogenic stimulation 
3 the angiogenic stimulus is unknown , and the period of angiogenic stimulation is brief . NULL NULL NULL NULL NULL NULL 
17 angiogenic stimulus is unknown , and the period of angiogenic stimulation is brief . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL with the recent ability to clone capillary endothelial cells and to carry them in 
19 NULL NULL NULL NULL NULL with the recent ability to clone capillary endothelial cells and to carry them in long-term culture 
19 clone capillary endothelial cells and to carry them in long-term culture , it has been possible to further delineate the mechanism 
0 culture , it has been possible to further delineate the mechanism of capillary growth . NULL NULL NULL NULL NULL NULL 
4 has been possible to further delineate the mechanism of capillary growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 helper cell for capillary endothelial cells , in some way speeding up their rate of directional migration . NULL NULL NULL 
14 , in some way speeding up their rate of directional migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 , heparin appears to be the principal mast cell factor responsible for this effect on capillary endothelial cells . NULL NULL 
16 to be the principal mast cell factor responsible for this effect on capillary endothelial cells . NULL NULL NULL NULL NULL 
2 NULL NULL one theoretical possibility is that mast cells may prepare the matrix , perhaps by slow release of heparin , 
0 one theoretical possibility is that mast cells may prepare the matrix , perhaps by slow release of heparin , so that 
0 that mast cells may prepare the matrix , perhaps by slow release of heparin , so that capillary sprouts can more 
14 mast cells may prepare the matrix , perhaps by slow release of heparin , so that capillary sprouts can more easily 
3 capillary sprouts can more easily move through it toward their angiogenic target . NULL NULL NULL NULL NULL NULL NULL NULL 
0 sprouts can more easily move through it toward their angiogenic target . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL while the study of angiogenesis as a phenomenon is still in an early phase , 
17 and in vivo techniques , to more thoroughly understand the initiation and control of capillary growth . NULL NULL NULL NULL 
16 vivo techniques , to more thoroughly understand the initiation and control of capillary growth . NULL NULL NULL NULL NULL NULL 
4 to more thoroughly understand the initiation and control of capillary growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL protection from experimental ocular herpetic keratitis by a heat-killed virus vaccine 
0 NULL NULL NULL NULL NULL new zealand white rabbits were given limbal inoculations of a heat-killed suspension of herpes simplex virus 
19 NULL NULL NULL new zealand white rabbits were given limbal inoculations of a heat-killed suspension of herpes simplex virus ( hsv 
19 to 14 days , the animals were challenged by intrastromal inoculation with 10 , 000 plaque-forming units of viable hsv . 
0 animals were challenged by intrastromal inoculation with 10 , 000 forming units of viable hsv . NULL NULL NULL NULL NULL 
3 epithelial keratitis , disciform edema , and necrotizing keratitis with neovascularization of the cornea developed in control animals . NULL NULL 
2 edema , and necrotizing keratitis with neovascularization of the cornea developed in control animals . NULL NULL NULL NULL NULL NULL 
0 and necrotizing keratitis with neovascularization of the cornea developed in control animals . NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL NULL NULL epithelial keratitis and corneal edema also developed in the immunized animals during the first week after virus 
3 NULL NULL NULL NULL NULL the absence of iritis , neovascularization , and necrotizing keratitis in the corneas of the immunized 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL subretinal neovascularization following rubella retinopathy . NULL NULL NULL NULL NULL NULL 
0 17-year-old girl and an 11-year-old girl with rubella retinopathy had decreased vision in one eye secondary to subretinal neovascularization and hemorrhage 
3 retinopathy had decreased vision in one eye secondary to subretinal neovascularization and hemorrhage . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in both cases a disciform scar with permanent decrease in central vision resulted . NULL NULL NULL NULL NULL 
0 in both cases a disciform scar with permanent decrease in central vision resulted . NULL NULL NULL NULL NULL NULL NULL 
0 cases a disciform scar with permanent decrease in central vision resulted . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis . NULL 
0 NULL NULL NULL NULL molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis . NULL NULL NULL NULL 
0 NULL molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 mediators of interactions with extracellular matrix components in metastasis and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL metastasis and tumor angiogenesis are invasive phenomena and share many common 
0 NULL NULL NULL NULL NULL NULL NULL NULL metastasis and tumor angiogenesis are invasive phenomena and share many common properties at 
3 NULL NULL NULL NULL NULL NULL NULL metastasis and tumor angiogenesis are invasive phenomena and share many common properties at the 
0 and tumor angiogenesis are invasive phenomena and share many common properties at the physiological level and some similarities at the molecular 
15 NULL NULL NULL NULL each consists of repetitive cycles of interaction with adjacent extracellular matrix components by mediating cellular adhesion , 
0 each consists of repetitive cycles of interaction with adjacent extracellular matrix components by mediating cellular adhesion , matrix dissolution , and 
16 repetitive cycles of interaction with adjacent extracellular matrix components by mediating cellular adhesion , matrix dissolution , and cellular motility to 
15 of interaction with adjacent extracellular matrix components by mediating cellular adhesion , matrix dissolution , and cellular motility to achieve metastasis 
6 with adjacent extracellular matrix components by mediating cellular adhesion , matrix dissolution , and cellular motility to achieve metastasis of cancer 
6 adjacent extracellular matrix components by mediating cellular adhesion , matrix dissolution , and cellular motility to achieve metastasis of cancer cells 
14 by mediating cellular adhesion , matrix dissolution , and cellular motility to achieve metastasis of cancer cells or neovascularization of tumors 
14 adhesion , matrix dissolution , and cellular motility to achieve metastasis of cancer cells or neovascularization of tumors . NULL NULL 
3 and cellular motility to achieve metastasis of cancer cells or neovascularization of tumors . NULL NULL NULL NULL NULL NULL NULL 
0 reviewed , as are several signal transduction components which may regulate them . NULL NULL NULL NULL NULL NULL NULL NULL 
0 potentially promising prognostic , diagnostic , and therapeutic modalities for tumor angiogenesis and metastatic disease are also discussed . NULL NULL 
3 promising prognostic , diagnostic , and therapeutic modalities for tumor angiogenesis and metastatic disease are also discussed . NULL NULL NULL 
0 , diagnostic , and therapeutic modalities for tumor angiogenesis and metastatic disease are also discussed . NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL vegf165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo 
0 NULL NULL NULL NULL NULL NULL vegf165 expressed by a deficient recombinant adenovirus vector induces angiogenesis in vivo . NULL NULL 
17 NULL NULL vegf165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo . NULL NULL NULL NULL NULL NULL 
3 NULL vegf165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL to evaluate the concept that localized delivery of angiogenic factors via virus-mediated gene transfer may be 
0 NULL NULL NULL NULL to evaluate the concept that localized delivery of angiogenic factors via virus-mediated gene transfer may be useful 
3 NULL NULL to evaluate the concept that localized delivery of angiogenic factors via virus-mediated gene transfer may be useful in the 
0 evaluate the concept that localized delivery of angiogenic factors via mediated gene transfer may be useful in the treatment of ischemic 
0 factors via virus-mediated gene transfer may be useful in the treatment of ischemic disorders , the replication-deficient adenovirus ( ad ) 
0 be useful in the treatment of ischemic disorders , the deficient adenovirus ( ad ) vector adcmv.vegf165 ( where cmv is 
0 ( where cmv is cytomegalovirus and vegf is vascular endothelial growth factor ) containing the cdna for human vegf165 , a 
0 factor ) containing the cdna for human vegf165 , a secreted endothelial cell-specific angiogenic growth factor , was constructed . NULL 
3 the cdna for human vegf165 , a secreted endothelial cell-specific angiogenic growth factor , was constructed . NULL NULL NULL NULL 
0 cdna for human vegf165 , a secreted endothelial cell-specific angiogenic growth factor , was constructed . NULL NULL NULL NULL NULL 
0 , a secreted endothelial cell-specific angiogenic growth factor , was constructed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 ) and rat aorta smooth muscle cells ( rasmcs ) infected with adcmv.vegf165 ( 5 and 20 plaque-forming units [ pfu 
0 ( rasmcs ) infected with adcmv.vegf165 ( 5 and 20 forming units [ pfu ] per cell ) demonstrated vegf mrna 
0 plaque-forming units [ pfu ] per cell ) demonstrated vegf mrna expression and protein secretion into the supernatant . NULL NULL 
10 units [ pfu ] per cell ) demonstrated vegf mrna expression and protein secretion into the supernatant . NULL NULL NULL 
0 pfu ] per cell ) demonstrated vegf mrna expression and protein secretion into the supernatant . NULL NULL NULL NULL NULL 
14 ] per cell ) demonstrated vegf mrna expression and protein secretion into the supernatant . NULL NULL NULL NULL NULL NULL 
17 NULL NULL furthermore , the conditioned medium from these cells enhanced vascular permeability in vivo . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL in contrast , neither vegf mrna nor secreted protein was found in uninfected huvecs or rasmcs 
14 NULL NULL NULL in contrast , neither vegf mrna nor secreted protein was found in uninfected huvecs or rasmcs or in 
0 NULL NULL in contrast , neither vegf mrna nor secreted protein was found in uninfected huvecs or rasmcs or in cells 
19 , neither vegf mrna nor secreted protein was found in uninfected huvecs or rasmcs or in cells infected with the control 
19 was found in uninfected huvecs or rasmcs or in cells infected with the control vector adcmv.beta gal ( where beta gal 
0 uninfected huvecs or rasmcs or in cells infected with the control vector adcmv.beta gal ( where beta gal is beta-galactosidase ) 
19 starved huvecs at 14 days demonstrated sixfold more cells for infected huvecs ( 20 pfu per cell ) than for either 
19 huvecs ( 20 pfu per cell ) than for either infected or uninfected control cells . NULL NULL NULL NULL NULL 
19 20 pfu per cell ) than for either infected or uninfected control cells . NULL NULL NULL NULL NULL NULL NULL 
0 pfu per cell ) than for either infected or uninfected control cells . NULL NULL NULL NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL NULL NULL rasmc proliferation was unaffected by infection with adcmv.vegf165 . NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL rasmc proliferation was unaffected by infection with adcmv.vegf165 . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL rasmc proliferation was unaffected by infection with adcmv.vegf165 . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL when plated in 2 % serum on dishes precoated with reconstituted basement 
0 when plated in 2 % serum on dishes precoated with reconstituted basement membrane ( matrigel ) , huvecs infected with adcmv.vegf165 
19 precoated with reconstituted basement membrane ( matrigel ) , huvecs infected with adcmv.vegf165 ( 20 pfu per cell ) differentiated into 
2 huvecs infected with adcmv.vegf165 ( 20 pfu per cell ) differentiated into capillary-like structures . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL under similar conditions , both uninfected huvecs and huvecs infected with adcmv.beta gal did not differentiate 
19 NULL under similar conditions , both uninfected huvecs and huvecs infected with adcmv.beta gal did not differentiate . NULL NULL NULL 
2 uninfected huvecs and huvecs infected with adcmv.beta gal did not differentiate . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL to evaluate the ability of adcmv.vegf165 to function in vivo , either adcmv . 
0 NULL NULL NULL to evaluate the ability of adcmv.vegf165 to function in vivo , either adcmv . NULL NULL NULL NULL 
19 ( 2 x 10 ( 10 ) pfu ) was resuspended in 0.5 ml matrigel and injected subcutaneously into mice . 
19 ) pfu ) was resuspended in 0.5 ml matrigel and injected subcutaneously into mice . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL immunohistochemical staining demonstrated vegf in the tissues surrounding the matrigel plugs 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL immunohistochemical staining demonstrated vegf in the tissues surrounding the matrigel plugs containing 
19 the matrigel plugs containing adcmv.vegf165 up to 3 weeks after injection , whereas no vegf was found in the control plugs 
0 after injection , whereas no vegf was found in the control plugs with adcmv.beta gal . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL two weeks after injection , there was histological evidence of neovascularization in the tissues 
3 two weeks after injection , there was histological evidence of neovascularization in the tissues surrounding the matrigel containing adcmv.vegf165 , whereas 
0 the tissues surrounding the matrigel containing adcmv.vegf165 , whereas no significant angiogenesis was observed in response to adcmv.beta gal . NULL 
3 tissues surrounding the matrigel containing adcmv.vegf165 , whereas no significant angiogenesis was observed in response to adcmv.beta gal . NULL NULL 
0 the matrigel containing adcmv.vegf165 , whereas no significant angiogenesis was observed in response to adcmv.beta gal . NULL NULL NULL NULL 
16 containing adcmv.vegf165 , whereas no significant angiogenesis was observed in response to adcmv.beta gal . NULL NULL NULL NULL NULL NULL 
0 ad vectors may provide a useful strategy for efficient local delivery of vegf165 in the treatment of ischemic diseases . NULL 
0 useful strategy for efficient local delivery of vegf165 in the treatment of ischemic diseases . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effects of doxycycline on in vitro growth , migration , and 
1 NULL NULL NULL NULL effects of doxycycline on in vitro growth , migration , and gelatinase activity of breast carcinoma cells 
14 NULL NULL effects of doxycycline on in vitro growth , migration , and gelatinase activity of breast carcinoma cells . NULL 
0 doxycycline on in vitro growth , migration , and gelatinase activity of breast carcinoma cells . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL metastatic disease is one of the major causes of death from 
0 NULL NULL NULL NULL metastatic disease is one of the major causes of death from cancer in human beings . NULL 
5 NULL metastatic disease is one of the major causes of death from cancer in human beings . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL several enzyme systems have been implicated in the metastatic process , but the metalloproteinases ( mps 
0 NULL NULL several enzyme systems have been implicated in the metastatic process , but the metalloproteinases ( mps ) appear to 
0 but the metalloproteinases ( mps ) appear to be the major group involved in most instances of neoplastic invasion . NULL 
0 metalloproteinases ( mps ) appear to be the major group involved in most instances of neoplastic invasion . NULL NULL NULL 
0 be the major group involved in most instances of neoplastic invasion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL increased mp activity has been correlated with the metastatic potential of 
0 NULL NULL NULL NULL NULL NULL NULL NULL increased mp activity has been correlated with the metastatic potential of many cancers 
0 NULL NULL increased mp activity has been correlated with the metastatic potential of many cancers , including breast cancer . NULL 
0 NULL increased mp activity has been correlated with the metastatic potential of many cancers , including breast cancer . NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL mps also play a role in tumor angiogenesis . NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL mps also play a role in tumor angiogenesis . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL mps also play a role in tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL mps also play a role in tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL tetracyclines are antimicrobial agents that can suppress mp activity in a variety of tissues , including gingiva 
0 NULL NULL tetracyclines are antimicrobial agents that can suppress mp activity in a variety of tissues , including gingiva , bone 
18 NULL NULL NULL several reports have indicated that tetracyclines can suppress tumor mps as well . NULL NULL NULL NULL NULL 
0 NULL NULL several reports have indicated that tetracyclines can suppress tumor mps as well . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL a synthetic tetracycline , doxycycline , inhibits migration of human mda-mb-435 breast adenocarcinoma cells through a reconstituted 
14 NULL NULL NULL a synthetic tetracycline , doxycycline , inhibits migration of human mda-mb-435 breast adenocarcinoma cells through a reconstituted basement 
7 inhibits migration of human mda-mb-435 breast adenocarcinoma cells through a reconstituted basement membrane ( matrigel ) , an assay used as 
0 a reconstituted basement membrane ( matrigel ) , an assay used as an in vitro surrogate for the in vivo process 
0 an in vitro surrogate for the in vivo process of tumor invasion through basement membranes . NULL NULL NULL NULL NULL 
14 in vitro surrogate for the in vivo process of tumor invasion through basement membranes . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL additionally , doxycycline diminishes the proliferation of this breast cancer cell line and also 
1 NULL NULL NULL NULL NULL additionally , doxycycline diminishes the proliferation of this breast cancer cell line and also decreases its 
0 the proliferation of this breast cancer cell line and also decreases its gelatinolytic activity , as determined by gel zymography . 
0 this breast cancer cell line and also decreases its gelatinolytic activity , as determined by gel zymography . NULL NULL NULL 
16 of somatostatin receptors in veins surrounding human cancer tissue : role in tumor-host interaction ? NULL NULL NULL NULL NULL NULL 
15 in veins surrounding human cancer tissue : role in tumor-host interaction ? NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL somatostatin receptors were detected in peritumoral veins of various human cancer tissue specimens . 
0 adenocarcinomas , 13 carcinoids , 6 renal-cell carcinomas and 7 malignant lymphomas were analyzed for somatostatin receptors by use of quantitative 
0 and 7 malignant lymphomas were analyzed for somatostatin receptors by use of quantitative receptor autoradiography . NULL NULL NULL NULL NULL 
9 NULL NULL in colonic carcinoma specimens , the peritumoral vessels expressed a high density of somatostatin receptors , whereas the neoplastic 
9 of somatostatin receptors , whereas the neoplastic tissue itself was negative in many cases . NULL NULL NULL NULL NULL NULL 
2 density of somatostatin receptors in peritumoral vessels was low in differentiated gastrointestinal and bronchial carcinoids , in contrast to the high 
0 to the high density of such receptors in the carcinoid tumor tissue . NULL NULL NULL NULL NULL NULL NULL NULL 
0 autochthonous vessels surrounding other tumors such as renal-cell carcinomas or malignant lymphomas also frequently expressed somatostatin receptors . NULL NULL NULL 
9 tumors such as renal-cell carcinomas or malignant lymphomas also frequently expressed somatostatin receptors . NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL in all cases , the somatostatin receptors were localized in veins , particularly in the smooth-muscle cell layer . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL they exhibited specific and high-affinity binding of somatostatin-14 , somatostatin-28 and octreotide 
0 NULL NULL NULL NULL NULL NULL they exhibited specific and affinity binding of somatostatin-14 , somatostatin-28 and octreotide , suggesting a 
15 NULL NULL NULL NULL NULL they exhibited specific and high-affinity binding of somatostatin-14 , somatostatin-28 and octreotide , suggesting a preferential 
9 of somatostatin-14 , somatostatin-28 and octreotide , suggesting a preferential expression of the sstr2 receptor subtype . NULL NULL NULL NULL 
17 or lymphatic organs , have few somatostatin receptors , the increased somatostatin receptor expression in peritumoral vessels observed in this study 
9 , have few somatostatin receptors , the increased somatostatin receptor expression in peritumoral vessels observed in this study may be linked 
0 receptors , the increased somatostatin receptor expression in peritumoral vessels observed in this study may be linked to the neoplastic process 
0 expression in peritumoral vessels observed in this study may be linked to the neoplastic process itself . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results suggest that somatostatin and somatostatin receptors may play a regulatory 
16 NULL the results suggest that somatostatin and somatostatin receptors may play a regulatory role for hemodynamic tumor-host interactions , possibly involving 
16 results suggest that somatostatin and somatostatin receptors may play a regulatory role for hemodynamic tumor-host interactions , possibly involving tumor stroma 
16 suggest that somatostatin and somatostatin receptors may play a regulatory role for hemodynamic tumor-host interactions , possibly involving tumor stroma generation 
15 somatostatin receptors may play a regulatory role for hemodynamic tumor-host interactions , possibly involving tumor stroma generation , tumor environment , 
16 play a regulatory role for hemodynamic tumor-host interactions , possibly involving tumor stroma generation , tumor environment , angiogenesis and , 
0 a regulatory role for hemodynamic tumor-host interactions , possibly involving tumor stroma generation , tumor environment , angiogenesis and , particularly 
2 role for hemodynamic tumor-host interactions , possibly involving tumor stroma generation , tumor environment , angiogenesis and , particularly , vascular 
0 hemodynamic tumor-host interactions , possibly involving tumor stroma generation , tumor environment , angiogenesis and , particularly , vascular drainage of 
3 , possibly involving tumor stroma generation , tumor environment , angiogenesis and , particularly , vascular drainage of poorly differentiated neoplasms 
2 , angiogenesis and , particularly , vascular drainage of poorly differentiated neoplasms . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth 
14 NULL NULL NULL NULL NULL NULL stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms 
0 stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin , osteopontin 
0 by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin , osteopontin , and thrombin . NULL 
3 NULL NULL we have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor ( vpf/vegf ) 
0 mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor ( vpf/vegf ) likely regulates endothelial cells ( ec 
16 vascular permeability factor/vascular endothelial growth factor ( vpf/vegf ) likely regulates endothelial cells ( ec ) migration . NULL NULL NULL 
14 ( vpf/vegf ) likely regulates endothelial cells ( ec ) migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL vpf/vegf induced dermal microvascular ec expression of mrnas encoding the alphav and 
10 NULL NULL NULL NULL NULL vpf/vegf induced dermal microvascular ec expression of mrnas encoding the alphav and beta3 integrin subunits resulting 
0 expression of mrnas encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell 
17 mrnas encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface , 
0 encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface , and 
17 alphavbeta3 heterodimer at the cell surface , and vpf/vegf also induced mrna encoding osteopontin ( opn ) , an alphavbeta3 ligand 
0 heterodimer at the cell surface , and vpf/vegf also induced mrna encoding osteopontin ( opn ) , an alphavbeta3 ligand . 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL opn promoted ec migration in vitro ; and vpf/vegf induction of alphavbeta3 
14 NULL NULL NULL NULL NULL NULL NULL opn promoted ec migration in vitro ; and vpf/vegf induction of alphavbeta3 was accompanied 
17 NULL opn promoted ec migration in vitro ; and vpf/vegf induction of alphavbeta3 was accompanied by increased ec migration toward opn 
17 vitro ; and vpf/vegf induction of alphavbeta3 was accompanied by increased ec migration toward opn . NULL NULL NULL NULL NULL 
14 and vpf/vegf induction of alphavbeta3 was accompanied by increased ec migration toward opn . NULL NULL NULL NULL NULL NULL NULL 
11 NULL NULL NULL NULL NULL NULL NULL NULL because thrombin cleavage of opn results in substantial enhancement of opn 's adhesive 
17 NULL NULL NULL NULL NULL NULL NULL NULL because thrombin cleavage of opn results in substantial enhancement of opn 's adhesive 
0 NULL NULL NULL NULL NULL because thrombin cleavage of opn results in substantial enhancement of opn 's adhesive properties , and 
17 NULL NULL because thrombin cleavage of opn results in substantial enhancement of opn 's adhesive properties , and because vpf/vegf promotes 
0 cleavage of opn results in substantial enhancement of opn 's adhesive properties , and because vpf/vegf promotes increased microvascular permeability leading 
0 of opn results in substantial enhancement of opn 's adhesive properties , and because vpf/vegf promotes increased microvascular permeability leading to 
17 enhancement of opn 's adhesive properties , and because vpf/vegf promotes increased microvascular permeability leading to activation of the extrinsic coagulation 
17 of opn 's adhesive properties , and because vpf/vegf promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway 
0 adhesive properties , and because vpf/vegf promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway , we also 
17 , and because vpf/vegf promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway , we also investigated whether 
16 the extrinsic coagulation pathway , we also investigated whether vpf/vegf facilitates thrombin cleavage of opn in vivo . NULL NULL NULL 
11 coagulation pathway , we also investigated whether vpf/vegf facilitates thrombin cleavage of opn in vivo . NULL NULL NULL NULL NULL 
17 coagulation pathway , we also investigated whether vpf/vegf facilitates thrombin cleavage of opn in vivo . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL consistent with this hypothesis , co-injection of vpf/vegf together with opn resulted in rapid cleavage of 
0 with this hypothesis , co-injection of vpf/vegf together with opn resulted in rapid cleavage of opn by endogenous thrombin . NULL 
11 , co-injection of vpf/vegf together with opn resulted in rapid cleavage of opn by endogenous thrombin . NULL NULL NULL NULL 
17 , co-injection of vpf/vegf together with opn resulted in rapid cleavage of opn by endogenous thrombin . NULL NULL NULL NULL 
11 NULL NULL furthermore , in comparison with native opn , cleaved opn stimulated a greater rate of ec migration in vitro 
17 NULL NULL furthermore , in comparison with native opn , cleaved opn stimulated a greater rate of ec migration in vitro 
17 furthermore , in comparison with native opn , thrombin-cleaved opn stimulated a greater rate of ec migration in vitro , which 
14 opn , thrombin-cleaved opn stimulated a greater rate of ec migration in vitro , which was additive to the increased migration 
0 ec migration in vitro , which was additive to the increased migration associated with induction of alpha v beta 3 . 
0 migration in vitro , which was additive to the increased migration associated with induction of alpha v beta 3 . NULL 
0 in vitro , which was additive to the increased migration associated with induction of alpha v beta 3 . NULL NULL 
17 , which was additive to the increased migration associated with induction of alpha v beta 3 . NULL NULL NULL NULL 
16 NULL thus , these data demonstrate cooperative mechanisms for vpf/vegf regulation of ec migration involving the alphavbeta3 integrin , the alphavbeta3 
14 these data demonstrate cooperative mechanisms for vpf/vegf regulation of ec migration involving the alphavbeta3 integrin , the alphavbeta3 ligand opn , 
0 data demonstrate cooperative mechanisms for vpf/vegf regulation of ec migration involving the alphavbeta3 integrin , the alphavbeta3 ligand opn , and 
11 alphavbeta3 integrin , the alphavbeta3 ligand opn , and thrombin cleavage of opn . NULL NULL NULL NULL NULL NULL NULL 
17 alphavbeta3 integrin , the alphavbeta3 ligand opn , and thrombin cleavage of opn . NULL NULL NULL NULL NULL NULL NULL 
0 NULL these findings also illustrate an operational link between vpf/vegf induction of ec gene expression and vpf/vegf enhancement of microvascular permeability 
0 illustrate an operational link between vpf/vegf induction of ec gene expression and vpf/vegf enhancement of microvascular permeability , suggesting that these 
17 link between vpf/vegf induction of ec gene expression and vpf/vegf enhancement of microvascular permeability , suggesting that these distinct biological activities 
0 enhancement of microvascular permeability , suggesting that these distinct biological activities may act accordingly to stimulate ec migration during angiogenesis . 
0 microvascular permeability , suggesting that these distinct biological activities may act accordingly to stimulate ec migration during angiogenesis . NULL NULL 
17 suggesting that these distinct biological activities may act accordingly to stimulate ec migration during angiogenesis . NULL NULL NULL NULL NULL 
14 these distinct biological activities may act accordingly to stimulate ec migration during angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 biological activities may act accordingly to stimulate ec migration during angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 of naked dna encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo . NULL NULL NULL 
17 dna encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo . NULL NULL NULL NULL NULL 
2 for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) is a naturally secreted endothelial cell-specific 
14 vascular endothelial growth factor ( vegf ) is a naturally secreted endothelial cell-specific mitogen . NULL NULL NULL NULL NULL NULL 
0 the hypothesis that naked dna encoding for vegf could be used in a strategy of arterial gene therapy to stimulate collateral 
19 encoding for vegf could be used in a strategy of arterial gene therapy to stimulate collateral artery development . NULL NULL 
19 vegf could be used in a strategy of arterial gene therapy to stimulate collateral artery development . NULL NULL NULL NULL 
17 be used in a strategy of arterial gene therapy to stimulate collateral artery development . NULL NULL NULL NULL NULL NULL 
2 a strategy of arterial gene therapy to stimulate collateral artery development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 to the hydrogel polymer coating of an angioplasty balloon and delivered percutaneously to one iliac artery of rabbits with operatively induced 
0 delivered percutaneously to one iliac artery of rabbits with operatively induced hindlimb ischemia . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL compared with control animals transfected with lacz , site-specific transfection of phvegf resulted 
19 NULL NULL NULL NULL NULL NULL compared with control animals transfected with lacz , site-specific transfection of phvegf resulted in augmented 
19 NULL NULL compared with control animals transfected with lacz , site-specific transfection of phvegf resulted in augmented collateral vessel development documented 
19 NULL compared with control animals transfected with lacz , site-specific transfection of phvegf resulted in augmented collateral vessel development documented by 
17 control animals transfected with lacz , site-specific transfection of phvegf resulted in augmented collateral vessel development documented by serial angiography , 
2 , site-specific transfection of phvegf resulted in augmented collateral vessel development documented by serial angiography , and improvement in calf blood 
0 phvegf resulted in augmented collateral vessel development documented by serial angiography , and improvement in calf blood pressure ratio ( ischemic 
0 blood pressure ratio ( ischemic to normal limb ) , resting and maximum blood flow , and capillary to myocyte ratio 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL similar results were obtained with phvegf121 , phvegf165 , and phvegf189 , 
0 NULL NULL NULL NULL NULL NULL NULL similar results were obtained with phvegf121 , phvegf165 , and phvegf189 , which suggests 
3 these isoforms are biologically equivalent with respect to in vivo angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 the fact that viral or other adjunctive vectors were not required further suggests that secreted gene products may have potential therapeutic 
0 or other adjunctive vectors were not required further suggests that secreted gene products may have potential therapeutic utility even when the 
0 not required further suggests that secreted gene products may have potential therapeutic utility even when the number of successfully transfected cells 
0 have potential therapeutic utility even when the number of successfully transfected cells remains low . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL arterial gene transfer of naked dna encoding for a secreted angiogenic 
0 NULL arterial gene transfer of naked dna encoding for a secreted angiogenic cytokine , thus , represents a potential alternative to 
3 arterial gene transfer of naked dna encoding for a secreted angiogenic cytokine , thus , represents a potential alternative to recombinant 
0 for a secreted angiogenic cytokine , thus , represents a potential alternative to recombinant protein administration for stimulating collateral vessel development 
0 cytokine , thus , represents a potential alternative to recombinant protein administration for stimulating collateral vessel development . NULL NULL NULL 
0 , thus , represents a potential alternative to recombinant protein administration for stimulating collateral vessel development . NULL NULL NULL NULL 
17 , represents a potential alternative to recombinant protein administration for stimulating collateral vessel development . NULL NULL NULL NULL NULL NULL 
2 potential alternative to recombinant protein administration for stimulating collateral vessel development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL induction of ets-1 in endothelial cells during reendothelialization after denuding injury 
3 NULL NULL NULL induction of ets-1 in endothelial cells during reendothelialization after denuding injury . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL ets-1 , a transcription factor , is induced in endothelial cells ( ecs ) 
17 NULL NULL NULL ets-1 , a transcription factor , is induced in endothelial cells ( ecs ) during angiogenesis . NULL 
3 , is induced in endothelial cells ( ecs ) during angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL here , we investigated the expression of ets-1 during reendothelialization . NULL NULL NULL NULL NULL 
3 NULL here , we investigated the expression of ets-1 during reendothelialization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 human umbilical vein endothelial cell line , ecv304 , was denuded , ecv304 at the wound edge expressed ets-1 . NULL 
9 ecv304 , was denuded , ecv304 at the wound edge expressed ets-1 . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL an immunohistochemical analysis revealed that ets-1 accumulated in migrating cells at the 
17 NULL NULL NULL NULL an immunohistochemical analysis revealed that ets-1 accumulated in migrating cells at the wound edge and returned to 
0 NULL NULL an immunohistochemical analysis revealed that ets-1 accumulated in migrating cells at the wound edge and returned to basal level 
3 at the wound edge and returned to basal level when reendothelialization was accomplished . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL this induction of ets-1 could be reproduced in in vivo denudation of 
17 NULL NULL NULL NULL this induction of ets-1 could be reproduced in in vivo denudation of rat aortic endothelium by a 
19 this induction of ets-1 could be reproduced in in vivo denudation of rat aortic endothelium by a balloon catheter . NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the induction of ets-1 in ecs after denudation was regulated transcriptionally , 
19 NULL NULL NULL the induction of ets-1 in ecs after denudation was regulated transcriptionally , and humeral factors released from injured 
16 NULL the induction of ets-1 in ecs after denudation was regulated transcriptionally , and humeral factors released from injured ecs might 
14 ecs after denudation was regulated transcriptionally , and humeral factors released from injured ecs might not be responsible . NULL NULL 
0 and humeral factors released from injured ecs might not be responsible . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL activated protein kinase ( mapk ) activities were investigated to explore 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL mitogen-activated protein kinase ( mapk ) activities were investigated to explore the 
0 NULL NULL NULL NULL mitogen-activated protein kinase ( mapk ) activities were investigated to explore the mechanism of this induction . 
0 kinase ( mapk ) activities were investigated to explore the mechanism of this induction . NULL NULL NULL NULL NULL NULL 
17 ) activities were investigated to explore the mechanism of this induction . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL although extracellular regulated protein kinase 1/2 ( erk1/2 ) , c-jun n-terminal kinase 
0 NULL NULL NULL NULL NULL NULL NULL although extracellular signal-regulated protein kinase 1/2 ( erk1/2 ) , c-jun n-terminal kinase 1 
17 n-terminal kinase 1 ( jnk1 ) , and p38 were activated after denudation , the activation of erk1 and p38 was 
0 1 ( jnk1 ) , and p38 were activated after denudation , the activation of erk1 and p38 was more rapid 
17 ) , and p38 were activated after denudation , the activation of erk1 and p38 was more rapid and prominent . 
0 pd98059 , a specific mapk/erk kinase ( mek ) 1 inhibitor , did not affect the induction of ets-1 mrna , 
16 mapk/erk kinase ( mek ) 1 inhibitor , did not affect the induction of ets-1 mrna , whereas sb203580 , a 
17 ( mek ) 1 inhibitor , did not affect the induction of ets-1 mrna , whereas sb203580 , a specific p38 
0 1 inhibitor , did not affect the induction of ets-1 mrna , whereas sb203580 , a specific p38 inhibitor , almost 
0 of ets-1 mrna , whereas sb203580 , a specific p38 inhibitor , almost completely abrogated its induction . NULL NULL NULL 
18 whereas sb203580 , a specific p38 inhibitor , almost completely abrogated its induction . NULL NULL NULL NULL NULL NULL NULL 
17 , a specific p38 inhibitor , almost completely abrogated its induction . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate that ets-1 is induced in ecs after denudation through 
17 NULL NULL NULL NULL these results indicate that ets-1 is induced in ecs after denudation through activation of p38 . NULL 
19 these results indicate that ets-1 is induced in ecs after denudation through activation of p38 . NULL NULL NULL NULL NULL 
17 indicate that ets-1 is induced in ecs after denudation through activation of p38 . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL this induction of ets-1 may be relevant for reendothelialization by regulating the 
3 NULL NULL this induction of ets-1 may be relevant for reendothelialization by regulating the expression of certain genes . NULL NULL 
0 this induction of ets-1 may be relevant for reendothelialization by regulating the expression of certain genes . NULL NULL NULL NULL 
0 of ets-1 may be relevant for reendothelialization by regulating the expression of certain genes . NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL store-operated calcium entry promotes shape change in pulmonary endothelial cells expressing trp1 . 
17 NULL NULL NULL NULL NULL NULL NULL store-operated calcium entry promotes shape change in pulmonary endothelial cells expressing trp1 . NULL 
2 NULL NULL NULL NULL NULL NULL store-operated calcium entry promotes shape change in pulmonary endothelial cells expressing trp1 . NULL NULL 
2 NULL NULL NULL NULL NULL store-operated calcium entry promotes shape change in pulmonary endothelial cells expressing trp1 . NULL NULL NULL 
9 store-operated calcium entry promotes shape change in pulmonary endothelial cells expressing trp1 . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL activation of ca2+ entry is known to produce endothelial cell shape 
14 NULL NULL NULL NULL NULL NULL NULL activation of ca2+ entry is known to produce endothelial cell shape change , leading 
16 NULL NULL NULL activation of ca2+ entry is known to produce endothelial cell shape change , leading to increased permeability , 
2 activation of ca2+ entry is known to produce endothelial cell shape change , leading to increased permeability , leukocyte migration , 
2 of ca2+ entry is known to produce endothelial cell shape change , leading to increased permeability , leukocyte migration , and 
0 entry is known to produce endothelial cell shape change , leading to increased permeability , leukocyte migration , and initiation of 
0 known to produce endothelial cell shape change , leading to increased permeability , leukocyte migration , and initiation of angiogenesis in 
14 cell shape change , leading to increased permeability , leukocyte migration , and initiation of angiogenesis in conduit-vessel endothelial cells . 
17 , leading to increased permeability , leukocyte migration , and initiation of angiogenesis in conduit-vessel endothelial cells . NULL NULL NULL 
3 to increased permeability , leukocyte migration , and initiation of angiogenesis in conduit-vessel endothelial cells . NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL the mode of ca2+ entry regulating cell shape is unknown . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the mode of ca2+ entry regulating cell shape is unknown . NULL NULL NULL NULL NULL 
0 NULL NULL NULL the mode of ca2+ entry regulating cell shape is unknown . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL we hypothesized that activation of store-operated ca2+ channels ( socs ) is sufficient to 
0 that activation of store-operated ca2+ channels ( socs ) is sufficient to promote cell shape change necessary for these processes . 
0 of store-operated ca2+ channels ( socs ) is sufficient to promote cell shape change necessary for these processes . NULL NULL 
2 ca2+ channels ( socs ) is sufficient to promote cell shape change necessary for these processes . NULL NULL NULL NULL 
2 channels ( socs ) is sufficient to promote cell shape change necessary for these processes . NULL NULL NULL NULL NULL 
0 is sufficient to promote cell shape change necessary for these processes . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL soc activation in rat pulmonary arterial endothelial cells increased free cytosolic ca2+ 
0 NULL NULL NULL NULL NULL soc activation in rat pulmonary arterial endothelial cells increased free cytosolic ca2+ that was dependent on 
17 NULL NULL soc activation in rat pulmonary arterial endothelial cells increased free cytosolic ca2+ that was dependent on a membrane current 
0 NULL soc activation in rat pulmonary arterial endothelial cells increased free cytosolic ca2+ that was dependent on a membrane current having 
17 pulmonary arterial endothelial cells increased free cytosolic ca2+ that was dependent on a membrane current having a net inward component of 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL changes in endothelial cell shape accompanied soc activation and were dependent 
0 NULL NULL NULL NULL NULL NULL changes in endothelial cell shape accompanied soc activation and were dependent on ca2+ entry-induced reconfiguration 
0 NULL NULL NULL changes in endothelial cell shape accompanied soc activation and were dependent on ca2+ entry-induced reconfiguration of peripheral ( 
17 changes in endothelial cell shape accompanied soc activation and were dependent on ca2+ entry-induced reconfiguration of peripheral ( cortical ) filamentous 
14 cell shape accompanied soc activation and were dependent on ca2+ entry reconfiguration of peripheral ( cortical ) filamentous actin ( f-actin 
17 cell shape accompanied soc activation and were dependent on ca2+ induced reconfiguration of peripheral ( cortical ) filamentous actin ( f-actin 
16 shape accompanied soc activation and were dependent on ca2+ entry-induced reconfiguration of peripheral ( cortical ) filamentous actin ( f-actin ) 
0 , but mammalian homologues of the drosophila melanogaster transient receptor potential ( trp ) gene have been proposed to form ca2+ 
0 receptor potential ( trp ) gene have been proposed to form ca2+ entry channels in nonexcitable cells , we performed rt-pcr 
14 ( trp ) gene have been proposed to form ca2+ entry channels in nonexcitable cells , we performed rt-pcr using trp 
0 using trp oligonucleotide primers in both rat and human pulmonary arterial endothelial cells . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL both cell types were found to express trp1 , but neither expressed trp3 nor trp6 . NULL 
9 cell types were found to express trp1 , but neither expressed trp3 nor trp6 . NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL our study indicates that 1 ) ca2+ entry in pulmonary endothelial cells through socs produces cell shape change 
16 1 ) ca2+ entry in pulmonary endothelial cells through socs produces cell shape change that is dependent on site-specific rearrangement of 
2 ca2+ entry in pulmonary endothelial cells through socs produces cell shape change that is dependent on site-specific rearrangement of the microfilamentous 
2 entry in pulmonary endothelial cells through socs produces cell shape change that is dependent on site-specific rearrangement of the microfilamentous cytoskeleton 
0 endothelial cells through socs produces cell shape change that is dependent on site-specific rearrangement of the microfilamentous cytoskeleton and 2 ) 
0 through socs produces cell shape change that is dependent on site-specific rearrangement of the microfilamentous cytoskeleton and 2 ) trp1 may 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effect of u-995 , a potent shark cartilage-derived angiogenesis inhibitor , 
0 NULL NULL NULL effect of u-995 , a potent shark derived angiogenesis inhibitor , on anti-angiogenesis and anti-tumor activities . NULL 
3 NULL NULL effect of u-995 , a potent shark cartilage-derived angiogenesis inhibitor , on anti-angiogenesis and anti-tumor activities . NULL NULL 
0 NULL effect of u-995 , a potent shark cartilage-derived angiogenesis inhibitor , on anti-angiogenesis and anti-tumor activities . NULL NULL NULL 
3 u-995 , a potent shark cartilage-derived angiogenesis inhibitor , on angiogenesis and anti-tumor activities . NULL NULL NULL NULL NULL NULL 
18 potent shark cartilage-derived angiogenesis inhibitor , on anti-angiogenesis and anti-tumor activities . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL background : a potent angiogenesis inhibitor , u-995 , has been purified from the cartilage 
0 NULL NULL NULL NULL NULL background : a potent angiogenesis inhibitor , u-995 , has been purified from the cartilage of 
19 : a potent angiogenesis inhibitor , u-995 , has been purified from the cartilage of the blue shark ( prionace glauca 
14 to study human umbilical vein endothelial cell ( huvec ) migration and proliferation in vitro and angiogenesis induced by tnf alpha 
1 human umbilical vein endothelial cell ( huvec ) migration and proliferation in vitro and angiogenesis induced by tnf alpha in chicken 
3 cell ( huvec ) migration and proliferation in vitro and angiogenesis induced by tnf alpha in chicken chorioallantoic membrane ( cam 
17 ( huvec ) migration and proliferation in vitro and angiogenesis induced by tnf alpha in chicken chorioallantoic membrane ( cam ) 
0 NULL NULL NULL NULL NULL furthermore , we determined the ability of u-995 to inhibiting tumor cell growth and metastasis . 
18 NULL furthermore , we determined the ability of u-995 to inhibiting tumor cell growth and metastasis . NULL NULL NULL NULL 
0 furthermore , we determined the ability of u-995 to inhibiting tumor cell growth and metastasis . NULL NULL NULL NULL NULL 
1 we determined the ability of u-995 to inhibiting tumor cell growth and metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 the ability of u-995 to inhibiting tumor cell growth and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : u-995 ( 15 and 30 micrograms/ml ) markedly inhibited 
18 results : u-995 ( 15 and 30 micrograms/ml ) markedly inhibited huvec migration and , at 15-50 micrograms/ml produced a dose-dependent 
14 u-995 ( 15 and 30 micrograms/ml ) markedly inhibited huvec migration and , at 15-50 micrograms/ml produced a dose-dependent decline in 
0 ) markedly inhibited huvec migration and , at 15-50 micrograms/ml produced a dose-dependent decline in [ 3h ] -thymidine incorporation . 
0 inhibited huvec migration and , at 15-50 micrograms/ml produced a dependent decline in [ 3h ] -thymidine incorporation . NULL NULL 
0 huvec migration and , at 15-50 micrograms/ml produced a dose-dependent decline in [ 3h ] -thymidine incorporation . NULL NULL NULL 
0 micrograms/ml produced a dose-dependent decline in [ 3h ] -thymidine incorporation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL 30 and 50 micrograms/ml of u-995 , when added to tnf alpha-induced angiogenesis caused discontinuous and disrupted blood vessels 
17 and 50 micrograms/ml of u-995 , when added to tnf induced angiogenesis caused discontinuous and disrupted blood vessels . NULL NULL 
3 50 micrograms/ml of u-995 , when added to tnf alpha-induced angiogenesis caused discontinuous and disrupted blood vessels . NULL NULL NULL 
17 micrograms/ml of u-995 , when added to tnf alpha-induced angiogenesis caused discontinuous and disrupted blood vessels . NULL NULL NULL NULL 
6 , when added to tnf alpha-induced angiogenesis caused discontinuous and disrupted blood vessels . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL moreover , u-995 ( 30 micrograms/ml ) markedly prevented collagenase-induced collagenolysis . NULL NULL NULL NULL NULL NULL NULL 
17 NULL moreover , u-995 ( 30 micrograms/ml ) markedly prevented induced collagenolysis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 moreover , u-995 ( 30 micrograms/ml ) markedly prevented collagenase-induced collagenolysis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , when 200 micrograms u-995 was injected i.p . NULL 
19 NULL NULL in addition , when 200 micrograms u-995 was injected i.p . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL into mice it suppressed sarcoma-180 cell growth and b16-f10 mouse melanoma cell metastasis in 
1 NULL NULL NULL NULL into mice it suppressed sarcoma-180 cell growth and b16-f10 mouse melanoma cell metastasis in vivo . NULL 
14 it suppressed sarcoma-180 cell growth and b16-f10 mouse melanoma cell metastasis in vivo . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusions : these results suggest that the anti-angiogenic effects of u-995 may be be 
3 NULL NULL NULL conclusions : these results suggest that the angiogenic effects of u-995 may be be due to interference with 
18 NULL NULL conclusions : these results suggest that the anti-angiogenic effects of u-995 may be be due to interference with the 
18 the anti-angiogenic effects of u-995 may be be due to interference with the proliferation and migration of huvecs as well as 
1 of u-995 may be be due to interference with the proliferation and migration of huvecs as well as inhibition of collagenolysis 
14 may be be due to interference with the proliferation and migration of huvecs as well as inhibition of collagenolysis , thereby 
18 with the proliferation and migration of huvecs as well as inhibition of collagenolysis , thereby leading to inhibition of both angiogenesis 
0 proliferation and migration of huvecs as well as inhibition of collagenolysis , thereby leading to inhibition of both angiogenesis and tumor 
0 of huvecs as well as inhibition of collagenolysis , thereby leading to inhibition of both angiogenesis and tumor cell growth . 
18 as well as inhibition of collagenolysis , thereby leading to inhibition of both angiogenesis and tumor cell growth . NULL NULL 
3 inhibition of collagenolysis , thereby leading to inhibition of both angiogenesis and tumor cell growth . NULL NULL NULL NULL NULL 
0 collagenolysis , thereby leading to inhibition of both angiogenesis and tumor cell growth . NULL NULL NULL NULL NULL NULL NULL 
1 thereby leading to inhibition of both angiogenesis and tumor cell growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
